[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "Acrokeratosis paraneoplastica is a rare skin condition that is characterized by the development of thick, rough, and scaly patches of skin on the fingers, toes, and soles of the feet. These patches are caused by the body's immune system reacting to a cancerous tumor in the body.\n\nThere are several synonyms for acrokeratosis paraneoplastica, including:\n\n1. Acrokeratotic paraneoplastic pemphigus\n2. Acrokeratotic paraneoplastic pemphigoid\n3. Acrokeratotic paraneoplastic dermatitis\n4. Acrokeratotic paraneoplastic eczema\n5. Acrokeratotic paraneoplastic psoriasis\n6. Acrokeratotic paraneoplastic lichen planus\n7. Acrokeratotic paraneoplastic scleroderma\n8. Acrokeratotic paraneoplastic discoid lupus erythematosus\n9. Acrokeratotic paraneoplastic lupus erythematosus\n10. Acrokeratotic paraneoplastic dermatomyositis.",
    "llama-7b_fact_raw": "1. Acrokeratosis paraneoplastica is characterized by the development of thick, rough, and scaly patches of skin.\n2. The patches associated with acrokeratosis paraneoplastica appear on the fingers, toes, and soles of the feet.\n3. Acrokeratosis paraneoplastica is a rare skin condition.\n4. The condition is caused by the body's immune system reacting to a cancerous tumor.\n5. \"Acrokeratotic paraneoplastic pemphigus\" is a synonym for acrokeratosis paraneoplastica.",
    "llama-7b_fact": [
      "Acrokeratosis paraneoplastica is characterized by the development of thick, rough, and scaly patches of skin.",
      "The patches associated with acrokeratosis paraneoplastica appear on the fingers, toes, and soles of the feet.",
      "Acrokeratosis paraneoplastica is a rare skin condition.",
      "The condition is caused by the body's immune system reacting to a cancerous tumor.",
      "\"Acrokeratotic paraneoplastic pemphigus\" is a synonym for acrokeratosis paraneoplastica."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Acrokeratosis paraneoplastica, also known as Bazex syndrome, is characterized by psoriasiform lesions, particularly on the hands, feet, and in some cases, the nose and ears.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Acrokeratotic paraneoplastic pemphigus is not a synonym for acrokeratosis paraneoplastica. Paraneoplastic pemphigus is a different condition associated with neoplasms and involves blistering, while acrokeratosis paraneoplastica (Bazex syndrome) does not involve blistering.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect growth and development, but they are distinct conditions with different genetic causes and clinical features.\n\nWeaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is caused by mutations in the GH1 gene on chromosome 17q21. This gene encodes for the growth hormone receptor, which plays a crucial role in regulating growth and development. Individuals with Weaver syndrome have characteristic physical features such as macrocephaly (large head), hypotonia (low muscle tone), and distinctive facial features such as a broad forehead, low-set and malformed ears, and a single crease in the palm of the hand. Intellectual disability and delayed puberty are also common in this condition.\n\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene on chromosome 5q31. This gene encodes for a transcription factor that plays a crucial role in regulating gene expression during embryonic development. Individuals with Sotos syndrome have characteristic physical features such as a large head, wide-set eyes, and a distinctive facial structure with a broad forehead, full cheeks, and a flat nasal bridge. Intellectual disability and rapid growth during childhood are also common in this condition.\n\nWhile both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development, they differ in their genetic causes and clinical features. Weaver syndrome is caused by mutations in the GH1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene. Additionally, individuals with Weaver syndrome have characteristic physical features such as macrocephaly, hypotonia, and distinctive facial features, while individuals with Sotos syndrome have characteristic physical features such as a large head, wide-set eyes, and a distinctive facial structure. It is important for healthcare professionals to accurately diagnose these conditions in order to provide appropriate management and support to affected individuals and their families.",
    "llama-7b_fact_raw": "1. Weaver syndrome and Sotos syndrome are both genetic disorders that impact growth and development.\n2. Weaver syndrome is caused by mutations in the GH1 gene located on chromosome 17q21.\n3. Sotos syndrome is caused by mutations in the NSD1 gene located on chromosome 5q31.\n4. Individuals with Weaver syndrome typically have features such as macrocephaly, hypotonia, and distinctive facial characteristics.\n5. Characteristics of individuals with Sotos syndrome include a large head, wide-set eyes, and a distinctive facial structure.",
    "llama-7b_fact": [
      "Weaver syndrome and Sotos syndrome are both genetic disorders that impact growth and development.",
      "Weaver syndrome is caused by mutations in the GH1 gene located on chromosome 17q21.",
      "Sotos syndrome is caused by mutations in the NSD1 gene located on chromosome 5q31.",
      "Individuals with Weaver syndrome typically have features such as macrocephaly, hypotonia, and distinctive facial characteristics.",
      "Characteristics of individuals with Sotos syndrome include a large head, wide-set eyes, and a distinctive facial structure."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene located on chromosome 7q36.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a widely used database of protein-coding transcription factor binding profiles. Here are the releases of the JASPAR database, along with their corresponding years:\n\n1. JASPAR 2004 Release: This was the first release of the JASPAR database, which was published in 2004. It contained binding profiles for 18 transcription factors.\n2. JASPAR 2007 Release: This release of the JASPAR database was published in 2007 and contained binding profiles for 35 transcription factors.\n3. JASPAR 2010 Release: This release of the JASPAR database was published in 2010 and contained binding profiles for 45 transcription factors.\n4. JASPAR 2012 Release: This release of the JASPAR database was published in 2012 and contained binding profiles for 55 transcription factors.\n5. JASPAR 2014 Release: This release of the JASPAR database was published in 2014 and contained binding profiles for 65 transcription factors.\n6. JASPAR 2016 Release: This release of the JASPAR database was published in 2016 and contained binding profiles for 75 transcription factors.\n7. JASPAR 2018 Release: This release of the JASPAR database was published in 2018 and contained binding profiles for 85 transcription factors.\n8. JASPAR 2020 Release: This release of the JASPAR database was published in 2020 and contained binding profiles for 95 transcription factors.",
    "llama-7b_fact_raw": "1. The JASPAR 2004 Release was published in 2004 with binding profiles for 18 transcription factors.\n2. The JASPAR 2007 Release was published in 2007 with binding profiles for 35 transcription factors.\n3. The JASPAR 2010 Release was published in 2010 with binding profiles for 45 transcription factors.\n4. The JASPAR 2012 Release was published in 2012 with binding profiles for 55 transcription factors.\n5. The JASPAR 2014 Release was published in 2014 with binding profiles for 65 transcription factors.",
    "llama-7b_fact": [
      "The JASPAR 2004 Release was published in 2004 with binding profiles for 18 transcription factors.",
      "The JASPAR 2007 Release was published in 2007 with binding profiles for 35 transcription factors.",
      "The JASPAR 2010 Release was published in 2010 with binding profiles for 45 transcription factors.",
      "The JASPAR 2012 Release was published in 2012 with binding profiles for 55 transcription factors.",
      "The JASPAR 2014 Release was published in 2014 with binding profiles for 65 transcription factors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nI can confirm that JASPAR 2004 Release was indeed published in 2004. However, without the specific details regarding the number of transcription factors included in the JASPAR database for the releases of 2007, 2010, 2012, and 2014, I cannot verify the accuracy of the statements 2-5. The JASPAR database is updated with new binding profiles periodically, but the exact numbers for these releases are not commonly known facts and would require access to specific archival data from the JASPAR database history or related publications.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a member of the herpesvirus family. The KP4 protein is also known as ORF73, and it is one of the largest and most complex viral proteins produced by KSHV.\n\nThe function of the KP4 protein is not fully understood, but it is believed to play a crucial role in the life cycle of the virus. The KP4 protein is synthesized as a precursor protein that is cleaved into two smaller proteins, K1 and K2, which are then transported to the cell membrane.\n\nOne of the functions of the KP4 protein is to help the virus evade the host immune system. Studies have shown that the KP4 protein can interact with immune cells, such as macrophages and dendritic cells, and prevent them from recognizing and attacking the virus. This helps the virus to establish a persistent infection in the host.\n\nIn addition to its role in immune evasion, the KP4 protein may also play a role in the replication of the virus. Studies have shown that the KP4 protein is localized to the nucleus of infected cells and may be involved in the transcription of viral genes.\n\nOverall, the function of the KP4 protein is complex and not fully understood, but it is clear that it plays an important role in the life cycle of the Kaposi's sarcoma-associated herpesvirus. Further research is needed to fully understand the role of the KP4 protein in the virus's replication and pathogenesis.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. KP4 is also known as ORF73.\n3. KP4 is involved in the viral life cycle and evasion of the host immune system.\n4. The KP4 protein interacts with immune cells such as macrophages and dendritic cells to prevent virus recognition and attack.\n5. The KP4 protein is found in the nucleus of infected cells and may be involved in the transcription of viral genes.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "KP4 is also known as ORF73.",
      "KP4 is involved in the viral life cycle and evasion of the host immune system.",
      "The KP4 protein interacts with immune cells such as macrophages and dendritic cells to prevent virus recognition and attack.",
      "The KP4 protein is found in the nucleus of infected cells and may be involved in the transcription of viral genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The protein associated with Kaposi's sarcoma-associated herpesvirus (KSHV) that plays a role in the viral life cycle and evasion of the host immune system is called LANA (Latency-Associated Nuclear Antigen), not KP4. LANA is encoded by ORF73.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: It is LANA that interacts with immune cells such as macrophages and dendritic cells to impact virus recognition and attack. KP4 refers to a viral protein, but there's no evidence suggesting that it prevents virus recognition specifically by interacting with macrophages and dendritic cells.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is structurally similar to triiodothyronine (T3), one of the two primary hormones produced by the thyroid gland. However, DITPA has an iodine atom replaced by an iodine analog, which results in increased potency and stability compared to T3.\n\nDITPA has been studied for its potential to treat a variety of thyroid-related conditions, including hypothyroidism, hyperthyroidism, and thyroid cancer. In animal studies, DITPA has been shown to improve thyroid hormone levels, increase metabolism, and reduce weight gain. Additionally, DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism, with some evidence suggesting that it may be more effective than traditional thyroid hormone replacement therapy.\n\nHowever, more research is needed to fully understand the safety and efficacy of DITPA in humans, and its use is currently limited to experimental and clinical studies.",
    "llama-7b_fact_raw": "1. 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog.\n2. DITPA has been utilized in both experimental and clinical studies.\n3. DITPA is structurally similar to triiodothyronine (T3), which is a primary hormone produced by the thyroid gland.\n4. In animal studies, DITPA has been shown to improve thyroid hormone levels and increase metabolism.\n5. DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism.",
    "llama-7b_fact": [
      "3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog.",
      "DITPA has been utilized in both experimental and clinical studies.",
      "DITPA is structurally similar to triiodothyronine (T3), which is a primary hormone produced by the thyroid gland.",
      "In animal studies, DITPA has been shown to improve thyroid hormone levels and increase metabolism.",
      "DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: DITPA has not been used to treat hyperthyroidism in clinical trials; it has been investigated primarily for its potential use in treating conditions such as heart failure and metabolic disorders, not hyperthyroidism. Hyperthyroidism is typically treated with other medications such as antithyroid drugs, radioactive iodine, or surgery, not DITPA.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST) that is used to generate cryptographic key pairs and other cryptographic operations. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n\nThe COUGER tool is designed to be a flexible and extensible tool that can be used to perform a wide range of cryptographic operations, including key generation, encryption, decryption, signature generation, and signature verification. It can be used to generate key pairs using a variety of cryptographic algorithms, including RSA, ElGamal, Diffie-Hellman, and more.\n\nOne of the key features of the COUGER tool is its ability to generate large key sizes, making it suitable for use in high-security applications. It can also generate key pairs with different levels of security, allowing users to choose the level of security that is appropriate for their needs.\n\nIn addition to key generation, the COUGER tool can also be used to perform other cryptographic operations, such as encryption and decryption of data, generation of digital signatures, and verification of digital signatures. It can also be used to generate random numbers, which are often used in cryptographic operations.\n\nOverall, the COUGER tool is a powerful and flexible tool that can be used to perform a wide range of cryptographic operations, making it a valuable tool for anyone working with cryptography.",
    "llama-7b_fact_raw": "1. The COUGER tool is developed by the National Institute of Standards and Technology (NIST).\n2. COUGER is used to generate cryptographic key pairs and perform other cryptographic operations.\n3. The acronym COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n4. COUGER can generate key pairs using cryptographic algorithms like RSA, ElGamal, and Diffie-Hellman.\n5. The COUGER tool is capable of generating large key sizes for high-security applications.",
    "llama-7b_fact": [
      "The COUGER tool is developed by the National Institute of Standards and Technology (NIST).",
      "COUGER is used to generate cryptographic key pairs and perform other cryptographic operations.",
      "The acronym COUGER stands for \"Cryptographic Operations Using Generated Keys.\"",
      "COUGER can generate key pairs using cryptographic algorithms like RSA, ElGamal, and Diffie-Hellman.",
      "The COUGER tool is capable of generating large key sizes for high-security applications."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The context provided does not specify the developer of the COUGER tool, and there is no widely recognized tool with this name known to be developed by NIST as of my last update.\n2. UNKNOWN: Without additional context, it is not possible to confirm whether COUGER is used for generating cryptographic key pairs or performing other cryptographic operations.\n3. FALSE [correction]: There is no widely recognized acronym COUGER related to cryptography that stands for \"Cryptographic Operations Using Generated Keys.\" COUGER is not a known standard acronym in the field of cryptography.\n4. UNKNOWN: It is unclear whether a tool named COUGER exists and, if it does, whether it can generate key pairs using the mentioned cryptographic algorithms.\n5. UNKNOWN: Without further information or context regarding the capabilities of the COUGER tool, it is not possible to confirm whether it can generate large key sizes for high-security applications.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that is transmitted to humans through the bite of an infected tick. There are several different viruses that can cause TBE, including the European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV).\n\nTreatment for TBE typically involves supportive care to manage symptoms such as fever, headache, and muscle weakness. There is no specific antiviral treatment for TBE, and antibiotics are not effective against viral infections.\n\nIn some cases, hospitalization may be necessary to manage complications such as seizures, coma, or respiratory failure.\n\nThere are no specific drugs that have been proven to be effective in preventing or treating TBE. However, there are vaccines available that can provide protection against TBEV and FEV. These vaccines are generally recommended for people who are at high risk of exposure to TBE, such as travelers to endemic areas, outdoor workers, and people who live in rural or forested areas.",
    "llama-7b_fact_raw": "1. Tick-borne encephalitis (TBE) is transmitted to humans through the bite of an infected tick.\n2. The European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV) are different viruses that can cause TBE.\n3. There is no specific antiviral treatment available for TBE.\n4. Antibiotics are ineffective against the viral infection of TBE.\n5. Vaccines are available that can provide protection against TBEV and FEV.",
    "llama-7b_fact": [
      "Tick-borne encephalitis (TBE) is transmitted to humans through the bite of an infected tick.",
      "The European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV) are different viruses that can cause TBE.",
      "There is no specific antiviral treatment available for TBE.",
      "Antibiotics are ineffective against the viral infection of TBE.",
      "Vaccines are available that can provide protection against TBEV and FEV."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The correct terms for the viruses are the European tick-borne encephalitis virus (TBEV), Far Eastern tick-borne encephalitis virus (FEV should be TBEV-FE, a subtype of TBEV), and the Siberian tick-borne encephalitis virus (TBEV-S, another subtype of TBEV). All of them are subtypes or strains of the same virus that can cause TBE rather than entirely different viruses.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "There are several genome browser databases for DNA shape annotations that are available. Some of the most popular ones include:\n\n1. UCSC Genome Browser: This is a free, online genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n2. Ensembl Genome Browser: This is another free, online genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n3. Integrative Genomics Viewer (IGV): This is a free, open-source genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n4. Genome Analysis Toolkit (GATK): This is a free, open-source software suite that provides tools for analyzing and interpreting genomic data, including DNA shape annotations. The suite includes tools for aligning genomic data, calling variants, and analyzing population genetics data.\n\nOverall, these genome browser databases provide a wealth of information and resources for studying DNA shape annotations and other aspects of genomic data.",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is an online platform that offers access to genomic data, including DNA shape annotations.\n2. Ensembl Genome Browser is another online genome browser that provides DNA shape annotations as part of its genomic data offerings.\n3. Integrative Genomics Viewer (IGV) is a free, open-source genome browser that includes DNA shape annotations in its data resources.\n4. Genome Analysis Toolkit (GATK) is an open-source software suite that offers tools for the analysis of genomic data, including DNA shape annotations.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is an online platform that offers access to genomic data, including DNA shape annotations.",
      "Ensembl Genome Browser is another online genome browser that provides DNA shape annotations as part of its genomic data offerings.",
      "Integrative Genomics Viewer (IGV) is a free, open-source genome browser that includes DNA shape annotations in its data resources.",
      "Genome Analysis Toolkit (GATK) is an open-source software suite that offers tools for the analysis of genomic data, including DNA shape annotations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The Ensembl Genome Browser provides a variety of genomic data, but DNA shape annotations are not typically included as part of its standard offerings.\n3. FALSE [correction]: While Integrative Genomics Viewer (IGV) is a free, open-source genome browser, it primarily focuses on the visualization of genomic datasets, and DNA shape annotations are not a central part of its data resources.\n4. FALSE [correction]: The Genome Analysis Toolkit (GATK) is indeed an open-source software suite for analyzing genomic data, but it does not specifically provide tools for DNA shape annotations; it is primarily used for SNP and indel discovery, as well as variant genotyping.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "The EZH2 gene encodes for an enzyme called enhancer of zeste homolog 2, which is involved in the regulation of gene expression. Mutations in the EZH2 gene have been associated with several syndromes, including:\n\n1. Wolf-Hirschhorn syndrome: This is a genetic disorder that is caused by a deletion on chromosome 4, which includes the EZH2 gene. The syndrome is characterized by intellectual disability, developmental delays, and abnormal facial features.\n2. DICER1 syndrome: This is a rare genetic disorder that is caused by mutations in the DICER1 gene, which is located on chromosome 7. DICER1 syndrome is characterized by a wide range of symptoms, including hearing loss, developmental delays, and abnormal facial features.\n3. Beckwith-Wiedemann syndrome: This is a genetic disorder that is caused by mutations in the IGF2 gene, which is located on chromosome 11. Beckwith-Wiedemann syndrome is characterized by macroglossia (enlarged tongue), macrocephaly (large head), and an increased risk of developing tumors, including Wilms' tumor and hepatoblastoma.\n4. PTEN hamartoma tumor syndrome: This is a genetic disorder that is caused by mutations in the PTEN gene, which is located on chromosome 10. PTEN hamartoma tumor syndrome is characterized by the development of benign tumors in various parts of the body, including the brain, kidneys, and skin. The syndrome is also associated with intellectual disability, developmental delays, and abnormal facial features.\n\nIn summary, mutations in the EZH2 gene have been associated with several syndromes, including Wolf-Hirschhorn syndrome, DICER1 syndrome, Beckwith-Wiedemann syndrome, and PTEN hamartoma tumor syndrome. These syndromes are characterized by a wide range of symptoms and are caused by mutations in different genes.",
    "llama-7b_fact_raw": "1. Wolf-Hirschhorn syndrome is associated with a deletion on chromosome 4, which includes the EZH2 gene.\n2. Mutations in the EZH2 gene are associated with several syndromes.\n3. Beckwith-Wiedemann syndrome is characterized by an enlarged tongue, large head, and an increased risk of developing tumors.\n4. The EZH2 gene is involved in the regulation of gene expression.\n5. PTEN hamartoma tumor syndrome is caused by mutations in the PTEN gene and is characterized by the development of benign tumors in various parts of the body.",
    "llama-7b_fact": [
      "Wolf-Hirschhorn syndrome is associated with a deletion on chromosome 4, which includes the EZH2 gene.",
      "Mutations in the EZH2 gene are associated with several syndromes.",
      "Beckwith-Wiedemann syndrome is characterized by an enlarged tongue, large head, and an increased risk of developing tumors.",
      "The EZH2 gene is involved in the regulation of gene expression.",
      "PTEN hamartoma tumor syndrome is caused by mutations in the PTEN gene and is characterized by the development of benign tumors in various parts of the body."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. These proteins are characterized by having multiple copies of the same protein molecule come together to form a larger, more complex structure. Some examples of proteins that undergo this transition include:\n\n1. Hemoglobin: Hemoglobin is a protein found in red blood cells that carries oxygen throughout the body. It is a tetramer made up of two alpha and two beta subunits.\n2. Myoglobin: Myoglobin is a protein found in muscle cells that helps to store and transport oxygen. It is a dimer made up of two alpha subunits.\n3. Cytochrome C: Cytochrome C is a protein found in the mitochondria of cells that plays a role in cellular respiration. It is a tetramer made up of two alpha and two beta subunits.\n4. Ferritin: Ferritin is a protein found in cells that helps to store iron. It is a tetramer made up of four identical subunits.\n5. Ceruloplasmin: Ceruloplasmin is a protein found in the blood that helps to transport iron throughout the body. It is a tetramer made up of two alpha and two beta subunits.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. The dimer-to-tetramer transition is a common structural feature of many proteins and plays an important role in their function.",
    "llama-7b_fact_raw": "1. Hemoglobin in red blood cells is a protein that undergoes a dimer-to-tetramer transition and is composed of two alpha and two beta subunits.\n2. Myoglobin in muscle cells is known to be a dimer consisting of two alpha subunits.\n3. Cytochrome C, which aids cellular respiration in mitochondria, is described as a tetramer with two alpha and two beta subunits.\n4. Ferritin, involved in iron storage within cells, forms a tetramer composed of four identical subunits.\n5. Ceruloplasmin, a blood protein involved in iron transport, undergoes a transition to a tetramer, made up of two alpha and two beta subunits.",
    "llama-7b_fact": [
      "Hemoglobin in red blood cells is a protein that undergoes a dimer-to-tetramer transition and is composed of two alpha and two beta subunits.",
      "Myoglobin in muscle cells is known to be a dimer consisting of two alpha subunits.",
      "Cytochrome C, which aids cellular respiration in mitochondria, is described as a tetramer with two alpha and two beta subunits.",
      "Ferritin, involved in iron storage within cells, forms a tetramer composed of four identical subunits.",
      "Ceruloplasmin, a blood protein involved in iron transport, undergoes a transition to a tetramer, made up of two alpha and two beta subunits."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin in red blood cells is a protein that is composed of two alpha and two beta subunits but it does not undergo a dimer-to-tetramer transition; it exists as a tetramer.\n2. FALSE [correction]: Myoglobin in muscle cells is known to be a monomer, not a dimer, consisting of a single polypeptide chain.\n3. FALSE [correction]: Cytochrome C is not a tetramer but rather a small heme protein found loosely associated with the inner membrane of the mitochondria, and it is a monomer.\n4. FALSE [correction]: Ferritin forms a hollow spherical structure and can be composed of 24 subunits of two types (heavy and light polypeptides), not a tetramer of identical subunits.\n5. FALSE [correction]: Ceruloplasmin is a single protein that contains multiple copper atoms; it does not undergo a transition to a tetramer made up of two alpha and two beta subunits. It is a glycoprotein with a single polypeptide chain.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "Phospholamban (PLN) is a protein that plays a crucial role in the regulation of cardiovascular function. It has been found to interact with a number of other proteins, including the anti-apoptotic protein Bcl-xL.\n\nBcl-xL is a member of the Bcl-2 family of proteins, which are involved in the regulation of programmed cell death (apoptosis). Bcl-xL is an anti-apoptotic protein, which means that it helps to prevent cells from undergoing programmed cell death. It does this by binding to and inhibiting the activity of pro-apoptotic proteins, such as Bax and Bak.\n\nStudies have shown that PLN and Bcl-xL interact with each other and that this interaction is important for the regulation of cardiovascular function. For example, it has been shown that the interaction between PLN and Bcl-xL is important for the maintenance of cardiac contractility and for the prevention of cardiac remodeling following myocardial infarction.\n\nIn summary, the anti-apoptotic protein Bcl-xL has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein that helps to prevent cells from undergoing programmed cell death. The interaction between PLN and Bcl-xL is important for the regulation of cardiovascular function.",
    "llama-7b_fact_raw": "1. Phospholamban (PLN) is a protein that regulates cardiovascular function.\n2. Bcl-xL is an anti-apoptotic protein that interacts with PLN.\n3. Bcl-xL is a member of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis.\n4. Bcl-xL prevents cell death by inhibiting the activity of pro-apoptotic proteins such as Bax and Bak.\n5. The interaction between PLN and Bcl-xL is significant for maintaining cardiac contractility and preventing cardiac remodeling after a myocardial infarction.",
    "llama-7b_fact": [
      "Phospholamban (PLN) is a protein that regulates cardiovascular function.",
      "Bcl-xL is an anti-apoptotic protein that interacts with PLN.",
      "Bcl-xL is a member of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis.",
      "Bcl-xL prevents cell death by inhibiting the activity of pro-apoptotic proteins such as Bax and Bak.",
      "The interaction between PLN and Bcl-xL is significant for maintaining cardiac contractility and preventing cardiac remodeling after a myocardial infarction."
    ],
    "llama-7b_judge_raw": "1. TRUE: Phospholamban (PLN) is indeed a protein that regulates the calcium pump in cardiac muscle, which is essential for cardiovascular function.\n2. UNKNOWN: There is limited information to verify the direct interaction between Bcl-xL and PLN without access to specific scientific studies or data that support this interaction.\n3. TRUE: Bcl-xL is a member of the Bcl-2 protein family, which plays a crucial role in the regulation of apoptosis.\n4. TRUE: Bcl-xL does indeed prevent cell death by inhibiting the activity of pro-apoptotic proteins such as Bax and Bak.\n5. UNKNOWN: Without specific scientific evidence, it is difficult to determine whether the interaction between PLN and Bcl-xL is significant for maintaining cardiac contractility and preventing cardiac remodeling after a myocardial infarction.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. Several studies have found that vitamin D supplementation can reduce the risk of falls in older adults, particularly those who are deficient in vitamin D.\n\nFor example, a meta-analysis of 25 randomized controlled trials found that vitamin D supplementation significantly reduced the risk of falls in older adults by 19%. Another study found that vitamin D supplementation reduced the risk of falls by 22% in older adults who were deficient in vitamin D.\n\nThese findings suggest that maintaining adequate levels of vitamin D through diet or supplementation may be an important strategy for preventing falls in older adults. However, it is worth noting that more research is needed to fully understand the relationship between vitamin D and falls in older adults, and the optimal dosage and form of vitamin D supplementation for fall prevention.",
    "llama-7b_fact_raw": "1. Vitamin D supplementation has been associated with a reduction in the incidence of falls in older adults, according to several studies.\n2. A meta-analysis of 25 randomized controlled trials indicated that vitamin D supplementation led to a significant 19% reduction in the risk of falls among older adults.\n3. Vitamin D supplementation was found to reduce the risk of falls by 22% in older adults who were deficient in the vitamin, as per one study.\n4. Adequate levels of vitamin D may be an important preventive measure against falls in the older population.\n5. Further research is needed to fully understand how vitamin D relates to fall prevention in older adults and to determine the optimal dosage and form for supplementation.",
    "llama-7b_fact": [
      "Vitamin D supplementation has been associated with a reduction in the incidence of falls in older adults, according to several studies.",
      "A meta-analysis of 25 randomized controlled trials indicated that vitamin D supplementation led to a significant 19% reduction in the risk of falls among older adults.",
      "Vitamin D supplementation was found to reduce the risk of falls by 22% in older adults who were deficient in the vitamin, as per one study.",
      "Adequate levels of vitamin D may be an important preventive measure against falls in the older population.",
      "Further research is needed to fully understand how vitamin D relates to fall prevention in older adults and to determine the optimal dosage and form for supplementation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE (Assuming the statement is accurately reflective of a specific meta-analysis; in reality, such precise figures should be verified with the source.)\n3. TRUE (Again, this is assuming the statement reflects findings from an actual study; the exact percentage should be verified with the source.)\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "There is some evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells.\n\nmiR-155 is a microRNA that has been implicated in the regulation of Th17 cell differentiation and function. It has been shown to negatively regulate the expression of genes involved in Th17 cell differentiation, including the transcription factor RORgt, which is a key regulator of Th17 cell differentiation. miR-155 has also been shown to negatively regulate the expression of genes involved in the production of IL-17, a key cytokine produced by Th17 cells.\n\nJarid2, on the other hand, is a non-coding RNA that has been shown to play a role in the regulation of gene expression at the level of transcription. It has been shown to negatively regulate the expression of genes involved in Th17 cell differentiation and function, including the transcription factor RORgt. Jarid2 has also been shown to negatively regulate the expression of genes involved in the production of IL-17 in Th17 cells.\n\nWhile there is some evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells, the exact mechanism by which they interact is not fully understood. It is possible that Jarid2 and miR-155 may work together to negatively regulate the expression of genes involved in Th17 cell differentiation and function. Alternatively, they may act independently of each other to regulate gene expression in Th17 cells. Further research is needed to fully understand the relationship between Jarid2 and miR-155 in the regulation of Th17 cells.",
    "llama-7b_fact_raw": "1. miR-155 negatively regulates the expression of genes important for Th17 cell differentiation.\n2. The transcription factor RORgt, crucial for Th17 cell differentiation, is negatively regulated by miR-155.\n3. miR-155 negatively affects the expression of genes involved in the production of IL-17 by Th17 cells.\n4. Jarid2 negatively regulates the expression of genes linked to Th17 cell differentiation and function.\n5. Both miR-155 and Jarid2 negatively impact the expression of the transcription factor RORgt and genes related to IL-17 production in Th17 cells.",
    "llama-7b_fact": [
      "miR-155 negatively regulates the expression of genes important for Th17 cell differentiation.",
      "The transcription factor RORgt, crucial for Th17 cell differentiation, is negatively regulated by miR-155.",
      "miR-155 negatively affects the expression of genes involved in the production of IL-17 by Th17 cells.",
      "Jarid2 negatively regulates the expression of genes linked to Th17 cell differentiation and function.",
      "Both miR-155 and Jarid2 negatively impact the expression of the transcription factor RORgt and genes related to IL-17 production in Th17 cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The transcription factor RORγt, crucial for Th17 cell differentiation, is not negatively regulated by miR-155. RORγt is a positive regulator of Th17 cell differentiation and miR-155 generally promotes Th17 cell differentiation by targeting negative regulators of the process.\n3. FALSE [correction]: miR-155 generally promotes Th17 cell differentiation and function, so it would not be expected to negatively affect the expression of genes involved in the production of IL-17 by Th17 cells.\n4. TRUE\n5. FALSE [correction]: miR-155 actually has a positive impact on the expression of RORγt as it targets inhibitors of the Th17 cell differentiation pathway, whereas Jarid2 negatively regulates the expression of genes linked to Th17 cell differentiation and function.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 11 genes.",
    "llama-7b_fact_raw": "1. The human HOXD cluster is composed of 11 genes.",
    "llama-7b_fact": [
      "The human HOXD cluster is composed of 11 genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster is composed of 9 genes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "Casein Kinase 1 (CK1) is an enzyme that catalyzes the transfer of the phosphate group from ATP to a target protein, resulting in phosphorylation. There are several different consensus motifs for CK1 phosphorylation sites, which are based on the amino acid sequence of the target protein and the specific residues that are most likely to be phosphorylated by CK1. Here are a few examples of CK1 phosphorylation consensus motifs:\n\n1. S/T-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-",
    "llama-7b_fact_raw": "1. Casein Kinase 1 (CK1) catalyzes the transfer of a phosphate group from ATP to a target protein.\n2. Phosphorylation by CK1 involves specific consensus motifs based on the amino acid sequence of the target protein.\n3. The consensus motif for CK1 typically starts with a serine (S) or threonine (T).\n4. The consensus motif mentioned for CK1 includes a sequence with numerous unspecified amino acids, represented by the letter 'x'.\n5. The sequence provided in the answer for the consensus motif contains at least fifty unspecified amino acids following an initial serine (S) or threonine (T).",
    "llama-7b_fact": [
      "Casein Kinase 1 (CK1) catalyzes the transfer of a phosphate group from ATP to a target protein.",
      "Phosphorylation by CK1 involves specific consensus motifs based on the amino acid sequence of the target protein.",
      "The consensus motif for CK1 typically starts with a serine (S) or threonine (T).",
      "The consensus motif mentioned for CK1 includes a sequence with numerous unspecified amino acids, represented by the letter 'x'.",
      "The sequence provided in the answer for the consensus motif contains at least fifty unspecified amino acids following an initial serine (S) or threonine (T)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The consensus motif for CK1 does not necessarily contain at least fifty unspecified amino acids following an initial serine (S) or threonine (T); it typically has a few unspecified amino acids (often denoted as 'x'), but the exact number can vary and is usually not as high as fifty.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of aspartate and other amino acids. The gene is located on the long (q) arm of chromosome 12 at position 12q24.3.\n\nThere are several different transcript variants of the ASPH gene, which can result from alternative splicing of the gene's pre-mRNA. These transcript variants can encode different isoforms of the aspartate beta-hydroxylase enzyme, which may have different functions or substrate specificities.\n\nSome of the different isoforms of aspartate beta-hydroxylase encoded by the ASPH gene include:\n\n1. Aspartate beta-hydroxylase 1 (ASPH1): This isoform is primarily expressed in the liver and kidneys, and is involved in the metabolism of aspartate and other amino acids.\n2. Aspartate beta-hydroxylase 2 (ASPH2): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n3. Aspartate beta-hydroxylase 3 (ASPH3): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n4. Aspartate beta-hydroxylase 4 (ASPH4): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n5. Aspartate beta-hydroxylase 5 (ASPH5): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n6. Aspartate beta-hydroxylase 6 (ASPH6): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n7. Aspartate beta-h",
    "llama-7b_fact_raw": "1. The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.\n2. The ASPH gene is located on the long (q) arm of chromosome 12 at position 12q24.3.\n3. Alternative splicing of the ASPH gene's pre-mRNA results in different transcript variants.\n4. These transcript variants can encode different isoforms of the aspartate beta-hydroxylase enzyme.\n5. Isoforms such as ASPH1, ASPH2, and ASPH3 are involved in the metabolism of aspartate and other amino acids and have varying expressions in different organs like the liver, kidneys, brain, and testes.",
    "llama-7b_fact": [
      "The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.",
      "The ASPH gene is located on the long (q) arm of chromosome 12 at position 12q24.3.",
      "Alternative splicing of the ASPH gene's pre-mRNA results in different transcript variants.",
      "These transcript variants can encode different isoforms of the aspartate beta-hydroxylase enzyme.",
      "Isoforms such as ASPH1, ASPH2, and ASPH3 are involved in the metabolism of aspartate and other amino acids and have varying expressions in different organs like the liver, kidneys, brain, and testes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While it is true that alternative splicing can result in different enzyme isoforms with varying expression in different tissues, there is no standardized naming convention such as \"ASPH1,\" \"ASPH2,\" and \"ASPH3\" for the isoforms of aspartate beta-hydroxylase encoded by the ASPH gene. Instead, any isoforms would be identified by specific names or descriptors relating to their structure or function. The mention of specific isoforms involved in the metabolism of aspartate and other amino acids and their expression in various organs is speculative without supporting references.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "Empagliflozin, also known by the brand name Jardiance, was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014, for the treatment of adults with type 2 diabetes. Empagliflozin is a medication that is used in combination with diet and exercise to improve glycemic control in patients with type 2 diabetes. It works by helping the body to excrete excess glucose through the urine. Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.",
    "llama-7b_fact_raw": "1. Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014.\n2. The approval was specific to the treatment of adults with type 2 diabetes.\n3. Empagliflozin is used in combination with diet and exercise to improve glycemic control.\n4. The medication works by helping the body excrete excess glucose through the urine.\n5. Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.",
    "llama-7b_fact": [
      "Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014.",
      "The approval was specific to the treatment of adults with type 2 diabetes.",
      "Empagliflozin is used in combination with diet and exercise to improve glycemic control.",
      "The medication works by helping the body excrete excess glucose through the urine.",
      "Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) on August 1, 2014.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Lon1 is a protein that plays an important role in the regulation of protein homeostasis in various organisms, including plants. In the plant Arabidopsis, loss of the Lon1 protein has been shown to result in various changes in the plant's growth and development.\n\nOne of the most notable effects of Lon1 loss in Arabidopsis is an increase in the accumulation of misfolded and damaged proteins in the endoplasmic reticulum (ER) of the plant cells. This accumulation of misfolded proteins can lead to the formation of protein aggregates, which can disrupt the normal functioning of the ER and cause cellular stress. As a result, the plant cells may undergo programmed cell death, leading to the death of the plant tissue.\n\nAnother effect of Lon1 loss in Arabidopsis is an alteration in the expression of various genes involved in the plant's response to stress. For example, Lon1 loss has been shown to increase the expression of genes involved in the plant's defense response, such as those encoding for reactive oxygen species (ROS) scavenging enzymes and antioxidant proteins. This increase in defense gene expression may help the plant to cope with the increased cellular stress caused by the accumulation of misfolded proteins.\n\nAdditionally, Lon1 loss in Arabidopsis has been shown to affect the plant's growth and development. For example, Lon1 loss has been shown to result in reduced plant height, reduced leaf size, and delayed flowering. These effects may be due to the altered expression of genes involved in plant growth and development, as well as the increased cellular stress caused by the accumulation of misfolded proteins.\n\nOverall, the loss of the protein Lon1 in the plant Arabidopsis results in changes in the plant's growth and development, as well as an increase in the accumulation of misfolded proteins in the ER and an alteration in the expression of genes involved in the plant's response to stress.",
    "llama-7b_fact_raw": "1. Lon1 is a protein that regulates protein homeostasis in various organisms, including the plant Arabidopsis.\n2. Loss of the Lon1 protein in Arabidopsis leads to increased accumulation of misfolded and damaged proteins in the endoplasmic reticulum.\n3. Accumulation of misfolded proteins in Arabidopsis due to Lon1 loss can lead to protein aggregates and cellular stress, resulting in programmed cell death.\n4. Arabidopsis plants without Lon1 protein show increased expression of genes involved in defense response, such as those for ROS scavenging enzymes and antioxidant proteins.\n5. Arabidopsis plants deficient in Lon1 protein exhibit reduced plant height, reduced leaf size, and delayed flowering.",
    "llama-7b_fact": [
      "Lon1 is a protein that regulates protein homeostasis in various organisms, including the plant Arabidopsis.",
      "Loss of the Lon1 protein in Arabidopsis leads to increased accumulation of misfolded and damaged proteins in the endoplasmic reticulum.",
      "Accumulation of misfolded proteins in Arabidopsis due to Lon1 loss can lead to protein aggregates and cellular stress, resulting in programmed cell death.",
      "Arabidopsis plants without Lon1 protein show increased expression of genes involved in defense response, such as those for ROS scavenging enzymes and antioxidant proteins.",
      "Arabidopsis plants deficient in Lon1 protein exhibit reduced plant height, reduced leaf size, and delayed flowering."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Loss of the Lon1 protein in Arabidopsis does not lead to increased accumulation of misfolded and damaged proteins in the endoplasmic reticulum, but rather affects mitochondria where Lon1 is located and involved in the degradation of misfolded proteins.\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nNote: The specific effects of the Lon1 protein deficiency on plant morphology such as height, leaf size, and flowering time can vary depending on the study and the context in which the gene is being analyzed, and without specific information detailing these effects, the statement's accuracy can't be determined.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome. Linker histones are a type of histone protein that helps to package DNA into nucleosomes, which are the basic units of chromatin. In yeast, there are three types of linker histones: H1a, H1b, and H1c. These histones are involved in the regulation of gene expression and play a role in the formation of higher-order chromatin structures.",
    "llama-7b_fact_raw": "1. Linker histones are present in the yeast genome.\n2. Linker histones help package DNA into nucleosomes, which are the basic units of chromatin.\n3. In yeast, the types of linker histones include H1a, H1b, and H1c.\n4. Linker histones in yeast are involved in the regulation of gene expression.\n5. Linker histones play a role in the formation of higher-order chromatin structures.",
    "llama-7b_fact": [
      "Linker histones are present in the yeast genome.",
      "Linker histones help package DNA into nucleosomes, which are the basic units of chromatin.",
      "In yeast, the types of linker histones include H1a, H1b, and H1c.",
      "Linker histones in yeast are involved in the regulation of gene expression.",
      "Linker histones play a role in the formation of higher-order chromatin structures."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Linker histones are generally not present in the yeast genome. Saccharomyces cerevisiae, the most extensively studied yeast, does not have canonical H1 linker histones.\n2. TRUE\n3. FALSE [correction]: Yeast, such as Saccharomyces cerevisiae, do not have the types of linker histones listed (H1a, H1b, H1c). These names resemble variants that might be found in multicellular eukaryotes, not in yeast.\n4. UNKNOWN: Since Saccharomyces cerevisiae does not have canonical H1 linker histones, we cannot definitively say that linker histones in yeast are involved in gene regulation. If speaking of other less-studied yeast species possibly having analogous proteins, more information would be required for a true evaluation.\n5. TRUE: Although yeast does not have canonical H1 linker histones, the general role of linker histones in eukaryotes includes playing a role in the formation of higher-order chromatin structures. If there were analogous proteins in yeast serving a similar function, they could potentially play a role in chromatin architecture.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "There is limited evidence to support the claim that tomato juice can lower cholesterol levels. While tomatoes are a rich source of lycopene, a phytochemical that has been shown to have potential cholesterol-lowering properties, the amount of lycopene found in tomato juice is not sufficient to have a significant impact on cholesterol levels.\n\nA study published in the Journal of the American College of Nutrition in 2009 found that consuming tomato juice daily for four weeks did not significantly reduce cholesterol levels in healthy adults. The study suggested that other factors, such as the type and amount of fat in the diet, may play a more significant role in regulating cholesterol levels than the lycopene content of tomato products.\n\nAnother study published in the Journal of Nutrition in 2012 found that supplementing with lycopene did not significantly reduce cholesterol levels in overweight or obese adults.\n\nWhile tomato juice may have other health benefits, such as its high vitamin C and potassium content, there is currently insufficient evidence to support the claim that it can lower cholesterol levels. It is always best to consult with a healthcare professional before making dietary changes to manage cholesterol levels.",
    "llama-7b_fact_raw": "1. Tomatoes are rich in lycopene, which has potential cholesterol-lowering properties.\n2. A study published in 2009 by the Journal of the American College of Nutrition did not find a significant reduction in cholesterol levels after daily consumption of tomato juice for four weeks in healthy adults.\n3. The 2009 study concluded that the type and amount of fat in the diet may be more influential in regulating cholesterol levels than the lycopene content in tomato products.\n4. A 2012 study published in the Journal of Nutrition found that lycopene supplementation did not significantly reduce cholesterol levels in overweight or obese adults.\n5. Tomato juice is high in vitamin C and potassium.",
    "llama-7b_fact": [
      "Tomatoes are rich in lycopene, which has potential cholesterol-lowering properties.",
      "A study published in 2009 by the Journal of the American College of Nutrition did not find a significant reduction in cholesterol levels after daily consumption of tomato juice for four weeks in healthy adults.",
      "The 2009 study concluded that the type and amount of fat in the diet may be more influential in regulating cholesterol levels than the lycopene content in tomato products.",
      "A 2012 study published in the Journal of Nutrition found that lycopene supplementation did not significantly reduce cholesterol levels in overweight or obese adults.",
      "Tomato juice is high in vitamin C and potassium."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are two types of heat shock proteins (HSPs) that play important roles in protecting cells from stress and maintaining cellular homeostasis. One of the functions of Hsp70 and Hsp110 is to regulate the stability of messenger RNA (mRNA).\n\nmRNA stability refers to the length of time that an mRNA molecule remains intact and functional within a cell. In general, mRNAs have a relatively short half-life, which means that they are degraded quickly by enzymes such as ribonuclease (RNase).\n\nHsp70 and Hsp110 can affect mRNA stability in several ways:\n\n1. Chaperone activity: Hsp70 and Hsp110 can bind to and stabilize mRNAs by acting as chaperones. They help to protect mRNAs from degradation by RNase and other enzymes, allowing them to remain intact and functional for longer periods of time.\n2. mRNA translation: Hsp70 and Hsp110 can also affect mRNA stability by regulating the translation of mRNAs. For example, they can bind to and inhibit the activity of eukaryotic initiation factor 4E (eIF4E), which is an important regulator of mRNA translation. By inhibiting eIF4E, Hsp70 and Hsp110 can reduce the rate of mRNA translation and prolong the half-life of mRNAs.\n3. mRNA decay: Hsp70 and Hsp110 can also participate in the process of mRNA decay, which is the breakdown of mRNAs by enzymes such as RNase. By binding to and inhibiting the activity of these enzymes, Hsp70 and Hsp110 can slow down the rate of mRNA decay and extend the half-life of mRNAs.\n\nIn summary, Hsp70 and Hsp110 can affect mRNA stability by acting as chaperones, regulating mRNA translation, and participating in the process of mRNA decay. These functions help to protect mRNAs from degradation",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are types of heat shock proteins that help in protecting cells from stress and in maintaining cellular homeostasis.\n2. Hsp70 and Hsp110 can regulate the stability of messenger RNA (mRNA) in cells.\n3. Hsp70 and Hsp110 can act as chaperones to bind and stabilize mRNAs, protecting them from degradation by enzymes like ribonuclease (RNase).\n4. These proteins can affect mRNA stability by regulating the translation of mRNAs, including inhibiting the activity of eukaryotic initiation factor 4E (eIF4E).\n5. Hsp70 and Hsp110 can participate in the process of mRNA decay by inhibiting the activity of enzymes involved in mRNA breakdown, which can slow down mRNA decay rates and extend mRNA half-life.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are types of heat shock proteins that help in protecting cells from stress and in maintaining cellular homeostasis.",
      "Hsp70 and Hsp110 can regulate the stability of messenger RNA (mRNA) in cells.",
      "Hsp70 and Hsp110 can act as chaperones to bind and stabilize mRNAs, protecting them from degradation by enzymes like ribonuclease (RNase).",
      "These proteins can affect mRNA stability by regulating the translation of mRNAs, including inhibiting the activity of eukaryotic initiation factor 4E (eIF4E).",
      "Hsp70 and Hsp110 can participate in the process of mRNA decay by inhibiting the activity of enzymes involved in mRNA breakdown, which can slow down mRNA decay rates and extend mRNA half-life."
    ],
    "llama-7b_judge_raw": "1. TRUE: Hsp70 and Hsp110 are indeed types of heat shock proteins that play a role in protecting cells from stress and helping to maintain cellular homeostasis.\n2. UNKNOWN: While Hsp70 and Hsp110 are known for their role in protein folding and stress response, the direct regulation of messenger RNA (mRNA) stability by these specific proteins is not universally established and may depend on the cellular context or additional factors.\n3. UNKNOWN: Hsp70 and similar proteins can act as molecular chaperones, however, their specific interaction with mRNAs for stabilization is less well-defined in the literature compared to their recognized role in protein folding and preventing protein aggregation. The statement may be true in certain contexts, but without specific evidence referenced, it's difficult to verify.\n4. UNKNOWN: While eukaryotic initiation factor 4E (eIF4E) is involved in the initiation of translation, and certain regulatory proteins can influence its activity, it is unclear from the statement provided if Hsp70 and Hsp110 directly regulate eIF4E or translation of mRNAs. The specific interaction with translation machinery can vary based on context and experimental conditions, so the statement requires more detailed evidence.\n5. UNKNOWN: The role of Hsp70 and Hsp110 in mRNA decay is not commonly highlighted. These proteins are generally known for their role in protein metabolism, not directly in mRNA decay mechanisms. Some heat shock proteins have been implicated in RNA-related processes, but claiming a specific inhibitory action on mRNA decay enzymes by Hsp70 and Hsp110 is not widely recognized without more specific evidence.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that convert one type of thyroid hormone into another. There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).\n\nSkeletal muscle contains all three types of deiodinases. D1 is the most abundant type of deiodinase in skeletal muscle and is responsible for converting T4 to the active form of thyroid hormone, T3. D2 is also present in skeletal muscle and is responsible for converting T4 to the less active form of thyroid hormone, T2. D3 is the least abundant type of deiodinase in skeletal muscle and is responsible for converting T3 to the inactive form of thyroid hormone, rT3.\n\nIt is worth noting that the activity of these deiodinases can be regulated by a variety of factors, including thyroid hormone levels, nutrition, and exercise. For example, exercise can increase the activity of D1 and D2 in skeletal muscle, leading to an increase in T3 levels and improved muscle function.",
    "llama-7b_fact_raw": "1. There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).\n2. Skeletal muscle contains all three types of deiodinases: D1, D2, and D3.\n3. D1 is the most abundant type of deiodinase in skeletal muscle and converts T4 to T3, the active form of thyroid hormone.\n4. D2 is responsible for converting T4 to T2, which is a less active form of thyroid hormone, in skeletal muscle.\n5. D3 is the least abundant type of deiodinase in skeletal muscle and converts T3 to rT3, an inactive form of thyroid hormone.",
    "llama-7b_fact": [
      "There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).",
      "Skeletal muscle contains all three types of deiodinases: D1, D2, and D3.",
      "D1 is the most abundant type of deiodinase in skeletal muscle and converts T4 to T3, the active form of thyroid hormone.",
      "D2 is responsible for converting T4 to T2, which is a less active form of thyroid hormone, in skeletal muscle.",
      "D3 is the least abundant type of deiodinase in skeletal muscle and converts T3 to rT3, an inactive form of thyroid hormone."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: D2 is the most abundant type of deiodinase in skeletal muscle and converts T4 to T3, the active form of thyroid hormone.\n4. FALSE [correction]: D2 is responsible for converting T4 to T3, not T2. It is D1 that has some role in converting T4 to T2.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the Aurora B kinase and the Polycomb protein Ring1B.\n\nAurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of mitotic spindles and the separation of chromosomes during cell division. Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.\n\nStudies have shown that Aurora B and Ring1B interact with each other and that this interaction is important for the regulation of mitosis. Specifically, Aurora B phosphorylates Ring1B at multiple sites, which leads to the degradation of Ring1B and the repression of target genes. Conversely, the degradation of Ring1B leads to the activation of target genes, including those involved in the regulation of mitosis.\n\nFurthermore, studies have shown that the interaction between Aurora B and Ring1B is important for the regulation of cell proliferation and the development of cancer. For example, overexpression of Aurora B and Ring1B has been observed in various types of cancer, and these proteins have been implicated in the development of resistance to chemotherapy in cancer cells.\n\nIn summary, there is a clear link between Aurora B and Ring1B, and this link is important for the regulation of mitosis and the control of gene expression. Dysregulation of this interaction has been implicated in the development of cancer and other diseases.",
    "llama-7b_fact_raw": "1. Aurora B kinase is a serine/threonine kinase involved in mitosis regulation.\n2. Ring1B is a member of the Polycomb family of proteins, which regulate gene expression.\n3. Aurora B kinase phosphorylates Ring1B at multiple sites, influencing Ring1B's degradation and gene repression.\n4. An interaction between Aurora B kinase and Ring1B influences cell proliferation and cancer development.\n5. Overexpression of Aurora B kinase and Ring1B has been linked to various types of cancer and chemotherapy resistance.",
    "llama-7b_fact": [
      "Aurora B kinase is a serine/threonine kinase involved in mitosis regulation.",
      "Ring1B is a member of the Polycomb family of proteins, which regulate gene expression.",
      "Aurora B kinase phosphorylates Ring1B at multiple sites, influencing Ring1B's degradation and gene repression.",
      "An interaction between Aurora B kinase and Ring1B influences cell proliferation and cancer development.",
      "Overexpression of Aurora B kinase and Ring1B has been linked to various types of cancer and chemotherapy resistance."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN - The specific relationship between Aurora B kinase and Ring1B involving phosphorylation and influence on degradation and gene repression would need to be supported by specific scientific literature or data, which are not provided here.\n4. TRUE - Interactions between proteins like Aurora B kinase and members of the Polycomb family (such as Ring1B) can influence cell proliferation and cancer development as they play significant roles in regulating cell division and gene expression.\n5. TRUE - Overexpression of proteins involved in cell cycle regulation, such as Aurora B kinase, and those involved in gene expression, such as Ring1B, has been widely linked to cancer progression and the development of resistance to chemotherapy in various studies.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates include:\n\n1. GT-AG motif at the donor splice site: This is the canonical splice site motif and is recognized by the spliceosome.\n2. AT-AC motif at the acceptor splice site: This motif is also recognized by the spliceosome and plays a role in regulating alternative splicing.\n3. GU-AG motif at the donor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n4. UG-AG motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n5. CU-AG motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n6. GU-UA motif at the donor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n7. UG-UA motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n8. CU-UA motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n\nThese non-canonical motifs can affect splicing efficiency and may play a role in regulating alternative splicing events.",
    "llama-7b_fact_raw": "1. The GT-AG motif at the donor splice site is the canonical splice site motif recognized by the spliceosome.\n2. The AT-AC motif at the acceptor splice site is recognized by the spliceosome and is involved in alternative splicing regulation.\n3. The GU-AG motif at the donor splice site is recognized by the spliceosome and found in species including humans.\n4. The UG-AG motif at the acceptor splice site is recognized by the spliceosome and found in species including humans.\n5. Non-canonical motifs such as CU-AG, GU-UA, UG-UA, and CU-UA at splice sites are found in some species including humans and are recognized by the spliceosome.",
    "llama-7b_fact": [
      "The GT-AG motif at the donor splice site is the canonical splice site motif recognized by the spliceosome.",
      "The AT-AC motif at the acceptor splice site is recognized by the spliceosome and is involved in alternative splicing regulation.",
      "The GU-AG motif at the donor splice site is recognized by the spliceosome and found in species including humans.",
      "The UG-AG motif at the acceptor splice site is recognized by the spliceosome and found in species including humans.",
      "Non-canonical motifs such as CU-AG, GU-UA, UG-UA, and CU-UA at splice sites are found in some species including humans and are recognized by the spliceosome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The AT-AC motif is not typically at the acceptor splice site; instead, it defines a rare class of introns (called AT-AC introns) that have distinct splice site consensus sequences. The canonical acceptor splice site motif is commonly rich in pyrimidines and ends with AG just before the exon.\n3. TRUE\n4. FALSE [correction]: The common motif at the acceptor splice site is not UG-AG; it is generally a pyrimidine-rich tract followed by an AG dinucleotide at the end of an intron, right before the exon starts.\n5. FALSE [correction]: While non-canonical motifs can exist, the examples given such as CU-AG, GU-UA, UG-UA, and CU-UA are not standard splice site motifs recognized by the spliceosome in humans. Non-canonical splice sites do exist but are much less common and typically not represented by these sequences.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "The acetylation of S6K1 (S6 kinase 1) is a post-translational modification that is regulated by a variety of signaling pathways. One event that can result in the acetylation of S6K1 is the activation of the mammalian target of rapamycin (mTOR) pathway.\n\nThe mTOR pathway is a key regulator of cell growth and metabolism, and it is activated in response to a variety of stimuli, including growth factors, nutrients, and energy. When the mTOR pathway is activated, it leads to the phosphorylation and activation of S6K1, which in turn stimulates the translation of a number of key cellular proteins, including ribosomal proteins.\n\nThe acetylation of S6K1 is thought to play a role in the regulation of its activity and stability. Acetylation of S6K1 can inhibit its activity by preventing its association with ribosomes, and it can also promote its degradation by the proteasome.\n\nTherefore, the activation of the mTOR pathway, which leads to the phosphorylation and activation of S6K1, is one event that can result in the acetylation of S6K1.",
    "llama-7b_fact_raw": "1. The acetylation of S6K1 is a post-translational modification.\n2. The mammalian target of rapamycin (mTOR) pathway activation can result in the acetylation of S6K1.\n3. The mTOR pathway is activated by stimuli such as growth factors, nutrients, and energy.\n4. Activation of the mTOR pathway leads to the phosphorylation and activation of S6K1.\n5. Acetylation of S6K1 can inhibit its activity and promote its degradation by the proteasome.",
    "llama-7b_fact": [
      "The acetylation of S6K1 is a post-translational modification.",
      "The mammalian target of rapamycin (mTOR) pathway activation can result in the acetylation of S6K1.",
      "The mTOR pathway is activated by stimuli such as growth factors, nutrients, and energy.",
      "Activation of the mTOR pathway leads to the phosphorylation and activation of S6K1.",
      "Acetylation of S6K1 can inhibit its activity and promote its degradation by the proteasome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Acetylation of S6K1 generally stabilizes the protein and may also regulate its activity, but it does not promote its degradation by the proteasome. Phosphorylation, on the other hand, can often be a signal for proteasomal degradation.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "Episodic ataxia type 6 is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene provides instructions for making a protein called the alpha-1A subunit of the voltage-gated calcium channel, which is responsible for regulating the flow of calcium ions into nerve cells.\n\nThe CACNA1A gene is located on the long (q) arm of chromosome 12. Mutations in this gene can lead to changes in the function of the alpha-1A subunit of the voltage-gated calcium channel, which can disrupt the normal communication between nerve cells in the brain and the rest of the body.\n\nEpisodic ataxia type 6 is characterized by recurrent episodes of ataxia, which is a lack of coordination in the muscles, especially in the arms and legs. These episodes can be triggered by a variety of stimuli, such as stress, exercise, or exposure to heat or cold. Other symptoms of episodic ataxia type 6 may include dizziness, vertigo, nausea, and vomiting.\n\nThe severity of the symptoms can vary greatly from person to person, and some individuals may only experience a few episodes in their lifetime, while others may have frequent and severe episodes. There is currently no cure for episodic ataxia type 6, but medications can be used to manage the symptoms and prevent episodes from occurring.",
    "llama-7b_fact_raw": "1. Episodic ataxia type 6 is a rare genetic disorder caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene is responsible for making a protein that forms part of a voltage-gated calcium channel.\n3. This gene is located on the long (q) arm of chromosome 12.\n4. Mutations in the CACNA1A gene affect the flow of calcium ions into nerve cells, disrupting normal communication between nerve cells in the brain and the rest of the body.\n5. Symptoms of episodic ataxia type 6 include recurrent episodes of ataxia, dizziness, vertigo, nausea, and vomiting.",
    "llama-7b_fact": [
      "Episodic ataxia type 6 is a rare genetic disorder caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene is responsible for making a protein that forms part of a voltage-gated calcium channel.",
      "This gene is located on the long (q) arm of chromosome 12.",
      "Mutations in the CACNA1A gene affect the flow of calcium ions into nerve cells, disrupting normal communication between nerve cells in the brain and the rest of the body.",
      "Symptoms of episodic ataxia type 6 include recurrent episodes of ataxia, dizziness, vertigo, nausea, and vomiting."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The CACNA1A gene is located on the short (p) arm of chromosome 19 at position 13.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play a role in regulating gene expression. They are found in many organisms, including animals. In animals, chromomethylases are typically found in the nucleus of cells and are involved in a variety of processes, including DNA replication, transcription, and repair. Some examples of animals that have been shown to have chromomethylases include humans, mice, and fruit flies.",
    "llama-7b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add methyl groups to DNA.\n3. These enzymes play a role in regulating gene expression.\n4. In animals, chromomethylases are generally located in the cell nucleus.\n5. Humans, mice, and fruit flies are examples of animals that possess chromomethylases.",
    "llama-7b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "These enzymes play a role in regulating gene expression.",
      "In animals, chromomethylases are generally located in the cell nucleus.",
      "Humans, mice, and fruit flies are examples of animals that possess chromomethylases."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are present in plant genomes, not animal genomes.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since chromomethylases are not present in animal genomes, the location of these enzymes within animals is not applicable.\n5. FALSE [correction]: Humans, mice, and fruit flies do not possess chromomethylases as these enzymes are typically found in plants.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Some of the most commonly used packages are:\n\n1. Chipster: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome.\n2. Bedtools: This package provides tools for working with bed files, which are used to store genomic data. It includes functions for sorting, filtering, and aligning bed files, as well as functions for visualizing the distribution of peaks across the genome.\n3. GenomicRanges: This package provides tools for working with genomic ranges, which are used to store genomic data. It includes functions for sorting, filtering, and aligning genomic ranges, as well as functions for visualizing the distribution of peaks across the genome.\n4. TopHat: This package provides tools for aligning RNA-seq data to a reference genome. It includes functions for detecting transcription start sites, splice junctions, and transcription factor binding sites.\n5. Cistrome: This package provides tools for the analysis of ChIP-seq data from chromatin immunoprecipitation experiments. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome.\n6. HOMER: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome. It also includes functions for modeling the binding sites of transcription factors and for predicting the binding sites of unknown transcription factors.\n7. RegulatoryGenomics: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome. It also includes functions for modeling the binding sites of transcription factors and for predicting the binding sites of unknown transcription factors.\n\nThese are just a few of the many packages available in R/Bioconductor for",
    "llama-7b_fact_raw": "1. Chipster is a package in R/Bioconductor designed for the analysis of ChIP-chip and ChIP-seq data.\n2. Bedtools is an R/Bioconductor package that includes tools for working with bed files for genomic data storage.\n3. GenomicRanges is a package in R/Bioconductor which provides tools for sorting, filtering, and aligning genomic ranges.\n4. The TopHat package in R/Bioconductor provides tools for aligning RNA-seq data to a reference genome with transcription factor binding sites detection capabilities.\n5. Cistrome is an R/Bioconductor package tailored for ChIP-seq data analysis from chromatin immunoprecipitation experiments.",
    "llama-7b_fact": [
      "Chipster is a package in R/Bioconductor designed for the analysis of ChIP-chip and ChIP-seq data.",
      "Bedtools is an R/Bioconductor package that includes tools for working with bed files for genomic data storage.",
      "GenomicRanges is a package in R/Bioconductor which provides tools for sorting, filtering, and aligning genomic ranges.",
      "The TopHat package in R/Bioconductor provides tools for aligning RNA-seq data to a reference genome with transcription factor binding sites detection capabilities.",
      "Cistrome is an R/Bioconductor package tailored for ChIP-seq data analysis from chromatin immunoprecipitation experiments."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Bedtools is not an R/Bioconductor package but a set of command-line tools for genomic data manipulation, not limited to working with bed files.\n3. TRUE\n4. FALSE [correction]: TopHat is not an R/Bioconductor package. It is a standalone program that was used for aligning RNA-seq data to a reference genome, but it doesn't have transcription factor binding sites detection capabilities; this is more typical of ChIP-seq analysis tools.\n5. FALSE [correction]: Cistrome is not a package but rather a suite of web-based tools for ChIP-seq data analysis, and it is not specifically in R/Bioconductor.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Sure, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention with Resistance Training and Nutritional Supplementation (SPRINT): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing sarcopenia in older adults.\n2. Sarcopenia: Prevention and Treatment (SPARC): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n3. Sarcopenia: Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTAN): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n4. Sarcopenia Prevention and Treatment Trial (SPATT): This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n5. Sarcopenia Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTS): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n\nThese are just a few examples of clinical trials that are currently being conducted or have been conducted in the past to study the prevention of sarcopenia.",
    "llama-7b_fact_raw": "1. The Sarcopenia Prevention with Resistance Training and Nutritional Supplementation (SPRINT) trial is a randomized, double-blind, placebo-controlled clinical trial.\n2. The Sarcopenia: Prevention and Treatment (SPARC) trial is evaluating resistance training and nutritional supplementation in a multicenter study.\n3. The Sarcopenia: Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTAN) trial is designed to determine the effectiveness of resistance training and nutritional supplements in the prevention and treatment of sarcopenia.\n4. The Sarcopenia Prevention and Treatment Trial (SPATT) conducts evaluations on the effectiveness of resistance training and nutritional supplementation in both preventing and treating sarcopenia.\n5. The Sarcopenia Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTS) trial aims to determine the effectiveness of these interventions specifically for sarcopenia prevention and treatment.",
    "llama-7b_fact": [
      "The Sarcopenia Prevention with Resistance Training and Nutritional Supplementation (SPRINT) trial is a randomized, double-blind, placebo-controlled clinical trial.",
      "The Sarcopenia: Prevention and Treatment (SPARC) trial is evaluating resistance training and nutritional supplementation in a multicenter study.",
      "The Sarcopenia: Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTAN) trial is designed to determine the effectiveness of resistance training and nutritional supplements in the prevention and treatment of sarcopenia.",
      "The Sarcopenia Prevention and Treatment Trial (SPATT) conducts evaluations on the effectiveness of resistance training and nutritional supplementation in both preventing and treating sarcopenia.",
      "The Sarcopenia Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTS) trial aims to determine the effectiveness of these interventions specifically for sarcopenia prevention and treatment."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThese statements refer to clinical trials by their acronyms (SPRINT, SPARC, SPARTAN, SPATT, and SPARTS), which are not standard and can vary widely by institution and study. There is not enough information to determine the accuracy of the statements without consulting a specific source that discusses them. If this is a hypothetical context or if the acronyms are created for the task, it would not be possible to verify the statements without additional context. If these are real clinical trials, one would need to research each one to find accurate information about their design, aims, and whether they exist under these acronyms.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "There are several databases that contain information on molecular recognition features in membrane proteins, including:\n\n1. The Protein Data Bank (PDB): The PDB is a public database of three-dimensional structural data for proteins, nucleic acids, and complex assemblies. It contains a large number of structures of membrane proteins, including those with molecular recognition features.\n2. The Database of Membrane Proteins (DMP): The DMP is a comprehensive database of three-dimensional structures of membrane proteins. It contains structures of a wide range of membrane proteins, including those with molecular recognition features.\n3. The Membrane Protein Data Bank (MPDB): The MPDB is a subset of the PDB that contains only structures of membrane proteins. It contains a large number of structures of membrane proteins with molecular recognition features.\n4. The Membrane Protein Structure and Function Resource (MPSF): The MPSF is a database that provides information on the structure, function, and evolution of membrane proteins. It contains a large number of structures of membrane proteins with molecular recognition features.\n\nOverall, these databases provide a wealth of information on the structure and function of membrane proteins, including those with molecular recognition features.",
    "llama-7b_fact_raw": "1. The Protein Data Bank (PDB) is a public database that includes three-dimensional structural data for proteins, nucleic acids, and complex assemblies.\n2. The Database of Membrane Proteins (DMP) is a comprehensive database specifically for three-dimensional structures of membrane proteins.\n3. The Membrane Protein Data Bank (MPDB) is a subset of the PDB dedicated to membrane proteins only.\n4. The Membrane Protein Structure and Function Resource (MPSF) provides information on the structure, function, and evolution of membrane proteins.\n5. All four databases mentioned—PDB, DMP, MPDB, and MPSF—contain structures of membrane proteins with molecular recognition features.",
    "llama-7b_fact": [
      "The Protein Data Bank (PDB) is a public database that includes three-dimensional structural data for proteins, nucleic acids, and complex assemblies.",
      "The Database of Membrane Proteins (DMP) is a comprehensive database specifically for three-dimensional structures of membrane proteins.",
      "The Membrane Protein Data Bank (MPDB) is a subset of the PDB dedicated to membrane proteins only.",
      "The Membrane Protein Structure and Function Resource (MPSF) provides information on the structure, function, and evolution of membrane proteins.",
      "All four databases mentioned—PDB, DMP, MPDB, and MPSF—contain structures of membrane proteins with molecular recognition features."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized database specifically called the Database of Membrane Proteins (DMP) for three-dimensional structures of membrane proteins. However, there are resources such as the Orientations of Proteins in Membranes (OPM) database which provides structural data on membrane proteins.\n3. FALSE [correction]: There is no specific subset of the PDB called the Membrane Protein Data Bank (MPDB) dedicated exclusively to membrane proteins. The PDB itself includes structures of membrane proteins among many other biological molecules.\n4. UNKNOWN: Without additional context or a widely recognized database or resource by the exact name of the \"Membrane Protein Structure and Function Resource\" (MPSF), it's not possible to confirm the veracity of this statement.\n5. FALSE [correction]: Since the DMP and MPSF mentioned are not verified databases or resources, and the MPDB does not exist as a subset of the PDB, we cannot state that all four databases contain structures of membrane proteins with molecular recognition features. The PDB does include such structures, but the other databases mentioned either do not exist or are not verified in this context.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver through glucuronidation and sulfation. However, the kidneys also play a role in the metabolism of rivaroxaban by eliminating unchanged drug and its metabolites in the urine.\n\nThe metabolism of rivaroxaban is primarily mediated by the cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9. These enzymes are primarily located in the liver, but they can also be expressed in other organs, including the kidneys. Therefore, the kidneys can contribute to the metabolism of rivaroxaban by expressing these enzymes and metabolizing the drug.\n\nIn addition, the kidneys play a role in the elimination of rivaroxaban and its metabolites. Unchanged rivaroxaban and its metabolites are excreted in the urine, and the kidneys are responsible for filtering and eliminating the drug and its metabolites from the body.\n\nTherefore, while the liver is the primary site of metabolism for rivaroxaban, the kidneys also play a role in its metabolism and elimination from the body.",
    "llama-7b_fact_raw": "1. Rivaroxaban is a direct factor Xa inhibitor.\n2. The primary metabolism of rivaroxaban occurs in the liver through processes such as glucuronidation and sulfation.\n3. The kidneys eliminate unchanged rivaroxaban and its metabolites in the urine.\n4. The cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9, which are mainly located in the liver, mediate the metabolism of rivaroxaban and can also be expressed in the kidneys.\n5. The kidneys filter and eliminate rivaroxaban and its metabolites from the body.",
    "llama-7b_fact": [
      "Rivaroxaban is a direct factor Xa inhibitor.",
      "The primary metabolism of rivaroxaban occurs in the liver through processes such as glucuronidation and sulfation.",
      "The kidneys eliminate unchanged rivaroxaban and its metabolites in the urine.",
      "The cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9, which are mainly located in the liver, mediate the metabolism of rivaroxaban and can also be expressed in the kidneys.",
      "The kidneys filter and eliminate rivaroxaban and its metabolites from the body."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE - While CYP3A4 and CYP2C9 are indeed involved in the metabolism of rivaroxaban, it's important to clarify that only a small part of rivaroxaban is metabolized by CYP enzymes (including CYP3A4), and other enzymes such as CYP2J2 are also involved. Also, while CYP enzymes are expressed in the kidneys, their role there in the metabolism of rivaroxaban is limited compared to their hepatic function. However, since the statement does not assert the extent of the involvement, it can't be deemed false based on the information available.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "TRalpha2, also known as thyroid hormone receptor alpha 2, is a nuclear receptor that plays a crucial role in regulating the expression of genes involved in various physiological processes, including metabolism, development, and growth. In the heart, TRalpha2 has been shown to play a role in the regulation of cardiac function and development.\n\nStudies have identified several genes that are regulated by TRalpha2 in the heart. For example, TRalpha2 has been shown to regulate the expression of genes involved in the development and maturation of cardiac muscle cells, including genes that encode proteins involved in the formation of cardiac muscle fibers, the regulation of heart rate, and the maintenance of cardiac contractility.\n\nAdditionally, TRalpha2 has been shown to regulate the expression of genes involved in the response to stress and injury in the heart. For example, TRalpha2 has been shown to regulate the expression of genes involved in the production of antioxidant enzymes, such as superoxide dismutase and catalase, which help to protect the heart against oxidative stress and injury.\n\nOverall, TRalpha2 plays an important role in regulating the expression of genes involved in the development, maturation, and maintenance of cardiac function, as well as the response to stress and injury in the heart.",
    "llama-7b_fact_raw": "1. TRalpha2 is a nuclear receptor involved in regulating gene expression relating to metabolism, development, and growth.\n2. In the heart, TRalpha2 regulates genes involved in the development and maturation of cardiac muscle cells.\n3. TRalpha2 influences genes that are responsible for the formation of cardiac muscle fibers.\n4. TRalpha2 affects the regulation of heart rate and maintenance of cardiac contractility.\n5. TRalpha2 is involved in regulating the expression of genes that produce antioxidant enzymes like superoxide dismutase and catalase in the heart.",
    "llama-7b_fact": [
      "TRalpha2 is a nuclear receptor involved in regulating gene expression relating to metabolism, development, and growth.",
      "In the heart, TRalpha2 regulates genes involved in the development and maturation of cardiac muscle cells.",
      "TRalpha2 influences genes that are responsible for the formation of cardiac muscle fibers.",
      "TRalpha2 affects the regulation of heart rate and maintenance of cardiac contractility.",
      "TRalpha2 is involved in regulating the expression of genes that produce antioxidant enzymes like superoxide dismutase and catalase in the heart."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering systems available, including:\n\n1. Clinical Question Answering (CRAQ) system: This system is designed to answer clinical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n2. Biocreative 2 system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n3. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n4. Biomedical Text Analysis and Knowledge Extraction (BTAKE) system: This system is designed to extract biomedical knowledge from unstructured text. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n5. Biomedical Text Mining (BTM) system: This system is designed to extract biomedical knowledge from unstructured text. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n6. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n7. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n8. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n9. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n10.",
    "llama-7b_fact_raw": "1. The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using natural language processing and machine learning techniques.\n2. The Biocreative 2 system is tailored for answering biomedical questions with a combination of natural language processing and machine learning.\n3. The Biomedical Question Answering (Bio-QA) system aims at providing answers to biomedical inquiries through the use of natural language processing and machine learning.\n4. The Biomedical Text Analysis and Knowledge Extraction (BTAKE) system extracts biomedical knowledge using natural language processing and machine learning methodologies.\n5. The Biomedical Text Mining (BTM) system is developed to extract biomedical knowledge from unstructured text employing natural language processing and machine learning.",
    "llama-7b_fact": [
      "The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using natural language processing and machine learning techniques.",
      "The Biocreative 2 system is tailored for answering biomedical questions with a combination of natural language processing and machine learning.",
      "The Biomedical Question Answering (Bio-QA) system aims at providing answers to biomedical inquiries through the use of natural language processing and machine learning.",
      "The Biomedical Text Analysis and Knowledge Extraction (BTAKE) system extracts biomedical knowledge using natural language processing and machine learning methodologies.",
      "The Biomedical Text Mining (BTM) system is developed to extract biomedical knowledge from unstructured text employing natural language processing and machine learning."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific details about a system named \"Clinical Question Answering (CRAQ),\" it is not possible to confirm or deny the details of this statement.\n2. UNKNOWN: \"Biocreative\" often refers to a series of challenges in the bioinformatics community aimed at evaluating text mining and information extraction systems, but without more information, the specifics of the \"Biocreative 2 system\" cannot be confirmed.\n3. TRUE: This statement broadly aligns with the goals of systems developed in the field of biomedical question answering which aim to provide answers to biomedical inquiries through the use of natural language processing (NLP) and machine learning (ML).\n4. UNKNOWN: While this statement seems plausible and aligns with the objectives of computational systems in the field of biomedical research, without specific information about a system named \"Biomedical Text Analysis and Knowledge Extraction (BTAKE),\" the statement’s accuracy cannot be confirmed.\n5. TRUE: This statement accurately describes the broad goal of biomedical text mining (BTM) systems which utilize NLP and ML to extract knowledge from unstructured biomedical text. Whether there is a specific system called \"BTM\" cannot be verified without further context, but the description is generally correct for such systems.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The betalain pathway is activated by the transcription factor MYB.\n\nMYB is a transcription factor that belongs to the MYB family of proteins. It is a DNA-binding protein that plays a crucial role in the regulation of gene expression by binding to specific DNA sequences known as MYB boxes.\n\nIn the case of the betalain pathway, MYB binds to specific MYB boxes located in the promoter region of genes involved in the biosynthesis of betalain pigments. Once bound to these MYB boxes, MYB activates the transcription of these genes, leading to the production of enzymes involved in the biosynthesis of betalain pigments.\n\nThe activation of the betalain pathway by MYB is a complex process that involves multiple steps. First, MYB binds to specific DNA sequences known as MYB boxes, which are located in the promoter region of genes involved in betalain biosynthesis. Once bound to these MYB boxes, MYB recruits other transcription factors and co-factors, which help to activate the transcription of these genes.\n\nIn addition to activating the transcription of genes involved in betalain biosynthesis, MYB also plays a role in the regulation of gene expression at the post-transcriptional level. It has been shown to interact with microRNAs, which are small non-coding RNAs that play a role in the regulation of gene expression at the post-transcriptional level.\n\nIn summary, the transcription factor MYB plays a crucial role in the activation of the betalain pathway by binding to specific DNA sequences known as MYB boxes located in the promoter region of genes involved in betalain biosynthesis. It activates the transcription of these genes and also plays a role in the regulation of gene expression at the post-transcriptional level.",
    "llama-7b_fact_raw": "1. The transcription factor MYB activates the betalain pathway.\n2. MYB belongs to the MYB family of DNA-binding proteins.\n3. The MYB protein binds to specific DNA sequences called MYB boxes in the promoter region of genes.\n4. The binding of MYB to MYB boxes leads to the transcription of genes involved in the biosynthesis of betalain pigments.\n5. MYB also interacts with microRNAs, which regulate gene expression at the post-transcriptional level.",
    "llama-7b_fact": [
      "The transcription factor MYB activates the betalain pathway.",
      "MYB belongs to the MYB family of DNA-binding proteins.",
      "The MYB protein binds to specific DNA sequences called MYB boxes in the promoter region of genes.",
      "The binding of MYB to MYB boxes leads to the transcription of genes involved in the biosynthesis of betalain pigments.",
      "MYB also interacts with microRNAs, which regulate gene expression at the post-transcriptional level."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that are commonly used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n\n1. TiO2 beads: TiO2 beads are one of the most widely used technologies for the enrichment of phosphorylated peptides. They are coated with TiO2 nanoparticles that have a high affinity for phosphorylated serine/threonine residues. The beads are mixed with the sample and then washed to remove unbound peptides. The phosphorylated peptides are then eluted and subjected to mass spectrometry analysis.\n2. IMAC (immobilized metal affinity chromatography): IMAC is another popular technology for the enrichment of phosphorylated peptides. In this method, metal ions such as nickel or gold are immobilized on a column and the sample is passed through the column. Phosphorylated peptides bind to the metal ions, while non-phosphorylated peptides do not. The bound peptides are then eluted and subjected to mass spectrometry analysis.\n3. StrepTactin beads: StrepTactin beads are another type of beads that are used for the enrichment of phosphorylated peptides. They are coated with a protein called StrepTactin that has a high affinity for phosphorylated tyrosine residues. The beads are mixed with the sample and then washed to remove unbound peptides. The phosphorylated peptides are then eluted and subjected to mass spectrometry analysis.\n4. Phosphopeptide enrichment by liquid chromatography (LC): Liquid chromatography (LC) can also be used for the enrichment of phosphorylated peptides. In this method, the sample is passed through a column that is coated with a ligand that selectively binds to phosphorylated peptides. The bound peptides are then eluted and subjected to mass spectrometry analysis.\n\nOverall, the choice of technology for the enrichment of phosphoryl",
    "llama-7b_fact_raw": "1. TiO2 beads are widely used for the enrichment of phosphorylated peptides and their affinity is for phosphorylated serine/threonine residues.\n2. Immobilized metal affinity chromatography (IMAC) is a technology that enriches phosphorylated peptides by utilizing metal ions like nickel or gold on a column to which phosphorylated peptides bind.\n3. StrepTactin beads are used to enrich phosphorylated peptides due to their affinity for phosphorylated tyrosine residues.\n4. Liquid chromatography (LC) is employed for phosphorylated peptide enrichment through the use of a ligand-coated column that selectively binds phosphorylated peptides.\n5. Mass spectrometry analysis is a subsequent step following the enrichment of phosphorylated peptides using the mentioned technologies.",
    "llama-7b_fact": [
      "TiO2 beads are widely used for the enrichment of phosphorylated peptides and their affinity is for phosphorylated serine/threonine residues.",
      "Immobilized metal affinity chromatography (IMAC) is a technology that enriches phosphorylated peptides by utilizing metal ions like nickel or gold on a column to which phosphorylated peptides bind.",
      "StrepTactin beads are used to enrich phosphorylated peptides due to their affinity for phosphorylated tyrosine residues.",
      "Liquid chromatography (LC) is employed for phosphorylated peptide enrichment through the use of a ligand-coated column that selectively binds phosphorylated peptides.",
      "Mass spectrometry analysis is a subsequent step following the enrichment of phosphorylated peptides using the mentioned technologies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: StrepTactin beads are typically used for the purification of proteins that are engineered to have a Strep-tag affinity tag, and not specifically for enriching phosphorylated peptides.\n4. FALSE [correction]: Liquid chromatography is a broader technique used for separating mixtures of compounds and is not solely employed for phosphorylated peptide enrichment. Specific types of liquid chromatography such as Ion Exchange Chromatography or Hydrophilic Interaction Liquid Chromatography (HILIC) can be utilized for such purposes, but LC itself is not inherently selective for phosphorylated peptides without the appropriate stationary phase.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "The Palmini classification is a system used to rate the severity of eating disorders, such as anorexia nervosa, bulimia nervosa, and binge eating disorder. The classification is based on the patient's body mass index (BMI), which is calculated by dividing a person's weight in kilograms by their height in meters squared.\n\nThe Palmini classification is as follows:\n\n* Class 1: BMI < 17.5\n* Class 2: BMI 17.5-18.4\n* Class 3: BMI 18.5-20.9\n* Class 4: BMI 21-23.9\n* Class 5: BMI 24-27.4\n* Class 6: BMI 27.5-30.9\n* Class 7: BMI 31-34.9\n* Class 8: BMI 35-39.9\n* Class 9: BMI 40-49.9\n* Class 10: BMI 50-59.9\n* Class 11: BMI 60-69.9\n* Class 12: BMI 70-81.9\n* Class 13: BMI 82-91.9\n* Class 14: BMI 92-100\n* Class 15: BMI 101-110\n* Class 16: BMI 111-120\n* Class 17: BMI 121-130\n* Class 18: BMI 131-140\n* Class 19: BMI 141-150\n* Class 20: BMI 151-160\n* Class 21: BMI 161-170\n* Class 22: BMI 171-180\n* Class 23: BMI 181-190\n* Class 24: BMI 191-200\n* Class 25: BMI 201-2",
    "llama-7b_fact_raw": "1. The Palmini classification is used to rate the severity of eating disorders.\n2. The Palmini classification measures the severity using the patient's body mass index (BMI).\n3. Anorexia nervosa, bulimia nervosa, and binge eating disorder are examples of eating disorders rated by Palmini classification.\n4. Class 1 of the Palmini classification is characterized by a BMI of less than 17.5.\n5. The Palmini classification extends up to Class 25, where a BMI of 201-2 is indicated.",
    "llama-7b_fact": [
      "The Palmini classification is used to rate the severity of eating disorders.",
      "The Palmini classification measures the severity using the patient's body mass index (BMI).",
      "Anorexia nervosa, bulimia nervosa, and binge eating disorder are examples of eating disorders rated by Palmini classification.",
      "Class 1 of the Palmini classification is characterized by a BMI of less than 17.5.",
      "The Palmini classification extends up to Class 25, where a BMI of 201-2 is indicated."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of eating disorders; instead, it is a classification system for hippocampal sclerosis observed in epilepsy.\n2. FALSE [correction]: Since the Palmini classification is related to epilepsy and not eating disorders, it does not measure severity using the patient's body mass index (BMI).\n3. FALSE [correction]: Anorexia nervosa, bulimia nervosa, and binge eating disorder are indeed examples of eating disorders but they are not rated by the Palmini classification, which is associated with epilepsy.\n4. FALSE [correction]: Class 1 of the Palmini classification does not pertain to BMI at all, as it is a classification system related to epilepsy; class 1 may describe the extent of hippocampal sclerosis in epilepsy.\n5. FALSE [correction]: The Palmini classification does not extend to Class 25, and the reference to a BMI of 201-2 is incorrect within this context. Palmini classification does not concern BMI.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "No, viruses are not typically involved in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition of the thyroid gland that is typically caused by a viral infection of the upper respiratory tract, such as a cold or the flu. However, the association between viral infections and subacute thyroiditis is not well established, and other factors, such as autoimmune disorders, may also play a role in the development of this condition.",
    "llama-7b_fact_raw": "1. Viruses are not typically involved in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is an inflammatory condition of the thyroid gland.\n3. Subacute thyroiditis is typically caused by a viral infection of the upper respiratory tract.\n4. Common viral infections of the upper respiratory tract include colds and the flu.\n5. Other factors, such as autoimmune disorders, may play a role in the development of subacute thyroiditis.",
    "llama-7b_fact": [
      "Viruses are not typically involved in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is an inflammatory condition of the thyroid gland.",
      "Subacute thyroiditis is typically caused by a viral infection of the upper respiratory tract.",
      "Common viral infections of the upper respiratory tract include colds and the flu.",
      "Other factors, such as autoimmune disorders, may play a role in the development of subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE: Viruses are not typically involved in the etiology of human subacute thyroiditis. This statement is largely true because the exact cause of subacute thyroiditis is not well understood, and while it may be associated with viral infections, it is not definitively proven or the sole cause.\n2. TRUE: Subacute thyroiditis is indeed an inflammatory condition of the thyroid gland.\n3. FALSE [correction]: While it is commonly thought that subacute thyroiditis can follow a viral infection of the upper respiratory tract, the definitive causative role of viruses has not been clearly established.\n4. TRUE: Common viral infections of the upper respiratory tract do include conditions such as colds and the flu.\n5. TRUE: Other factors like autoimmune disorders may contribute to the development of subacute thyroiditis, although the condition is not typically classified as an autoimmune disease.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "STAT3 (signal transducer and activator of transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. STAT3 has been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of cellular components. However, the role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood.\n\nEIF2AK2 (eukaryotic initiation factor 2 alpha kinase 2), also known as PKR (double-stranded RNA-dependent protein kinase), is a protein kinase that plays a key role in the regulation of cellular stress responses, including the suppression of autophagy. EIF2AK2 has been shown to interact with STAT3 and regulate its transcriptional activity. However, the precise mechanism by which EIF2AK2 regulates STAT3 in the suppression of autophagy is not fully understood.\n\nSome studies have suggested that STAT3 may play a role in the regulation of autophagy. For example, STAT3 has been shown to regulate the expression of autophagy-related genes, such as BECN1 (Beclin 1) and ATG5 (autophagy-related 5), which are key components of the autophagy machinery. Additionally, STAT3 has been shown to interact with and regulate the activity of other autophagy-related proteins, such as ULK1 (unc-51-like kinase 1) and ATG9 (autophagy-related 9). However, the role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood.\n\nIn summary, while there is some evidence to suggest that STAT3 may be involved in the regulation of autophagy, the precise role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood. Further research is needed to elucidate the precise mechanisms by which STAT3 and EIF2AK2 interact to regulate autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor that plays a crucial role in cell growth, differentiation, and immune response.\n2. EIF2AK2, also known as PKR, is a protein kinase that plays a key role in suppression of autophagy during cellular stress responses.\n3. STAT3 has been implicated in the regulation of autophagy by regulating the expression of autophagy-related genes like BECN1 and ATG5.\n4. STAT3 has been shown to interact with other autophagy-related proteins, including ULK1 and ATG9.\n5. The precise role of STAT3 in EIF2AK2-dependent suppression of autophagy is not clearly understood, necessitating further research.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor that plays a crucial role in cell growth, differentiation, and immune response.",
      "EIF2AK2, also known as PKR, is a protein kinase that plays a key role in suppression of autophagy during cellular stress responses.",
      "STAT3 has been implicated in the regulation of autophagy by regulating the expression of autophagy-related genes like BECN1 and ATG5.",
      "STAT3 has been shown to interact with other autophagy-related proteins, including ULK1 and ATG9.",
      "The precise role of STAT3 in EIF2AK2-dependent suppression of autophagy is not clearly understood, necessitating further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: EIF2AK2, also known as PKR, is a protein kinase that plays a key role in the antiviral response and can have a role in the regulation of autophagy, but it is not principally characterized by the suppression of autophagy during cellular stress responses. It is rather involved in the stress-induced activation of autophagy, among other functions.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data sets. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as identify genetic variations that may be associated with disease.\n\nTheatre allows users to view and analyze genomic data on a large scale, making it easier to identify patterns and relationships that may not be visible using other tools. It can be used to visualize and analyze a wide range of genomic data, including whole-genome and exome sequencing data, as well as data from other types of genomic studies.\n\nOne of the key features of Theatre is its ability to handle large data sets. It can be used to analyze data from thousands of individuals, allowing researchers to identify patterns and relationships that may not be visible using other tools. This makes it a valuable tool for identifying genetic variants that may be associated with disease, as well as for studying the genetic basis of complex traits and diseases.\n\nIn addition to its ability to handle large data sets, Theatre also has a number of other features that make it a powerful tool for genomic analysis. It includes a range of visualization tools that allow users to explore and analyze genomic data in a variety of ways. It also includes a number of analysis tools that can be used to identify genetic variants that may be associated with disease, as well as to study the genetic basis of complex traits and diseases.\n\nOverall, the Theatre software tool is a valuable tool for genomic analysis. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as identify genetic variations that may be associated with disease. Its ability to handle large data sets and its range of visualization and analysis tools make it a powerful tool for genomic analysis.",
    "llama-7b_fact_raw": "1. The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.\n2. Theatre helps in understanding the structure and organization of the human genome.\n3. The tool can identify genetic variations that may be associated with disease.\n4. Theatre is capable of analyzing data from thousands of individuals.\n5. Theatre includes visualization and analysis tools for studying the genetic basis of complex traits and diseases.",
    "llama-7b_fact": [
      "The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.",
      "Theatre helps in understanding the structure and organization of the human genome.",
      "The tool can identify genetic variations that may be associated with disease.",
      "Theatre is capable of analyzing data from thousands of individuals.",
      "Theatre includes visualization and analysis tools for studying the genetic basis of complex traits and diseases."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note for clarification: The name \"Theatre\" is not recognized as a standard tool for genomic data analysis. Without more context or clarification about this specific software, its functions, and capabilities, it is impossible to determine the truthfulness of these statements. If \"Theatre\" is a hypothetical or proprietary system not widely recognized, more information would be needed to verify these claims.]",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the gap penalty and gap extension parameters used in the algorithm.\n\nIn general, the execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned. For example, the time complexity of the algorithm for aligning two sequences of length n is O(n^2). This means that as the length of the sequences increases, the algorithm becomes slower and slower.\n\nThe Smith-Waterman algorithm also has a time complexity that depends on the similarity between the sequences being aligned. Sequences that are more similar will take less time to align than sequences that are less similar.\n\nThe gap penalty and gap extension parameters used in the Smith-Waterman algorithm also affect the execution time of the algorithm. Gap penalties are used to penalize the algorithm for inserting or deleting gaps in the alignment, while gap extensions are used to extend the length of gaps in the alignment. The choice of gap penalty and gap extension parameters can significantly affect the execution time of the algorithm.\n\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences, the similarity between the sequences, and the gap penalty and gap extension parameters used in the algorithm. The time complexity of the algorithm is generally O(n^2) and can be affected by the similarity between the sequences and the choice of gap penalty and gap extension parameters.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is a dynamic programming algorithm used for sequence alignment.\n2. The execution time (complexity) of the Smith-Waterman algorithm generally increases exponentially with the length of the sequences being aligned.\n3. The time complexity of the algorithm for aligning two sequences of length n is O(n^2).\n4. The execution time of the Smith-Waterman algorithm can be affected by the similarity between the sequences being aligned.\n5. The selection of gap penalty and gap extension parameters impacts the execution time of the Smith-Waterman algorithm.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is a dynamic programming algorithm used for sequence alignment.",
      "The execution time (complexity) of the Smith-Waterman algorithm generally increases exponentially with the length of the sequences being aligned.",
      "The time complexity of the algorithm for aligning two sequences of length n is O(n^2).",
      "The execution time of the Smith-Waterman algorithm can be affected by the similarity between the sequences being aligned.",
      "The selection of gap penalty and gap extension parameters impacts the execution time of the Smith-Waterman algorithm."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The execution time (complexity) of the Smith-Waterman algorithm does not increase exponentially with the length of the sequences being aligned. It increases quadratically, as it is based on dynamic programming.\n3. TRUE\n4. UNKNOWN: While the similarity between the sequences might affect the actual runtime performance by influencing factors such as caching effectiveness or branch prediction in the underlying hardware, this does not change the theoretical time complexity of the Smith-Waterman algorithm.\n5. FALSE [correction]: The selection of gap penalty and gap extension parameters impacts the scores and resulting alignments produced by the Smith-Waterman algorithm, but it does not change the execution time complexity, which remains quadratic.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "FLVCR1, also known as folliculin, is a protein that belongs to the SLC26 family of solute carrier transporters. The SLC26 family is one of the subfamilies of the larger SLC (Solute Carrier) family of transporters, which are involved in the transport of a wide variety of molecules across cell membranes.\n\nThe SLC26 family is specifically involved in the transport of small molecules, such as ions, amino acids, and sugars, and is found in a wide range of organisms, including bacteria, plants, and animals. The family includes several subfamilies, each of which is characterized by a specific structure and function.\n\nFLVCR1 is a member of the SLC26A1 subfamily, which is specifically involved in the transport of small molecules such as amino acids, sugars, and other organic compounds. The SLC26A1 subfamily is found in a wide range of organisms, including bacteria, plants, and animals, and is involved in a variety of cellular processes, including metabolism, signaling, and transport.\n\nIn summary, FLVCR1 is a member of the SLC26 family, which is a subfamily of the larger SLC family of transporters. The SLC26 family is specifically involved in the transport of small molecules, and FLVCR1 is a member of the SLC26A1 subfamily, which is involved in the transport of amino acids, sugars, and other organic compounds.",
    "llama-7b_fact_raw": "1. FLVCR1 is a protein that is part of the SLC26 family of solute carrier transporters.\n2. The SLC26 family includes subfamilies each with specific structures and functions, involved in the transport of small molecules like ions, amino acids, and sugars.\n3. The SLC26 family is found in a wide range of organisms such as bacteria, plants, and animals.\n4. FLVCR1 is specifically a member of the SLC26A1 subfamily within the SLC26 family.\n5. The SLC26A1 subfamily is involved in the transport of small molecules including amino acids, sugars, and other organic compounds.",
    "llama-7b_fact": [
      "FLVCR1 is a protein that is part of the SLC26 family of solute carrier transporters.",
      "The SLC26 family includes subfamilies each with specific structures and functions, involved in the transport of small molecules like ions, amino acids, and sugars.",
      "The SLC26 family is found in a wide range of organisms such as bacteria, plants, and animals.",
      "FLVCR1 is specifically a member of the SLC26A1 subfamily within the SLC26 family.",
      "The SLC26A1 subfamily is involved in the transport of small molecules including amino acids, sugars, and other organic compounds."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC26 family of solute carrier transporters, it is a member of the Major Facilitator Superfamily (MFS).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: FLVCR1 is not a member of the SLC26A1 subfamily or the SLC26 family; it is part of a different family involved in the transport of heme.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in regulating the expression of genes involved in various cellular processes, including hematopoiesis, cardiovascular development, and immune function. GATA-1 interacts with a variety of proteins to regulate its target genes, and the biotinylation tagging approach has been used to identify some of these interacting partners.\n\nOne study used the biotinylation tagging approach to identify proteins that interact with GATA-1 in hematopoietic stem cells (HSCs). The study found that GATA-1 interacts with several proteins involved in HSC self-renewal and differentiation, including the transcription factors RUNX1, PU.1, and Gfi-1b, as well as the protein kinase AKT1.\n\nAnother study used the biotinylation tagging approach to identify proteins that interact with GATA-1 in cardiac progenitor cells. The study found that GATA-1 interacts with several proteins involved in cardiac development and maturation, including the transcription factors NKX2.5 and GATA4, as well as the protein kinase AKT1.\n\nOverall, the biotinylation tagging approach has identified several proteins that interact with GATA-1, including transcription factors, kinases, and other proteins involved in various cellular processes. These interactions provide insight into the mechanisms by which GATA-1 regulates gene expression and contributes to cellular function.",
    "llama-7b_fact_raw": "1. GATA-1 is a transcription factor that regulates gene expression in hematopoiesis, cardiovascular development, and immune function.\n2. The biotinylation tagging approach has been used to identify GATA-1 interacting partners.\n3. GATA-1 was found to interact with transcription factors RUNX1, PU.1, and Gfi-1b in hematopoietic stem cells.\n4. GATA-1 was also found to interact with the protein kinase AKT1 in hematopoietic stem cells.\n5. In cardiac progenitor cells, GATA-1 was found to interact with transcription factors NKX2.5 and GATA4.",
    "llama-7b_fact": [
      "GATA-1 is a transcription factor that regulates gene expression in hematopoiesis, cardiovascular development, and immune function.",
      "The biotinylation tagging approach has been used to identify GATA-1 interacting partners.",
      "GATA-1 was found to interact with transcription factors RUNX1, PU.1, and Gfi-1b in hematopoietic stem cells.",
      "GATA-1 was also found to interact with the protein kinase AKT1 in hematopoietic stem cells.",
      "In cardiac progenitor cells, GATA-1 was found to interact with transcription factors NKX2.5 and GATA4."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: In cardiac progenitor cells, it is GATA4 that interacts with transcription factors like NKX2.5, not GATA-1. GATA-1 is primarily associated with hematopoiesis.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor that plays a crucial role in the regulation of gene expression in various tissues and cell types. The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in various biological processes, including cell growth, differentiation, and development.\n\nThe outcome of TAF10 interacting with GATA1 depends on the specific context and the target genes being regulated. However, in general, the interaction between TAF10 and GATA1 leads to the recruitment of TAF10 to the promoter region of target genes, where it helps to stabilize the interaction between GATA1 and other transcriptional co-activators, such as CBP and p300. This, in turn, enhances the recruitment of RNA polymerase II and other transcriptional machinery to the promoter, leading to increased transcription of target genes.\n\nThe specific genes that are activated by the interaction between TAF10 and GATA1 depend on the tissue and cell type in question. For example, in hematopoietic cells, the interaction between TAF10 and GATA1 has been shown to play a crucial role in the regulation of genes involved in the differentiation and maturation of immune cells. In particular, the interaction between TAF10 and GATA1 has been shown to activate genes involved in the differentiation of T cells, B cells, and dendritic cells.\n\nIn summary, the outcome of TAF10 interacting with GATA1 is the activation of target genes involved in various biological processes, including cell growth, differentiation, and development. The specific genes that are activated by this interaction depend on the tissue and cell type in question.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor.\n2. The interaction between TAF10 and GATA1 generally leads to the recruitment of TAF10 to the promoter region of target genes.\n3. This interaction helps stabilize the interaction between GATA1 and other transcriptional co-activators, including CBP and p300.\n4. The result of the interaction enhances the recruitment of RNA polymerase II, leading to increased transcription of target genes.\n5. In hematopoietic cells, the interaction between TAF10 and GATA1 is crucial for regulating genes involved in the differentiation of immune cells such as T cells, B cells, and dendritic cells.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor.",
      "The interaction between TAF10 and GATA1 generally leads to the recruitment of TAF10 to the promoter region of target genes.",
      "This interaction helps stabilize the interaction between GATA1 and other transcriptional co-activators, including CBP and p300.",
      "The result of the interaction enhances the recruitment of RNA polymerase II, leading to increased transcription of target genes.",
      "In hematopoietic cells, the interaction between TAF10 and GATA1 is crucial for regulating genes involved in the differentiation of immune cells such as T cells, B cells, and dendritic cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: In hematopoietic cells, the interaction between TAF10 and GATA1 is crucial for regulating genes involved in the development and function of erythroid (red blood cell lineage) and megakaryocytic (platelet lineage) cells, not specifically immune cells such as T cells, B cells, and dendritic cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a protein that plays a role in the process of angiogenesis, which is the formation of new blood vessels. It is a glycoprotein that is synthesized and secreted by a variety of cells, including endothelial cells, fibroblasts, and smooth muscle cells.\n\nAngiogenin is primarily localized to the cytoplasm of cells, although it can also be found in the nucleus of some cells. It is thought to play a role in the regulation of gene expression, and has been shown to bind to specific DNA sequences known as angiogenin response elements (AngREs). These AngREs are found in the promoter regions of genes that are involved in the process of angiogenesis, and the binding of angiogenin to these elements is thought to play a role in the regulation of gene expression.\n\nIn addition to its role in angiogenesis, angiogenin has also been implicated in the regulation of cell proliferation, differentiation, and survival. It has been shown to promote the growth and survival of endothelial cells, and to play a role in the development of tumors.\n\nOverall, the subcellular localization of angiogenin is primarily in the cytoplasm, although it can also be found in the nucleus of some cells. It plays a role in the regulation of gene expression, and has been implicated in the regulation of cell proliferation, differentiation, and survival.",
    "llama-7b_fact_raw": "1. Angiogenin is a protein involved in angiogenesis, the formation of new blood vessels.\n2. It is a glycoprotein that is synthesized and secreted by cells such as endothelial cells, fibroblasts, and smooth muscle cells.\n3. Angiogenin is primarily localized to the cytoplasm of cells.\n4. It can also be found in the nucleus of some cells.\n5. Angiogenin binds to specific DNA sequences called angiogenin response elements (AngREs) in the promoter regions of genes involved in angiogenesis.",
    "llama-7b_fact": [
      "Angiogenin is a protein involved in angiogenesis, the formation of new blood vessels.",
      "It is a glycoprotein that is synthesized and secreted by cells such as endothelial cells, fibroblasts, and smooth muscle cells.",
      "Angiogenin is primarily localized to the cytoplasm of cells.",
      "It can also be found in the nucleus of some cells.",
      "Angiogenin binds to specific DNA sequences called angiogenin response elements (AngREs) in the promoter regions of genes involved in angiogenesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Although angiogenin does play a role in angiogenesis, it is not classified as a glycoprotein. It is a ribonuclease that is involved in the process.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin does not bind to specific DNA sequences. It is known to enter the nucleus and affect RNA, but it does not directly bind to DNA in the context described.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "Ranolazine is a medication that is used to treat chronic angina, a type of chest pain that occurs when the heart muscle does not receive enough oxygen-rich blood. It works by blocking the voltage-gated sodium channels in the heart, which helps to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nOne of the ways that ranolazine affects kinase signaling activation in the heart is by inhibiting the activity of protein kinases. Protein kinases are enzymes that play a key role in many cellular processes, including signal transduction pathways that are involved in the regulation of the heart's electrical activity. By inhibiting the activity of protein kinases, ranolazine can help to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nIn addition to inhibiting protein kinases, ranolazine also affects kinase signaling activation in the heart by inhibiting the activity of other enzymes that are involved in the regulation of the heart's electrical activity. For example, ranolazine has been shown to inhibit the activity of the enzyme L-type calcium channels, which are involved in the regulation of the heart's electrical activity. By inhibiting the activity of L-type calcium channels, ranolazine can help to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nOverall, ranolazine affects kinase signaling activation in the heart by inhibiting the activity of protein kinases and other enzymes that are involved in the regulation of the heart's electrical activity. This helps to reduce the electrical activity in the heart and reduce the frequency of angina attacks.",
    "llama-7b_fact_raw": "1. Ranolazine is used to treat chronic angina by blocking voltage-gated sodium channels in the heart.\n2. Inhibiting protein kinases is one way ranolazine affects kinase signaling activation in the heart.\n3. Protein kinases play a significant role in signal transduction pathways relating to the heart's electrical activity regulation.\n4. Ranolazine inhibits the activity of L-type calcium channels in the heart.\n5. The inhibition of protein kinases and L-type calcium channels by ranolazine helps reduce the electrical activity in the heart and the frequency of angina attacks.",
    "llama-7b_fact": [
      "Ranolazine is used to treat chronic angina by blocking voltage-gated sodium channels in the heart.",
      "Inhibiting protein kinases is one way ranolazine affects kinase signaling activation in the heart.",
      "Protein kinases play a significant role in signal transduction pathways relating to the heart's electrical activity regulation.",
      "Ranolazine inhibits the activity of L-type calcium channels in the heart.",
      "The inhibition of protein kinases and L-type calcium channels by ranolazine helps reduce the electrical activity in the heart and the frequency of angina attacks."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine primarily works by inhibiting late phase sodium channels, not by inhibiting protein kinases.\n3. TRUE\n4. FALSE [correction]: While ranolazine does have an effect on L-type calcium channels, it is not its primary mechanism of action; its known effect is on the late phase sodium channels.\n5. FALSE [correction]: While the inhibition of sodium channels by ranolazine helps reduce the electrical activity in the heart and the frequency of angina attacks, it is not primarily through the inhibition of protein kinases and L-type calcium channels.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "The regulation of the VSR endonuclease in bacteria is not necessarily independent of the growth phase. While the expression of VSR endonuclease has been shown to be influenced by growth phase in some studies, other studies have found that the regulation of VSR endonuclease is complex and can be influenced by a variety of factors, including growth phase, environmental cues, and the presence of antibiotics.\n\nFor example, one study found that the expression of VSR endonuclease in Escherichia coli was influenced by growth phase, with the highest levels of expression occurring in the stationary phase of growth. However, other studies have found that the regulation of VSR endonuclease is more complex, with the expression of the enzyme being influenced by a variety of factors, including the presence of antibiotics, nutrient availability, and environmental cues.\n\nOverall, while the regulation of VSR endonuclease in bacteria may be influenced by growth phase in some cases, the regulation of the enzyme is likely to be complex and influenced by a variety of factors. Further research is needed to fully understand the regulation of VSR endonuclease in bacteria and how it is influenced by growth phase and other factors.",
    "llama-7b_fact_raw": "1. The expression of VSR endonuclease in bacteria can be influenced by the growth phase.\n2. Studies have shown that Escherichia coli's VSR endonuclease expression levels are highest during the stationary phase of growth.\n3. The regulation of VSR endonuclease is complex and may be influenced by environmental cues.\n4. The presence of antibiotics can influence the expression of VSR endonuclease in bacteria.\n5. The regulation of VSR endonuclease in bacteria may also be affected by nutrient availability.",
    "llama-7b_fact": [
      "The expression of VSR endonuclease in bacteria can be influenced by the growth phase.",
      "Studies have shown that Escherichia coli's VSR endonuclease expression levels are highest during the stationary phase of growth.",
      "The regulation of VSR endonuclease is complex and may be influenced by environmental cues.",
      "The presence of antibiotics can influence the expression of VSR endonuclease in bacteria.",
      "The regulation of VSR endonuclease in bacteria may also be affected by nutrient availability."
    ],
    "llama-7b_judge_raw": "1. TRUE: The expression of various endonucleases, including VSR endonuclease, in bacteria can indeed be influenced by the growth phase of the bacteria.\n2. UNKNOWN: Without specific details regarding the studies on Escherichia coli's VSR endonuclease expression, it is difficult to confirm the accuracy of this statement. Different bacteria may express enzymes like VSR endonucleases differently during their growth phases.\n3. TRUE: The regulation of various enzymes, including endonucleases like VSR, is generally complex and can be influenced by multiple environmental factors.\n4. TRUE: The presence of antibiotics can act as an environmental stressor or cue that influences the expression of certain bacterial enzymes, including endonucleases such as VSR endonuclease, due to the need for the bacteria to respond to such stress.\n5. TRUE: Nutrient availability is often a key environmental cue that influences the regulation of bacterial genes, including those encoding enzymes like VSR endonuclease, as part of the cellular response to nutrient scarcity or abundance.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the most popular ones:\n\n1. TMHMM: TMHMM (Transmembrane Helices of Microbial Homologues) is a web-based tool that uses hidden Markov models to predict transmembrane helices in proteins. It can also predict beta-barrels, which are composed of multiple transmembrane helices. TMHMM has a high accuracy in predicting transmembrane helices and beta-barrels, and it is widely used in bioinformatics research.\n2. SMART: SMART (Simple Modular Architecture Research Tool) is a web-based tool that predicts the occurrence of domains and functional sites in proteins. It can also predict beta-barrels and transmembrane helices. SMART has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n3. PSIPRED: PSIPRED (Protein Secondary Structure Prediction by Hidden Markov Models) is a web-based tool that uses hidden Markov models to predict protein secondary structure. It can also predict beta-barrels, which are composed of multiple transmembrane helices. PSIPRED has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n4. IUPred: IUPred (Improved Prediction of Protein Secondary Structure) is a web-based tool that uses machine learning algorithms to predict protein secondary structure. It can also predict beta-barrels, which are composed of multiple transmembrane helices. IUPred has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n\nOverall, these computational tools are useful for predicting beta-barrel transmembrane proteins, and they can be used in combination to improve the accuracy of the predictions.",
    "llama-7b_fact_raw": "1. TMHMM is a computational tool used to predict transmembrane helices and beta-barrels in proteins.\n2. SMART is a web-based tool that predicts domains, functional sites, beta-barrels, and transmembrane helices in proteins.\n3. PSIPRED uses hidden Markov models to predict protein secondary structure, including beta-barrels composed of transmembrane helices.\n4. IUPred employs machine learning algorithms to predict protein secondary structure and is capable of predicting beta-barrels and transmembrane helices.\n5. The computational tools TMHMM, SMART, PSIPRED, and IUPred are widely used in bioinformatics research for the prediction of beta-barrel transmembrane proteins.",
    "llama-7b_fact": [
      "TMHMM is a computational tool used to predict transmembrane helices and beta-barrels in proteins.",
      "SMART is a web-based tool that predicts domains, functional sites, beta-barrels, and transmembrane helices in proteins.",
      "PSIPRED uses hidden Markov models to predict protein secondary structure, including beta-barrels composed of transmembrane helices.",
      "IUPred employs machine learning algorithms to predict protein secondary structure and is capable of predicting beta-barrels and transmembrane helices.",
      "The computational tools TMHMM, SMART, PSIPRED, and IUPred are widely used in bioinformatics research for the prediction of beta-barrel transmembrane proteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TMHMM is a computational tool used to predict transmembrane helices in proteins, but not specifically beta-barrels.\n2. FALSE [correction]: SMART is a web-based tool that predicts domains and functional sites in proteins, but does not predict beta-barrels or transmembrane helices.\n3. FALSE [correction]: PSIPRED uses artificial neural networks to predict protein secondary structure, not hidden Markov models, and it predicts alpha-helix and beta-strand content, rather than beta-barrels composed of transmembrane helices.\n4. FALSE [correction]: IUPred predicts disordered regions within proteins using statistical methods, not protein secondary structure, and it does not predict beta-barrels or transmembrane helices.\n5. UNKNOWN\n\nNote: The corrections are based on common knowledge regarding these bioinformatics tools as of my last update. For the most accurate and updated information about the capabilities of these tools, please refer to the specific documentation or publications related to the tools.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "Galassi classification is a system used to classify the severity of aortic stenosis, a condition in which the aortic valve narrows, making it difficult for blood to flow properly from the heart to the rest of the body. The classification system is based on the degree of narrowing of the aortic valve and is named after the Italian cardiologist who first described it, Giuseppe Galassi.\n\nGalassi classifies aortic stenosis into three categories:\n\n1. Galassi I: Mild aortic stenosis with a mean aortic valve area of 1.0 cm² or more.\n2. Galassi II: Moderate aortic stenosis with a mean aortic valve area of 0.6-1.0 cm².\n3. Galassi III: Severe aortic stenosis with a mean aortic valve area of less than 0.6 cm².\n\nGalassi classification is used to determine the severity of aortic stenosis and guide treatment options. It is typically used in conjunction with other diagnostic tests, such as echocardiography, to assess the condition of the aortic valve and determine the best course of treatment.",
    "llama-7b_fact_raw": "1. The Galassi classification is used to classify the severity of aortic stenosis.\n2. Aortic stenosis is a condition where the aortic valve narrows, hindering proper blood flow from the heart to the body.\n3. Giuseppe Galassi, an Italian cardiologist, first described the Galassi classification system.\n4. Galassi classification divides aortic stenosis into three categories: Galassi I (mild), Galassi II (moderate), and Galassi III (severe).\n5. Galassi III classification indicates severe aortic stenosis with a mean aortic valve area of less than 0.6 cm².",
    "llama-7b_fact": [
      "The Galassi classification is used to classify the severity of aortic stenosis.",
      "Aortic stenosis is a condition where the aortic valve narrows, hindering proper blood flow from the heart to the body.",
      "Giuseppe Galassi, an Italian cardiologist, first described the Galassi classification system.",
      "Galassi classification divides aortic stenosis into three categories: Galassi I (mild), Galassi II (moderate), and Galassi III (severe).",
      "Galassi III classification indicates severe aortic stenosis with a mean aortic valve area of less than 0.6 cm²."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is used to classify the anatomical types of accessory pathways or bypass tracts in patients with preexcitation syndromes, not the severity of aortic stenosis.\n2. TRUE\n3. UNKNOWN (The statement refers to a specific name, but without more context or background information, it's unclear if Giuseppe Galassi, an Italian cardiologist, described this system, or if it pertains to another field or context. Moreover, the Galassi classification typically known in the medical community is related to wrist anatomy pertinent to catheterization, not cardiac bypass tracts.)\n4. FALSE [correction]: The Galassi classification referred to in the medical literature often classifies wrist anatomy with respect to radial artery catheterization and not aortic stenosis. Also, the statement incorrectly describes categories of aortic stenosis instead of types of accessory pathways in patients with preexcitation syndromes or anatomy of the radial artery.\n5. FALSE [correction]: Since the Galassi classification does not pertain to aortic stenosis, the statement regarding the details of the Galassi III classification in the context of aortic stenosis is incorrect. The classification of aortic stenosis severity is typically based on various metrics, but is not divided into Galassi categories. Severe aortic stenosis based on the aortic valve area is generally defined as an area of less than 1.0 cm², not the 0.6 cm² mentioned.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "BRAG1 (BRCA1-associated glycoprotein 1) is a protein that plays a role in the repair of damaged DNA. Mutations in the BRAG1 gene have been linked to an increased risk of certain types of cancer, including breast, ovarian, and prostate cancer.\n\nSpecifically, mutations in the BRAG1 gene have been found to be associated with an increased risk of hereditary breast and ovarian cancer syndrome (HBOC), which is a genetic disorder that increases the risk of developing breast and ovarian cancer. Individuals with mutations in the BRAG1 gene may also have an increased risk of developing other types of cancer, such as prostate cancer.\n\nIn summary, mutations in the BRAG1 gene have been linked to an increased risk of cancer, particularly breast, ovarian, and prostate cancer. These mutations are associated with hereditary breast and ovarian cancer syndrome and may also increase the risk of developing other types of cancer.",
    "llama-7b_fact_raw": "1. Mutations in the BRAG1 gene are linked to an increased risk of certain types of cancer.\n2. BRAG1 (BRCA1-associated glycoprotein 1) is involved in the DNA repair process.\n3. Mutations in the BRAG1 gene are associated with an increased risk of breast cancer.\n4. Mutations in the BRAG1 gene are associated with an increased risk of ovarian cancer.\n5. Hereditary breast and ovarian cancer syndrome (HBOC) is linked to mutations in the BRAG1 gene.",
    "llama-7b_fact": [
      "Mutations in the BRAG1 gene are linked to an increased risk of certain types of cancer.",
      "BRAG1 (BRCA1-associated glycoprotein 1) is involved in the DNA repair process.",
      "Mutations in the BRAG1 gene are associated with an increased risk of breast cancer.",
      "Mutations in the BRAG1 gene are associated with an increased risk of ovarian cancer.",
      "Hereditary breast and ovarian cancer syndrome (HBOC) is linked to mutations in the BRAG1 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the BRCA1 gene, not BRAG1, are linked to an increased risk of certain types of cancer.\n2. FALSE [correction]: BRCA1 (Breast Cancer 1, early onset) is the gene involved in the DNA repair process, not BRAG1.\n3. FALSE [correction]: Mutations in the BRCA1 gene, not BRAG1, are associated with an increased risk of breast cancer.\n4. FALSE [correction]: Mutations in the BRCA1 gene, not BRAG1, are associated with an increased risk of ovarian cancer.\n5. FALSE [correction]: Hereditary breast and ovarian cancer syndrome (HBOC) is linked to mutations in the BRCA1 gene, not BRAG1.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "The main inhibitor of protein phosphatase 1 (PP1) is a protein called \"protein inhibitor of activated STAT1 (PIAS1)\". PIAS1 is a member of the protein inhibitor of activated STAT (PIAS) family of proteins, which are known to inhibit a variety of protein kinases and phosphatases, including PP1.\n\nPP1 is a serine/threonine protein phosphatase that plays a crucial role in regulating a variety of cellular processes, including cell growth, differentiation, and apoptosis. It is activated by the binding of its regulatory subunit, PP1gamma, to its substrate, protein kinase A (PKA). However, PP1 activity can also be inhibited by the binding of specific inhibitors, such as PIAS1.\n\nPIAS1 is a ubiquitously expressed protein that binds to and inhibits the activity of STAT1, a transcription factor that plays a key role in the immune response. PIAS1 also has been shown to inhibit a number of other protein kinases and phosphatases, including PP1.\n\nIn summary, PIAS1 is the main inhibitor of protein phosphatase 1 (PP1), and it plays an important role in regulating cellular processes by inhibiting the activity of a variety of protein kinases and phosphatases, including PP1.",
    "llama-7b_fact_raw": "1. Protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PP1 is a serine/threonine protein phosphatase involved in cellular processes like cell growth, differentiation, and apoptosis.\n3. PIAS1 is a member of the protein inhibitor of activated STAT family, which inhibits various protein kinases and phosphatases.\n4. PIAS1 ubiquitously binds to and inhibits the activity of STAT1, a transcription factor important for the immune response.\n5. PP1 is activated by the binding of its regulatory subunit PP1gamma to its substrate, protein kinase A (PKA).",
    "llama-7b_fact": [
      "Protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PP1 is a serine/threonine protein phosphatase involved in cellular processes like cell growth, differentiation, and apoptosis.",
      "PIAS1 is a member of the protein inhibitor of activated STAT family, which inhibits various protein kinases and phosphatases.",
      "PIAS1 ubiquitously binds to and inhibits the activity of STAT1, a transcription factor important for the immune response.",
      "PP1 is activated by the binding of its regulatory subunit PP1gamma to its substrate, protein kinase A (PKA)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Protein inhibitor of activated STAT1 (PIAS1) is known for its role in inhibiting the function of STAT proteins, particularly STAT1, rather than being the main inhibitor of protein phosphatase 1 (PP1).\n2. TRUE\n3. FALSE [correction]: PIAS proteins are involved in the regulation of STAT proteins and can also SUMOylate various proteins, but they are not known for inhibiting various protein kinases and phosphatases directly. Their main function involves the regulation of gene expression via interaction with STAT proteins.\n4. TRUE\n5. FALSE [correction]: PP1 is regulated by various regulatory subunits but PP1gamma is a catalytic subunit of protein phosphatase 1. The binding of protein kinase A (PKA) to a regulatory subunit is not what activates PP1. Instead, specific regulatory subunits determine PP1's subcellular localization and substrate specificity.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria, such as Bacillus subtilis, undergo a significant increase in mutation rates in response to stressful conditions, such as starvation or exposure to antibiotics. This increase in mutation rates allows the bacteria to adapt and survive in these stressful environments.\n\nThere are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. DNA Damage: One of the key mechanisms underlying adaptive mutagenesis is DNA damage. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, they undergo a significant increase in DNA damage. This DNA damage can lead to mutations, which can help the bacteria adapt and survive in these environments.\n2. Mutator Mutations: Another mechanism that underlies adaptive mutagenesis is the presence of mutator mutations. Mutator mutations are mutations that increase the mutation rate in the bacteria. These mutations can occur spontaneously or be passed down from one generation to the next. When bacteria with mutator mutations are exposed to stressful conditions, they undergo a significant increase in mutation rates, allowing them to adapt and survive in these environments.\n3. RecA Protein: The RecA protein is a key player in the repair of DNA damage in bacteria. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, the RecA protein is activated, leading to an increase in the mutation rate. This increase in mutation rate allows the bacteria to repair DNA damage and adapt to the stressful environment.\n4. Transcriptional Activation: Another mechanism that underlies adaptive mutagenesis is transcriptional activation. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, certain genes are activated, leading to an increase in the mutation rate. This increase in mutation rate allows the bacteria to adapt and survive in these environments.\n\nOverall, adaptive mutagenesis is a complex process that involves multiple mechanisms, including DNA damage, mutator mutations, the RecA protein,",
    "llama-7b_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis leads to an increased mutation rate in response to stressful conditions like starvation or antibiotics exposure.\n2. DNA damage is one of the mechanisms that contribute to the increased mutation rates during adaptive mutagenesis in Bacillus subtilis.\n3. Mutator mutations in Bacillus subtilis can increase the mutation rate, contributing to adaptive mutagenesis.\n4. The RecA protein plays a role in repairing DNA damage and increasing the mutation rate under stressful conditions in Bacillus subtilis.\n5. Transcriptional activation of certain genes in Bacillus subtilis can lead to an increased mutation rate during adaptive mutagenesis.",
    "llama-7b_fact": [
      "Adaptive mutagenesis in Bacillus subtilis leads to an increased mutation rate in response to stressful conditions like starvation or antibiotics exposure.",
      "DNA damage is one of the mechanisms that contribute to the increased mutation rates during adaptive mutagenesis in Bacillus subtilis.",
      "Mutator mutations in Bacillus subtilis can increase the mutation rate, contributing to adaptive mutagenesis.",
      "The RecA protein plays a role in repairing DNA damage and increasing the mutation rate under stressful conditions in Bacillus subtilis.",
      "Transcriptional activation of certain genes in Bacillus subtilis can lead to an increased mutation rate during adaptive mutagenesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucic acid is a type of fatty acid that is found in rapeseed (also known as canola) and other oilseed crops. Erucism is a condition that is caused by the consumption of foods that contain high levels of erucic acid.\n\nErucism is a rare condition that can cause a variety of symptoms, including nerve damage, muscle weakness, and heart problems. The exact cause of erucism is not fully understood, but it is believed to be related to the accumulation of erucic acid in the body.\n\nWhen erucic acid is consumed in large amounts, it can build up in the body and cause damage to cells and tissues. This can lead to a range of symptoms, including nerve damage, muscle weakness, and heart problems. Erucic acid can also interfere with the body's ability to use other fats, which can further contribute to the development of erucism.\n\nIt is worth noting that erucism is a rare condition and is typically only seen in people who consume large amounts of rapeseed oil or other foods that contain high levels of erucic acid. In most cases, the consumption of small amounts of rapeseed oil or other foods that contain erucic acid is not likely to cause any harm.",
    "llama-7b_fact_raw": "1. Erucism is a condition caused by the consumption of high levels of erucic acid found in foods.\n2. Erucic acid is found in rapeseed (also known as canola) and other oilseed crops.\n3. Symptoms of erucism may include nerve damage, muscle weakness, and heart problems.\n4. Accumulation of erucic acid in the body is linked to cell and tissue damage associated with erucism.\n5. Erucism is considered a rare condition, primarily affecting individuals who consume large amounts of foods high in erucic acid.",
    "llama-7b_fact": [
      "Erucism is a condition caused by the consumption of high levels of erucic acid found in foods.",
      "Erucic acid is found in rapeseed (also known as canola) and other oilseed crops.",
      "Symptoms of erucism may include nerve damage, muscle weakness, and heart problems.",
      "Accumulation of erucic acid in the body is linked to cell and tissue damage associated with erucism.",
      "Erucism is considered a rare condition, primarily affecting individuals who consume large amounts of foods high in erucic acid."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Symptoms of erucism are primarily characterized by myocardial lipidosis (fat infiltration of the heart), not specifically nerve damage or muscle weakness. Though some health concerns about heart problems associated with high levels of erucic acid intake have been raised, direct symptoms in humans are not clearly defined.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of urinary incontinence. Silicone is a synthetic material that is commonly used in medical devices and has been found to be effective in treating stress urinary incontinence (SUI), which is a type of incontinence that occurs due to pressure on the bladder during activities that put stress on the abdomen, such as coughing, sneezing, or lifting.\n\nSilicone is used to create a device called a urinary sling, which is a type of mesh implant that is placed around the urethra to support it and prevent urine from leaking out. The sling is typically made of silicone and is placed through a minimally invasive procedure that requires only small incisions in the abdomen.\n\nSilicone has several advantages as a material for urinary sling implants. It is biocompatible, meaning that it is not recognized as foreign by the body and is not likely to cause an immune response. It is also highly durable and can withstand the forces placed on the bladder during activities that cause SUI. Additionally, silicone is flexible and can conform to the shape of the body, which allows it to provide a stable support for the urethra while still allowing for normal movement and function.\n\nOverall, silicone has been found to be a safe and effective material for the treatment of urinary incontinence, particularly stress urinary incontinence. However, as with any medical treatment, there are potential risks and complications associated with the use of silicone implants, and patients should discuss the risks and benefits with their healthcare provider before deciding on a treatment option.",
    "llama-7b_fact_raw": "1. Silicone has been used in the treatment of urinary incontinence.\n2. Silicone is used to create a device known as a urinary sling to support the urethra and prevent urine from leaking out.\n3. The procedure for placing a urinary sling is minimally invasive, requiring only small incisions in the abdomen.\n4. Silicone is considered biocompatible, meaning it is not likely to cause an immune response when used in medical devices.\n5. Silicone has been found to be a safe and effective material for treating stress urinary incontinence (SUI).",
    "llama-7b_fact": [
      "Silicone has been used in the treatment of urinary incontinence.",
      "Silicone is used to create a device known as a urinary sling to support the urethra and prevent urine from leaking out.",
      "The procedure for placing a urinary sling is minimally invasive, requiring only small incisions in the abdomen.",
      "Silicone is considered biocompatible, meaning it is not likely to cause an immune response when used in medical devices.",
      "Silicone has been found to be a safe and effective material for treating stress urinary incontinence (SUI)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of the statements falls within the general understanding of medical uses of silicone, especially in the context of urological conditions, such as stress urinary incontinence (SUI). Silicone is indeed a material commonly used in medical devices due to its biocompatibility and has been used for the treatment of various conditions including urinary incontinence through devices like slings. The procedure for placing a sling can be minimally invasive, and silicone has been found to be a safe and effective material for this use.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association.\n\nIntracranial aneurysms are abnormal balloon-like bulges in the walls of blood vessels that supply the brain. These aneurysms can rupture and cause stroke, which is a leading cause of disability and death worldwide. Rupture of an intracranial aneurysm is a medical emergency that requires immediate treatment.\n\nSeveral studies have investigated the potential association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have found that the risk of rupture may be higher during certain phases of the moon, such as the full moon or the new moon. For example, one study found that the risk of rupture was highest during the full moon, while another study found that the risk was highest during the new moon.\n\nOther studies, however, have not found a consistent association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have suggested that the association may be due to confounding factors, such as changes in blood pressure or blood flow that occur during the different phases of the moon.\n\nOverall, the association between the moon cycle and the rupture risk of intracranial aneurysms is still not well understood, and more research is needed to clarify this relationship. It is important for patients with intracranial aneurysms to follow their doctor's recommendations for monitoring and management of their condition, regardless of the phase of the moon.",
    "llama-7b_fact_raw": "1. Some studies suggest a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others find no association.\n2. Intracranial aneurysms are balloon-like bulges in the walls of blood vessels in the brain, which can rupture and cause stroke.\n3. The rupture of an intracranial aneurysm is a leading cause of disability and death worldwide.\n4. One study found the risk of intracranial aneurysm rupture to be highest during the full moon phase.\n5. Another study found the risk of intracranial aneurysm rupture to be highest during the new moon phase.",
    "llama-7b_fact": [
      "Some studies suggest a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others find no association.",
      "Intracranial aneurysms are balloon-like bulges in the walls of blood vessels in the brain, which can rupture and cause stroke.",
      "The rupture of an intracranial aneurysm is a leading cause of disability and death worldwide.",
      "One study found the risk of intracranial aneurysm rupture to be highest during the full moon phase.",
      "Another study found the risk of intracranial aneurysm rupture to be highest during the new moon phase."
    ],
    "llama-7b_judge_raw": "1. TRUE: Some studies have indeed suggested a potential link between moon phases and various health outcomes, including the rupture risk of intracranial aneurysms, while others do not support such a link. This reflects the inconsistency in the literature.\n2. TRUE: Intracranial aneurysms are indeed balloon-like dilations of blood vessel walls in the brain, and their rupture can lead to a hemorrhagic stroke.\n3. TRUE: The rupture of an intracranial aneurysm can cause subarachnoid hemorrhage, which is a significant cause of stroke, disability, and death.\n4. UNKNOWN: Without specific references, it is impossible to confirm or deny the results of the study mentioned regarding the risk being highest during the full moon.\n5. UNKNOWN: Similarly, without specific references, it is not possible to ascertain the validity of the claim about the risk being highest during the new moon phase. If studies conflict on this matter, both statements 4 and 5 could be true, reflecting differing results from separate studies.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "The HuR (ELAVL1) protein is a member of the ELAV (embryonic lethal, abnormal vision) family of RNA-binding proteins, which play a role in the regulation of RNA metabolism. While there is evidence to suggest that HuR may be involved in the regulation of the splicing process, the precise mechanisms by which it does so are not fully understood.\n\nHuR has been shown to interact with a variety of RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs), and to play a role in the transport and stabilization of these RNAs. In addition, HuR has been implicated in the regulation of alternative splicing, a process by which different splicing variants of a single gene can be produced from a single gene transcript.\n\nFor example, studies have shown that HuR can interact with pre-mRNA splicing factors and modulate their activity, leading to changes in alternative splicing patterns. HuR has also been shown to interact with lncRNAs, which have been implicated in the regulation of alternative splicing, and to play a role in the transport and stabilization of these RNAs.\n\nOverall, while the precise mechanisms by which HuR regulates the splicing process are not fully understood, there is evidence to suggest that it may play a role in the regulation of alternative splicing by interacting with splicing factors and lncRNAs and modulating their activity. Further research is needed to fully elucidate the role of HuR in the regulation of the splicing process.",
    "llama-7b_fact_raw": "1. The HuR (ELAVL1) protein is a member of the ELAV family of RNA-binding proteins.\n2. HuR may be involved in the regulation of the splicing process, but the precise mechanisms are not fully understood.\n3. HuR has been shown to interact with various RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs).\n4. HuR has been implicated in the regulation of alternative splicing.\n5. Studies have shown that HuR can interact with pre-mRNA splicing factors and modulate their activity, affecting alternative splicing patterns.",
    "llama-7b_fact": [
      "The HuR (ELAVL1) protein is a member of the ELAV family of RNA-binding proteins.",
      "HuR may be involved in the regulation of the splicing process, but the precise mechanisms are not fully understood.",
      "HuR has been shown to interact with various RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs).",
      "HuR has been implicated in the regulation of alternative splicing.",
      "Studies have shown that HuR can interact with pre-mRNA splicing factors and modulate their activity, affecting alternative splicing patterns."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of the statements regarding HuR (ELAVL1) accurately describes the known functions and interactions of the protein based on current scientific understanding. HuR is indeed a member of the ELAV family of RNA-binding proteins that has been implicated in the regulation of various RNA processes, including alternative splicing. It interacts with different types of RNA molecules and has been shown to modulate the activity of splicing factors.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "Prothymosin alpha (PTMA) is a small protein that is expressed in a variety of tissues and plays a role in the regulation of cell growth and differentiation. The C-terminal peptide of PTMA, which is the portion of the protein that is located at the end of the polypeptide chain, has several known functions.\n\nOne known function of the PTMA C-terminal peptide is its ability to bind to and activate the JAK/STAT signaling pathway. The JAK/STAT pathway is a key signaling pathway that plays a role in the regulation of cell growth and differentiation, and it is activated in response to a variety of stimuli, such as growth factors and cytokines. The PTMA C-terminal peptide can bind to and activate the JAK/STAT pathway by interacting with the receptor for erythropoietin (EPO), which is a hormone that plays a role in the regulation of red blood cell production.\n\nAnother known function of the PTMA C-terminal peptide is its ability to regulate the activity of the androgen receptor (AR). The AR is a nuclear receptor that plays a role in the regulation of male sex characteristics, and it is activated in response to androgens, such as testosterone. The PTMA C-terminal peptide can bind to and activate the AR by interacting with the ligand-binding domain of the receptor.\n\nIn addition to its functions in the JAK/STAT and androgen receptor signaling pathways, the PTMA C-terminal peptide has also been shown to have other functions. For example, it has been shown to play a role in the regulation of cell survival and apoptosis, and it has also been shown to have anti-inflammatory effects.\n\nOverall, the PTMA C-terminal peptide has several known functions, including its ability to activate the JAK/STAT and androgen receptor signaling pathways, regulate cell survival and apoptosis, and have anti-inflammatory effects. These functions make the PTMA C-terminal peptide a promising target for the development of therapeutics for a",
    "llama-7b_fact_raw": "1. Prothymosin alpha (PTMA) is expressed in a variety of tissues and is involved in the regulation of cell growth and differentiation.\n2. The C-terminal peptide of PTMA can bind to and activate the JAK/STAT signaling pathway.\n3. The PTMA C-terminal peptide interacts with the receptor for erythropoietin (EPO) to regulate red blood cell production.\n4. The PTMA C-terminal peptide can regulate the activity of the androgen receptor (AR) by interacting with its ligand-binding domain.\n5. The PTMA C-terminal peptide is involved in regulation of cell survival and apoptosis, and exhibits anti-inflammatory effects.",
    "llama-7b_fact": [
      "Prothymosin alpha (PTMA) is expressed in a variety of tissues and is involved in the regulation of cell growth and differentiation.",
      "The C-terminal peptide of PTMA can bind to and activate the JAK/STAT signaling pathway.",
      "The PTMA C-terminal peptide interacts with the receptor for erythropoietin (EPO) to regulate red blood cell production.",
      "The PTMA C-terminal peptide can regulate the activity of the androgen receptor (AR) by interacting with its ligand-binding domain.",
      "The PTMA C-terminal peptide is involved in regulation of cell survival and apoptosis, and exhibits anti-inflammatory effects."
    ],
    "llama-7b_judge_raw": "1. TRUE: Prothymosin alpha (PTMA) is expressed in a variety of tissues and plays a role in cell proliferation and differentiation processes.\n2. UNKNOWN: The specific activity of the C-terminal peptide of PTMA on the JAK/STAT signaling pathway is not sufficiently defined in the provided context to confirm or correct.\n3. UNKNOWN: The interaction between the PTMA C-terminal peptide and the receptor for erythropoietin (EPO) to regulate red blood cell production cannot be assessed without additional context or scientific evidence.\n4. UNKNOWN: Without supporting evidence or scientific references, it is not possible to confirm or deny the statement about the PTMA C-terminal peptide's role in the regulation of the androgen receptor (AR) by interacting with its ligand-binding domain.\n5. TRUE: The PTMA C-terminal peptide has been implicated in the regulation of cell survival and apoptosis; however, while it has potential anti-inflammatory effects, this is a broad statement and would be dependent on the context in which the peptide is acting.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal domain (CTD) of cystatin C.\n\nCystatin C is a cysteine protease inhibitor that is widely expressed in various tissues and fluids, including plasma and urine. It plays an important role in regulating proteolytic activity and has been implicated in various physiological and pathological processes, including kidney function, inflammation, and neurodegeneration.\n\nCystatin C can exist in two forms: a soluble, monomeric form and a fibrillar, insoluble form. The fibrillar form of cystatin C is characterized by the formation of amyloid fibrils, which are insoluble, cross-linked aggregates of misfolded proteins. The fibrillization of cystatin C has been implicated in various diseases, including nephropathies, neurodegenerative disorders, and cardiovascular diseases.\n\nThe CTD of cystatin C has been shown to play a pivotal role in the fibrillization of cystatin C. The CTD is a highly conserved region of cystatin C that contains multiple disulfide bonds and is responsible for its enzymatic activity and interactions with other proteins. Studies have shown that mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and the development of cystatin C-related diseases.\n\nIn summary, the CTD of cystatin C plays a pivotal role in the fibrillization of cystatin C by promoting the formation of amyloid fibrils. Understanding the mechanisms underlying cystatin C fibrillization may provide insights into the pathogenesis of cystatin C-related diseases and may lead to the development of novel therapeutic strategies for their treatment.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is widely expressed in human tissues and fluids, including plasma and urine.\n3. Cystatin C acts as a cysteine protease inhibitor and is involved in regulating proteolytic activity.\n4. Amyloid fibrils formed during cystatin C fibrillization are insoluble, cross-linked aggregates of misfolded proteins.\n5. Mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and associated diseases.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is widely expressed in human tissues and fluids, including plasma and urine.",
      "Cystatin C acts as a cysteine protease inhibitor and is involved in regulating proteolytic activity.",
      "Amyloid fibrils formed during cystatin C fibrillization are insoluble, cross-linked aggregates of misfolded proteins.",
      "Mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and associated diseases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation:\n1. The C-terminal domain (CTD) of proteins often plays significant roles in their function and stability. In the case of cystatin C, changes in the CTD can indeed affect fibrillization, which is a key aspect in the formation of amyloid fibrils associated with diseases such as hereditary cerebral amyloid angiopathy.\n2. Cystatin C is a well-known cysteine protease inhibitor found in various human tissues and body fluids.\n3. The function of cystatin C as a potent inhibitor of cysteine proteases like cathepsins is well-established.\n4. Amyloid fibrils, in general, are identified as insoluble, cross-linked aggregates of misfolded proteins. This is a characteristic feature of fibrillization.\n5. Mutations in proteins, including those in cystatin C, particularly in regions important for maintaining their stable conformation, can indeed lead to misfolding and amyloid fibril formation, resulting in diseases.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "The concentration of protein hypoxia-inducible factor 1 alpha (HIF-1α) has not been extensively studied in relation to the administration of the cytoprotective prodrug amifostine (ethyol). However, there is some evidence to suggest that amifostine may protect against hypoxia-induced HIF-1α accumulation.\n\nHIF-1α is a transcription factor that plays a crucial role in the response to hypoxia. Under normoxic conditions, HIF-1α is rapidly degraded by the proteasome. However, under hypoxic conditions, HIF-1α accumulates and translocates to the nucleus, where it binds to DNA and activates the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, erythropoiesis, and glycolysis.\n\nAmifostine is a cytoprotective prodrug that has been shown to protect against the toxic effects of chemotherapy and radiation by reducing oxidative stress and inflammation. Amifostine has also been shown to protect against hypoxia-induced cell death in vitro and in vivo. However, the mechanisms by which amifostine exerts its cytoprotective effects are not fully understood.\n\nIt is possible that amifostine may protect against hypoxia-induced HIF-1α accumulation by reducing oxidative stress and inflammation. Oxidative stress and inflammation have been shown to play a role in the accumulation of HIF-1α under hypoxic conditions. Therefore, it is possible that amifostine may protect against hypoxia-induced HIF-1α accumulation by reducing oxidative stress and inflammation.\n\nIn summary, while there is some evidence to suggest that amifostine may protect against hypoxia-induced HIF-1α accumulation, the concentration of HIF-1α has not been extensively studied in relation to the administration of amifostine. Further research is needed to fully understand the mechanisms by which amifostine exerts its cytoprotective effects.",
    "llama-7b_fact_raw": "1. The concentration of HIF-1α in relation to amifostine administration has not been extensively studied.\n2. HIF-1α is a transcription factor involved in the body's response to hypoxia.\n3. Under normoxic conditions, HIF-1α is rapidly degraded, but under hypoxic conditions, it accumulates and activates genes related to hypoxia adaptation.\n4. Amifostine is known to protect against the toxic effects of chemotherapy and radiation by reducing oxidative stress and inflammation.\n5. There is evidence suggesting that amifostine may protect against hypoxia-induced HIF-1α accumulation.",
    "llama-7b_fact": [
      "The concentration of HIF-1α in relation to amifostine administration has not been extensively studied.",
      "HIF-1α is a transcription factor involved in the body's response to hypoxia.",
      "Under normoxic conditions, HIF-1α is rapidly degraded, but under hypoxic conditions, it accumulates and activates genes related to hypoxia adaptation.",
      "Amifostine is known to protect against the toxic effects of chemotherapy and radiation by reducing oxidative stress and inflammation.",
      "There is evidence suggesting that amifostine may protect against hypoxia-induced HIF-1α accumulation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe provided statements about the scientific characteristics of HIF-1α (hypoxia-inducible factor 1-alpha), amifostine, and their interactions under specific conditions may require specialized knowledge or access to specific scientific studies that are beyond common knowledge or the data available as of my last update. Hence, statements 1 and 5 are classified as UNKNOWN without additional context or references to specific research findings.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is an enzyme that adds a methyl group to histone H3 lysine 9 (H3K9me2) and histone H3 lysine 27 (H3K27me3) to mark specific regions of the genome for transcriptional repression.\n\nH3K9me2 is a mark that is associated with transcriptionally active regions of the genome, such as promoters and enhancers. It is deposited by Set7 and other histone methyltransferases, including G9a and ESET. H3K9me2 is typically found in euchromatic regions of the genome and is thought to play a role in the regulation of gene expression during development and differentiation.\n\nH3K27me3 is a mark that is associated with transcriptionally repressed regions of the genome, such as heterochromatin. It is deposited by Set7 and other histone methyltransferases, including G9a and ESET. H3K27me3 is typically found in heterochromatic regions of the genome and is thought to play a role in the silencing of repetitive elements and transposable elements.\n\nIn summary, Set7 deposits both H3K9me2 and H3K27me3 histone marks, which are involved in the regulation of gene expression and the silencing of repetitive elements and transposable elements in the genome.",
    "llama-7b_fact_raw": "1. Set7 adds a methyl group to histone H3 lysine 9, resulting in the histone mark H3K9me2.\n2. Set7 also adds a methyl group to histone H3 lysine 27, resulting in the histone mark H3K27me3.\n3. The histone mark H3K9me2 is associated with transcriptionally active regions of the genome.\n4. The histone mark H3K27me3 is associated with transcriptionally repressed regions of the genome.\n5. Other histone methyltransferases besides Set7, such as G9a and ESET, can also deposit H3K9me2 and H3K27me3 marks.",
    "llama-7b_fact": [
      "Set7 adds a methyl group to histone H3 lysine 9, resulting in the histone mark H3K9me2.",
      "Set7 also adds a methyl group to histone H3 lysine 27, resulting in the histone mark H3K27me3.",
      "The histone mark H3K9me2 is associated with transcriptionally active regions of the genome.",
      "The histone mark H3K27me3 is associated with transcriptionally repressed regions of the genome.",
      "Other histone methyltransferases besides Set7, such as G9a and ESET, can also deposit H3K9me2 and H3K27me3 marks."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Set7 adds a methyl group to histone H3 lysine 4, resulting in the histone mark H3K4me1.\n2. FALSE [correction]: Set7 does not add a methyl group to histone H3 lysine 27; rather, this mark is added by other methyltransferases like EZH2, which is a part of the Polycomb Repressive Complex 2 (PRC2).\n3. FALSE [correction]: The histone mark H3K9me2 is typically associated with transcriptionally repressed regions of the genome, not active ones.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is produced primarily by hepatocytes in the liver and acts as a negative regulator of iron absorption from the gut. Hepcidin binds to the iron transporter divalent metal transporter 1 (DMT1) on the surface of enterocytes in the small intestine, leading to the internalization and degradation of DMT1. This in turn reduces the absorption of dietary iron.\n\nDisulfide bridges are covalent bonds between two cysteine residues that have been oxidized and then reduced, resulting in the formation of a disulfide bond. The number of disulfide bridges in a protein can provide information about its structure, stability, and function.\n\nTo answer the question of how many disulfide bridges hepcidin has, we need to determine the amino acid sequence of the protein. Disulfide bridges are formed between cysteine residues that are located within a certain distance of each other, typically no more than 60-80 amino acids apart. Therefore, the number of disulfide bridges in hepcidin will depend on the number of cysteine residues present in the protein and their proximity to each other.\n\nIt is not possible for me to accurately determine the number of disulfide bridges in hepcidin without access to the amino acid sequence of the protein. However, it is known that hepcidin contains several cysteine residues, which are likely to form disulfide bridges. The exact number of disulfide bridges in hepcidin will depend on the specific amino acid sequence of the protein.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "DNAJC11 is a protein that is encoded by a gene located on chromosome 11q23.3. It is a member of the DNAJ (HSP40) family of proteins, which are involved in the transport and folding of proteins within the endoplasmic reticulum (ER) of eukaryotic cells.\n\nThe localization of DNAJC11 within the cell is important for its function in protein folding and transport. Studies have shown that DNAJC11 is primarily localized to the ER lumen, where it interacts with other ER-resident chaperones and proteins to facilitate the folding and assembly of newly synthesized proteins.\n\nIn addition to its role in protein folding, DNAJC11 has also been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of damaged organelles and proteins. Studies have shown that DNAJC11 can interact with autophagy-related proteins and play a role in the formation of autophagosomes, the membrane-bound structures that engulf and degrade damaged organelles and proteins.\n\nOverall, the localization of DNAJC11 to the ER lumen and its involvement in autophagy make it an important protein for maintaining cellular homeostasis and preventing the accumulation of damaged proteins and organelles.",
    "llama-7b_fact_raw": "1. The gene encoding DNAJC11 is located on chromosome 11q23.3.\n2. DNAJC11 is a member of the DNAJ (HSP40) family of proteins.\n3. DNAJC11 is involved in protein folding and transport within the endoplasmic reticulum.\n4. Studies indicate that DNAJC11 is primarily localized to the ER lumen.\n5. DNAJC11 has been implicated in the regulation of autophagy and may play a role in the formation of autophagosomes.",
    "llama-7b_fact": [
      "The gene encoding DNAJC11 is located on chromosome 11q23.3.",
      "DNAJC11 is a member of the DNAJ (HSP40) family of proteins.",
      "DNAJC11 is involved in protein folding and transport within the endoplasmic reticulum.",
      "Studies indicate that DNAJC11 is primarily localized to the ER lumen.",
      "DNAJC11 has been implicated in the regulation of autophagy and may play a role in the formation of autophagosomes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DNAJC11 is involved in mitochondrial morphogenesis and the maintenance of mitochondrial DNA, not primarily in protein folding and transport within the endoplasmic reticulum.\n4. FALSE [correction]: DNAJC11 is primarily localized to the mitochondria, not to the ER lumen.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are non-coding regions of the human genome that are highly conserved across different individuals and populations. They are defined as regions of at least 200 nucleotides that are identical in at least 95% of the human population. UCEs are thought to be functionally important and have been implicated in a variety of biological processes, including embryonic development, gene regulation, and disease susceptibility.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome. CNVs can arise through a variety of mechanisms, including duplication, deletion, and translocation, and have been implicated in a number of human diseases, including autism, schizophrenia, and cancer.\n\nIt is not clear whether UCEs are depleted among CNVs. Some studies have reported that UCEs are overrepresented among CNVs, suggesting that CNVs may be more likely to disrupt UCEs than other regions of the genome. However, other studies have found that UCEs are underrepresented among CNVs, suggesting that CNVs may be less likely to disrupt UCEs than other regions of the genome.\n\nOverall, the relationship between UCEs and CNVs is complex and not well understood. Further research is needed to clarify the frequency and impact of UCEs among CNVs.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are regions of at least 200 nucleotides that are identical in at least 95% of the human population.\n2. UCEs are highly conserved across different individuals and populations.\n3. UCEs have been implicated in embryonic development, gene regulation, and disease susceptibility.\n4. Copy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome.\n5. CNVs have been implicated in a number of human diseases, including autism, schizophrenia, and cancer.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are regions of at least 200 nucleotides that are identical in at least 95% of the human population.",
      "UCEs are highly conserved across different individuals and populations.",
      "UCEs have been implicated in embryonic development, gene regulation, and disease susceptibility.",
      "Copy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome.",
      "CNVs have been implicated in a number of human diseases, including autism, schizophrenia, and cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ultraconserved elements (UCEs) are regions of at least 200 nucleotides that are identical across different vertebrate species, not necessarily within the human population.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "The Haspin kinase is a serine/threonine kinase that plays a role in regulating the mitotic spindle assembly checkpoint in eukaryotic cells. During mitosis, the Haspin kinase is activated in response to spindle damage or kinetochore misalignment, and it phosphorylates several proteins to prevent the progression of anaphase until all spindle checkpoint proteins are properly attached to kinetochores.\n\nThe substrate of the Haspin kinase during mitosis is not well understood, and there is ongoing research to identify the specific proteins that are phosphorylated by the Haspin kinase. However, some studies have suggested that the Haspin kinase may phosphorylate and activate the protein BubR1, which is a key regulator of the mitotic spindle assembly checkpoint. Other potential substrates of the Haspin kinase during mitosis include the protein Mad2, which is also involved in the spindle checkpoint, and the protein Aurora B, which is involved in the formation and maintenance of the mitotic spindle.\n\nOverall, the substrate of the Haspin kinase during mitosis is an area of active research, and further studies are needed to fully understand the specific proteins that are phosphorylated by the Haspin kinase and how these phosphorylation events contribute to the regulation of the mitotic spindle assembly checkpoint.",
    "llama-7b_fact_raw": "1. The Haspin kinase is a serine/threonine kinase involved in regulating the mitotic spindle assembly checkpoint.\n2. The Haspin kinase becomes activated during mitosis in response to spindle damage or kinetochore misalignment.\n3. Studies have suggested that the Haspin kinase may phosphorylate the protein BubR1 during mitosis.\n4. The protein Mad2, involved in the spindle checkpoint, is a potential substrate of the Haspin kinase during mitosis.\n5. Aurora B, a protein involved in mitotic spindle formation and maintenance, might be phosphorylated by the Haspin kinase during mitosis.",
    "llama-7b_fact": [
      "The Haspin kinase is a serine/threonine kinase involved in regulating the mitotic spindle assembly checkpoint.",
      "The Haspin kinase becomes activated during mitosis in response to spindle damage or kinetochore misalignment.",
      "Studies have suggested that the Haspin kinase may phosphorylate the protein BubR1 during mitosis.",
      "The protein Mad2, involved in the spindle checkpoint, is a potential substrate of the Haspin kinase during mitosis.",
      "Aurora B, a protein involved in mitotic spindle formation and maintenance, might be phosphorylated by the Haspin kinase during mitosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Mad2, involved in the spindle checkpoint, is not a known substrate of Haspin kinase. Haspin kinase is known to phosphorylate histone H3 at threonine 3 (H3T3ph) during mitosis.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "Viroid replication is a process that occurs in the cytoplasm of infected plant cells. Viroids are small, circular, single-stranded RNA molecules that lack a protein coat and are unable to replicate on their own. Instead, they rely on the host cell's machinery for replication.\n\nThe mechanism of viroid replication involves the following steps:\n\n1. Entry into the host cell: Viroids enter the host cell through various mechanisms, such as by penetration of the cell membrane or uptake via endocytosis.\n2. Uncoating of the viroid: Once inside the host cell, the viroid is released from its protein coat.\n3. RNA replication: The viroid uses the host cell's ribonucleic acid (RNA) polymerase to synthesize a complementary strand of RNA. This process is initiated at the 5' end of the viroid and proceeds in the 5' to 3' direction.\n4. Maturation of the viroid: Once the complementary strand of RNA has been synthesized, the viroid undergoes maturation to form a double-stranded RNA molecule. This process involves the formation of a stem-loop structure at the 3' end of the viroid.\n5. Release of the mature viroid: The mature viroid is released from the host cell and can infect other cells.\n\nOverall, the mechanism of viroid replication involves the use of the host cell's RNA polymerase to synthesize a complementary strand of RNA, followed by maturation of the viroid into a double-stranded RNA molecule. This process occurs in the cytoplasm of infected plant cells and is essential for the survival and spread of viroids.",
    "llama-7b_fact_raw": "1. Viroid replication occurs in the cytoplasm of infected plant cells.\n2. Viroids are composed of small, circular, single-stranded RNA molecules without a protein coat.\n3. The replication of viroids involves hijacking the host cell's RNA polymerase to synthesize a complementary strand of RNA.\n4. The replication process of viroids starts at the 5' end and proceeds in the 5' to 3' direction.\n5. The mature viroid forms a double-stranded RNA molecule that includes a stem-loop structure at the 3' end.",
    "llama-7b_fact": [
      "Viroid replication occurs in the cytoplasm of infected plant cells.",
      "Viroids are composed of small, circular, single-stranded RNA molecules without a protein coat.",
      "The replication of viroids involves hijacking the host cell's RNA polymerase to synthesize a complementary strand of RNA.",
      "The replication process of viroids starts at the 5' end and proceeds in the 5' to 3' direction.",
      "The mature viroid forms a double-stranded RNA molecule that includes a stem-loop structure at the 3' end."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Viroid replication typically occurs in the nucleus of infected plant cells, not the cytoplasm.\n2. TRUE\n3. TRUE\n4. UNKNOWN: Without specific details on the polarity of viroid replication, it is difficult to confirm whether it starts at the 5' end and proceeds in the 5' to 3' direction. Viroid replication mechanisms might involve rolling-circle or asymmetric rolling-circle replication, and these processes can be complex.\n5. FALSE [correction]: The mature viroid is a single-stranded RNA molecule that can form a closed-loop structure due to internal base pairing, which often includes a stem-loop structure, but it is not double-stranded RNA.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that plays a role in cell-matrix adhesion and is found in the extracellular matrix. It is not a serum biomarker for Duchenne muscular dystrophy.\n\nDuchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The disease is caused by mutations in the dystrophin gene, which results in the absence of the protein dystrophin. Dystrophin is essential for maintaining the structure and function of muscle fibers.\n\nFibronectin is a protein that is found in the extracellular matrix and plays a role in cell-matrix adhesion. It is not directly related to the pathophysiology of DMD. While fibronectin has been studied in the context of muscular dystrophy, it has not been shown to be a serum biomarker for DMD.\n\nThere are several serum biomarkers that have been studied in the context of DMD, including creatine kinase, muscle-specific kinase, and myoglobin. These biomarkers can be used to diagnose and monitor the progression of the disease. However, they are not specific to DMD and can also be elevated in other muscle disorders.\n\nIn summary, while fibronectin is a protein that plays a role in muscle function, it is not a serum biomarker for Duchenne muscular dystrophy. There are other serum biomarkers that have been studied in the context of DMD, including creatine kinase, muscle-specific kinase, and myoglobin. These biomarkers can be used to diagnose and monitor the progression of the disease, but they are not specific to DMD and can also be elevated in other muscle disorders.",
    "llama-7b_fact_raw": "1. Fibronectin is not a serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Duchenne muscular dystrophy is caused by mutations in the dystrophin gene.\n3. The absence of the dystrophin protein leads to progressive muscle degeneration and weakness in DMD.\n4. Fibronectin plays a role in cell-matrix adhesion and is found in the extracellular matrix.\n5. Creatine kinase, muscle-specific kinase, and myoglobin are examples of serum biomarkers studied in the context of DMD.",
    "llama-7b_fact": [
      "Fibronectin is not a serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Duchenne muscular dystrophy is caused by mutations in the dystrophin gene.",
      "The absence of the dystrophin protein leads to progressive muscle degeneration and weakness in DMD.",
      "Fibronectin plays a role in cell-matrix adhesion and is found in the extracellular matrix.",
      "Creatine kinase, muscle-specific kinase, and myoglobin are examples of serum biomarkers studied in the context of DMD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Fibronectin has been studied as a serum biomarker for Duchenne muscular dystrophy (DMD).\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. ENCODE (Encyclopedia of DNA Elements): This project aims to identify and characterize all functional elements in the human genome, including regulatory elements such as promoters, enhancers, and silencers. The ENCODE data in DeepBlue includes ChIP-seq (chromatin immunoprecipitation sequencing) data for histone modifications, transcription factors, and other regulatory elements.\n2. Roadmap Epigenomics Project: This project aims to create a comprehensive resource for epigenomic data across human cells and tissues. The Roadmap Epigenomics data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n3. Epigenomic Roadmap Project: This project aims to create a comprehensive resource for epigenomic data across mouse cells and tissues. The Epigenomic Roadmap data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n4. Human Epigenome Atlas: This project aims to create a comprehensive resource for epigenomic data across a variety of human tissues and cell types. The Human Epigenome Atlas data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n\nThese are just a few examples of the major epigenome projects that are represented in the DeepBlue epigenomic data server. The server also contains data from many other smaller projects and individual research groups, providing a comprehensive resource for epigenomic data across a wide range of organisms and tissues.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project, which focuses on identifying all functional elements in the human genome.\n2. The ENCODE project data within DeepBlue includes ChIP-seq data for histone modifications and transcription factors.\n3. The Roadmap Epigenomics Project data, which is aimed at creating a comprehensive resource for human epigenomic data, is contained within the DeepBlue epigenomic data server.\n4. The Epigenomic Roadmap Project, aiming at mouse cells and tissues, also contributes epigenomic data to the DeepBlue epigenomic data server.\n5. The DeepBlue epigenomic data server includes data from the Human Epigenome Atlas, which provides epigenomic data across various human tissues and cell types.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project, which focuses on identifying all functional elements in the human genome.",
      "The ENCODE project data within DeepBlue includes ChIP-seq data for histone modifications and transcription factors.",
      "The Roadmap Epigenomics Project data, which is aimed at creating a comprehensive resource for human epigenomic data, is contained within the DeepBlue epigenomic data server.",
      "The Epigenomic Roadmap Project, aiming at mouse cells and tissues, also contributes epigenomic data to the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server includes data from the Human Epigenome Atlas, which provides epigenomic data across various human tissues and cell types."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Roadmap Epigenomics Project focuses on human cells and tissues, not mouse cells and tissues.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the software package PAML (Phylogenetic Analysis by Maximum Likelihood).\n\nSOMs are a type of unsupervised machine learning algorithm that can be used to analyze and visualize high-dimensional data. In the context of codon usage analysis, SOMs can be used to identify clusters of synonymous codons that exhibit similar patterns of usage across different species.\n\nPAML is a widely used software package for conducting phylogenetic analysis of molecular sequences. It includes a module called \"ModelAver\" that can be used to analyze synonymous codon usage patterns across different species. ModelAver uses SOMs to identify clusters of synonymous codons that exhibit similar patterns of usage, and it can also perform statistical tests to compare the usage patterns of different codons within each cluster.\n\nOverall, PAML is a powerful tool for analyzing synonymous codon usage patterns across multiple species, and its use of SOMs provides a useful way to visualize and interpret the results of these analyses.",
    "llama-7b_fact_raw": "1. Self-organizing maps (SOMs) are employed by the software package PAML for analyzing synonymous codon usage.\n2. SOMs are a type of unsupervised machine learning algorithm.\n3. PAML is a software package used for conducting phylogenetic analysis of molecular sequences.\n4. The module \"ModelAver\" within PAML can analyze synonymous codon usage patterns across different species.\n5. ModelAver in PAML uses SOMs to identify clusters of synonymous codons with similar usage patterns and can perform statistical tests within clusters.",
    "llama-7b_fact": [
      "Self-organizing maps (SOMs) are employed by the software package PAML for analyzing synonymous codon usage.",
      "SOMs are a type of unsupervised machine learning algorithm.",
      "PAML is a software package used for conducting phylogenetic analysis of molecular sequences.",
      "The module \"ModelAver\" within PAML can analyze synonymous codon usage patterns across different species.",
      "ModelAver in PAML uses SOMs to identify clusters of synonymous codons with similar usage patterns and can perform statistical tests within clusters."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Self-organizing maps (SOMs) are not employed by the software package PAML for analyzing synonymous codon usage. PAML is used for phylogenetic analyses, and while it might analyze codon usage, it does not use self-organizing maps for this purpose.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: There is no indication that a module named \"ModelAver\" exists within PAML, and even if it did, based on the previous corrections, it is unlikely that it uses SOMs for the analysis of synonymous codon usage. PAML uses maximum likelihood estimation for statistical inference but not SOMs for this purpose.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MINDY-1.\" Can you provide more context or information about what you are referring to? This will help me better understand your question and provide a more accurate answer.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n\n1. RepeatMasker: RepeatMasker is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n2. RepeatScout: RepeatScout is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n3. Genomic Repeats Finder: Genomic Repeats Finder is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n4. RepeatAnno: RepeatAnno is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n5. RepeatModeler: RepeatModeler is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n\nThese are just a few examples of the many software packages available",
    "llama-7b_fact_raw": "1. RepeatMasker is a software tool used for identifying repetitive elements and predicting conserved genomic regions.\n2. RepeatScout is a software tool designed to identify repetitive elements in genomic DNA.\n3. Genomic Repeats Finder is used for identifying repetitive elements and predicting the location of conserved genomic regions.\n4. RepeatAnno can be utilized to identify repetitive elements such as microsatellites and transposable elements in genomic DNA.\n5. RepeatModeler is a software tool that helps in identifying repetitive elements and predicting conserved regions in genomic DNA.",
    "llama-7b_fact": [
      "RepeatMasker is a software tool used for identifying repetitive elements and predicting conserved genomic regions.",
      "RepeatScout is a software tool designed to identify repetitive elements in genomic DNA.",
      "Genomic Repeats Finder is used for identifying repetitive elements and predicting the location of conserved genomic regions.",
      "RepeatAnno can be utilized to identify repetitive elements such as microsatellites and transposable elements in genomic DNA.",
      "RepeatModeler is a software tool that helps in identifying repetitive elements and predicting conserved regions in genomic DNA."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RepeatMasker is a software tool used for identifying and masking repetitive elements in genomic DNA, not specifically for predicting conserved genomic regions.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: RepeatModeler is a software tool that helps in identifying de novo repeat families, not specifically predicting conserved regions in genomic DNA.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "The PIEZO2 gene is associated with several diseases, including:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that causes abnormal blood vessels to form in the skin, mucous membranes, and organs. The PIEZO2 gene plays a role in the development of blood vessels, and mutations in this gene can increase the risk of HHT.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. Mutations in the PIEZO2 gene have been associated with a specific subtype of EDS known as EDS type 3B.\n3. Autosomal dominant polycystic kidney disease (ADPKD): ADPKD is a genetic disorder that causes the kidneys to become enlarged and filled with cysts. The PIEZO2 gene plays a role in the development of the kidneys, and mutations in this gene can increase the risk of ADPKD.",
    "llama-7b_fact_raw": "1. PIEZO2 gene mutations can increase the risk of hereditary hemorrhagic telangiectasia (HHT).\n2. Mutations in the PIEZO2 gene have been associated with a specific subtype of Ehlers-Danlos syndrome (EDS) known as EDS type 3B.\n3. The PIEZO2 gene plays a role in kidney development, and mutations in this gene can increase the risk of autosomal dominant polycystic kidney disease (ADPKD).",
    "llama-7b_fact": [
      "PIEZO2 gene mutations can increase the risk of hereditary hemorrhagic telangiectasia (HHT).",
      "Mutations in the PIEZO2 gene have been associated with a specific subtype of Ehlers-Danlos syndrome (EDS) known as EDS type 3B.",
      "The PIEZO2 gene plays a role in kidney development, and mutations in this gene can increase the risk of autosomal dominant polycystic kidney disease (ADPKD)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: PIEZO2 gene mutations are known for causing a condition related to touch and proprioception issues, but they have not been associated with hereditary hemorrhagic telangiectasia (HHT), which is more commonly related to mutations in genes like ENG, ACVRL1, and SMAD4.\n2. FALSE [correction]: Mutations in the PIEZO2 gene have been associated with distal arthrogryposis and Gordon syndrome, but not with Ehlers-Danlos syndrome. EDS type 3, now known as the hypermobile type, has not been linked to the PIEZO2 gene but rather is often diagnosed based on clinical evaluation due to the lack of a definitive genetic marker.\n3. FALSE [correction]: The PIEZO2 gene is indeed implicated in the body's mechanical responses and proprioception, but there is no established link between PIEZO2 gene mutations and autosomal dominant polycystic kidney disease (ADPKD). ADPKD is more typically associated with mutations in the PKD1 and PKD2 genes.",
    "llama-7b_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two proteins that are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells (APCs), such as dendritic cells and macrophages. These proteins belong to the ERAP (endoplasmic reticulum aminopeptidase) family and play a crucial role in the maturation and presentation of peptides derived from pathogens and self-antigens.\n\nERAP1 and ERAP2 are both expressed in the endoplasmic reticulum (ER) of APCs, where they process and trim peptides derived from pathogens and self-antigens. ERAP1 and ERAP2 then transport these peptides to the Golgi apparatus, where they are further processed and presented on the surface of APCs in the context of major histocompatibility complex (MHC) molecules.\n\nERAP1 and ERAP2 can exist as monomers or dimers in the ER and Golgi apparatus. The dimerization of ERAP1 and ERAP2 has been shown to play an important role in the processing and presentation of antigenic peptides. When ERAP1 and ERAP2 form a dimer, they can interact with each other and process peptides more efficiently, leading to the production of higher-quality peptides that are better suited for presentation on the surface of APCs.\n\nIn addition, ERAP1-ERAP2 dimerization has been shown to play a role in the regulation of the immune response. For example, ERAP1 and ERAP2 can interact with each other and with other immune signaling molecules, such as Toll-like receptors (TLRs) and interleukin-1 (IL-1), to regulate the production of pro-inflammatory cytokines and the activation of immune cells.\n\nOverall, ERAP1-ERAP2 dimerization plays an important role in the processing and presentation of antigenic peptides, as well as in the regulation of the immune response. Dimerization allows ERAP1 and ERAP2 to interact with each other and with other immune signaling molecules, leading to the production of higher-quality peptides and the regulation of",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells.\n2. ERAP1-ERAP2 dimerization is important for the efficient processing and presentation of peptides in the context of major histocompatibility complex (MHC) molecules.\n3. ERAP1 and ERAP2 are part of the endoplasmic reticulum aminopeptidase (ERAP) family and are expressed in the endoplasmic reticulum of antigen-presenting cells.\n4. The dimerization of ERAP1 and ERAP2 leads to more efficient interaction and processing of peptides, resulting in higher-quality peptides for presentation.\n5. ERAP1-ERAP2 dimerization is involved in the regulation of the immune response, including the regulation of pro-inflammatory cytokines and the activation of immune cells.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells.",
      "ERAP1-ERAP2 dimerization is important for the efficient processing and presentation of peptides in the context of major histocompatibility complex (MHC) molecules.",
      "ERAP1 and ERAP2 are part of the endoplasmic reticulum aminopeptidase (ERAP) family and are expressed in the endoplasmic reticulum of antigen-presenting cells.",
      "The dimerization of ERAP1 and ERAP2 leads to more efficient interaction and processing of peptides, resulting in higher-quality peptides for presentation.",
      "ERAP1-ERAP2 dimerization is involved in the regulation of the immune response, including the regulation of pro-inflammatory cytokines and the activation of immune cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN - While it is known that ERAP1 and ERAP2 are involved in antigen processing, and dimerization might affect their function, the direct link to more efficient interaction and processing leading to higher-quality peptides due to dimerization is complex and can depend on the context. More information is needed to confirm this statement.\n5. TRUE - ERAP1 and ERAP2 are indeed involved in the regulation of the immune response, and their activity can affect the levels of pro-inflammatory cytokines and the activation of immune cells by influencing the presentation of antigenic peptides.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are two proteins that play important roles in the regulation of gallbladder development and function.\n\nR-spondin 1 is a member of the R-spondin family of proteins, which are secreted by various tissues and have been implicated in the regulation of bone growth and development. In the gallbladder, R-spondin 1 has been shown to play a role in the regulation of cholesterol synthesis and secretion. Specifically, R-spondin 1 has been shown to stimulate the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n\nNoggin, on the other hand, is a protein that has been shown to inhibit the activity of bone morphogenetic proteins (BMPs), which are signaling molecules that play important roles in the regulation of cell growth and differentiation. In the gallbladder, noggin has been shown to play a role in the regulation of cholesterol synthesis and secretion. Specifically, noggin has been shown to inhibit the activity of BMPs, which in turn has been shown to inhibit the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n\nIn summary, R-spondin 1 and noggin play important roles in the regulation of cholesterol synthesis and secretion in the gallbladder. R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion, while noggin inhibits the activity of BMPs, which in turn inhibits the expression of genes involved in cholesterol synthesis and secretion.",
    "llama-7b_fact_raw": "1. R-spondin 1 is involved in regulating cholesterol synthesis and secretion in gallbladder cells.\n2. R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n3. Noggin is known to inhibit the activity of bone morphogenetic proteins (BMPs).\n4. BMPs are involved in the regulation of cell growth and differentiation.\n5. In the gallbladder, noggin inhibits the expression of genes involved in cholesterol synthesis and secretion by affecting BMP activity.",
    "llama-7b_fact": [
      "R-spondin 1 is involved in regulating cholesterol synthesis and secretion in gallbladder cells.",
      "R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.",
      "Noggin is known to inhibit the activity of bone morphogenetic proteins (BMPs).",
      "BMPs are involved in the regulation of cell growth and differentiation.",
      "In the gallbladder, noggin inhibits the expression of genes involved in cholesterol synthesis and secretion by affecting BMP activity."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: There is no widely recognized or direct association between R-spondin 1 and cholesterol synthesis in gallbladder cells in the available scientific literature up to my knowledge cutoff date. R-spondin proteins are generally known for their role in the Wnt signaling pathway.\n2. UNKNOWN: As the role of R-spondin 1 in cholesterol synthesis in gallbladder cells is not established, it's not possible to confirm whether it stimulates the expression of genes involved without specific context or citation.\n3. TRUE: Noggin is indeed known to inhibit the activity of bone morphogenetic proteins (BMPs), which are involved in various developmental processes including bone formation.\n4. TRUE: BMPs (bone morphogenetic proteins) are indeed involved in the regulation of cell growth, differentiation, and are important for the development of bone and cartilage.\n5. UNKNOWN: Without specific context, it is difficult to verify whether noggin directly affects cholesterol synthesis and secretion in the gallbladder through inhibition of BMP activity. The function of noggin is to inhibit BMPs, but its specific role in gallbladder cells concerning cholesterol synthesis and secretion would require more detailed scientific insight.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires multiple subunits for its function. NOX5 is a member of the NADPH oxidase family of enzymes, which generate reactive oxygen species (ROS) through the oxidation of NADPH.\n\nNOX5 is composed of two catalytic subunits, p22phox and p40phox, and two regulatory subunits, p67phox and p41phox. The p22phox and p40phox subunits are required for the enzymatic activity of NOX5, while the p67phox and p41phox subunits play a role in the targeting and localization of NOX5 to specific cellular compartments.\n\nIn the absence of one or more of the NOX5 subunits, the enzymatic activity of NOX5 is reduced or absent, leading to a decrease in ROS production and a corresponding impact on cellular function. For example, mice lacking the p22phox subunit have a reduced ability to mount an immune response to bacterial infections, while mice lacking the p41phox subunit have an increased susceptibility to inflammation and tissue damage.\n\nOverall, NOX5 requires all of its subunits for proper function, and the absence of any one of these subunits can result in altered ROS production and cellular responses.",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires multiple subunits for its function.\n2. NOX5 includes two catalytic subunits named p22phox and p40phox.\n3. NOX5 contains two regulatory subunits called p67phox and p41phox.\n4. The enzymatic activity of NOX5 can be reduced or absent without one or more of its subunits.\n5. Mice lacking the p22phox subunit show a reduced ability to mount an immune response to bacterial infections.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires multiple subunits for its function.",
      "NOX5 includes two catalytic subunits named p22phox and p40phox.",
      "NOX5 contains two regulatory subunits called p67phox and p41phox.",
      "The enzymatic activity of NOX5 can be reduced or absent without one or more of its subunits.",
      "Mice lacking the p22phox subunit show a reduced ability to mount an immune response to bacterial infections."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is a calcium-dependent, single polypeptide enzyme that does not require multiple subunits for its function, unlike other NOX isoforms.\n2. FALSE [correction]: NOX5 does not contain the catalytic subunits p22phox and p40phox. These subunits are part of other NOX complexes but not NOX5, which is a standalone enzyme.\n3. FALSE [correction]: NOX5 does not contain the regulatory subunits p67phox and p47phox. Different conserved domains within its structure serve regulatory functions.\n4. TRUE: Since NOX5 is a single polypeptide enzyme, if parts of its structure are modified or absent, the enzymatic activity can indeed be reduced or absent.\n5. UNKNOWN: This statement is about the p22phox subunit, which is not a part of NOX5, and thus commenting on the immune response in mice lacking this subunit would require specific knowledge about studies conducted on mice with a deficiency in a NOX subunit other than NOX5.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are two distinct proteins that have different functions in the body. Furin is an enzyme that plays a role in the processing and activation of other proteins, while hepcidin is a hormone that regulates iron absorption and storage in the body.\n\nFurin is an asparaginyl endopeptidase enzyme that cleaves peptide bonds between asparagine residues in proteins. It is involved in the processing and activation of various proteins, including growth factors, cytokines, and hormones. Furin is expressed in many tissues, including the liver, kidney, and pancreas, and plays a role in the regulation of various physiological processes, including cell growth, differentiation, and inflammation.\n\nHepcidin, on the other hand, is a hormone that is produced by hepatocytes in the liver. It is the primary regulator of iron absorption and storage in the body. Hepcidin binds to and inhibits the expression of divalent metal transporter 1 (DMT1), a transmembrane protein that facilitates the uptake of iron from the diet into enterocytes in the small intestine. By inhibiting DMT1, hepcidin prevents the absorption of dietary iron and maintains iron homeostasis in the body.\n\nDespite their different functions, there is a connection between furin and hepcidin. Recent studies have shown that furin can play a role in the regulation of hepcidin expression and activity. For example, furin has been shown to cleave and activate hepcidin, which can enhance its biological activity and increase iron absorption. Conversely, inhibition of furin activity has been shown to decrease hepcidin expression and iron absorption.\n\nFurthermore, there is evidence to suggest that hepcidin can regulate the activity of furin. For example, hepcidin has been shown to inhibit the activity of furin, which can decrease the processing and activation of other proteins.\n\nIn summary, while furin and hepcidin are two distinct proteins with different functions, there is a connection between them. Furin can play a role in the",
    "llama-7b_fact_raw": "1. Furin is an enzyme that aids in processing and activating various proteins, such as growth factors, cytokines, and hormones.\n2. Hepcidin is a hormone produced by hepatocytes in the liver and regulates iron absorption and storage in the body.\n3. Furin is an asparaginyl endopeptidase that cleaves peptide bonds between asparagine residues in proteins.\n4. Hepcidin functions by binding to and inhibiting the expression of divalent metal transporter 1 (DMT1), impeding dietary iron absorption.\n5. Research suggests furin can regulate hepcidin expression and activity, and conversely, hepcidin can regulate the activity of furin.",
    "llama-7b_fact": [
      "Furin is an enzyme that aids in processing and activating various proteins, such as growth factors, cytokines, and hormones.",
      "Hepcidin is a hormone produced by hepatocytes in the liver and regulates iron absorption and storage in the body.",
      "Furin is an asparaginyl endopeptidase that cleaves peptide bonds between asparagine residues in proteins.",
      "Hepcidin functions by binding to and inhibiting the expression of divalent metal transporter 1 (DMT1), impeding dietary iron absorption.",
      "Research suggests furin can regulate hepcidin expression and activity, and conversely, hepcidin can regulate the activity of furin."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Furin is not an asparaginyl endopeptidase; rather, it is a subtilisin-like proprotein convertase that cleaves peptide bonds at specific arginine residues in proteins.\n4. FALSE [correction]: Hepcidin functions by binding to and causing the degradation of ferroportin, blocking iron export from cells, not by inhibiting the expression of divalent metal transporter 1 (DMT1).\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "The largest metabolic gene cluster in yeast is the pyruvate dehydrogenase (PDH) complex, which is responsible for converting pyruvate into acetyl-CoA, an important intermediate in cellular metabolism. The PDH complex is composed of four subunits: E1 (pyruvate dehydrogenase), E2 (dihydrolipoyl succinyltransferase), E3 (dihydrolipoyl dehydrogenase), and E4 (dihydrolipoyl dehydrogenase).\n\nThe PDH complex is one of the largest metabolic gene clusters in yeast because it is composed of multiple genes that are co-transcribed and co-translated. The genes for the four subunits of the PDH complex are located on different chromosomes, but they are transcribed as a single unit and translated as a single polypeptide chain. This co-transcription and co-translation of multiple genes is a common feature of many metabolic gene clusters in yeast and other organisms.\n\nThe PDH complex is also one of the largest metabolic gene clusters in yeast because it plays a critical role in cellular metabolism. The conversion of pyruvate into acetyl-CoA is an important step in the citric acid cycle, which is the primary means by which cells generate energy in the form of ATP. Disruption of the PDH complex can lead to a variety of metabolic disorders, including lactic acidosis, diabetes, and liver disease.\n\nOverall, the PDH complex is the largest metabolic gene cluster in yeast because it is composed of multiple genes that are co-transcribed and co-translated, and it plays a critical role in cellular metabolism.",
    "llama-7b_fact_raw": "1. The pyruvate dehydrogenase (PDH) complex is the largest metabolic gene cluster in yeast.\n2. The PDH complex is responsible for converting pyruvate into acetyl-CoA.\n3. The PDH complex is composed of four subunits: E1, E2, E3, and E4.\n4. The genes for the four subunits of the PDH complex are transcribed as a single unit and translated as a single polypeptide chain.\n5. Disruption of the PDH complex can lead to metabolic disorders such as lactic acidosis, diabetes, and liver disease.",
    "llama-7b_fact": [
      "The pyruvate dehydrogenase (PDH) complex is the largest metabolic gene cluster in yeast.",
      "The PDH complex is responsible for converting pyruvate into acetyl-CoA.",
      "The PDH complex is composed of four subunits: E1, E2, E3, and E4.",
      "The genes for the four subunits of the PDH complex are transcribed as a single unit and translated as a single polypeptide chain.",
      "Disruption of the PDH complex can lead to metabolic disorders such as lactic acidosis, diabetes, and liver disease."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without more specific information about gene clusters in yeast and the context in which this statement is made, it's hard to confirm if the PDH complex is the largest metabolic gene cluster in yeast.\n2. TRUE: The pyruvate dehydrogenase complex indeed catalyzes the conversion of pyruvate into acetyl-CoA, which is a critical step in cellular respiration.\n3. FALSE [correction]: The PDH complex is typically described as having three core enzymes: E1 (pyruvate dehydrogenase), E2 (dihydrolipoyl transacetylase), and E3 (dihydrolipoyl dehydrogenase). There is no widely recognized E4 subunit in the complex.\n4. FALSE [correction]: The genes for the subunits of the PDH complex are not transcribed and translated as a single unit or polypeptide chain. Each subunit is encoded by a separate gene and the proteins assemble into the complex after being synthesized.\n5. TRUE: Dysfunctions in the PDH complex can indeed lead to various metabolic disorders, including lactic acidosis. The relationship to diabetes and liver disease can be more indirect and part of a larger set of metabolic disruptions.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "Long non-coding RNA (lncRNA) LIMT has been shown to play a crucial role in various biological processes, including cell proliferation, differentiation, and apoptosis. LIMT lncRNA has also been implicated in the regulation of gene expression at the transcriptional level.\n\nOne of the key functions of LIMT lncRNA is to act as a competing endogenous RNA (ceRNA) molecule. ceRNAs are non-coding RNAs that can bind to microRNAs (miRNAs) and prevent them from binding to their target mRNAs, thereby regulating gene expression. LIMT lncRNA has been shown to function as a miRNA sponge, binding to miRNAs and preventing them from targeting specific mRNAs.\n\nFor example, LIMT lncRNA has been shown to bind to let-7 family miRNAs and prevent them from targeting PTEN, a tumor suppressor gene. This leads to the deregulation of PTEN expression and contributes to the development of various cancers.\n\nIn addition to its ceRNA function, LIMT lncRNA has also been shown to regulate gene expression at the transcriptional level. LIMT lncRNA has been shown to bind to the promoter region of target genes and recruit transcriptional co-activators, leading to the activation of gene transcription.\n\nFurthermore, LIMT lncRNA has also been shown to play a role in the regulation of cellular signaling pathways. For example, LIMT lncRNA has been shown to bind to the androgen receptor (AR) and enhance its transcriptional activity, thereby promoting the growth of prostate cancer cells.\n\nIn summary, LIMT lncRNA plays a crucial role in regulating gene expression at the transcriptional and post-transcriptional levels, and contributes to various biological processes, including cell proliferation, differentiation, and apoptosis. Its deregulation has been implicated in the development of various diseases, including cancer.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is involved in cell proliferation, differentiation, and apoptosis.\n2. LIMT lncRNA functions as a competing endogenous RNA (ceRNA) that can bind to microRNAs.\n3. LIMT lncRNA has been shown to bind to let-7 family microRNAs, affecting the expression of the PTEN tumor suppressor gene.\n4. LIMT lncRNA can bind to the promoter region of target genes and recruit transcriptional co-activators.\n5. LIMT lncRNA is implicated in enhancing the transcriptional activity of the androgen receptor (AR), affecting prostate cancer cell growth.",
    "llama-7b_fact": [
      "LIMT lncRNA is involved in cell proliferation, differentiation, and apoptosis.",
      "LIMT lncRNA functions as a competing endogenous RNA (ceRNA) that can bind to microRNAs.",
      "LIMT lncRNA has been shown to bind to let-7 family microRNAs, affecting the expression of the PTEN tumor suppressor gene.",
      "LIMT lncRNA can bind to the promoter region of target genes and recruit transcriptional co-activators.",
      "LIMT lncRNA is implicated in enhancing the transcriptional activity of the androgen receptor (AR), affecting prostate cancer cell growth."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - Based on the context given, assuming that the \"PTEN tumor suppressor gene\" is relevant to the LIMT lncRNA's mechanism of action and the specific microRNAs it binds to.\n4. FALSE [correction]: LncRNAs such as LIMT can interact with various molecules in the cell, but they do not directly bind to the promoter regions of genes. Instead, they may interact with other proteins that influence gene expression or may act through other mechanisms, but binding to promoter regions and recruiting transcriptional co-activators is generally a function of transcription factors, not lncRNAs.\n5. TRUE - Assuming this statement is drawn directly from research findings that specifically indicate LIMT lncRNA's role in enhancing the transcriptional activity of the androgen receptor (AR) and its implications for prostate cancer cell growth. Without context, this is taken as true, but it is specific enough that it seems informed by research.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "There are several R/Bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis, including:\n\n1. snpEff: The snpEff package is a widely used R/Bioconductor package for predicting the functional consequences of SNPs. It uses a combination of machine learning algorithms and databases of known functional SNPs to predict the effect of a given SNP on gene expression, protein function, and other biological processes.\n2. Genome-Wide Association Studies (GWAS): The GWAS package is another R/Bioconductor package that can be used for performing SNP enrichment analysis. It provides tools for analyzing genome-wide association studies (GWAS), which involve analyzing large datasets of SNPs to identify associations between SNPs and certain traits or diseases.\n3. GenABEL: The GenABEL package is a general-purpose R/Bioconductor package for analyzing gene expression data. It can be used for performing SNP enrichment analysis by comparing the expression levels of SNP-associated genes to those of non-SNP-associated genes.\n4. DESeq2: The DESeq2 package is another R/Bioconductor package that can be used for analyzing gene expression data. It can be used for performing SNP enrichment analysis by comparing the expression levels of SNP-associated genes to those of non-SNP-associated genes.\n\nOverall, the choice of which R/Bioconductor package to use for performing SNP enrichment analysis will depend on the specific goals of the analysis and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. The snpEff package is an R/Bioconductor package used for predicting the functional consequences of SNPs.\n2. The GWAS package is used for analyzing genome-wide association studies and can perform SNP enrichment analysis.\n3. The GenABEL package is a general-purpose R/Bioconductor package for analyzing gene expression data, including SNP enrichment analysis.\n4. DESeq2 is an R/Bioconductor package that can perform SNP enrichment analysis by comparing the expression levels of SNP-associated genes with non-SNP-associated genes.",
    "llama-7b_fact": [
      "The snpEff package is an R/Bioconductor package used for predicting the functional consequences of SNPs.",
      "The GWAS package is used for analyzing genome-wide association studies and can perform SNP enrichment analysis.",
      "The GenABEL package is a general-purpose R/Bioconductor package for analyzing gene expression data, including SNP enrichment analysis.",
      "DESeq2 is an R/Bioconductor package that can perform SNP enrichment analysis by comparing the expression levels of SNP-associated genes with non-SNP-associated genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The snpEff package is not an R/Bioconductor package. It is a standalone tool written in Java that is used for predicting the functional consequences of variants such as single nucleotide polymorphisms (SNPs).\n2. UNKNOWN: The statement refers to \"the GWAS package\" which is ambiguous. There are various R packages for GWAS analysis such as 'plink', 'GWASTools', etc., but without a specific package name, it's unclear which one is being referred to. Also, not all GWAS packages may perform SNP enrichment analysis.\n3. FALSE [correction]: The GenABEL package is actually designed for genome-wide analysis of large datasets in association with traits, not specifically for analyzing gene expression data. It is an R package focused on statistical tests, predictive models, and graphics for genome-wide association studies.\n4. FALSE [correction]: DESeq2 is an R/Bioconductor package used for analyzing count-based NGS data like RNA-Seq. It is designed to compare differential expression levels of genes across different conditions, but it does not perform SNP enrichment analysis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that give rise to the ependymal cells that line the ventricular system of the brain and spinal cord. The process of radial glial specification to ependymal cells involves a series of molecular signals and cellular interactions that occur during embryonic development.\n\nOne of the key players in the specification of radial glial cells to ependymal cells is the transcription factor Sox2. Sox2 is expressed in radial glial cells and is necessary for the specification of these cells to ependymal cells. Sox2 works by activating the expression of genes that are specific to ependymal cells, such as the ependymin gene.\n\nAnother key player in the specification of radial glial cells to ependymal cells is the transcription factor Nkx2.1. Nkx2.1 is expressed in a subset of radial glial cells and is necessary for the specification of these cells to ependymal cells. Nkx2.1 works by activating the expression of genes that are specific to ependymal cells, such as the ependymin gene.\n\nIn addition to Sox2 and Nkx2.1, other transcription factors that have been implicated in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1. These transcription factors work by activating the expression of genes that are specific to ependymal cells, or by inhibiting the expression of genes that are specific to other cell types.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay of molecular signals and cellular interactions. The transcription factors Sox2, Nkx2.1, Olig2, Ngn2, and Ascl1 are all important players in this process, and further research is needed to fully understand how they work together to specify radial glial cells to ependymal cells.",
    "llama-7b_fact_raw": "1. Radial glial cells give rise to ependymal cells that line the ventricular system of the brain and spinal cord.\n2. The transcription factor Sox2 is necessary for the specification of radial glial cells to ependymal cells.\n3. Sox2 activates the expression of genes specific to ependymal cells, including the ependymin gene.\n4. The transcription factor Nkx2.1 is expressed in radial glial cells and is necessary for their specification to ependymal cells.\n5. Other transcription factors involved in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1.",
    "llama-7b_fact": [
      "Radial glial cells give rise to ependymal cells that line the ventricular system of the brain and spinal cord.",
      "The transcription factor Sox2 is necessary for the specification of radial glial cells to ependymal cells.",
      "Sox2 activates the expression of genes specific to ependymal cells, including the ependymin gene.",
      "The transcription factor Nkx2.1 is expressed in radial glial cells and is necessary for their specification to ependymal cells.",
      "Other transcription factors involved in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Sox2 activates the expression of genes specific to ependymal cells, but ependymin is a gene associated with teleost fish and not directly related to mammalian ependymal cell gene expression.\n4. FALSE [correction]: Nkx2.1 is a transcription factor involved in the development of certain subpopulations of neurons and glia in the central nervous system, but it is not specifically necessary for radial glial cells' specification to ependymal cells.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple negative breast cancers are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of breast cancer. Triple negative breast cancers are more aggressive and tend to have a worse prognosis than other types of breast cancer. They are also more likely to recur and to metastasize to other parts of the body.\n\nTriple negative gliomas are a type of brain tumor that are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of gliomas. Triple negative gliomas are more aggressive and tend to have a worse prognosis than other types of gliomas. They are also more likely to recur and to metastasize to other parts of the body.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of cancer.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of cancer.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal",
    "llama-7b_fact_raw": "1. Triple negative gliomas are characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).\n2. HER2 overexpression is a positive prognostic factor in other types of gliomas and breast cancer, but not in triple negative gliomas.\n3. Triple negative gliomas tend to have a more aggressive behavior and worse prognosis compared to other glioma types.\n4. Triple negative gliomas are more likely to recur after treatment than other types of gliomas.\n5. Triple negative gliomas have a higher likelihood of metastasizing to other parts of the body compared to other glioma types.",
    "llama-7b_fact": [
      "Triple negative gliomas are characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).",
      "HER2 overexpression is a positive prognostic factor in other types of gliomas and breast cancer, but not in triple negative gliomas.",
      "Triple negative gliomas tend to have a more aggressive behavior and worse prognosis compared to other glioma types.",
      "Triple negative gliomas are more likely to recur after treatment than other types of gliomas.",
      "Triple negative gliomas have a higher likelihood of metastasizing to other parts of the body compared to other glioma types."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Triple negative gliomas are characterized by the absence of specific molecular markers, but not estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which are markers associated with breast cancer, not gliomas.\n2. FALSE [correction]: HER2 overexpression being a positive prognostic factor is generally discussed in the context of breast cancer, not gliomas. The relationship of HER2 overexpression and gliomas' prognosis would depend on the specific subtype of glioma and needs to be specified, so it's not accurate without further context.\n3. TRUE (but with caution): While triple-negative status in gliomas might indicate a more aggressive behavior similar to the concept in breast cancer, the term \"triple negative gliomas\" is not standard. Aggressiveness and prognosis would depend on the specific type and grade of glioma, but the concept generally aligns with the idea that lacking certain molecular targets can complicate treatment.\n4. TRUE (but with caution): Gliomas that are \"triple negative\" for certain standard therapy targets may have fewer treatment options and could potentially recur after treatment, but the term \"triple negative gliomas\" is not standard so the statement is true under the assumption that \"triple negative\" implies a lack of targets for current treatments.\n5. FALSE [correction]: Gliomas, including those that might metaphorically be referred to as \"triple negative,\" are known for their infiltration into the surrounding brain tissue rather than distant metastasis. While gliomas can be very aggressive, they typically spread within the central nervous system and are not commonly associated with metastasizing to other parts of the body.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptocurrency that was created in 2014 as a hard fork of the Litecoin blockchain. It is a peer-to-peer electronic cash system and a decentralized digital currency that operates on a proof-of-work consensus algorithm. TOPAZ1 is similar to Litecoin in many ways, but it has a few key differences, such as a different block time and a different proof-of-work algorithm. TOPAZ1 is not as widely used or well-known as some other cryptocurrencies, but it has a dedicated community of users and developers.",
    "llama-7b_fact_raw": "1. TOPAZ1 was created in 2014 as a hard fork of the Litecoin blockchain.\n2. It uses a proof-of-work consensus algorithm.\n3. TOPAZ1 has a different block time compared to Litecoin.\n4. TOPAZ1 employs a different proof-of-work algorithm than Litecoin.\n5. TOPAZ1 has a community of users and developers.",
    "llama-7b_fact": [
      "TOPAZ1 was created in 2014 as a hard fork of the Litecoin blockchain.",
      "It uses a proof-of-work consensus algorithm.",
      "TOPAZ1 has a different block time compared to Litecoin.",
      "TOPAZ1 employs a different proof-of-work algorithm than Litecoin.",
      "TOPAZ1 has a community of users and developers."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe given statements pertain to a cryptocurrency named TOPAZ1, which may or may not exist, and specific details about its creation, operation, and community. Without concrete information regarding TOPAZ1, it is not possible to accurately determine the veracity of these statements. If TOPAZ1 is a fictional cryptocurrency or not widely known or documented, there may not be available information to verify these claims.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "GATA-1 is a transcription factor that plays an important role in the development and function of various tissues, including the heart, kidney, and immune system. GATA-1 isoforms are different forms of the protein that are produced by alternative splicing of the GATA-1 mRNA.\n\nThe gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. Alternative splicing of the GATA-1 gene results in the production of multiple transcripts that can encode different isoforms of the GATA-1 protein. The choice of which exons to include in each transcript is determined by a complex network of regulatory elements in the GATA-1 gene, including promoter regions, enhancers, silencers, and other cis-acting elements.\n\nThe expression of GATA-1 isoforms can be regulated at different levels, including transcriptional, post-transcriptional, and post-translational modifications. For example, the transcriptional regulation of GATA-1 isoforms can be influenced by the binding of transcription factors to specific regulatory elements in the GATA-1 gene, as well as by the availability of cofactors and co-regulators that modulate the activity of the transcriptional machinery.\n\nOverall, the expression of GATA-1 isoforms is a complex process that involves the coordinated action of multiple genetic and epigenetic factors. The precise regulation of GATA-1 isoform expression is critical for the proper development and function of various tissues, and dysregulation of GATA-1 isoform expression has been implicated in a number of human diseases, including cardiovascular disease, immune disorders, and cancer.",
    "llama-7b_fact_raw": "1. GATA-1 is a transcription factor important for the development and function of heart, kidney, and immune system tissues.\n2. GATA-1 isoforms are produced through alternative splicing of the GATA-1 mRNA.\n3. The gene responsible for the expression of GATA-1 isoforms is the GATA-1 gene.\n4. The GATA-1 gene contains regulatory elements such as promoter regions, enhancers, silencers, and other cis-acting elements that determine exon inclusion during mRNA splicing.\n5. Dysregulation of GATA-1 isoform expression has been linked to human diseases, including cardiovascular disease, immune disorders, and cancer.",
    "llama-7b_fact": [
      "GATA-1 is a transcription factor important for the development and function of heart, kidney, and immune system tissues.",
      "GATA-1 isoforms are produced through alternative splicing of the GATA-1 mRNA.",
      "The gene responsible for the expression of GATA-1 isoforms is the GATA-1 gene.",
      "The GATA-1 gene contains regulatory elements such as promoter regions, enhancers, silencers, and other cis-acting elements that determine exon inclusion during mRNA splicing.",
      "Dysregulation of GATA-1 isoform expression has been linked to human diseases, including cardiovascular disease, immune disorders, and cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GATA-1 is a transcription factor important for the development and function of erythroid and megakaryocytic lineages, which give rise to red blood cells and platelets, not heart, kidney, and immune system tissues.\n2. TRUE\n3. TRUE\n4. TRUE (assuming general knowledge about gene structure; however, specific regulatory elements for GATA-1 can vary and the statement doesn't make specific claims)\n5. TRUE (GATA-1 dysregulation has been linked to several hematological disorders, which can include immune system dysfunctions and certain types of cancer. While it's not a central factor in cardiovascular disease broadly, mutations specifically affecting GATA-1 can have downstream effects related to blood and vascular health.)",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq (Mutually Informative Regions by Association) is a method used in genomics to identify regions of the genome that are associated with multiple traits or diseases. The method is based on the idea that regions of the genome that are associated with multiple traits or diseases are likely to contain genes that are involved in common biological pathways or processes.\n\nMIRA-seq works by comparing the genetic information of individuals with a particular trait or disease to a reference population without the trait or disease. The method identifies regions of the genome that are overrepresented in the individuals with the trait or disease compared to the reference population. These regions are then prioritized for further investigation to determine if they contain genes that are involved in common biological pathways or processes.\n\nOne advantage of MIRA-seq is that it can identify regions of the genome that may be involved in multiple traits or diseases, which can be difficult to identify using other methods. Additionally, MIRA-seq can be used to identify genes that are involved in common biological pathways or processes, which can provide insights into the underlying biology of a particular trait or disease.\n\nOverall, MIRA-seq is a powerful method for identifying regions of the genome that are associated with multiple traits or diseases, and can provide valuable insights into the biology of complex traits and diseases.",
    "llama-7b_fact_raw": "1. MIRA-seq stands for Mutually Informative Regions by Association.\n2. MIRA-seq is used to identify genomic regions associated with multiple traits or diseases.\n3. The method compares genetic information of affected individuals to a reference population without the trait or disease.\n4. MIRA-seq is used to find overrepresented genomic regions in individuals with certain traits or diseases compared to a reference population.\n5. The identified regions from MIRA-seq are prioritized for further investigation to explore common biological pathways or processes.",
    "llama-7b_fact": [
      "MIRA-seq stands for Mutually Informative Regions by Association.",
      "MIRA-seq is used to identify genomic regions associated with multiple traits or diseases.",
      "The method compares genetic information of affected individuals to a reference population without the trait or disease.",
      "MIRA-seq is used to find overrepresented genomic regions in individuals with certain traits or diseases compared to a reference population.",
      "The identified regions from MIRA-seq are prioritized for further investigation to explore common biological pathways or processes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylation-based Inference of Regulatory Activity sequencing.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "The indication of ARCALYST (rilonacept) is the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children who are at least 12 years old. ARCALYST is also used to treat adults and children who are at least 12 years old with Familial Mediterranean Fever (FMF) who are intolerant of, or have failed, colchicine treatment.",
    "llama-7b_fact_raw": "1. ARCALYST (rilonacept) is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).\n2. ARCALYST is used to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).\n3. The medication is approved for use in adults and children who are at least 12 years old.\n4. ARCALYST is also indicated for the treatment of Familial Mediterranean Fever (FMF) in those who are intolerant of, or have failed, colchicine treatment.\n5. The medication can be used for FMF in both adults and children aged 12 or older.",
    "llama-7b_fact": [
      "ARCALYST (rilonacept) is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).",
      "ARCALYST is used to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).",
      "The medication is approved for use in adults and children who are at least 12 years old.",
      "ARCALYST is also indicated for the treatment of Familial Mediterranean Fever (FMF) in those who are intolerant of, or have failed, colchicine treatment.",
      "The medication can be used for FMF in both adults and children aged 12 or older."
    ],
    "llama-7b_judge_raw": "1. TRUE: ARCALYST (rilonacept) is indeed indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), which is a group of rare genetic inflammatory disorders.\n2. TRUE: ARCALYST is used to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are part of the CAPS spectrum.\n3. FALSE [correction]: As of my last update, ARCALYST is approved for use in children aged 4 years and older, not just adults and children who are at least 12 years old.\n4. TRUE: ARCALYST is also indicated for the treatment of Familial Mediterranean Fever (FMF) in patients who are intolerant of, or have contraindications to, colchicine.\n5. FALSE [correction]: The approval for the use of ARCALYST for FMF in children might have different age criteria compared to CAPS. Historically, FDA approvals for pediatric use can vary depending on the specific condition and evidence available, so the age specification for FMF treatment with ARCALYST should be confirmed with the current prescribing information.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that results in the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are:\n\n1. Chromosome 16 and Chromosome 17\n2. Chromosome 21 and Chromosome 22\n3. Chromosome 22 and Chromosome 23\n4. Chromosome 23 and Chromosome 24\n5. Chromosome 24 and Chromosome 25\n6. Chromosome 25 and Chromosome 26\n7. Chromosome 26 and Chromosome 27\n8. Chromosome 27 and Chromosome 28\n9. Chromosome 28 and Chromosome 29\n10. Chromosome 29 and Chromosome 30\n11. Chromosome 30 and Chromosome 31\n12. Chromosome 31 and Chromosome 32\n13. Chromosome 32 and Chromosome 33\n14. Chromosome 33 and Chromosome 34\n15. Chromosome 34 and Chromosome 35\n16. Chromosome 35 and Chromosome 36\n17. Chromosome 36 and Chromosome 37\n18. Chromosome 37 and Chromosome 38\n19. Chromosome 38 and Chromosome 39\n20. Chromosome 39 and Chromosome 40\n21. Chromosome 40 and Chromosome 41\n22. Chromosome 41 and Chromosome 42\n23. Chromosome 42 and Chromosome 43\n24. Chromosome 43 and Chromosome 44\n25. Chromosome 44",
    "llama-7b_fact_raw": "1. The answer lists Chromosome 16 as an acrocentric chromosome involved in Robertsonian translocation.\n2. The answer lists Chromosome 21 as an acrocentric chromosome involved in Robertsonian translocation.\n3. The answer lists Chromosome 22 as an acrocentric chromosome involved in Robertsonian translocation.\n4. The answer suggests Chromosome 23 is an acrocentric chromosome; however, humans only have 23 pairs of chromosomes, numbering up to 46 total.\n5. Robertsonian translocation is described as a fusion of two acrocentric chromosomes.",
    "llama-7b_fact": [
      "The answer lists Chromosome 16 as an acrocentric chromosome involved in Robertsonian translocation.",
      "The answer lists Chromosome 21 as an acrocentric chromosome involved in Robertsonian translocation.",
      "The answer lists Chromosome 22 as an acrocentric chromosome involved in Robertsonian translocation.",
      "The answer suggests Chromosome 23 is an acrocentric chromosome; however, humans only have 23 pairs of chromosomes, numbering up to 46 total.",
      "Robertsonian translocation is described as a fusion of two acrocentric chromosomes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromosome 16 is not an acrocentric chromosome involved in Robertsonian translocation. It is a metacentric chromosome.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Chromosome number 23 refers to the sex chromosomes (X or Y), which are not acrocentric chromosomes. Additionally, humans have 22 pairs of autosomes and 1 pair of sex chromosomes, making a total of 23 pairs.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There is no single R package that can be used for the identification of pediatric brain tumors. However, there are several R packages that can be used for analyzing and visualizing data related to brain tumors, including pediatric brain tumors. Some of these packages include:\n\n1. ggplot2: This package is used for data visualization and can be used to create plots and charts of brain tumor data, including pediatric brain tumors.\n2. RColorBrewer: This package is used for creating color palettes and can be used to create color-coded maps of brain tumor data, including pediatric brain tumors.\n3. reshape2: This package is used for reshaping and munging data and can be used to restructure brain tumor data, including pediatric brain tumors, for analysis.\n4. dplyr: This package is used for data manipulation and can be used to filter and aggregate brain tumor data, including pediatric brain tumors.\n5. tidyr: This package is used for data tidying and can be used to restructure brain tumor data, including pediatric brain tumors, for analysis.\n6. caret: This package is used for machine learning and can be used to build predictive models for the identification of pediatric brain tumors.\n7. survival: This package is used for survival analysis and can be used to analyze and interpret time-to-event data, such as survival data for pediatric brain tumor patients.\n\nOverall, the choice of R package(s) for analyzing and visualizing brain tumor data, including pediatric brain tumors, will depend on the specific research question and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. ggplot2 is an R package used for data visualization, including plots and charts of brain tumor data.\n2. RColorBrewer is an R package that provides color palettes for color-coding maps, applicable to brain tumor data.\n3. reshape2 is an R package intended for reshaping and munging data, usable for restructuring brain tumor data.\n4. dplyr is an R package used for data manipulation tasks such as filtering and aggregating brain tumor data.\n5. caret is an R package designed for machine learning, and can be used for building predictive models in the context of pediatric brain tumors.",
    "llama-7b_fact": [
      "ggplot2 is an R package used for data visualization, including plots and charts of brain tumor data.",
      "RColorBrewer is an R package that provides color palettes for color-coding maps, applicable to brain tumor data.",
      "reshape2 is an R package intended for reshaping and munging data, usable for restructuring brain tumor data.",
      "dplyr is an R package used for data manipulation tasks such as filtering and aggregating brain tumor data.",
      "caret is an R package designed for machine learning, and can be used for building predictive models in the context of pediatric brain tumors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the given statements are true and accurately describe the capabilities of the mentioned R packages in the context of data analysis tasks that could include brain tumor data.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "No, NEMO (NF-κB essential modulator) is not a zinc finger protein.\n\nZinc finger proteins are a class of proteins that contain zinc ions bound to amino acid residues in their structure, which allows them to recognize and bind to specific DNA or RNA sequences. Zinc finger proteins are known for their ability to regulate gene expression by binding to specific DNA sequences and modulating the activity of other proteins.\n\nNEMO, on the other hand, is a protein that plays a crucial role in the regulation of the NF-κB signaling pathway. NF-κB is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses. NEMO acts as a negative regulator of NF-κB by inhibiting its activation and preventing it from binding to DNA.\n\nWhile NEMO does not contain zinc finger domains, it does contain several other domains that are important for its function in regulating the NF-κB signaling pathway. These domains include an N-terminal death domain, a central ring finger domain, and a C-terminal coiled-coil domain that interacts with other proteins to regulate NF-κB activity.\n\nIn summary, while NEMO is not a zinc finger protein, it is an important regulator of the NF-κB signaling pathway and plays a crucial role in the regulation of immune and inflammatory responses.",
    "llama-7b_fact_raw": "1. NEMO (NF-κB essential modulator) is not a zinc finger protein.\n2. Zinc finger proteins have zinc ions bound to amino acid residues that help them bind to specific DNA or RNA sequences.\n3. NEMO plays a role in regulating the NF-κB signaling pathway.\n4. NF-κB is a transcription factor that regulates genes involved in immune and inflammatory responses.\n5. NEMO contains a death domain, a central ring finger domain, and a C-terminal coiled-coil domain.",
    "llama-7b_fact": [
      "NEMO (NF-κB essential modulator) is not a zinc finger protein.",
      "Zinc finger proteins have zinc ions bound to amino acid residues that help them bind to specific DNA or RNA sequences.",
      "NEMO plays a role in regulating the NF-κB signaling pathway.",
      "NF-κB is a transcription factor that regulates genes involved in immune and inflammatory responses.",
      "NEMO contains a death domain, a central ring finger domain, and a C-terminal coiled-coil domain."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO does not contain a death domain. Instead, it contains a leucine zipper domain, a central zinc finger, and a C-terminal coiled-coil domain.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II-mediated transcription. It is involved in the formation of the pre-initiation complex, which is the first step in the transcription process.\n\nDuring the formation of the pre-initiation complex, TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors, such as TFIIE and TFIIB. This interaction helps to position the RNA polymerase II holoenzyme at the promoter region of the gene, where it can initiate transcription.\n\nIn addition to its role in positioning the RNA polymerase II holoenzyme, TFIIS can also affect nucleosome positioning. Nucleosomes are the basic units of chromatin, which consist of DNA wrapped around a core of histone proteins. The positioning of nucleosomes can affect the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors, which can in turn affect the rate and efficiency of transcription.\n\nTFIIS has been shown to interact with histone proteins, such as histone H1 and histone H3. These interactions can affect the positioning of nucleosomes and the accessibility of the DNA to the RNA polymerase II holoenzyme. For example, TFIIS has been shown to stimulate the dissociation of nucleosomes from the promoter region of the gene, which can increase the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors.\n\nIn summary, TFIIS can affect nucleosome positioning by interacting with histone proteins and stimulating the dissociation of nucleosomes from the promoter region of the gene, which can increase the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors. This, in turn, can affect the rate and efficiency of transcription.",
    "llama-7b_fact_raw": "1. TFIIS is involved in the formation of the pre-initiation complex, which is important for the initiation of RNA polymerase II-mediated transcription.\n2. TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors to help position the holoenzyme at the promoter region of a gene.\n3. Nucleosomes are composed of DNA wrapped around a core of histone proteins and are fundamental units of chromatin.\n4. The positioning of nucleosomes influences the accessibility of DNA to the RNA polymerase II holoenzyme and other transcription factors, impacting transcription rates and efficiency.\n5. TFIIS has been shown to stimulate the dissociation of nucleosomes from the promoter region of genes, thus potentially increasing DNA accessibility to transcriptional machinery.",
    "llama-7b_fact": [
      "TFIIS is involved in the formation of the pre-initiation complex, which is important for the initiation of RNA polymerase II-mediated transcription.",
      "TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors to help position the holoenzyme at the promoter region of a gene.",
      "Nucleosomes are composed of DNA wrapped around a core of histone proteins and are fundamental units of chromatin.",
      "The positioning of nucleosomes influences the accessibility of DNA to the RNA polymerase II holoenzyme and other transcription factors, impacting transcription rates and efficiency.",
      "TFIIS has been shown to stimulate the dissociation of nucleosomes from the promoter region of genes, thus potentially increasing DNA accessibility to transcriptional machinery."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TFIIS is not involved in the formation of the pre-initiation complex; this is the role of general transcription factors such as TFIIH, TFIID, TFIIE, and TFIIF. TFIIS is instead involved in transcription elongation, where it facilitates RNA polymerase II's ability to cleave and extend the nascent RNA transcript after transcriptional pausing or stalling.\n\n2. FALSE [correction]: TFIIS does not interact directly with the RNA polymerase II holoenzyme and other transcription factors to position the holoenzyme at the promoter. This statement appears to conflate the roles of general transcription factors with that of TFIIS. TFIIS is primarily involved in the process of transcript elongation and error correction by RNA polymerase II, not in the positioning of the enzyme at promoters.\n\n3. TRUE\n\n4. TRUE\n\n5. FALSE [correction]: It is not established that TFIIS plays a role in the dissociation of nucleosomes from the promoter region to increase DNA accessibility to transcriptional machinery. TFIIS is known for its role in the process of transcription elongation and proofreading, not for chromatin remodeling functions, which involve other proteins such as chromatin remodelers and histone-modifying enzymes.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The question of whether origins of replication close to yeast centromeres fire early or late is an important one in the field of genetics and cell biology. The answer to this question has important implications for our understanding of how chromosomes are duplicated during the cell cycle, and how errors in this process can lead to genetic instability and the development of cancer.\n\nTo understand the answer to this question, it is first necessary to understand a bit about the process of DNA replication and the structure of chromosomes. During DNA replication, the double helix structure of DNA is unwound, and each strand of DNA is copied by an enzyme called DNA polymerase. The process of replication begins at specific points on the chromosome, known as origins of replication, and proceeds in the direction of the chromosome.\n\nIn yeast, as in many other organisms, the origins of replication are clustered near the centromere region of the chromosome. The centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of chromosomes during cell division.\n\nThe question of whether origins of replication close to yeast centromeres fire early or late refers to the timing of the initiation of DNA replication at these origins. Do the origins of replication fire early, before the chromosomes reach the centromere, or do they fire late, after the chromosomes have reached the centromere?\n\nThe answer to this question is not straightforward, and has been the subject of much research in the field of genetics and cell biology. Some studies have suggested that origins of replication close to yeast centromeres fire early, before the chromosomes reach the centromere, while other studies have suggested that they fire late, after the chromosomes have reached the centromere.\n\nThe exact timing of replication initiation at origins of replication close to yeast centromeres is likely to depend on a variety of factors, including the structure of the chromosome, the activity of specific proteins that regulate replication, and the cellular environment in which replication is taking place.\n\nIn summary, the answer to the question of whether origins of replication close to yeast centromeres fire early",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that have been identified in a wide range of mammalian tissues, including the brain, heart, liver, kidney, and pancreas. They are typically found in the cytoplasm of cells and are thought to play a role in regulating gene expression.\n\nOne of the key properties of mammalian GA-sequences is their length, which is typically between 200 and 400 nucleotides in length. They are also characterized by the presence of two distinct regions: a 5' untranslated region (UTR) and a 3' UTR. The 5' UTR is typically longer than the 3' UTR and is thought to play a role in regulating the stability and translation of the GA-sequence.\n\nAnother important property of mammalian GA-sequences is their ability to form complexes with other non-coding RNAs, including microRNAs (miRNAs) and small interfering RNAs (siRNAs). These complexes have been shown to play a role in regulating gene expression by targeting specific mRNAs for degradation or translational inhibition.\n\nIn addition to their role in regulating gene expression, mammalian GA-sequences have also been implicated in a number of other cellular processes, including cell differentiation, cell proliferation, and cell death. They have also been shown to play a role in the development of certain diseases, including cancer.\n\nOverall, the properties of mammalian GA-sequences make them an important and intriguing area of research, with potential applications in the development of new therapeutics for a wide range of diseases.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are a type of non-coding RNA found in various tissues including the brain, heart, liver, kidney, and pancreas.\n2. The typical length of mammalian GA-sequences ranges between 200 and 400 nucleotides.\n3. Mammalian GA-sequences consist of two distinct regions: a longer 5' untranslated region (UTR) and a shorter 3' UTR.\n4. These sequences can form complexes with other non-coding RNAs such as microRNAs (miRNAs) and small interfering RNAs (siRNAs).\n5. Mammalian GA-sequences are implicated in cellular processes like differentiation, proliferation, and cell death, as well as in the development of diseases like cancer.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are a type of non-coding RNA found in various tissues including the brain, heart, liver, kidney, and pancreas.",
      "The typical length of mammalian GA-sequences ranges between 200 and 400 nucleotides.",
      "Mammalian GA-sequences consist of two distinct regions: a longer 5' untranslated region (UTR) and a shorter 3' UTR.",
      "These sequences can form complexes with other non-coding RNAs such as microRNAs (miRNAs) and small interfering RNAs (siRNAs).",
      "Mammalian GA-sequences are implicated in cellular processes like differentiation, proliferation, and cell death, as well as in the development of diseases like cancer."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific scientific context or details defining \"GA-sequences,\" it's not possible to determine the truthfulness of this statement.\n2. UNKNOWN: The typical length of a genetic sequence, including non-coding RNA, is specific to the sequence in question and cannot be verified as true or false without more specific information.\n3. UNKNOWN: The structure described is generally applicable to mRNA rather than non-coding RNAs, and without further context to what GA-sequences refer to, this statement's accuracy cannot be determined.\n4. TRUE: Non-coding RNAs, including some specific sequences not defined here as \"GA-sequences,\" can indeed form complexes with other non-coding RNAs such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), influencing gene expression and regulation.\n5. TRUE: Non-coding RNAs, broadly speaking, are known to be involved in various cellular processes, including differentiation, proliferation, and cell death, and have been implicated in numerous diseases, including cancer. However, without specific details on \"GA-sequences,\" this statement cannot be fully verified for this exact type of non-coding RNA.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is not a fixed or well-defined quantity. The term \"Groucho-related genes\" can refer to a family of transcriptional repressors that share structural similarity with the Groucho protein, which is involved in regulating the expression of certain genes in the Drosophila melanogaster (fruit fly) and Caenorhabditis elegans (roundworm) genomes. However, the extent to which these genes are present and functional in the mouse genome is not well understood.\n\nThere are several genes in the mouse genome that have been identified as members of the Groucho family of transcriptional repressors, but the number of these genes can vary depending on the specific criteria used for identification. For example, some studies have identified as few as three Groucho-related genes in the mouse genome, while other studies have identified as many as nine Groucho-related genes.\n\nIn summary, the number of Groucho-related genes (GRG) contained in the mouse genome is not a fixed or well-defined quantity, and can vary depending on the specific criteria used for identification.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "RNA polymerase II is the enzyme responsible for transcribing DNA into RNA in eukaryotic cells. It is composed of multiple subunits, and one of these subunits, the RNA cleavage subunit, carries the RNA cleavage activity.\n\nThe RNA cleavage subunit of RNA polymerase II is called PTC1. PTC1 is a component of the RNA polymerase II holoenzyme, which is the active form of the enzyme that is responsible for transcribing DNA into RNA. PTC1 is involved in the process of transcription elongation, which is the phase of transcription where the RNA polymerase II holoenzyme moves along the DNA template and transcribes the genetic information into RNA.\n\nDuring transcription elongation, PTC1 interacts with the DNA template and with other components of the RNA polymerase II holoenzyme. It also plays a role in the process of transcription termination, which is the phase of transcription where the RNA polymerase II holoenzyme stops transcribing the DNA template and disassembles.\n\nIn summary, PTC1 is the RNA cleavage subunit of RNA polymerase II, and it is involved in the process of transcription elongation and transcription termination. It carries the RNA cleavage activity and is a key component of the RNA polymerase II holoenzyme, which is responsible for transcribing DNA into RNA in eukaryotic cells.",
    "llama-7b_fact_raw": "1. RNA polymerase II is responsible for transcribing DNA into RNA in eukaryotic cells.\n2. RNA polymerase II is composed of multiple subunits.\n3. The RNA cleavage subunit of RNA polymerase II is referred to as PTC1.\n4. PTC1 is involved in the process of transcription elongation.\n5. PTC1 also plays a role in the process of transcription termination.",
    "llama-7b_fact": [
      "RNA polymerase II is responsible for transcribing DNA into RNA in eukaryotic cells.",
      "RNA polymerase II is composed of multiple subunits.",
      "The RNA cleavage subunit of RNA polymerase II is referred to as PTC1.",
      "PTC1 is involved in the process of transcription elongation.",
      "PTC1 also plays a role in the process of transcription termination."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The term \"RNA cleavage subunit of RNA polymerase II\" is not accurate. RNA polymerase II does have a cleavage and polyadenylation factor that is involved in the cleavage of nascent RNA and addition of the poly(A) tail, but it is not referred to as PTC1.\n4. UNKNOWN: Without context, it's difficult to determine the role of PTC1 as it's not a standard designation for a component related to RNA polymerase II. Additionally, transcription elongation typically involves factors other than just RNA polymerase's subunits.\n5. UNKNOWN: Similar to the above, without proper context, the role of PTC1 in transcription termination cannot be determined, especially since PTC1 is not a recognized term in relation to RNA polymerase II's known subunits or associated factors.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder that is characterized by a range of physical and developmental abnormalities. The genetic basis of Ohdo syndrome is complex and involves mutations in multiple genes.\n\nThe disorder is caused by mutations in the genes that encode for proteins involved in the development and function of various tissues and organs. Some of the genes that have been associated with Ohdo syndrome include:\n\n1. FGFR3: Fibroblast growth factor receptor 3 (FGFR3) is a protein that plays a crucial role in the development of bones and other tissues. Mutations in the FGFR3 gene have been identified in a significant proportion of patients with Ohdo syndrome. These mutations can lead to the formation of extra digits (polydactyly) and other skeletal abnormalities.\n2. PHOX2B: PHOX2B is a gene that encodes for a protein involved in the development of the respiratory system. Mutations in the PHOX2B gene have been associated with Ohdo syndrome, as they can lead to abnormal development of the lungs and other respiratory structures.\n3. KCNQ3: KCNQ3 is a gene that encodes for a protein involved in the function of heart muscle cells (cardiomyocytes). Mutations in the KCNQ3 gene have been associated with Ohdo syndrome, as they can lead to abnormal heart rhythms and other cardiac abnormalities.\n4. TBX1: TBX1 is a gene that encodes for a transcription factor involved in the development of various tissues and organs, including the heart, kidneys, and limbs. Mutations in the TBX1 gene have been associated with Ohdo syndrome, as they can lead to abnormal development of these structures.\n\nIn summary, the genetic basis of Ohdo syndrome involves mutations in multiple genes, including FGFR3, PHOX2B, KCNQ3, and TBX1. These mutations can disrupt the normal development and function of various tissues and organs, leading to the range of physical and developmental abnormalities characteristic of the disorder.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder characterized by a range of physical and developmental abnormalities.\n2. Mutations in the FGFR3 gene have been identified in patients with Ohdo syndrome and can lead to skeletal abnormalities like polydactyly.\n3. Mutations in the PHOX2B gene are associated with Ohdo syndrome and can affect the development of the respiratory system.\n4. Mutations in the KCNQ3 gene, related to Ohdo syndrome, can cause abnormal heart rhythms and other cardiac issues.\n5. TBX1 gene mutations are associated with Ohdo syndrome and can lead to abnormal development of the heart, kidneys, and limbs.",
    "llama-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder characterized by a range of physical and developmental abnormalities.",
      "Mutations in the FGFR3 gene have been identified in patients with Ohdo syndrome and can lead to skeletal abnormalities like polydactyly.",
      "Mutations in the PHOX2B gene are associated with Ohdo syndrome and can affect the development of the respiratory system.",
      "Mutations in the KCNQ3 gene, related to Ohdo syndrome, can cause abnormal heart rhythms and other cardiac issues.",
      "TBX1 gene mutations are associated with Ohdo syndrome and can lead to abnormal development of the heart, kidneys, and limbs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the FGFR3 gene are not associated with Ohdo syndrome but rather with conditions leading to skeletal abnormalities such as achondroplasia. Ohdo syndrome has been linked to mutations in genes like SALL1 and KAT6B.\n3. FALSE [correction]: Mutations in the PHOX2B gene are not associated with Ohdo syndrome but are related to conditions such as Congenital Central Hypoventilation Syndrome (CCHS), which affects the respiratory system. Ohdo syndrome is associated with mutations in genes like SALL1 and KAT6B.\n4. FALSE [correction]: Mutations in the KCNQ3 gene are associated with neurological conditions, such as benign familial neonatal epilepsy, and not typically with Ohdo syndrome or cardiac issues.\n5. FALSE [correction]: TBX1 gene mutations are associated with DiGeorge syndrome (22q11.2 deletion syndrome), which can lead to the development of several organs and tissues including the heart, and not with Ohdo syndrome.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "You MUST give a detailed answer to the following question: Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "One R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is the \"PsychiatricGWAS\" package. This package provides tools for the analysis of genome-wide association studies (GWAS) of psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder.\n\nThe package includes functions for genotype imputation, association testing, and gene set analysis, as well as tools for visualizing and interpreting the results of these analyses. It also provides access to a large database of psychiatric GWAS data, which can be used to perform these analyses on a large scale.\n\nIn addition to the \"PsychiatricGWAS\" package, there are several other R/Bioconductor packages that may be useful for the analysis of psychiatric disease genes, including the \"rnaseqtest\" package for RNA sequencing data analysis, the \"edgeR\" package for gene expression analysis, and the \"limma\" package for microarray data analysis. These packages can be used in combination with the \"PsychiatricGWAS\" package to perform more comprehensive analyses of psychiatric disease genes.",
    "llama-7b_fact_raw": "1. The \"PsychiatricGWAS\" package is an R/Bioconductor package developed for the analysis of psychiatric disease genes.\n2. The \"PsychiatricGWAS\" package specifically caters to genome-wide association studies (GWAS) of psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder.\n3. Functions within the \"PsychiatricGWAS\" package allow for genotype imputation, association testing, and gene set analysis.\n4. The package \"PsychiatricGWAS\" includes tools for result visualization and interpretation.\n5. The \"PsychiatricGWAS\" package provides access to a large database of psychiatric GWAS data.",
    "llama-7b_fact": [
      "The \"PsychiatricGWAS\" package is an R/Bioconductor package developed for the analysis of psychiatric disease genes.",
      "The \"PsychiatricGWAS\" package specifically caters to genome-wide association studies (GWAS) of psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder.",
      "Functions within the \"PsychiatricGWAS\" package allow for genotype imputation, association testing, and gene set analysis.",
      "The package \"PsychiatricGWAS\" includes tools for result visualization and interpretation.",
      "The \"PsychiatricGWAS\" package provides access to a large database of psychiatric GWAS data."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correctness of the statements about the \"PsychiatricGWAS\" package depends on the actual features provided by the package. As of my knowledge cutoff date in March 2023, there is no widely known R/Bioconductor package by the exact name \"PsychiatricGWAS.\" However, because R/Bioconductor packages are frequently developed and named by individual researchers or research groups, it is possible that a specific package could exist by that name with the functions mentioned. To verify the truthfulness of these statements, one would need to consult the documentation of this particular package or the resource where the package is maintained, if it exists. Without access to up-to-date information about the \"PsychiatricGWAS\" package, the truth or falsehood of the first, third, fourth, and fifth statements cannot be ascertained. The second statement seems to describe plausibly what a package named \"PsychiatricGWAS\" might do, hence why it is marked as true.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "A swirl sign in intracerebral hemorrhage (ICH) is a radiologic finding that is seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain. It is characterized by a swirling pattern of blood within the hemisphere of the brain that is affected by the hemorrhage.\n\nThe swirl sign is caused by the movement of blood within the hemisphere as it spreads out from the site of the hemorrhage. This movement can cause the blood to appear as a swirling pattern on the CT or MRI scan. The swirl sign is typically seen in the early stages of ICH, before the hemorrhage has had a chance to expand significantly.\n\nThe swirl sign is an important radiologic finding because it can help diagnose ICH and guide treatment decisions. It is often used in conjunction with other radiologic findings, such as the location and size of the hemorrhage, to assess the severity of the injury and determine the best course of treatment.\n\nIn some cases, the swirl sign may be accompanied by other radiologic findings, such as midline shift or hematoma expansion. These findings can indicate a more severe injury and may require more aggressive treatment, such as surgical intervention.\n\nOverall, the swirl sign in ICH is an important radiologic finding that can help diagnose and assess the severity of this type of brain injury.",
    "llama-7b_fact_raw": "1. The swirl sign in intracerebral hemorrhage (ICH) is a radiologic finding that can be seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n2. This swirl sign is characterized by a pattern of blood that appears to be swirling within the affected hemisphere of the brain.\n3. It typically presents in the early stages of an ICH.\n4. The swirl sign is used to help diagnose ICH and make treatment decisions.\n5. Accompanying radiologic findings such as midline shift or hematoma expansion may indicate a more severe injury and could necessitate surgical intervention.",
    "llama-7b_fact": [
      "The swirl sign in intracerebral hemorrhage (ICH) is a radiologic finding that can be seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "This swirl sign is characterized by a pattern of blood that appears to be swirling within the affected hemisphere of the brain.",
      "It typically presents in the early stages of an ICH.",
      "The swirl sign is used to help diagnose ICH and make treatment decisions.",
      "Accompanying radiologic findings such as midline shift or hematoma expansion may indicate a more severe injury and could necessitate surgical intervention."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN: The statement indicates a typical presentation but does not specify whether this is always the case or if there are variations in when the swirl sign can be seen.\n4. TRUE: The swirl sign, among other imaging findings, can be used to help diagnose ICH and guide treatment decisions.\n5. TRUE: Accompanying radiologic findings such as midline shift or hematoma expansion are important in determining the severity of the injury and the potential need for surgical intervention.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "ROF1 (Regulator of Flowering 1) is a transcription factor that plays a crucial role in the regulation of flowering time in Arabidopsis thaliana. ROF1 expression is regulated by various environmental and developmental cues, including light, temperature, and hormones such as auxin and cytokinin.\n\nOne of the key inducers of ROF1 expression is light. ROF1 is a photoreceptor that responds to both red and far-red light. Exposure to these wavelengths of light leads to an increase in ROF1 expression, which in turn regulates the expression of downstream genes involved in flowering time control.\n\nAnother inducer of ROF1 expression is temperature. ROF1 expression is induced by both high and low temperatures, with higher temperatures leading to a more rapid increase in ROF1 expression. This suggests that ROF1 may play a role in the acclimation of plants to changing environmental temperatures.\n\nIn addition to light and temperature, ROF1 expression can also be regulated by hormones such as auxin and cytokinin. For example, auxin has been shown to inhibit ROF1 expression, while cytokinin has been shown to induce ROF1 expression.\n\nOverall, the regulation of ROF1 expression is complex and involves the integration of multiple environmental and developmental cues. A better understanding of the regulatory mechanisms controlling ROF1 expression may provide insights into the control of flowering time and the regulation of plant growth and development.",
    "llama-7b_fact_raw": "1. ROF1 (Regulator of Flowering 1) is involved in the regulation of flowering time in Arabidopsis thaliana.\n2. Light, including both red and far-red wavelengths, induces the expression of ROF1.\n3. ROF1 expression in Arabidopsis thaliana can be induced by extremes in temperature.\n4. The hormone cytokinin has been shown to induce the expression of ROF1.\n5. Auxin has been reported to inhibit the expression of ROF1.",
    "llama-7b_fact": [
      "ROF1 (Regulator of Flowering 1) is involved in the regulation of flowering time in Arabidopsis thaliana.",
      "Light, including both red and far-red wavelengths, induces the expression of ROF1.",
      "ROF1 expression in Arabidopsis thaliana can be induced by extremes in temperature.",
      "The hormone cytokinin has been shown to induce the expression of ROF1.",
      "Auxin has been reported to inhibit the expression of ROF1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\n1. ROF1 (Regulator of Flowering 1) involvement in the regulation of flowering time in Arabidopsis thaliana is consistent with the naming convention for genes involved in flowering processes, and such regulators are common in plant biology.\n2. In plants, it's well documented that light, including wavelengths in the red and far-red range, influences flowering time and gene expression related to flowering.\n3, 4, 5. Specific inducers of ROF1 expression such as temperature extremes, cytokinin, or auxin require more detailed information from scientific studies. Without that data, it is not possible to determine the truthfulness of these statements.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "The most common cause of hereditary renal amyloidosis is transthyretin (TTR). Amyloidosis is a group of diseases characterized by the deposit of an abnormal protein called amyloid in various tissues and organs of the body. Hereditary renal amyloidosis is a type of amyloidosis that affects the kidneys and is passed down through families. TTR is a protein that is normally found in the blood and is involved in transporting thyroid hormone and retinol (vitamin A) throughout the body. In hereditary renal amyloidosis, mutations in the TTR gene cause the production of abnormal TTR protein that accumulates in the kidneys, leading to damage and eventually loss of kidney function. Treatment for hereditary renal amyloidosis typically involves managing symptoms and slowing the progression of the disease, as there is currently no cure for the condition.",
    "llama-7b_fact_raw": "1. Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.\n2. Amyloidosis is characterized by the deposit of an abnormal protein called amyloid in tissues and organs.\n3. Hereditary renal amyloidosis specifically affects the kidneys and is genetic.\n4. TTR protein is normally involved in transporting thyroid hormone and retinol (vitamin A).\n5. Mutations in the TTR gene can lead to the accumulation of abnormal TTR protein in the kidneys.",
    "llama-7b_fact": [
      "Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.",
      "Amyloidosis is characterized by the deposit of an abnormal protein called amyloid in tissues and organs.",
      "Hereditary renal amyloidosis specifically affects the kidneys and is genetic.",
      "TTR protein is normally involved in transporting thyroid hormone and retinol (vitamin A).",
      "Mutations in the TTR gene can lead to the accumulation of abnormal TTR protein in the kidneys."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Transthyretin (TTR) amyloidosis is more commonly associated with cardiac and nervous system disorders, while hereditary renal amyloidosis is often caused by mutations in other genes, such as those encoding fibrinogen A alpha chain, apolipoprotein A1 or lysozyme.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed. The hippocampus is a region of the brain that is critical for learning and memory, and studies have used a variety of techniques to identify and characterize the proteins present in this region of the mouse brain.\n\nOne approach to studying the proteome of the mouse hippocampus is to use mass spectrometry, which can be used to identify and quantify proteins present in a sample. This approach has been used in a number of studies to identify and characterize the proteins present in the mouse hippocampus.\n\nFor example, one study used mass spectrometry to identify over 3,000 proteins present in the mouse hippocampus, including both known and novel proteins. The study also used bioinformatics tools to analyze the data and identify potential functions for many of the proteins identified.\n\nAnother study used a similar approach to identify over 2,000 proteins present in the mouse hippocampus, and also used bioinformatics tools to analyze the data and identify potential roles for many of the proteins identified.\n\nOverall, these studies have provided a wealth of information about the proteins present in the mouse hippocampus, and have helped to advance our understanding of the molecular mechanisms underlying learning and memory.",
    "llama-7b_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using various techniques.\n2. Mass spectrometry is one of the techniques used to study the mouse hippocampus proteome.\n3. Over 3,000 proteins have been identified in the mouse hippocampus in one study using mass spectrometry.\n4. Another study using mass spectrometry identified over 2,000 proteins in the mouse hippocampus.\n5. Bioinformatics tools have been used in conjunction with mass spectrometry to analyze proteins and identify potential functions in the mouse hippocampus.",
    "llama-7b_fact": [
      "The proteome of the mouse hippocampus has been analyzed using various techniques.",
      "Mass spectrometry is one of the techniques used to study the mouse hippocampus proteome.",
      "Over 3,000 proteins have been identified in the mouse hippocampus in one study using mass spectrometry.",
      "Another study using mass spectrometry identified over 2,000 proteins in the mouse hippocampus.",
      "Bioinformatics tools have been used in conjunction with mass spectrometry to analyze proteins and identify potential functions in the mouse hippocampus."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "No, mouse chromosomes are not acrocentric.\n\nAcrocentric chromosomes are a type of chromosome that have their centromeres located towards the ends of the chromosome rather than in the middle. This is in contrast to metacentric chromosomes, which have their centromeres located in the middle of the chromosome.\n\nIn the mouse genome, there are 20 autosomal chromosomes and two sex chromosomes (X and Y). The centromeres of the mouse autosomal chromosomes are located in the middle of each chromosome, which is consistent with the definition of metacentric chromosomes. Therefore, mouse chromosomes are not acrocentric.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.\n3. Metacentric chromosomes have their centromeres located in the middle of the chromosome.\n4. The mouse genome contains 20 autosomal chromosomes.\n5. The mouse genome includes two sex chromosomes, X and Y.",
    "llama-7b_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.",
      "Metacentric chromosomes have their centromeres located in the middle of the chromosome.",
      "The mouse genome contains 20 autosomal chromosomes.",
      "The mouse genome includes two sex chromosomes, X and Y."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The mouse genome contains 40 autosomal chromosomes.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "One siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer is GSK2879552.\n\nGSK2879552 is an RNA interference (RNAi) therapeutic candidate that is being developed by GlaxoSmithKline (GSK) for the treatment of various types of cancer, including pancreatic cancer. The drug works by using small interfering RNA (siRNA) molecules to silence specific genes that are involved in the growth and survival of cancer cells.\n\nGSK2879552 has shown promising results in preclinical studies, and it is currently being tested in phase 1 and phase 2 clinical trials for the treatment of various types of solid tumors, including pancreatic cancer. In these trials, the drug is being administered intravenously to patients with advanced or metastatic cancer.\n\nSo far, the results of the clinical trials have been encouraging, with some patients experiencing partial or complete responses to the treatment. However, more research is needed to fully understand the safety and efficacy of GSK2879552 for the treatment of pancreatic cancer, and the drug is not yet approved for use in patients.",
    "llama-7b_fact_raw": "1. GSK2879552 is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.\n2. The drug is developed by GlaxoSmithKline (GSK).\n3. GSK2879552 uses small interfering RNA (siRNA) molecules to silence genes involved in cancer cell growth and survival.\n4. The drug is currently being tested in phase 1 and phase 2 clinical trials for various types of solid tumors, including pancreatic cancer.\n5. GSK2879552 is administered intravenously to patients with advanced or metastatic cancer in the trials.",
    "llama-7b_fact": [
      "GSK2879552 is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.",
      "The drug is developed by GlaxoSmithKline (GSK).",
      "GSK2879552 uses small interfering RNA (siRNA) molecules to silence genes involved in cancer cell growth and survival.",
      "The drug is currently being tested in phase 1 and phase 2 clinical trials for various types of solid tumors, including pancreatic cancer.",
      "GSK2879552 is administered intravenously to patients with advanced or metastatic cancer in the trials."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GSK2879552 is not an siRNA-based drug; it is a small molecule LSD1 inhibitor.\n2. TRUE\n3. FALSE [correction]: GSK2879552 does not use siRNA molecules; it inhibits the activity of LSD1, a histone demethylase.\n4. UNKNOWN (as of my last update in early 2023, without current clinical trial databases or updates, I cannot confirm the current phases of the clinical trials for GSK2879552 or the types of cancers it is being tested for)\n5. UNKNOWN (without current information on the administration methods in the ongoing clinical trials for GSK2879552, I cannot confirm how it is being administered to patients)",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "The HPG (hypothalamus-pituitary-gonadal) axis is a system of hormonal communication between the hypothalamus, pituitary gland, and gonads (ovaries or testes) that regulates reproductive processes and other physiological functions. The HPG pore is a hypothetical structure that is thought to exist in the hypothalamus and regulate the release of hormones into the bloodstream.\n\nThe hypothalamus is a region of the brain that plays a key role in the regulation of many bodily functions, including reproductive processes. The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH) from the pituitary gland. GnRH is a peptide hormone that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn stimulate the ovaries or testes to produce sex hormones.\n\nThe HPG pore is a hypothetical structure that is thought to exist in the hypothalamus and regulate the release of hormones into the bloodstream. It is believed that the HPG pore opens and closes in response to various stimuli, allowing hormones to be released into the bloodstream and regulate reproductive processes and other physiological functions. However, there is currently no scientific evidence to support the existence of the HPG pore.",
    "llama-7b_fact_raw": "1. The HPG axis involves communication between the hypothalamus, pituitary gland, and gonads.\n2. The hypothalamus plays a key role in regulating reproductive processes.\n3. The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH).\n4. Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n5. The HPG pore is described as a hypothetical structure purported to regulate the release of hormones into the bloodstream from the hypothalamus.",
    "llama-7b_fact": [
      "The HPG axis involves communication between the hypothalamus, pituitary gland, and gonads.",
      "The hypothalamus plays a key role in regulating reproductive processes.",
      "The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH).",
      "Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.",
      "The HPG pore is described as a hypothetical structure purported to regulate the release of hormones into the bloodstream from the hypothalamus."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The hypothalamus releases gonadotropin-releasing hormone (GnRH), it does not produce hormones to regulate its own release.\n4. TRUE\n5. FALSE [correction]: The term \"HPG pore\" is not established in the context of endocrinology. The structure that facilitates the release of hormones from the hypothalamus to the pituitary gland is not referred to as a \"pore\"; instead, the hypothalamus releases GnRH into the hypothalamic-pituitary portal system to reach the pituitary gland.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of 959 species of roundworms, also known as nematodes. Nematodes are a diverse group of microscopic worms that are found in a wide range of environments, including soil, water, and the guts of animals. They are one of the most species-rich phyla of animals, with over 100,000 known species.\n\nThe 959 Nematode Genomes initiative is a collaborative effort between researchers from around the world, with the goal of creating a comprehensive resource for the study of nematode biology and evolution. The project involves sequencing the genomes of a representative sample of nematode species, using a combination of next-generation sequencing technologies and traditional Sanger sequencing. The sequenced genomes are then analyzed using a variety of computational methods, including comparative genomics, transcriptomics, and functional annotation.\n\nThe 959 Nematode Genomes initiative is expected to have a significant impact on our understanding of nematode biology and evolution. By analyzing the genomes of a diverse set of nematode species, researchers hope to identify conserved genes and functional modules that are shared across different species, as well as genes that are specific to individual species or groups of species. This information will be used to gain insights into the evolutionary history of nematodes, as well as to identify potential targets for the development of new drugs and other applications.\n\nOverall, the 959 Nematode Genomes initiative is a landmark project that will provide a valuable resource for the study of nematode biology and evolution, with implications for a wide range of fields, including medicine, agriculture, and ecology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms, also known as nematodes.\n2. Nematodes are found in a wide range of environments and there are over 100,000 known species of them.\n3. The initiative is a collaborative project involving researchers from around the world.\n4. Researchers are using a combination of next-generation sequencing technologies and traditional Sanger sequencing for the project.\n5. The goal of the 959 Nematode Genomes initiative is to provide insights into nematode biology and evolution, which may have implications for medicine, agriculture, and ecology.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms, also known as nematodes.",
      "Nematodes are found in a wide range of environments and there are over 100,000 known species of them.",
      "The initiative is a collaborative project involving researchers from around the world.",
      "Researchers are using a combination of next-generation sequencing technologies and traditional Sanger sequencing for the project.",
      "The goal of the 959 Nematode Genomes initiative is to provide insights into nematode biology and evolution, which may have implications for medicine, agriculture, and ecology."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There are over 25,000 that have been described, though estimates of the total number of nematode species range from 10,000 to one million.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the most popular ones include:\n\n1. \"NIPT\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n2. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n3. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n4. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n5. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n6. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n7. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n8. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n9. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using",
    "llama-7b_fact_raw": "1. The \"NIPT\" R package has been developed for analyzing and visualizing Non-invasive prenatal testing (NIPT) data.\n2. The \"NIPT\" R package includes functions for imputation of missing data.\n3. The \"NIPT\" R package provides functions for quality control.\n4. The \"NIPT\" R package offers statistical analysis functions for NIPT data.\n5. The \"NIPTdata\" R package has been developed for analyzing and visualizing Non-invasive prenatal testing (NIPT) data.",
    "llama-7b_fact": [
      "The \"NIPT\" R package has been developed for analyzing and visualizing Non-invasive prenatal testing (NIPT) data.",
      "The \"NIPT\" R package includes functions for imputation of missing data.",
      "The \"NIPT\" R package provides functions for quality control.",
      "The \"NIPT\" R package offers statistical analysis functions for NIPT data.",
      "The \"NIPTdata\" R package has been developed for analyzing and visualizing Non-invasive prenatal testing (NIPT) data."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There is no \"NIPTdata\" R package specifically designed for Non-invasive prenatal testing (NIPT) data. The correct package for analyzing and visualizing NIPT data is \"NIPT\" instead.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbach’s syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's triad, is a rare neurological disorder characterized by a triad of symptoms, including hemiparesis (weakness on one side of the body), ataxia (lack of coordination and balance), and cerebellar signs such as dysarthria (speech difficulties) and nystagmus (rapid, involuntary eye movements).\n\nThe syndrome is named after German neurologist August Achenbach, who first described it in 1881. It is believed to be caused by a lesion or injury to the cerebellum, which is a part of the brain responsible for coordination and balance.\n\nThe symptoms of Achenbach's syndrome can vary in severity and may be accompanied by other neurological symptoms such as dizziness, headache, and difficulty with speech and swallowing. The syndrome can occur at any age, but it is more common in older adults.\n\nDiagnosis of Achenbach's syndrome typically involves a thorough neurological examination, including tests to assess coordination, balance, and speech. Imaging tests such as MRI or CT scans may also be used to identify any lesions or other abnormalities in the brain.\n\nTreatment for Achenbach's syndrome typically focuses on managing symptoms and improving function. Physical therapy and rehabilitation may be helpful in improving coordination and balance, while medications may be used to manage symptoms such as dizziness and headache. In some cases, surgery may be necessary to treat a specific underlying cause of the syndrome.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is characterized by hemiparesis, ataxia, and cerebellar signs like dysarthria and nystagmus.\n2. August Achenbach, a German neurologist, is credited with the first description of Achenbach's syndrome in 1881.\n3. The suspected cause of Achenbach's syndrome is a lesion or injury to the cerebellum.\n4. Achenbach's syndrome can manifest with varying severity and may include additional symptoms like dizziness, headache, and difficulties with speech and swallowing.\n5. Treatment for Achenbach's syndrome may involve physical therapy, medications, and potentially surgery to address an underlying cause.",
    "llama-7b_fact": [
      "Achenbach's syndrome is characterized by hemiparesis, ataxia, and cerebellar signs like dysarthria and nystagmus.",
      "August Achenbach, a German neurologist, is credited with the first description of Achenbach's syndrome in 1881.",
      "The suspected cause of Achenbach's syndrome is a lesion or injury to the cerebellum.",
      "Achenbach's syndrome can manifest with varying severity and may include additional symptoms like dizziness, headache, and difficulties with speech and swallowing.",
      "Treatment for Achenbach's syndrome may involve physical therapy, medications, and potentially surgery to address an underlying cause."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by sudden, unexplained bruising on the hands or fingers, not neurological symptoms.\n2. FALSE [correction]: Achenbach's syndrome was described by the German physician Dr. Kurt Achenbach, not August Achenbach. There is also no reliable source confirming the year 1881 for the first description.\n3. FALSE [correction]: Achenbach's syndrome is not caused by a lesion or injury to the cerebellum. It is rather a benign and self-limiting condition affecting the hands.\n4. FALSE [correction]: Symptoms of Achenbach's syndrome do not include neurological deficits like dizziness, headache, difficulties with speech and swallowing, but rather spontaneous bruising of the hands or fingers.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "There are several algorithms that can be used for the detection of long repeat expansions. One such algorithm is the \"sliding window\" approach.\n\nIn this approach, a window of DNA sequence is scanned for the presence of the repeat sequence. The window is moved along the DNA sequence one nucleotide at a time, and for each nucleotide, the repeat sequence is compared to the DNA sequence in the window. If the repeat sequence matches the DNA sequence in the window, the window is incremented by one nucleotide and the process is repeated. If the repeat sequence does not match the DNA sequence in the window, the window is not incremented and the process is repeated for the next nucleotide.\n\nOnce the entire DNA sequence has been scanned, the size of the repeat expansion can be determined by counting the number of nucleotides in the window that match the repeat sequence. If the repeat expansion is shorter than a certain threshold, it is considered to be normal. If the repeat expansion is longer than the threshold, it is considered to be pathological and may indicate a genetic disorder.\n\nAnother algorithm that can be used for the detection of long repeat expansions is the \"markov model\".\n\nIn this approach, a Markov model is constructed using the repeat sequence and the surrounding DNA sequence. The Markov model represents the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence. The Markov model is then used to scan the DNA sequence for the presence of the repeat sequence.\n\nFor each nucleotide in the DNA sequence, the probability of that nucleotide being present in the repeat sequence is calculated using the Markov model. If the probability of the nucleotide being present in the repeat sequence is greater than a certain threshold, it is considered to be part of the repeat expansion and the process is repeated for the next nucleotide. If the probability of the nucleotide being present in the repeat sequence is less than the threshold, it is considered to be part of the surrounding DNA sequence and the process is repeated for the next nucleotide.\n\nOnce the entire DNA sequence has been scanned, the size of the repeat expansion can be determined by counting the number of nucleotides in the DNA sequence that match the repeat sequence. If the repeat expansion is shorter than a certain threshold, it is considered to be normal. If the repeat expansion is longer than the threshold, it is considered",
    "llama-7b_fact_raw": "1. The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions in DNA sequences.\n2. In the \"sliding window\" approach, a DNA sequence window is compared to a repeat sequence one nucleotide at a time.\n3. A Markov model can also be used to detect long repeat expansions by representing the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence.\n4. The size of a repeat expansion is considered pathological if it is longer than a certain threshold, indicating a possible genetic disorder.\n5. Both the \"sliding window\" approach and the Markov model involve scanning the entire DNA sequence to determine the size of the repeat expansion.",
    "llama-7b_fact": [
      "The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions in DNA sequences.",
      "In the \"sliding window\" approach, a DNA sequence window is compared to a repeat sequence one nucleotide at a time.",
      "A Markov model can also be used to detect long repeat expansions by representing the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence.",
      "The size of a repeat expansion is considered pathological if it is longer than a certain threshold, indicating a possible genetic disorder.",
      "Both the \"sliding window\" approach and the Markov model involve scanning the entire DNA sequence to determine the size of the repeat expansion."
    ],
    "llama-7b_judge_raw": "1. TRUE: The \"sliding window\" approach is indeed a method used in bioinformatics for various purposes, including the detection of repeat expansions in DNA sequences.\n2. TRUE: The sliding window approach involves comparing a fixed-length sequence window to another sequence incrementally, typically one nucleotide at a time.\n3. TRUE: A Markov model is a statistical model that can represent the probability of nucleotide occurrence based on previous nucleotides, making it useful for detecting patterns such as repeat expansions in DNA sequences.\n4. TRUE: A repeat expansion is considered pathological when it exceeds a certain length, which can be indicative of a genetic disorder.\n5. FALSE [correction]: While both the \"sliding window\" approach and Markov model scan portions of the DNA sequence to detect repeat expansions, they do not necessarily scan the \"entire\" sequence in the same way. The sliding window approach moves through the sequence incrementally, and the Markov model is often used to compute probabilities based on segments of the sequence rather than scanning linearly through the whole sequence. The exact implementation can differ based on the specific application or algorithm.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "Neuroligin-3 is a protein that has been implicated in the development and progression of various types of brain tumors, including gliomas. Gliomas are a type of brain tumor that arise from glial cells, which are supportive cells in the brain that help to maintain its structure and function.\n\nNeuroligin-3 has been found to be overexpressed in a number of different types of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas. These tumors are characterized by the abnormal proliferation of glial cells, and the overexpression of neuroligin-3 has been shown to promote the growth and survival of these cells.\n\nIn addition to promoting the growth of gliomas, neuroligin-3 has also been implicated in the development of other types of brain tumors, such as meningiomas and schwannomas. However, the role of neuroligin-3 in the development and progression of these tumors is not as well understood as it is in gliomas.\n\nOverall, the overexpression of neuroligin-3 has been implicated in the development and progression of a number of different types of brain tumors, including gliomas, meningiomas, and schwannomas. Further research is needed to fully understand the role of neuroligin-3 in the development and progression of these tumors, and to identify potential therapeutic targets for the treatment of brain tumors.",
    "llama-7b_fact_raw": "1. Neuroligin-3 is implicated in the development and progression of various types of brain tumors.\n2. Gliomas are brain tumors that arise from glial cells.\n3. Types of gliomas where neuroligin-3 is overexpressed include astrocytomas, oligodendrogliomas, and ependymomas.\n4. Overexpression of neuroligin-3 promotes the growth and survival of glial cells in gliomas.\n5. Neuroligin-3 has also been implicated in the development of brain tumors such as meningiomas and schwannomas.",
    "llama-7b_fact": [
      "Neuroligin-3 is implicated in the development and progression of various types of brain tumors.",
      "Gliomas are brain tumors that arise from glial cells.",
      "Types of gliomas where neuroligin-3 is overexpressed include astrocytomas, oligodendrogliomas, and ependymomas.",
      "Overexpression of neuroligin-3 promotes the growth and survival of glial cells in gliomas.",
      "Neuroligin-3 has also been implicated in the development of brain tumors such as meningiomas and schwannomas."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE \n4. TRUE\n5. FALSE [correction]: Neuroligin-3 has been most notably implicated in the promotion of growth and survival of glial cell-derived tumors such as gliomas, rather than meningiomas and schwannomas, which originate from meningeal and Schwann cells respectively.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles, are small, gas-filled organelles found in some bacteria and archaea. Their size can vary depending on the species of bacteria or archaea and can range from a few nanometers to several micrometers in diameter. In general, gas vacuoles are relatively small compared to the size of the bacterial cell, but they can still have a significant impact on the overall size and shape of the cell.",
    "llama-7b_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. Gas vesicles can range from a few nanometers to several micrometers in diameter.\n3. The size of gas vesicles can vary depending on the species of bacteria or archaea.\n4. Gas vesicles are small compared to the size of the bacterial cell.\n5. Gas vesicles can have a significant impact on the overall size and shape of the cell.",
    "llama-7b_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "Gas vesicles can range from a few nanometers to several micrometers in diameter.",
      "The size of gas vesicles can vary depending on the species of bacteria or archaea.",
      "Gas vesicles are small compared to the size of the bacterial cell.",
      "Gas vesicles can have a significant impact on the overall size and shape of the cell."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Gas vesicles usually range from a few tens of nanometers to several micrometers in diameter.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. They are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues on histone tails, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nThe BET protein family includes:\n\n1. BRD2 (Bromodomain and Extra-terminal domain 2)\n2. BRD3 (Bromodomain and Extra-terminal domain 3)\n3. BRD4 (Bromodomain and Extra-terminal domain 4)\n4. BAP1 (Bromodomain and Extra-terminal domain containing protein 1)\n5. BAP3 (Bromodomain and Extra-terminal domain containing protein 3)\n6. BAP2 (Bromodomain and Extra-terminal domain containing protein 2)\n7. BAP4 (Bromodomain and Extra-terminal domain containing protein 4)\n8. BAP5 (Bromodomain and Extra-terminal domain containing protein 5)\n9. BAP6 (Bromodomain and Extra-terminal domain containing protein 6)\n10. BAP7 (Bromodomain and Extra-terminal domain containing protein 7)\n11. BAP8 (Bromodomain and Extra-terminal domain containing protein 8)\n12. BAP9 (Bromodomain and Extra-terminal domain containing protein 9)\n13. BAP10 (Bromodomain and Extra-terminal domain containing protein 10)\n14. BAP11 (Bromodomain and Extra-terminal domain containing protein 11)\n15. BAP12 (Bromodomain and Extra-terminal domain containing protein 12)\n16. BAP13 (Bromodomain and Extra-terminal domain containing protein 13)\n17",
    "llama-7b_fact_raw": "1. BRD2, BRD3, and BRD4 are members of the BET protein family.\n2. BET proteins are epigenetic regulators involved in the regulation of gene expression.\n3. BET proteins are characterized by the presence of a bromodomain and an extra-terminal (ET) domain.\n4. The bromodomain of BET proteins recognizes acetylated lysine residues on histone tails.\n5. The extra-terminal (ET) domain of BET proteins is involved in protein-protein interactions and transcriptional regulation.",
    "llama-7b_fact": [
      "BRD2, BRD3, and BRD4 are members of the BET protein family.",
      "BET proteins are epigenetic regulators involved in the regulation of gene expression.",
      "BET proteins are characterized by the presence of a bromodomain and an extra-terminal (ET) domain.",
      "The bromodomain of BET proteins recognizes acetylated lysine residues on histone tails.",
      "The extra-terminal (ET) domain of BET proteins is involved in protein-protein interactions and transcriptional regulation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning. Some of the most popular ones include:\n\n1. DeepSubella: This is a deep learning-based algorithm that uses a convolutional neural network (CNN) to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2017 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n2. DeepLocal: This is another deep learning-based algorithm that uses a CNN to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2016 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n3. SMALLE: This is a deep learning-based algorithm that uses a recurrent neural network (RNN) to predict the subcellular localization of proteins. The algorithm was developed by Wang et al. in 2018 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n4. DeepSub: This is a deep learning-based algorithm that uses a CNN to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2015 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n\nOverall, these algorithms have been shown to be highly accurate in predicting the subcellular localization of proteins and have the potential to revolutionize the field of protein subcellular localization prediction.",
    "llama-7b_fact_raw": "1. The DeepSubella algorithm utilizes a convolutional neural network (CNN) for predicting protein subcellular localization and was developed by Li et al. in 2017.\n2. DeepLocal is an algorithm that also uses a CNN for the prediction of protein subcellular localization; it was created by Li et al. in 2016.\n3. The SMALLE algorithm, developed by Wang et al. in 2018, employs a recurrent neural network (RNN) for predicting protein subcellular localization.\n4. DeepSub is a predictive algorithm using a CNN for protein subcellular localization, developed by Li et al. in 2015.\n5. These deep learning-based algorithms have been reported to have high accuracy in protein subcellular localization prediction.",
    "llama-7b_fact": [
      "The DeepSubella algorithm utilizes a convolutional neural network (CNN) for predicting protein subcellular localization and was developed by Li et al. in 2017.",
      "DeepLocal is an algorithm that also uses a CNN for the prediction of protein subcellular localization; it was created by Li et al. in 2016.",
      "The SMALLE algorithm, developed by Wang et al. in 2018, employs a recurrent neural network (RNN) for predicting protein subcellular localization.",
      "DeepSub is a predictive algorithm using a CNN for protein subcellular localization, developed by Li et al. in 2015.",
      "These deep learning-based algorithms have been reported to have high accuracy in protein subcellular localization prediction."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely known algorithm called DeepLocal developed in 2016 for protein subcellular localization by Li et al. A known algorithm is called DeepLoc, developed by Almagro Armenteros et al. in 2017.\n3. UNKNOWN (There's no broad recognition of the SMALLE algorithm in the literature with the details given. Without additional information, its existence and claims cannot be verified.)\n4. FALSE [correction]: There is no widely known algorithm called DeepSub developed by Li et al. in 2015 for protein subcellular localization. However, DeepLoc is an algorithm developed in 2017 by Almagro Armenteros et al., as mentioned above.\n5. TRUE (Deep learning-based algorithms are indeed known for their high accuracy in various fields, including protein subcellular localization prediction, but the statement is general without specifics to the named algorithms.)",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MULTOVL.\" Can you provide more context or information about what you are asking?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15, also known as growth differentiation factor 15, is a protein that has been studied as a potential biomarker for various conditions, including diabetes. Metformin is a commonly used medication for treating type 2 diabetes, and it has been suggested that GDF15 may be a biomarker for the effectiveness of metformin treatment. However, the relationship between GDF15 and metformin treatment is complex and not yet fully understood.\n\nStudies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes. This suggests that metformin may be able to lower GDF15 levels by improving insulin sensitivity and glucose control. Lower levels of GDF15 have also been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes, which further supports the idea that GDF15 may be a biomarker for the effectiveness of metformin treatment.\n\nHowever, the relationship between GDF15 and metformin treatment is not always consistent. Some studies have found no association between GDF15 levels and the effectiveness of metformin treatment, while others have found conflicting results. Additionally, the relationship between GDF15 and metformin treatment may vary depending on the individual and the stage of diabetes.\n\nOverall, while GDF15 has been studied as a potential biomarker for the effectiveness of metformin treatment, the relationship between the two is complex and not yet fully understood. Further research is needed to clarify the role of GDF15 as a biomarker for metformin treatment.",
    "llama-7b_fact_raw": "1. GDF15 stands for growth differentiation factor 15.\n2. Metformin is commonly used for treating type 2 diabetes.\n3. Studies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes.\n4. Lower levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.\n5. The relationship between GDF15 and the effectiveness of metformin treatment is not consistently observed across studies.",
    "llama-7b_fact": [
      "GDF15 stands for growth differentiation factor 15.",
      "Metformin is commonly used for treating type 2 diabetes.",
      "Studies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes.",
      "Lower levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.",
      "The relationship between GDF15 and the effectiveness of metformin treatment is not consistently observed across studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Studies have shown that metformin can increase levels of GDF15 in the blood of people with type 2 diabetes.\n4. FALSE [correction]: Higher levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing is a process in which an intron is spliced out of an mRNA molecule and then spliced back into the same mRNA molecule, resulting in the creation of a new mRNA molecule with the intron removed. Recursive splicing can occur in both short and long introns, and the frequency of recursive splicing is not necessarily higher in short introns compared to long introns.\n\nThe frequency of recursive splicing is influenced by several factors, including the length of the intron, the presence of regulatory elements within the intron, and the presence of other splicing events in the vicinity of the intron. Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing, or if they are located in close proximity to other splicing events that require the removal and reinsertion of the intron.\n\nHowever, the frequency of recursive splicing is also influenced by the overall splicing efficiency of the mRNA molecule, which can vary depending on factors such as the abundance of splicing machinery, the stability of the mRNA molecule, and the presence of alternative splicing events. In general, recursive splicing is more likely to occur in mRNA molecules with high splicing efficiency, regardless of the length of the intron.\n\nIn summary, while recursive splicing can occur in both short and long introns, the frequency of recursive splicing is not necessarily higher in short introns compared to long introns. The frequency of recursive splicing is influenced by several factors, including the length of the intron, the presence of regulatory elements, and the overall splicing efficiency of the mRNA molecule.",
    "llama-7b_fact_raw": "1. Recursive splicing is a process where an intron is spliced out of mRNA and then spliced back into the same mRNA molecule.\n2. The frequency of recursive splicing is not necessarily higher in short introns compared to long introns.\n3. Factors that influence recursive splicing include intron length, presence of regulatory elements within the intron, and nearby splicing events.\n4. Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing or are close to other splicing events.\n5. The overall splicing efficiency of the mRNA molecule affects the likelihood of recursive splicing occurring.",
    "llama-7b_fact": [
      "Recursive splicing is a process where an intron is spliced out of mRNA and then spliced back into the same mRNA molecule.",
      "The frequency of recursive splicing is not necessarily higher in short introns compared to long introns.",
      "Factors that influence recursive splicing include intron length, presence of regulatory elements within the intron, and nearby splicing events.",
      "Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing or are close to other splicing events.",
      "The overall splicing efficiency of the mRNA molecule affects the likelihood of recursive splicing occurring."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is a process where a long intron is removed in multiple steps, with parts of the intron spliced out one by one rather than one continuous event.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD (Transcription Activator-Like Effector (TALE) proteins for the Identification of Disease-associated Variants) method is used for the identification of disease-associated variants in the human genome.\n\nTALE proteins are engineered DNA-binding proteins that can recognize specific DNA sequences with high specificity and affinity. The TALE-iD method uses TALE proteins to selectively bind to regions of the genome that contain disease-associated variants, such as single nucleotide polymorphisms (SNPs) or copy number variations (CNVs).\n\nThe TALE-iD method involves the following steps:\n\n1. Design of TALE proteins: TALE proteins are designed to recognize specific DNA sequences, such as those found in disease-associated variants.\n2. Target enrichment: The genome is targeted for enrichment using the TALE-protein-bound probes. This allows for the selective capture of regions of the genome that contain disease-associated variants.\n3. Sequencing: The captured regions of the genome are then sequenced to identify the disease-associated variants.\n4. Variant calling: The sequencing data is analyzed to identify the disease-associated variants.\n\nThe TALE-iD method has several advantages over other methods for the identification of disease-associated variants. It allows for the targeted enrichment of specific regions of the genome, which reduces the amount of sequencing required and increases the sensitivity of the analysis. It also allows for the identification of rare variants, which can be difficult to detect using other methods.\n\nOverall, the TALE-iD method is a powerful tool for the identification of disease-associated variants in the human genome, and has the potential to improve our understanding of the genetic basis of complex diseases and enable the development of personalized medicine.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of disease-associated variants in the human genome.\n2. TALE-iD employs engineered Transcription Activator-Like Effector proteins that bind to specific DNA sequences.\n3. The TALE-iD method facilitates the targeted enrichment of regions containing disease-associated variants for sequencing.\n4. TALE proteins in TALE-iD are specifically designed to recognize sequences associated with disease variants, such as SNPs or CNVs.\n5. The TALE-iD method is designed to increase the sensitivity of analyzing genomic data and identify rare variants.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of disease-associated variants in the human genome.",
      "TALE-iD employs engineered Transcription Activator-Like Effector proteins that bind to specific DNA sequences.",
      "The TALE-iD method facilitates the targeted enrichment of regions containing disease-associated variants for sequencing.",
      "TALE proteins in TALE-iD are specifically designed to recognize sequences associated with disease variants, such as SNPs or CNVs.",
      "The TALE-iD method is designed to increase the sensitivity of analyzing genomic data and identify rare variants."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe TALE-iD method does indeed involve the use of engineered Transcription Activator-Like Effector (TALE) proteins, which bind specific DNA sequences. It's employed for targeted enrichment, which would include regions containing disease-associated variants, making subsequent sequencing more efficient and sensitive, especially for identifying rare variants. Without further context or contradictory information, the statements given align with the typical description and purpose of technology like TALE-iD in genomics research.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Image Processing (CL-IP): CL-IP is a Common Lisp library for image processing and analysis. It provides a wide range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n2. QuickDraw CL: QuickDraw CL is a Common Lisp library for image processing and computer vision. It provides a range of functions for tasks such as image manipulation, feature extraction, and object recognition.\n3. LispWorks Image Processing Library (LIP): LIP is a LispWorks library for image processing and analysis. It provides a range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n4. SBCL Image Processing Library (SBCL-IP): SBCL-IP is a SBCL library for image processing and analysis. It provides a range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n\nOverall, there are several Lisp frameworks available for image processing, and the choice of which one to use will depend on the specific requirements of the project.",
    "llama-7b_fact_raw": "1. Common Lisp Image Processing (CL-IP) is a library developed for image processing and analysis in Common Lisp.\n2. QuickDraw CL is an image processing and computer vision library developed for use with Common Lisp.\n3. LispWorks Image Processing Library (LIP) is an image processing library available in LispWorks.\n4. SBCL Image Processing Library (SBCL-IP) is an image processing library for the SBCL implementation of Lisp.",
    "llama-7b_fact": [
      "Common Lisp Image Processing (CL-IP) is a library developed for image processing and analysis in Common Lisp.",
      "QuickDraw CL is an image processing and computer vision library developed for use with Common Lisp.",
      "LispWorks Image Processing Library (LIP) is an image processing library available in LispWorks.",
      "SBCL Image Processing Library (SBCL-IP) is an image processing library for the SBCL implementation of Lisp."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information on a library named \"Common Lisp Image Processing\" or \"CL-IP,\" it is not possible to determine the truth of this statement.\n2. FALSE [correction]: QuickDraw CL was not an image processing library but was actually a graphics library created by Apple for their Classic Mac OS.\n3. TRUE: LispWorks does include an Image Processing Library (LIP), which is used for image processing tasks.\n4. UNKNOWN: There is no widely recognized image processing library specifically called \"SBCL Image Processing Library\" or \"SBCL-IP\" for the Steel Bank Common Lisp (SBCL) implementation. It is possible this is a confusion or a less known library not broadly acknowledged in the Lisp community.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "The question of how many genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication event is a complex one that has been the subject of much research.\n\nS. cerevisiae is a eukaryotic, single-celled fungus that is widely used as a model organism in genetics and molecular biology. The genome of S. cerevisiae consists of 12 megabases (Mb) of DNA and contains approximately 6,000 protein-coding genes.\n\nAncient whole genome duplications (WGDs) are a common feature of the evolution of eukaryotic genomes. WGDs result in the duplication of large portions of the genome, leading to the formation of duplicate genes and the evolution of new gene functions.\n\nThere have been several studies that have attempted to identify the number of genes in S. cerevisiae that are the result of an ancient WGD. These studies have used a variety of approaches, including comparative genomics, gene family analysis, and phylogenetic reconstruction.\n\nOne of the earliest studies to address this question was published in 2001 by Li and Durbin, who used a comparative genomics approach to identify duplicated blocks of genes in the S. cerevisiae genome. They identified several large blocks of duplicated genes that were likely the result of an ancient WGD, and estimated that approximately 25% of the S. cerevisiae genes were the result of this event.\n\nMore recent studies have used a variety of approaches to estimate the number of genes in S. cerevisiae that are the result of an ancient WGD. For example, a study published in 2014 used a combination of gene family analysis and phylogenetic reconstruction to estimate that approximately 30% of the S. cerevisiae genes were the result of an ancient WGD.\n\nOverall, the number of genes in S. cerevisiae that are the result of an ancient WGD is estimated to be between 1500 and 3000. However, the exact number is difficult to determine with certainty, and further research is likely to refine",
    "llama-7b_fact_raw": "1. Saccharomyces cerevisiae, commonly known as baker's yeast, is a eukaryotic, single-celled fungus used as a model organism in genetics and molecular biology.\n2. The genome of S. cerevisiae is composed of 12 megabases (Mb) of DNA.\n3. S. cerevisiae contains approximately 6,000 protein-coding genes.\n4. An ancient whole genome duplication event is responsible for the duplication of a significant portion of the S. cerevisiae genome.\n5. Studies estimate that between 25% and 30% of S. cerevisiae's genes, roughly 1500 to 3000 genes, are the result of an ancient whole genome duplication.",
    "llama-7b_fact": [
      "Saccharomyces cerevisiae, commonly known as baker's yeast, is a eukaryotic, single-celled fungus used as a model organism in genetics and molecular biology.",
      "The genome of S. cerevisiae is composed of 12 megabases (Mb) of DNA.",
      "S. cerevisiae contains approximately 6,000 protein-coding genes.",
      "An ancient whole genome duplication event is responsible for the duplication of a significant portion of the S. cerevisiae genome.",
      "Studies estimate that between 25% and 30% of S. cerevisiae's genes, roughly 1500 to 3000 genes, are the result of an ancient whole genome duplication."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE: The genome of S. cerevisiae is indeed approximately 12 megabases.\n3. TRUE: S. cerevisiae does contain approximately 6,000 protein-coding genes.\n4. TRUE: The ancient whole genome duplication event did contribute to the duplication of a significant portion of the S. cerevisiae genome.\n5. FALSE [correction]: If about 50% of S. cerevisiae's genes, approximately 3000, are the result of an ancient whole genome duplication as stated in statement 4, then the 25% to 30% figure provided here, referring to 1500 to 1800 genes, seems too low. Hence, while there is a consensus on the occurrence of an ancient whole genome duplication event, the exact percentage of genes resulting from it can vary based on the study, and the numbers here seem to be underestimated given the context of the previous statement.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-7b_response": "Estrogen-related receptor β (Esrrb) is a member of the nuclear receptor superfamily of transcription factors. It is a ligand-activated transcription factor that binds to DNA and regulates the expression of target genes involved in a variety of biological processes, including development, differentiation, and homeostasis.\n\nEsrrb is primarily expressed in the brain, where it plays a role in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection. It has also been shown to play a role in the regulation of bone metabolism, lipid metabolism, and immune function.\n\nEsrrb is known to be bound by a variety of ligands, including estrogens, androgens, and other steroid hormones. It has also been shown to be bound by non-steroidal ligands, such as thyroid hormones and retinoic acid.\n\nThere is limited information available on the specific complex that is bound by Esrrb. However, it is known that Esrrb can form heterodimers with other nuclear receptors, such as estrogen receptor α (Esr1) and glucocorticoid receptor (GR). These heterodimers can bind to DNA and regulate the expression of target genes involved in a variety of biological processes.\n\nIn summary, while there is limited information available on the specific complex that is bound by Esrrb, it is known to form heterodimers with other nuclear receptors and regulate the expression of target genes involved in a variety of biological processes.",
    "llama-7b_fact_raw": "1. Estrogen-related receptor β (Esrrb) is part of the nuclear receptor superfamily of transcription factors.\n2. Esrrb is a ligand-activated transcription factor that binds to DNA to regulate expression of target genes.\n3. Esrrb primarily has roles in development, differentiation, and homeostasis.\n4. Esrrb is predominantly expressed in the brain and is involved in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection.\n5. Esrrb can form heterodimers with other nuclear receptors such as estrogen receptor α (Esr1) and glucocorticoid receptor (GR).",
    "llama-7b_fact": [
      "Estrogen-related receptor β (Esrrb) is part of the nuclear receptor superfamily of transcription factors.",
      "Esrrb is a ligand-activated transcription factor that binds to DNA to regulate expression of target genes.",
      "Esrrb primarily has roles in development, differentiation, and homeostasis.",
      "Esrrb is predominantly expressed in the brain and is involved in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection.",
      "Esrrb can form heterodimers with other nuclear receptors such as estrogen receptor α (Esr1) and glucocorticoid receptor (GR)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) is an orphan nuclear receptor and does not have a known endogenous ligand.\n3. TRUE\n4. FALSE [correction]: While Esrrb is expressed in the brain and involved in various functions there, it is not predominantly expressed in the brain, as its expression is also found in other tissues such as the embryonic stem cells where it plays roles in pluripotency and self-renewal.\n5. FALSE [correction]: Esrrb primarily forms homodimers rather than heterodimers, although it can potentially interact with other nuclear receptors, the specific interactions and functional significance of such heterodimers with Esr1 and GR are not clearly established.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17 is a gene that encodes for a protein called zinc finger CCCH-type containing 17. This protein is a member of the CCCH-type zinc finger family, which is a class of transcription factors that bind to DNA and regulate gene expression.\n\nThe exact function of ZCCHC17 is not fully understood, but it is believed to play a role in regulating the expression of genes involved in a variety of biological processes, including cell growth, differentiation, and immune response.\n\nStudies have shown that ZCCHC17 is expressed in a variety of tissues and cells, including immune cells such as T cells and B cells. It has been suggested that ZCCHC17 may play a role in regulating the activation and proliferation of these immune cells.\n\nIn addition, ZCCHC17 has been implicated in the development of certain types of cancer, including leukemia and lymphoma. It has been shown that overexpression of ZCCHC17 can promote the growth and survival of cancer cells, suggesting that it may be a potential target for cancer therapy.\n\nOverall, while more research is needed to fully understand the role of ZCCHC17, it is clear that this protein plays an important role in regulating gene expression and may have implications for a variety of biological processes, including immune response and cancer development.",
    "llama-7b_fact_raw": "1. ZCCHC17 is a gene that encodes the protein zinc finger CCCH-type containing 17.\n2. The protein ZCCHC17 is a member of the CCCH-type zinc finger family, which consists of transcription factors regulating gene expression.\n3. ZCCHC17 is believed to be involved in regulating the expression of genes important in cell growth, differentiation, and immune response.\n4. ZCCHC17 is expressed in various tissues and cells, including immune cells like T cells and B cells.\n5. Overexpression of ZCCHC17 has been observed to promote growth and survival of cancer cells in certain types of cancer, such as leukemia and lymphoma.",
    "llama-7b_fact": [
      "ZCCHC17 is a gene that encodes the protein zinc finger CCCH-type containing 17.",
      "The protein ZCCHC17 is a member of the CCCH-type zinc finger family, which consists of transcription factors regulating gene expression.",
      "ZCCHC17 is believed to be involved in regulating the expression of genes important in cell growth, differentiation, and immune response.",
      "ZCCHC17 is expressed in various tissues and cells, including immune cells like T cells and B cells.",
      "Overexpression of ZCCHC17 has been observed to promote growth and survival of cancer cells in certain types of cancer, such as leukemia and lymphoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation for UNKNOWN:\nWhile ZCCHC17 is a CCCH-type zinc finger protein and the roles mentioned in statements 2, 3, and 4 are typical of such proteins, research on the specific functions of ZCCHC17 is less commonly found in widely available sources. Without specific studies or evidence cited, the role of ZCCHC17 in cancer cell growth and survival in leukemia and lymphoma, as described in statement 5, cannot be confirmed or denied with the given information. More specialized or recent scientific research would be required to determine the accuracy of this statement.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore complex (NPC) is a large protein complex that forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells. The NPC consists of an outer ring of approximately 30 nucleoporins (Nups) and an inner ring of approximately 80 nucleoporins.\n\nThe proteins that form the nuclear pore basket are a group of nucleoporins that are involved in the formation of the inner ring of the NPC. These proteins include:\n\n1. Nup107-160\n2. Nup153\n3. Nup214\n4. Nup215\n5. Nup231\n6. Nup232\n7. Nup233\n8. Nup234\n9. Nup235\n10. Nup236\n11. Nup237\n12. Nup238\n13. Nup239\n14. Nup240\n15. Nup241\n16. Nup242\n17. Nup243\n18. Nup244\n19. Nup245\n20. Nup246\n21. Nup247\n22. Nup248\n23. Nup249\n24. Nup250\n25. Nup251\n26. Nup252\n27. Nup253\n28. Nup254\n29. Nup255\n30. Nup256\n31. Nup257\n32. Nup258\n33. Nup259\n34. Nup260\n35. Nup261\n36. Nup262\n37. Nup263\n38. Nup264\n39. Nup265\n40. Nup266\n41. Nup267\n42. Nup268\n43. Nup269\n44. Nup270\n45. Nup",
    "llama-7b_fact_raw": "1. The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells.\n2. The NPC is made up of an outer ring of approximately 30 nucleoporins and an inner ring of approximately 80 nucleoporins.\n3. Nucleoporins (Nups) are the proteins that constitute the nuclear pore complex.\n4. Nup107-160 and Nup153 are examples of nucleoporins that form the nuclear pore basket.\n5. The list of proteins provided as constituting the nuclear pore basket, ranging from Nup107-160 to Nup270, is likely incorrect or misrepresented, as there are typically fewer distinct nucleoporins in the NPC, and the naming convention does not usually employ a simple numerical sequence.\n\n(Note: The list of nucleoporins presented in the answer is either incorrect or misleading as there are not that many distinct nucleoporins known in the nuclear pore complex, and the numbers provided do not reflect the known nomenclature of nucleoporins. The factual statements have been generated based on conventional understanding and omit the long list of nucleoporins mentioned in the answer as this could not be independently verified.)",
    "llama-7b_fact": [
      "The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells.",
      "The NPC is made up of an outer ring of approximately 30 nucleoporins and an inner ring of approximately 80 nucleoporins.",
      "Nucleoporins (Nups) are the proteins that constitute the nuclear pore complex.",
      "Nup107-160 and Nup153 are examples of nucleoporins that form the nuclear pore basket.",
      "The list of proteins provided as constituting the nuclear pore basket, ranging from Nup107-160 to Nup270, is likely incorrect or misrepresented, as there are typically fewer distinct nucleoporins in the NPC, and the naming convention does not usually employ a simple numerical sequence.",
      "ote: The list of nucleoporins presented in the answer is either incorrect or misleading as there are not that many distinct nucleoporins known in the nuclear pore complex, and the numbers provided do not reflect the known nomenclature of nucleoporins. The factual statements have been generated based on conventional understanding and omit the long list of nucleoporins mentioned in the answer as this could not be independently verified.)"
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The NPC is not accurately described by a simple division into outer and inner rings with specific numbers of nucleoporins. It is a complex structure composed of multiple copies of around 30 different types of nucleoporins arranged into subcomplexes.\n3. TRUE\n4. TRUE (Nup107-160 complex and Nup153 are indeed nucleoporins, and Nup153 is associated with the nuclear basket.)\n5. TRUE (The information suggests a potential error in the list of nucleoporins, likely due to a misunderstanding of the nomenclature or the actual number of distinct nucleoporins.)\n6. TRUE (This note concurs that the presented list of nucleoporins is a misrepresentation and does not align with the standard nomenclature or the known composition of the NPC.)",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Gepotidacin is a topoisomerase I inhibitor.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"Canvas SPW.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is a method used to classify and organize software systems based on their architecture. It stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.\n\nThe SLIC-CAGE method uses a genetic algorithm to evolve a classification of software systems based on their architecture. The classification is based on a layered infrastructure model, which divides software systems into layers based on their functionality and the interactions between them.\n\nThe genetic algorithm used in SLIC-CAGE starts with a set of initial classifications of software systems, which are then evolved over time through a process of mutation and selection. The goal of the algorithm is to find a set of classifications that accurately reflect the architecture of the software systems and are consistent with each other.\n\nThe SLIC-CAGE method can be used to classify a wide range of software systems, including operating systems, web applications, and embedded systems. It can also be used to compare the architecture of different software systems and to identify patterns and trends in their design.\n\nOverall, SLIC-CAGE is a powerful tool for classifying and organizing software systems based on their architecture, and it has a wide range of potential applications in software engineering and research.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.\n2. SLIC-CAGE employs a genetic algorithm to evolve the classification of software systems based on their architecture.\n3. The classification system in SLIC-CAGE is based on a layered infrastructure model, which organizes software into layers by functionality and interaction.\n4. The process used in the SLIC-CAGE genetic algorithm involves mutation and selection to refine software system classifications.\n5. SLIC-CAGE can classify various types of software systems, including operating systems, web applications, and embedded systems.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.",
      "SLIC-CAGE employs a genetic algorithm to evolve the classification of software systems based on their architecture.",
      "The classification system in SLIC-CAGE is based on a layered infrastructure model, which organizes software into layers by functionality and interaction.",
      "The process used in the SLIC-CAGE genetic algorithm involves mutation and selection to refine software system classifications.",
      "SLIC-CAGE can classify various types of software systems, including operating systems, web applications, and embedded systems."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE (assuming the given acronym stands for a system that employs a genetic algorithm, mutation and selection are standard processes in genetic algorithms for evolution)\n5. UNKNOWN\n\nNote: The acronym \"SLIC-CAGE\" does not correspond to a widely recognized term in software engineering, so without additional context, it is impossible to verify the first three statements or the fifth statement. The fourth statement is presumed to be true based on the general knowledge that genetic algorithms involve mutation and selection.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3, also known as Lymphoid Enhancer-Binding Factor 3, is a transcription factor that plays a crucial role in the development and function of the immune system. It is primarily expressed in lymphoid tissues, such as the thymus and bone marrow, and regulates the expression of genes involved in T cell development, B cell differentiation, and antibody production.\n\nOne of the key functions of LEM-3 is to regulate the differentiation of T cells, which are a type of white blood cell that play a central role in the immune response. LEM-3 regulates the expression of genes involved in the activation and proliferation of T cells, as well as the production of cytokines and chemokines that attract other immune cells to the site of an infection or inflammation.\n\nIn addition to its role in T cell development, LEM-3 is also involved in the differentiation of B cells, which are a type of white blood cell that produce antibodies to protect the body against infections. LEM-3 regulates the expression of genes involved in the activation and maturation of B cells, as well as the production of antibodies.\n\nOverall, LEM-3 plays a critical role in the development and function of the immune system, and its dysregulation has been implicated in a number of immune disorders, including autoimmune diseases and cancer.",
    "llama-7b_fact_raw": "1. LEM-3, known as Lymphoid Enhancer-Binding Factor 3, is a transcription factor important for the immune system.\n2. LEM-3 is primarily expressed in lymphoid tissues like the thymus and bone marrow.\n3. It has a role in regulating the expression of genes involved in T cell development.\n4. LEM-3 influences the differentiation of B cells involved in antibody production.\n5. Dysregulation of LEM-3 is associated with immune disorders, including autoimmune diseases and cancer.",
    "llama-7b_fact": [
      "LEM-3, known as Lymphoid Enhancer-Binding Factor 3, is a transcription factor important for the immune system.",
      "LEM-3 is primarily expressed in lymphoid tissues like the thymus and bone marrow.",
      "It has a role in regulating the expression of genes involved in T cell development.",
      "LEM-3 influences the differentiation of B cells involved in antibody production.",
      "Dysregulation of LEM-3 is associated with immune disorders, including autoimmune diseases and cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LEM-3, known as Lethal(3)malignant Brain Tumor-like protein 3, is involved in DNA damage repair, not as a transcription factor for the immune system.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Dysregulation of LEM domain containing 3 (LEM-3) is not specifically associated with immune disorders. It is rather involved in the maintenance of genome stability and DNA repair processes.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"tmVar.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "The database of somatic mutations in normal cells is called the Cancer Genome Atlas (TCGA). TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to characterize the genetic changes that occur in cancer cells.\n\nTCGA collects and analyzes DNA and RNA sequencing data from tumors and normal tissue samples from patients with a wide range of cancer types. The data is used to identify somatic mutations, which are changes in the DNA or RNA that occur in cancer cells but not in normal cells.\n\nTCGA has generated a vast amount of data on somatic mutations in normal cells, which is publicly available and can be accessed through the TCGA Data Portal. Researchers can use this data to study the genetic changes that occur in normal cells and how they may contribute to the development of cancer.\n\nOverall, TCGA is an important resource for the study of somatic mutations in normal cells and their role in cancer development.",
    "llama-7b_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.\n2. TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n3. TCGA collects and analyzes DNA and RNA sequencing data from tumors as well as normal tissue samples.\n4. The TCGA Data Portal provides public access to the data generated by TCGA.\n5. Researchers utilize TCGA data to study genetic changes in normal cells and their contribution to cancer development.",
    "llama-7b_fact": [
      "The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.",
      "TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "TCGA collects and analyzes DNA and RNA sequencing data from tumors as well as normal tissue samples.",
      "The TCGA Data Portal provides public access to the data generated by TCGA.",
      "Researchers utilize TCGA data to study genetic changes in normal cells and their contribution to cancer development."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) is a database of somatic mutations in cancer cells, not normal cells.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Researchers utilize TCGA data to study genetic changes in cancer cells, not normal cells, and their contribution to cancer development.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "The SHERLOCKv2 platform integrates four key advances:\n\n1. Real-time analytics: SHERLOCKv2 uses real-time analytics to process and analyze large amounts of data in real-time, allowing for faster and more accurate decision-making.\n2. Artificial intelligence and machine learning: SHERLOCKv2 incorporates artificial intelligence and machine learning algorithms to improve the accuracy and speed of threat detection and response.\n3. Automation and orchestration: SHERLOCKv2 includes automation and orchestration capabilities, allowing for more efficient and effective incident response and remediation.\n4. Open architecture and extensibility: SHERLOCKv2 has an open architecture and is extensible, allowing for easy integration with other systems and tools, as well as the ability to add new capabilities as needed.",
    "llama-7b_fact_raw": "1. SHERLOCKv2 incorporates real-time analytics for processing and analyzing data.\n2. SHERLOCKv2 includes artificial intelligence and machine learning algorithms for threat detection and response.\n3. SHERLOCKv2 features automation and orchestration capabilities for incident response and remediation.\n4. SHERLOCKv2 is designed with an open architecture that is extensible and allows integration with other systems.",
    "llama-7b_fact": [
      "SHERLOCKv2 incorporates real-time analytics for processing and analyzing data.",
      "SHERLOCKv2 includes artificial intelligence and machine learning algorithms for threat detection and response.",
      "SHERLOCKv2 features automation and orchestration capabilities for incident response and remediation.",
      "SHERLOCKv2 is designed with an open architecture that is extensible and allows integration with other systems."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN \n2. UNKNOWN \n3. UNKNOWN \n4. UNKNOWN\n\nWithout specific context or a clear source defining what SHERLOCKv2 is and what its capabilities are, it is not possible to accurately determine the veracity of these statements. SHERLOCKv2 could be a fictional system or a proprietary technology that has these features, but without additional information, the truth of these statements remains unknown.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm, also known as the bartender problem, is a classic problem in computer science that involves scheduling a set of tasks to be executed on a set of processors. The problem is named after the bartender problem, which is a classic problem in artificial intelligence that involves a bartender trying to serve drinks to a group of customers as efficiently as possible.\n\nThe bartender algorithm is a scheduling algorithm that is used to determine the order in which tasks should be executed on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do.\n\nThe bartender algorithm is a simple and efficient algorithm that can be used to schedule a large number of tasks on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do.\n\nOne of the key advantages of the bartender algorithm is that it is simple to implement and does not require any complex data structures or algorithms. The algorithm is also highly efficient and can be used to schedule a large number of tasks on a set of processors.\n\nIn conclusion, the bartender algorithm is a classic problem in computer science that involves scheduling a set of tasks to be executed on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do. The bartender algorithm is a simple and efficient algorithm that can be used to schedule a large number of tasks on a set of processors.",
    "llama-7b_fact_raw": "1. The bartender algorithm is a scheduling algorithm used in computing for executing tasks on processors.\n2. It involves grouping tasks that can be executed concurrently and assigning them to separate processors.\n3. The bartender algorithm assigns the next task to the processor with the least amount of work remaining.\n4. The algorithm is known for its simplicity and does not require complex data structures for implementation.\n5. The bartender algorithm is efficient for scheduling a large number of tasks on multiple processors.",
    "llama-7b_fact": [
      "The bartender algorithm is a scheduling algorithm used in computing for executing tasks on processors.",
      "It involves grouping tasks that can be executed concurrently and assigning them to separate processors.",
      "The bartender algorithm assigns the next task to the processor with the least amount of work remaining.",
      "The algorithm is known for its simplicity and does not require complex data structures for implementation.",
      "The bartender algorithm is efficient for scheduling a large number of tasks on multiple processors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There is no commonly known scheduling algorithm called the \"bartender algorithm\" in the field of computing. Well-known scheduling algorithms include Round Robin, First Come First Served (FCFS), and Shortest Job First (SJF).\n2. UNKNOWN: Since the \"bartender algorithm\" is not a recognized computing term, the details of how it might group tasks or assign them to processors are not available.\n3. FALSE [correction]: Without recognition of a \"bartender algorithm\" within the computing discipline, there is no standard method it uses to assign tasks. However, the statement describes a characteristic of the \"Shortest Remaining Time First\" (SRTF) algorithm, which assigns the next task based on the shortest remaining time.\n4. UNKNOWN: The simplicity and data structure requirements of the \"bartender algorithm\" cannot be assessed as it is not an established term or method within the computing field.\n5. UNKNOWN: The efficiency of the \"bartender algorithm\" for scheduling tasks cannot be determined as it is not a known algorithm in computing. Efficiency characteristics are specific to each algorithm and depend on various factors like the nature of tasks, number of processors, and the particular implementation.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available that can be used to create and edit family trees online. Some of the most popular options include:\n\n1. Geni: Geni is a free online genealogy and family history platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and track ancestors.\n2. WeRelate: WeRelate is a free, open-source genealogy website that allows users to create and edit family trees. It offers a range of features, including the ability to search for ancestors, add photos and documents, and collaborate with other users.\n3. FamilySearch: FamilySearch is a free online genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n4. MyHeritage: MyHeritage is a paid genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n5. Ancestry: Ancestry is a paid genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n\nThese are just a few examples of the many web-based pedigree editors available. Each platform has its own unique features and benefits, so it's worth exploring a few options to find the one that best suits your needs.",
    "llama-7b_fact_raw": "1. Geni is a web-based genealogy platform where users can create, edit, and manage their family trees.\n2. WeRelate is an open-source genealogy website offering collaborative family tree editing features.\n3. FamilySearch is a free online genealogy platform that provides features for family tree management and ancestor searches.\n4. MyHeritage is a paid genealogy platform that includes collaborative features and allows adding photos and documents to family trees.\n5. Ancestry offers paid services for creating and managing family trees, including features for collaboration and document/photo adding.",
    "llama-7b_fact": [
      "Geni is a web-based genealogy platform where users can create, edit, and manage their family trees.",
      "WeRelate is an open-source genealogy website offering collaborative family tree editing features.",
      "FamilySearch is a free online genealogy platform that provides features for family tree management and ancestor searches.",
      "MyHeritage is a paid genealogy platform that includes collaborative features and allows adding photos and documents to family trees.",
      "Ancestry offers paid services for creating and managing family trees, including features for collaboration and document/photo adding."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MyHeritage is a genealogy platform that allows users to create and manage family trees, and while it offers paid subscriptions for advanced features, there is a free tier available with basic functionality.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. SpiderTox: SpiderTox is a database of spider venom toxins that was developed by researchers at the University of Melbourne in Australia. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n2. Arachnovibes: Arachnovibes is a database of spider venom toxins that was developed by researchers at the University of California, Riverside. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n3. SpiderGen: SpiderGen is a database of spider venom toxins that was developed by researchers at the University of California, Los Angeles. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n4. SpiderTech: SpiderTech is a database of spider venom toxins that was developed by researchers at the University of California, Irvine. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n\nThese databases are valuable resources for researchers studying spider venom toxins, as they provide a wealth of information on the biochemical and biological properties of these toxins, as well as their potential therapeutic applications.",
    "llama-7b_fact_raw": "1. SpiderTox is a database for spider venom toxins developed by researchers at the University of Melbourne in Australia.\n2. Arachnovibes is a database for spider venom toxins developed by researchers at the University of California, Riverside.\n3. SpiderGen is a database for spider venom toxins developed by researchers at the University of California, Los Angeles.\n4. SpiderTech is a database for spider venom toxins developed by researchers at the University of California, Irvine.",
    "llama-7b_fact": [
      "SpiderTox is a database for spider venom toxins developed by researchers at the University of Melbourne in Australia.",
      "Arachnovibes is a database for spider venom toxins developed by researchers at the University of California, Riverside.",
      "SpiderGen is a database for spider venom toxins developed by researchers at the University of California, Los Angeles.",
      "SpiderTech is a database for spider venom toxins developed by researchers at the University of California, Irvine."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ArachnoServer is a database for spider venom toxins developed by researchers at the University of Queensland in Australia.\n3. UNKNOWN\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a medication that is used to treat certain types of cancer, including pancreatic cancer. While there is some evidence to suggest that axitinib may be effective at prolonging survival in some patients with pancreatic cancer, the evidence is not definitive and more research is needed to fully understand its effects on survival in this population.\n\nOne study published in the journal Cancer Research in 2015 found that axitinib may be effective at prolonging survival in patients with advanced pancreatic cancer. In this study, patients who received axitinib had a median survival time of 6.1 months, compared to 4.7 months in patients who did not receive the medication. However, it is worth noting that this study was small and further research is needed to confirm these findings.\n\nAnother study published in the journal Clinical Cancer Research in 2018 found that axitinib may be effective at prolonging survival in patients with advanced pancreatic cancer who have already received chemotherapy. In this study, patients who received axitinib had a median survival time of 6.9 months, compared to 4.4 months in patients who did not receive the medication.\n\nOverall, while there is some evidence to suggest that axitinib may be effective at prolonging survival in patients with pancreatic cancer, more research is needed to fully understand its effects on survival in this population. It is important for patients to discuss the potential benefits and risks of axitinib with their healthcare provider, and to consider all available treatment options before making a decision about their care.",
    "llama-7b_fact_raw": "1. Axitinib is a medication used to treat certain types of cancer, including pancreatic cancer.\n2. A study published in Cancer Research in 2015 indicated that axitinib may prolong survival in patients with advanced pancreatic cancer, showing a median survival time of 6.1 months with the medication.\n3. The median survival time for patients who did not receive axitinib in the 2015 study was 4.7 months.\n4. Research published in Clinical Cancer Research in 2018 suggested that axitinib might prolong survival in patients with advanced pancreatic cancer who have received chemotherapy, reporting a median survival time of 6.9 months with the medication.\n5. The median survival time for patients who did not receive axitinib in the 2018 study was 4.4 months.",
    "llama-7b_fact": [
      "Axitinib is a medication used to treat certain types of cancer, including pancreatic cancer.",
      "A study published in Cancer Research in 2015 indicated that axitinib may prolong survival in patients with advanced pancreatic cancer, showing a median survival time of 6.1 months with the medication.",
      "The median survival time for patients who did not receive axitinib in the 2015 study was 4.7 months.",
      "Research published in Clinical Cancer Research in 2018 suggested that axitinib might prolong survival in patients with advanced pancreatic cancer who have received chemotherapy, reporting a median survival time of 6.9 months with the medication.",
      "The median survival time for patients who did not receive axitinib in the 2018 study was 4.4 months."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is a medication used to treat advanced renal cell carcinoma (kidney cancer) but there is no strong evidence to support its use in treating pancreatic cancer.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile it is known that axitinib is used for kidney cancer, without access to the specific publications or the most recent data, it is impossible to verify the validity of the statements regarding the survival times in patients with advanced pancreatic cancer from the studies mentioned in statements 2, 3, 4, and 5. Therefore, these statements are categorized as UNKNOWN.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "MLP (Microtubule-associated protein-like) is a protein that has been shown to play a role in regulating F-actin dynamics, which are the dynamics of the actin cytoskeleton. The actin cytoskeleton is a network of actin filaments that provides structural support to cells and plays a role in a variety of cellular processes, including cell division, cell motility, and cell shape.\n\nThere are several ways in which MLP can regulate F-actin dynamics. One way is through its interaction with the Arp2/3 complex, which is a protein complex that is involved in the formation of branched actin filaments. MLP has been shown to interact with the Arp2/3 complex and to play a role in regulating its activity, which in turn can affect the dynamics of the actin cytoskeleton.\n\nAnother way in which MLP can regulate F-actin dynamics is through its interaction with the Wiskott-Aldrich syndrome protein (WASP). WASP is a protein that is involved in the regulation of actin filament dynamics and is known to interact with the Arp2/3 complex. MLP has been shown to interact with WASP and to play a role in regulating its activity, which in turn can affect the dynamics of the actin cytoskeleton.\n\nOverall, MLP appears to regulate F-actin dynamics through its interactions with the Arp2/3 complex and WASP, which are both important players in the regulation of actin filament dynamics.",
    "llama-7b_fact_raw": "1. MLP stands for Microtubule-associated protein-like and plays a role in regulating F-actin dynamics.\n2. F-actin dynamics refer to the dynamics of the actin cytoskeleton, which provides structural support to cells.\n3. MLP interacts with the Arp2/3 complex, a protein complex involved in the formation of branched actin filaments, to regulate F-actin dynamics.\n4. MLP has been shown to regulate the activity of Arp2/3 complex.\n5. MLP interacts with the Wiskott-Aldrich syndrome protein (WASP), which is involved in actin filament dynamics regulation.",
    "llama-7b_fact": [
      "MLP stands for Microtubule-associated protein-like and plays a role in regulating F-actin dynamics.",
      "F-actin dynamics refer to the dynamics of the actin cytoskeleton, which provides structural support to cells.",
      "MLP interacts with the Arp2/3 complex, a protein complex involved in the formation of branched actin filaments, to regulate F-actin dynamics.",
      "MLP has been shown to regulate the activity of Arp2/3 complex.",
      "MLP interacts with the Wiskott-Aldrich syndrome protein (WASP), which is involved in actin filament dynamics regulation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MLP usually stands for \"Muscle LIM protein,\" or sometimes \"Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome,\" not Microtubule-associated protein-like. It is true that Muscle LIM protein plays a role in the regulation of various cellular structures and processes, including actin dynamics, but the acronym is not accurate for Microtubule-associated protein-like.\n2. TRUE\n3. UNKNOWN: Without the proper clarification of what MLP stands for in this context, it is difficult to determine the validity of MLP’s interaction with the Arp2/3 complex. If MLP refers to Muscle LIM protein, it is necessary to consult specific scientific literature to determine if this interaction occurs, as the typical role of Muscle LIM protein is associated with muscle development and function.\n4. UNKNOWN: Similar to the previous point, without accurate information on what MLP stands for, the statement about its regulation of the Arp2/3 complex's activity can't be reliably verified.\n5. UNKNOWN: Again, assuming MLP refers to Muscle LIM protein, whether it interacts with the Wiskott-Aldrich syndrome protein (WASP) requires specific reference to scientific research on the subject. WASP does regulate actin filament dynamics, but the interaction with MLP is not commonly known without specific context.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "The number of pseudokinases in the human kinome is not a fixed or well-defined quantity, as the definition of a pseudokinase can be somewhat subjective. However, it is generally accepted that pseudokinases are proteins that share structural and functional similarities with kinases, but lack the ability to phosphorylate proteins in the same way as true kinases.\n\nThere are several reasons why a protein may be classified as a pseudokinase:\n\n1. Lack of enzymatic activity: Some pseudokinases may lack the ability to phosphorylate proteins, either due to mutations that disrupt their catalytic activity or because they have evolved to perform other functions.\n2. Divergent evolution: Pseudokinases may have evolved from true kinases through a process of divergent evolution, in which they have acquired new functions or lost their enzymatic activity.\n3. Functional redundancy: In some cases, multiple proteins may share similar functions and be classified as pseudokinases, even though they have some residual enzymatic activity.\n\nThe number of pseudokinases in the human kinome is difficult to estimate with certainty, as the definition of a pseudokinase can be somewhat subjective and the boundaries between true kinases and pseudokinases can be fuzzy. However, recent studies have suggested that pseudokinases may make up a significant proportion of the human kinome, with estimates ranging from several hundred to several thousand.\n\nIt is worth noting that pseudokinases can play important roles in regulating cellular processes, even if they lack true kinase activity. For example, some pseudokinases may participate in signaling pathways by interacting with other proteins or modulating their activity, without directly phosphorylating proteins. As such, pseudokinases are an important and diverse component of the human kinome, and further research is needed to fully understand their functions and roles in cellular processes.",
    "llama-7b_fact_raw": "1. Pseudokinases share structural and functional similarities with kinases but typically lack the ability to phosphorylate proteins as true kinases do.\n2. The ability to classify a protein as a pseudokinase can be subjective, contributing to the difficulty in estimating their number in the human kinome.\n3. Some pseudokinases may lack enzymatic activity due to mutations or evolved functions different from phosphorylation.\n4. Pseudokinases may have evolved from true kinases through divergent evolution.\n5. Recent studies suggest that pseudokinases could make up a significant proportion of the human kinome, with estimates ranging from several hundred to several thousand.",
    "llama-7b_fact": [
      "Pseudokinases share structural and functional similarities with kinases but typically lack the ability to phosphorylate proteins as true kinases do.",
      "The ability to classify a protein as a pseudokinase can be subjective, contributing to the difficulty in estimating their number in the human kinome.",
      "Some pseudokinases may lack enzymatic activity due to mutations or evolved functions different from phosphorylation.",
      "Pseudokinases may have evolved from true kinases through divergent evolution.",
      "Recent studies suggest that pseudokinases could make up a significant proportion of the human kinome, with estimates ranging from several hundred to several thousand."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays a crucial role in the transport and metabolism of lipids in the blood. It is a major protein component of low-density lipoprotein (LDL) particles and is involved in the transport of cholesterol and other lipids throughout the body. ApoE is also involved in the regulation of immune function and has been implicated in the development of Alzheimer's disease.\n\nThere are three major isoforms of apoE: apoE2, apoE3, and apoE4. ApoE3 is the most common isoform and is associated with a lower risk of cardiovascular disease, while apoE4 is associated with an increased risk of Alzheimer's disease.\n\nMimetics are compounds or substances that mimic the function of a specific protein or hormone. Here are three examples of apoE mimetics:\n\n1. Resveratrol: Resveratrol is a polyphenol compound found in red wine, grapes, and peanuts. It has been shown to have anti-inflammatory and antioxidant properties and has been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Resveratrol has been shown to increase the expression of apoE in the brain and has been suggested as a potential mimetic of apoE.\n2. Curcumin: Curcumin is a polyphenol compound found in the spice turmeric. It has been shown to have anti-inflammatory and antioxidant properties and has been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Curcumin has been shown to increase the expression of apoE in the brain and has been suggested as a potential mimetic of apoE.\n3. Omega-3 fatty acids: Omega-3 fatty acids are essential fatty acids that are found in fatty fish, flaxseed, and chia seeds. They have been shown to have anti-inflammatory and neuroprotective properties and have been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Omega-3 fatty",
    "llama-7b_fact_raw": "1. There are three major isoforms of apoE: apoE2, apoE3, and apoE4.\n2. ApoE3 is commonly associated with a lower risk of cardiovascular disease.\n3. ApoE4 is associated with an increased risk of Alzheimer's disease.\n4. Resveratrol is a compound that has been suggested as a potential apoE mimetic.\n5. Curcumin and Omega-3 fatty acids have been shown to increase the expression of apoE and have been suggested as potential apoE mimetics.",
    "llama-7b_fact": [
      "There are three major isoforms of apoE: apoE2, apoE3, and apoE4.",
      "ApoE3 is commonly associated with a lower risk of cardiovascular disease.",
      "ApoE4 is associated with an increased risk of Alzheimer's disease.",
      "Resveratrol is a compound that has been suggested as a potential apoE mimetic.",
      "Curcumin and Omega-3 fatty acids have been shown to increase the expression of apoE and have been suggested as potential apoE mimetics."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: While curcumin and omega-3 fatty acids have been researched for their potential beneficial effects on apoE expression and brain health, referring to them as apoE mimetics may not be accurate. ApoE mimetics are usually designed peptides or molecules that mimic the structure or function of apoE, and as of my last update, curcumin and omega-3 fatty acids have not been formally classified as such. They have been suggested to have beneficial effects possibly related to apoE, but to say they increase expression of apoE and are apoE mimetics is an oversimplification. Further research would be necessary to support such a claim.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females.\n\nSAMHD1 is an RNA-dependent DNA helicase that plays a critical role in regulating the replication of HIV-1 in CD4+ T cells. It has been shown that SAMHD1 activity is high in immune cells, such as CD4+ T cells and dendritic cells, and is low in non-immune cells, such as fibroblasts and epithelial cells.\n\nStudies have shown that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract. This may be due to the fact that the female reproductive tract has a higher concentration of immune cells, such as CD4+ T cells and dendritic cells, which require high levels of SAMHD1 activity to prevent HIV-1 replication.\n\nIt is also worth noting that there are sex differences in the prevalence of HIV-1 infection, with HIV-1 being more prevalent in men than in women. This may be due to differences in sexual behavior, such as the number of sexual partners and the likelihood of being exposed to HIV-1.\n\nOverall, while there is some evidence to suggest that there may be sex differences in SAMHD1 activity, more research is needed to fully understand the role of SAMHD1 in regulating HIV-1 replication in males and females.",
    "llama-7b_fact_raw": "1. SAMHD1 is an RNA-dependent DNA helicase involved in regulating the replication of HIV-1 in CD4+ T cells.\n2. SAMHD1 activity is high in immune cells, including CD4+ T cells and dendritic cells.\n3. SAMHD1 activity is low in non-immune cells like fibroblasts and epithelial cells.\n4. Studies suggest that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract.\n5. HIV-1 is more prevalent in men than in women.",
    "llama-7b_fact": [
      "SAMHD1 is an RNA-dependent DNA helicase involved in regulating the replication of HIV-1 in CD4+ T cells.",
      "SAMHD1 activity is high in immune cells, including CD4+ T cells and dendritic cells.",
      "SAMHD1 activity is low in non-immune cells like fibroblasts and epithelial cells.",
      "Studies suggest that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract.",
      "HIV-1 is more prevalent in men than in women."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SAMHD1 is actually a dNTP triphosphohydrolase that regulates the level of the deoxynucleoside triphosphates (dNTPs) available for DNA synthesis, not an RNA-dependent DNA helicase. It is involved in restricting the replication of HIV-1 in non-dividing cells such as CD4+ T cells.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Globally, HIV-1 is more prevalent in women than in men, with women accounting for more than half of all people living with HIV. However, this prevalence can vary depending on the region and the specific populations studied.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development. It has been extensively studied in the context of hematopoiesis and osteogenesis, but its role in the differentiation of other cell types, including astrocytes, has also been investigated.\n\nSeveral studies have shown that RUNX2 can inhibit astrocyte differentiation. For example, in vitro experiments have demonstrated that overexpression of RUNX2 in neural progenitor cells leads to a decrease in the number of cells that differentiate into astrocytes and an increase in the number of cells that differentiate into oligodendrocytes. Similarly, knockdown of RUNX2 in astrocyte cultures has been shown to promote astrocyte differentiation.\n\nThese findings suggest that RUNX2 may play a role in regulating the balance between astrocyte and oligodendrocyte differentiation in the developing nervous system. However, the precise mechanisms by which RUNX2 regulates astrocyte differentiation are not fully understood and require further investigation.",
    "llama-7b_fact_raw": "1. RUNX2 inhibits astrocyte differentiation.\n2. RUNX2 is a transcription factor involved in gene expression regulation during embryonic development.\n3. Overexpression of RUNX2 in neural progenitor cells leads to fewer cells differentiating into astrocytes.\n4. Overexpression of RUNX2 in neural progenitor cells results in more cells differentiating into oligodendrocytes.\n5. Knockdown of RUNX2 in astrocyte cultures promotes astrocyte differentiation.",
    "llama-7b_fact": [
      "RUNX2 inhibits astrocyte differentiation.",
      "RUNX2 is a transcription factor involved in gene expression regulation during embryonic development.",
      "Overexpression of RUNX2 in neural progenitor cells leads to fewer cells differentiating into astrocytes.",
      "Overexpression of RUNX2 in neural progenitor cells results in more cells differentiating into oligodendrocytes.",
      "Knockdown of RUNX2 in astrocyte cultures promotes astrocyte differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Overexpression of RUNX2 in neural progenitor cells results in fewer cells differentiating into oligodendrocytes.\n5. FALSE [correction]: Knockdown of RUNX2 in astrocyte cultures inhibits astrocyte differentiation.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint. It involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the medial or lateral compartment of the knee joint. The procedure is typically performed on an outpatient basis under regional or general anesthesia.\n\nThe Cobb-Stainsby excision arthroplasty is typically performed on the medial or lateral compartment of the knee joint, depending on the location of the osteoarthritis. The medial compartment of the knee joint is located on the inside of the knee, and the lateral compartment is located on the outside of the knee.\n\nDuring the surgical procedure, the surgeon will make an incision over the affected knee joint and expose the joint surface. The Cobb-Stainsby excision arthroplasty involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the medial or lateral compartment of the knee joint. The underlying bone is then resurfaced with a bone graft or a metal or plastic implant, depending on the surgeon's preference.\n\nThe Cobb-Stainsby excision arthroplasty is a surgical option for patients with osteoarthritis of the knee joint who have not responded to non-surgical treatments such as physical therapy and medications. The procedure can help reduce pain and improve knee function, but it may not be suitable for all patients and may have potential risks and complications. It is important for patients to discuss the risks and benefits of the Cobb-Stainsby excision arthroplasty with their surgeon to determine if the procedure is right for them.",
    "llama-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint.\n2. This procedure involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone.\n3. The Cobb-Stainsby excision arthroplasty can be performed on either the medial or lateral compartment of the knee joint.\n4. The surgical option includes resurfacing the underlying bone with a bone graft or a metal or plastic implant after the removal of the cartilage and bone.\n5. The Cobb-Stainsby excision arthroplasty is considered for patients who have not responded to non-surgical treatments like physical therapy and medications.",
    "llama-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint.",
      "This procedure involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone.",
      "The Cobb-Stainsby excision arthroplasty can be performed on either the medial or lateral compartment of the knee joint.",
      "The surgical option includes resurfacing the underlying bone with a bone graft or a metal or plastic implant after the removal of the cartilage and bone.",
      "The Cobb-Stainsby excision arthroplasty is considered for patients who have not responded to non-surgical treatments like physical therapy and medications."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat various conditions of the hip joint, not the knee joint.\n2. UNKNOWN: Without the context specifically stating the details of the Cobb-Stainsby procedure, the description of the surgical process is difficult to determine as true or false. Generally, excision arthroplasty involves the removal of part of a joint, but the specific technique for Cobb-Stainsby is not detailed here.\n3. FALSE [correction]: As the Cobb-Stainsby excision arthroplasty is a procedure performed on the hip joint, it would not pertain to the medial or lateral compartments of the knee joint.\n4. UNKNOWN: Without specific context, it's difficult to determine the exact surgical options included in the Cobb-Stainsby excision arthroplasty. However, it's common in excision arthroplasty procedures to consider resurfacing bone, although the specifics can vary.\n5. TRUE: In general, excision arthroplasty, including the Cobb-Stainsby technique, may be considered for patients who have not responded well to non-surgical treatments.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).\n\nGRHL2, also known as E-cadherin repressor 2, is a transcriptional repressor that plays a crucial role in the regulation of E-cadherin expression. E-cadherin is a cell-cell adhesion protein that is essential for maintaining epithelial cell structure and function. During EMT, cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, which is characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal markers, and the ability to migrate and invade.\n\nGRHL2 has been shown to play a crucial role in the regulation of E-cadherin expression during EMT. Over-expression of GRHL2 has been shown to lead to the down-regulation of E-cadherin expression, resulting in the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype. Furthermore, GRHL2 has also been shown to interact with and repress the transcription of the E-cadherin gene.\n\nIn summary, GRHL2 over-expression can lead to EMT by down-regulating E-cadherin expression and promoting the acquisition of a mesenchymal phenotype.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression can result in the induction of epithelial-to-mesenchymal transition (EMT).\n2. GRHL2 is also known as Grainyhead-like 2 or E-cadherin repressor 2.\n3. E-cadherin is important for maintaining the structure and function of epithelial cells.\n4. Over-expression of GRHL2 leads to the down-regulation of E-cadherin expression.\n5. The down-regulation of E-cadherin expression by GRHL2 over-expression facilitates the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.",
    "llama-7b_fact": [
      "GRHL2 over-expression can result in the induction of epithelial-to-mesenchymal transition (EMT).",
      "GRHL2 is also known as Grainyhead-like 2 or E-cadherin repressor 2.",
      "E-cadherin is important for maintaining the structure and function of epithelial cells.",
      "Over-expression of GRHL2 leads to the down-regulation of E-cadherin expression.",
      "The down-regulation of E-cadherin expression by GRHL2 over-expression facilitates the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype."
    ],
    "llama-7b_judge_raw": "1. TRUE: GRHL2 over-expression can indeed result in the induction of epithelial-to-mesenchymal transition (EMT), which is a process where epithelial cells lose their characteristics and gain mesenchymal properties.\n2. FALSE [correction]: GRHL2 is known as Grainyhead-like 2, but it is not directly referred to as E-cadherin repressor 2. Its exact role may include regulation of E-cadherin but it is not named as such.\n3. TRUE: E-cadherin is indeed important for maintaining the structure and function of epithelial cells, as it is crucial for cell-cell adhesion junctions.\n4. TRUE: Over-expression of GRHL2 has been associated with the down-regulation of E-cadherin expression, a hallmark event in EMT.\n5. TRUE: The down-regulation of E-cadherin expression by GRHL2 over-expression facilitates the loss of cell-cell adhesion, which is a characteristic of epithelial cells, and contributes to the acquisition of a mesenchymal phenotype, a process involved in EMT.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "T-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system'",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151, also known as G protein-coupled receptor 151, is an orphan receptor that belongs to the G protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other molecules. GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex, and has been implicated in a number of neurological processes, including learning and memory, anxiety, and depression. However, little is known about the function of GPR151, and further research is needed to fully understand its role in the brain.",
    "llama-7b_fact_raw": "1. GPR151 is also known as G protein-coupled receptor 151.\n2. GPR151 belongs to the G protein-coupled receptor (GPCR) family.\n3. GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex.\n4. GPR151 has been implicated in various neurological processes such as learning and memory, anxiety, and depression.\n5. The function of GPR151 is not well understood, indicating a need for further research.",
    "llama-7b_fact": [
      "GPR151 is also known as G protein-coupled receptor 151.",
      "GPR151 belongs to the G protein-coupled receptor (GPCR) family.",
      "GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex.",
      "GPR151 has been implicated in various neurological processes such as learning and memory, anxiety, and depression.",
      "The function of GPR151 is not well understood, indicating a need for further research."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of four influenza strains: influenza virus type A/California/7/2009 (H1N1), influenza virus type A/Victoria/361/2011 (H1N1), influenza virus type A/Perth/16/2009 (H3N2), and influenza virus type B/Brisbane/60/2008.",
    "llama-7b_fact_raw": "NO FACTS\n\n(The statement about the vaccine content is incorrect; Fluzone Intradermal Quadrivalent vaccine contains inactivated viruses, not live attenuated viruses.)",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor 2 gene, is associated with systemic lupus erythematosus (SLE) through several genetic variants. SLE is an autoimmune disorder in which the immune system attacks healthy cells and tissues in the body, leading to inflammation and damage to various organs and tissues.\n\nOne of the genetic variants associated with SLE is a single nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene. This SNP, known as -138G/A, has been found to be associated with an increased risk of developing SLE. The -138G/A SNP alters the binding of transcription factors to the promoter region of the TNFR2 gene, leading to altered expression of the TNFR2 gene and potentially increased susceptibility to SLE.\n\nAnother genetic variant associated with SLE is a copy number variation (CNV) in the TNFR2 gene. This CNV involves duplication of a region of the TNFR2 gene, leading to increased expression of the TNFR2 gene and potentially increased susceptibility to SLE.\n\nOverall, the TNFR2 gene is genetically associated with SLE through both SNPs and CNVs, with the -138G/A SNP and the TNFR2 CNV being the most well-studied genetic variants associated with SLE.",
    "llama-7b_fact_raw": "1. The TNFR2 gene is associated with systemic lupus erythematosus (SLE).\n2. A single nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene, known as -138G/A, is associated with an increased risk of developing SLE.\n3. The -138G/A SNP affects the binding of transcription factors to the promoter region of the TNFR2 gene.\n4. A copy number variation (CNV) involving duplication of a part of the TNFR2 gene is associated with SLE.\n5. Increased expression of the TNFR2 gene due to genetic variants like -138G/A SNP and CNV may lead to increased susceptibility to SLE.",
    "llama-7b_fact": [
      "The TNFR2 gene is associated with systemic lupus erythematosus (SLE).",
      "A single nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene, known as -138G/A, is associated with an increased risk of developing SLE.",
      "The -138G/A SNP affects the binding of transcription factors to the promoter region of the TNFR2 gene.",
      "A copy number variation (CNV) involving duplication of a part of the TNFR2 gene is associated with SLE.",
      "Increased expression of the TNFR2 gene due to genetic variants like -138G/A SNP and CNV may lead to increased susceptibility to SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE: The TNFR2 (tumor necrosis factor receptor 2) gene has been associated with systemic lupus erythematosus (SLE) in some scientific studies, indicating a potential role in the disease's pathogenesis.\n\n2. TRUE: Certain studies have suggested that single nucleotide polymorphisms (SNPs) in the TNFR2 gene, such as the -138G/A SNP in the promoter region, are associated with an increased risk of developing SLE. However, the strength of this association can vary across different populations and studies.\n\n3. TRUE: SNPs like -138G/A in the promoter region of a gene can affect the binding of transcription factors, which in turn can influence the gene’s expression. In the case of TNFR2, such an SNP may affect the gene's regulation and contribute to the pathophysiology of SLE.\n\n4. UNKNOWN: While copy number variations (CNVs) in various genes have been associated with different diseases, including autoimmune disorders, without specific evidence or references for the TNFR2 gene and SLE, it is difficult to determine the validity of this statement.\n\n5. UNKNOWN: While it is plausible that increased expression of the TNFR2 gene due to genetic variants like SNPs and potentially CNVs may lead to increased susceptibility to SLE, without specific evidence on the effects of these variants on gene expression and SLE susceptibility, the statement remains speculative.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "No, there is currently no vaccine for peanut allergy. Peanut allergy is an immune system disorder that affects the way the body responds to proteins found in peanuts and other nuts. It is caused by an overreaction of the immune system to these proteins, which can lead to a range of symptoms including itching, hives, difficulty breathing, and anaphylaxis.\n\nWhile there are treatments available for peanut allergy, such as epinephrine and antihistamines, there is currently no cure or vaccine for the condition. Researchers are working on developing a vaccine, but it is still in the early stages of development and has not yet been approved for use.",
    "llama-7b_fact_raw": "1. There is currently no vaccine for peanut allergy.\n2. Peanut allergy is considered an immune system disorder.\n3. Symptoms of peanut allergy may include itching, hives, difficulty breathing, and anaphylaxis.\n4. Treatments available for peanut allergy include epinephrine and antihistamines.\n5. Research is being conducted to develop a vaccine for peanut allergy, but it is not yet approved for use.",
    "llama-7b_fact": [
      "There is currently no vaccine for peanut allergy.",
      "Peanut allergy is considered an immune system disorder.",
      "Symptoms of peanut allergy may include itching, hives, difficulty breathing, and anaphylaxis.",
      "Treatments available for peanut allergy include epinephrine and antihistamines.",
      "Research is being conducted to develop a vaccine for peanut allergy, but it is not yet approved for use."
    ],
    "llama-7b_judge_raw": "1. TRUE (as of my knowledge cutoff in early 2023, no vaccine for peanut allergy had been approved for use)\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The mouse Fxy gene is located on the X chromosome, which is one of the two sex chromosomes in mice. Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.\n\nThe position of the Fxy gene on the X chromosome is particular because it is located in a region that is known to be prone to rearrangements and deletions, which can lead to genetic abnormalities. This region of the X chromosome is known as the \"X-inactivation center\" and is responsible for the process of X-chromosome inactivation, which occurs during embryonic development in female mice.\n\nDuring inactivation, one of the two X chromosomes in female mice is randomly chosen to be silenced, while the other X chromosome is maintained in an active state. This process helps to prevent the expression of X-linked genes from interfering with the expression of genes on the active X chromosome.\n\nThe Fxy gene is located near the center of the X-inactivation center, which means that it is at a higher risk of being inactivated than other genes on the X chromosome. This is because the X-inactivation center is a hotspot for genetic rearrangements and deletions, which can lead to the inactivation of genes in this region.\n\nOverall, the position of the Fxy gene on the X chromosome is particular because it is located in a region that is prone to genetic rearrangements and deletions, which can lead to genetic abnormalities and increase the risk of the gene being inactivated during embryonic development.",
    "llama-7b_fact_raw": "1. The mouse Fxy gene is located on the X chromosome, which is a sex chromosome in mice.\n2. Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.\n3. The Fxy gene is located in a region of the X chromosome known as the \"X-inactivation center.\"\n4. The region known as the X-inactivation center is responsible for the process of X-chromosome inactivation during embryonic development in female mice.\n5. The Fxy gene's location near the center of the X-inactivation center puts it at a higher risk of being inactivated due to its proximity to a hotspot for genetic rearrangements and deletions.",
    "llama-7b_fact": [
      "The mouse Fxy gene is located on the X chromosome, which is a sex chromosome in mice.",
      "Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.",
      "The Fxy gene is located in a region of the X chromosome known as the \"X-inactivation center.\"",
      "The region known as the X-inactivation center is responsible for the process of X-chromosome inactivation during embryonic development in female mice.",
      "The Fxy gene's location near the center of the X-inactivation center puts it at a higher risk of being inactivated due to its proximity to a hotspot for genetic rearrangements and deletions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The mouse Fxy gene is actually known as the Fxyd5 gene which is not located on the X chromosome; it is located on chromosome 11.\n2. TRUE\n3. FALSE [correction]: Since the Fxy (Fxyd5) gene is not located on the X chromosome, it cannot be in the X-inactivation center.\n4. TRUE\n5. FALSE [correction]: Since the Fxy (Fxyd5) gene is not located on the X chromosome, it is not positioned near the center of the X-inactivation center, nor is it at risk of being inactivated due to its proximity to that specific region.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "Methylation propyl-EDTA sequencing (MPE-seq) is a method used to study DNA methylation, which is the addition of a methyl group to cytosine residues in the DNA molecule. The method involves the use of a compound called methyl-propyl-EDTA, which is a derivative of EDTA (ethylenediaminetetraacetic acid).\n\nThe basis of the MPE-seq method is the ability of methyl-propyl-EDTA to recognize and bind to methylated cytosine residues in the DNA molecule. Methyl-propyl-EDTA has a negatively charged nitrogen atom that can interact with the positively charged methyl group on the cytosine residue. This interaction results in the formation of a stable complex between the methyl-propyl-EDTA and the methylated cytosine residue.\n\nTo perform MPE-seq, DNA samples are first treated with methyl-propyl-EDTA to form complexes between the methyl-propyl-EDTA and the methylated cytosine residues. The complexes are then isolated and purified, and the DNA is released from the complexes. The purified complexes are then subjected to mass spectrometry analysis to determine the sequence of the DNA molecule.\n\nThe mass spectrometry analysis involves the use of a mass spectrometer to measure the mass-to-charge ratio of the complexes. The mass-to-charge ratio of the complexes is determined by the mass of the methyl-propyl-EDTA molecule and the number of methylated cytosine residues in the DNA molecule. By comparing the mass-to-charge ratios of the complexes from different DNA samples, it is possible to determine the sequence of the DNA molecule.\n\nOverall, the basis of the MPE-seq method is the ability of methyl-propyl-EDTA to recognize and bind to methylated cytosine residues in the DNA molecule, allowing for the sequencing of DNA molecules using mass spectrometry analysis.",
    "llama-7b_fact_raw": "1. Methylation propyl-EDTA sequencing (MPE-seq) is used to study DNA methylation, the addition of a methyl group to cytosine residues in DNA.\n2. Methyl-propyl-EDTA, a derivative of EDTA (ethylenediaminetetraacetic acid), is utilized in the MPE-seq method.\n3. Methyl-propyl-EDTA can recognize and bind to methylated cytosine residues due to interactions between its negatively charged nitrogen atom and the positively charged methyl group on the cytosine.\n4. MPE-seq involves treating DNA samples with methyl-propyl-EDTA, isolating and purifying complexes formed, then determining the DNA sequence using mass spectrometry.\n5. Mass spectrometry analysis in MPE-seq measures the mass-to-charge ratio of DNA-methyl-propyl-EDTA complexes to identify DNA methylation patterns.",
    "llama-7b_fact": [
      "Methylation propyl-EDTA sequencing (MPE-seq) is used to study DNA methylation, the addition of a methyl group to cytosine residues in DNA.",
      "Methyl-propyl-EDTA, a derivative of EDTA (ethylenediaminetetraacetic acid), is utilized in the MPE-seq method.",
      "Methyl-propyl-EDTA can recognize and bind to methylated cytosine residues due to interactions between its negatively charged nitrogen atom and the positively charged methyl group on the cytosine.",
      "MPE-seq involves treating DNA samples with methyl-propyl-EDTA, isolating and purifying complexes formed, then determining the DNA sequence using mass spectrometry.",
      "Mass spectrometry analysis in MPE-seq measures the mass-to-charge ratio of DNA-methyl-propyl-EDTA complexes to identify DNA methylation patterns."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: There is no commonly known methylation study technique called Methylation propyl-EDTA sequencing (MPE-seq), and \"Methyl-propyl-EDTA\" is not a recognized derivative of EDTA in the context of DNA methylation studies. Standard methods for studying DNA methylation include bisulfite sequencing and the use of methyl-sensitive enzymes in various sequencing methods.\n3. FALSE [correction]: Since \"Methyl-propyl-EDTA\" is not a recognized chemical used in the study of DNA methylation, the statement about it recognizing and binding to methylated cytosine is incorrect. In actual studies of DNA methylation, methylated cytosine is detected by its resistance to conversion during bisulfite treatment or by the use of antibodies specific to methyl-cytosine.\n4. FALSE [correction]: As \"Methyl-propyl-EDTA\" is not part of standard DNA methylation study methods, the described procedure of treating DNA with such a chemical and isolating complexes is not accurate. Standard methods for determining DNA methylation patterns involve bisulfite treatment followed by sequencing, or enrichment methods followed by sequencing.\n5. FALSE [correction]: Mass spectrometry is not typically used to directly measure DNA methylation through mass-to-charge ratio of DNA complexes. It might be used in the analysis of global DNA methylation levels or in mass spectrometry-based proteomics to study proteins involved in DNA methylation processes, but sequencing technology is more commonly used to identify specific DNA methylation patterns.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"GWAR.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and eventual paralysis. There is currently no cure for ALS, and the prognosis is typically poor, with a median survival time of 2-5 years from the onset of symptoms.\n\nXaliproden is a drug that has been investigated for its potential to slow the progression of ALS. It is a selective agonist of the melanocortin-4 receptor (MC-4R), which is a G-protein-coupled receptor that is expressed in several tissues, including the brain. Activation of the MC-4R has been shown to have neuroprotective effects in animal models of ALS, by reducing inflammation and promoting the survival of motor neurons.\n\nSeveral studies have investigated the use of xaliproden in patients with ALS, with mixed results. Some studies have reported that xaliproden may slow the progression of ALS, as measured by the rate of decline in muscle strength and function, as well as the duration of survival after the onset of symptoms. However, other studies have not found any beneficial effects of xaliproden on the prognosis of ALS.\n\nIn summary, while some studies have suggested that xaliproden may improve the prognosis of ALS, the evidence is not conclusive. Further research is needed to determine the efficacy and safety of xaliproden in patients with ALS.",
    "llama-7b_fact_raw": "1. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.\n2. The median survival time from the onset of symptoms of ALS is typically 2-5 years.\n3. Xaliproden is a drug that has been investigated for its potential to slow the progression of ALS.\n4. Xaliproden is a selective agonist of the melanocortin-4 receptor (MC-4R).\n5. There is no consensus in the scientific community regarding the efficacy of xaliproden in improving the prognosis of ALS, with some studies reporting potential benefits and others finding no beneficial effects.",
    "llama-7b_fact": [
      "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.",
      "The median survival time from the onset of symptoms of ALS is typically 2-5 years.",
      "Xaliproden is a drug that has been investigated for its potential to slow the progression of ALS.",
      "Xaliproden is a selective agonist of the melanocortin-4 receptor (MC-4R).",
      "There is no consensus in the scientific community regarding the efficacy of xaliproden in improving the prognosis of ALS, with some studies reporting potential benefits and others finding no beneficial effects."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Xaliproden is not a selective agonist of the melanocortin-4 receptor (MC-4R). Xaliproden is known for its potential neuroprotective effects and has been investigated for a variety of neurodegenerative diseases, but it is not an MC-4R agonist.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the case of the LiPS-A3S line, the transgenes are inserted into the X chromosome.",
    "llama-7b_fact_raw": "1. Transgenes in the LiPS-A3S line are inserted into the X chromosome.",
    "llama-7b_fact": [
      "Transgenes in the LiPS-A3S line are inserted into the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nThe statement's accuracy regarding the insertion of transgenes in the LiPS-A3S line into the X chromosome depends on specific scientific research or genetic engineering details that are not provided. Without additional context, it is not possible to determine the truthfulness of this statement.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools that exist for predicting drug synergy with deep learning, including:\n\n1. DeepDrug: This is a deep learning-based approach for predicting drug-target interactions. It uses a neural network to predict the binding affinity of small molecules to a given protein target.\n2. DrugPredict: This is a machine learning-based approach for predicting drug-target interactions. It uses a random forest classifier to predict the binding affinity of small molecules to a given protein target.\n3. SynergyNet: This is a deep learning-based approach for predicting drug synergy. It uses a neural network to predict the effect of combining two drugs on the growth of cancer cells.\n4. DrugSynth: This is a machine learning-based approach for predicting drug synergy. It uses a random forest classifier to predict the effect of combining two drugs on the growth of cancer cells.\n\nOverall, there are several tools available for predicting drug synergy with deep learning, each with its own strengths and weaknesses. The choice of tool will depend on the specific application and the available data.",
    "llama-7b_fact_raw": "1. DeepDrug is a deep learning approach used to predict drug-target interactions by estimating the binding affinity of molecules to protein targets.\n2. DrugPredict leverages a random forest classifier to predict drug-target interactions.\n3. SynergyNet utilizes deep learning to predict drug synergy effects on cancer cell growth.\n4. DrugSynth applies a machine learning strategy using a random forest classifier to predict the effects of drug combinations on cancer cell growth.",
    "llama-7b_fact": [
      "DeepDrug is a deep learning approach used to predict drug-target interactions by estimating the binding affinity of molecules to protein targets.",
      "DrugPredict leverages a random forest classifier to predict drug-target interactions.",
      "SynergyNet utilizes deep learning to predict drug synergy effects on cancer cell growth.",
      "DrugSynth applies a machine learning strategy using a random forest classifier to predict the effects of drug combinations on cancer cell growth."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n\nIn cases where a specific tool or machine learning model like DrugPredict or DrugSynth is mentioned, without more context on what they actually do or utilize, it's difficult to confirm the veracity of the statements. Therefore, for statements 2 and 4, I cannot provide a true or false judgment, and they remain UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS), including:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (Database of Genotypes and Phenotypes): dbGaP is a public database that provides access to genotype and phenotype data from large-scale genetic studies, including GWAS. Researchers can use dbGaP to compare GWAS data from different studies and identify potential genetic associations.\n2. The National Institutes of Health's (NIH) National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO): GEO is a public database that provides access to gene expression data from a variety of studies, including GWAS. Researchers can use GEO to compare gene expression data from different studies and identify potential genetic associations.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress: ArrayExpress is a public database that provides access to array-based gene expression data from a variety of studies, including GWAS. Researchers can use ArrayExpress to compare gene expression data from different studies and identify potential genetic associations.\n\nOverall, these cloud-based platforms provide researchers with the tools they need to compare GWAS data and identify potential genetic associations.",
    "llama-7b_fact_raw": "1. The National Center for Biotechnology Information's dbGaP is a database for accessing genotype and phenotype data from genetic studies.\n2. The dbGaP database includes GWAS data that can be used for comparison and identifying genetic associations.\n3. The Gene Expression Omnibus (GEO) is a public database hosted by the National Institutes of Health's National Center for Biotechnology Information.\n4. GEO provides access to gene expression data which includes information from GWAS.\n5. ArrayExpress, hosted by the European Bioinformatics Institute, offers array-based gene expression data, including GWAS.",
    "llama-7b_fact": [
      "The National Center for Biotechnology Information's dbGaP is a database for accessing genotype and phenotype data from genetic studies.",
      "The dbGaP database includes GWAS data that can be used for comparison and identifying genetic associations.",
      "The Gene Expression Omnibus (GEO) is a public database hosted by the National Institutes of Health's National Center for Biotechnology Information.",
      "GEO provides access to gene expression data which includes information from GWAS.",
      "ArrayExpress, hosted by the European Bioinformatics Institute, offers array-based gene expression data, including GWAS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GEO provides access to gene expression data which includes information from microarray, next-generation sequencing, and other forms of high-throughput functional genomics data, but not specifically from GWAS.\n5. FALSE [correction]: ArrayExpress offers array-based gene expression data, but it does not include GWAS data. GWAS data are typically stored in databases such as dbGaP or EGA (European Genome-phenome Archive).",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "CMB305 is a monoclonal antibody that is currently being studied for its potential use in the treatment of various types of cancer, including sarcomas. Sarcomas are a type of cancer that develops in the soft tissues of the body, such as muscles, tendons, and fat, as well as in the bones and cartilage.\n\nCMB305 is an antibody that is designed to target a protein called CD47, which is a \"don't eat me\" signal that is often expressed on the surface of cancer cells, including sarcoma cells. When CMB305 binds to CD47 on the surface of sarcoma cells, it tags the cells for destruction by the body's immune system. This can help to stimulate an immune response against the cancer cells and potentially lead to their destruction.\n\nWhile CMB305 has shown promise in preclinical studies as a potential treatment for sarcomas, it has not yet been tested in clinical trials in patients with this type of cancer. Therefore, it is not yet clear whether CMB305 will be effective in the treatment of sarcomas or whether it will have any side effects.\n\nIt is important for anyone considering the use of CMB305 or any other treatment for sarcomas to discuss their options with their healthcare provider and to carefully consider the potential benefits and risks of the treatment.",
    "llama-7b_fact_raw": "1. CMB305 is a monoclonal antibody being studied for use in treating various types of cancer, including sarcomas.\n2. Sarcomas are a type of cancer that develops in the soft tissues or in the bones and cartilage of the body.\n3. CMB305 is designed to target CD47, a protein on the surface of cancer cells that signals the immune system not to destroy them.\n4. CMB305 works by binding to CD47 on sarcoma cells, marking them for destruction by the body's immune system.\n5. CMB305 has not yet been tested in clinical trials for patients with sarcomas.",
    "llama-7b_fact": [
      "CMB305 is a monoclonal antibody being studied for use in treating various types of cancer, including sarcomas.",
      "Sarcomas are a type of cancer that develops in the soft tissues or in the bones and cartilage of the body.",
      "CMB305 is designed to target CD47, a protein on the surface of cancer cells that signals the immune system not to destroy them.",
      "CMB305 works by binding to CD47 on sarcoma cells, marking them for destruction by the body's immune system.",
      "CMB305 has not yet been tested in clinical trials for patients with sarcomas."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: CMB305 is a cancer vaccine that targets the NY-ESO-1 protein, not CD47.\n4. FALSE [correction]: Since CMB305 is not designed to target CD47, the statement about its working mechanism is incorrect. CMB305 works by helping the immune system recognize and respond to cancer cells expressing the NY-ESO-1 antigen.\n5. FALSE [correction]: CMB305 has been tested in clinical trials for patients with sarcomas, specifically in those whose tumors express the NY-ESO-1 protein.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad refer to the various ways in which the three aspects of the divine - the Father, the Son, and the Holy Spirit - can be experienced and expressed in the world. These manifestations can take many different forms, and can vary depending on the cultural and religious context in which they are encountered.\n\nOne common manifestation of the Saint's Triad is through prayer and worship. In many religious traditions, prayer and worship are seen as ways of experiencing and expressing the presence of the divine. Prayer can take many different forms, such as silent meditation, spoken words, or sung hymns, and can be directed towards the Father, the Son, or the Holy Spirit, or all three. Worship can also take many different forms, such as singing, dancing, or offering gifts, and can be seen as a way of honoring and glorifying the divine.\n\nAnother manifestation of the Saint's Triad is through acts of service and compassion. In many religious traditions, acts of service and compassion are seen as ways of expressing the love and grace of the divine. These acts can take many different forms, such as feeding the hungry, clothing the naked, or visiting the sick and imprisoned. They can also include more abstract forms of service, such as advocating for social justice or working to protect the environment.\n\nA third manifestation of the Saint's Triad is through the experience of spiritual gifts. In many religious traditions, spiritual gifts are seen as ways in which the divine can be experienced and expressed in the world. These gifts can take many different forms, such as prophecy, healing, or speaking in tongues, and can be seen as evidence of the presence and power of the divine.\n\nOverall, the manifestations of the Saint's Triad can be seen as different ways in which the divine can be experienced and expressed in the world. They can take many different forms, and can vary depending on the cultural and religious context in which they are encountered.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Overexpression of LY6K has not been consistently associated with better prognosis for non-small cell lung cancer (NSCLC) patients. While some studies have suggested that high levels of LY6K may be associated with improved survival in NSCLC, other studies have found no such association or have even suggested that high levels of LY6K may be associated with worse outcomes.\n\nOne study published in the journal Cancer Research in 2016 found that high levels of LY6K were associated with improved overall survival in patients with NSCLC. The study included 186 patients with NSCLC and found that those with high levels of LY6K had a significantly better overall survival compared to those with low levels of LY6K.\n\nHowever, another study published in the journal Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in patients with NSCLC. The study included 422 patients with NSCLC and found that high levels of LY6K were not associated with improved overall survival.\n\nAdditionally, a study published in the journal Oncotarget in 2019 found that high levels of LY6K were associated with worse overall survival in patients with NSCLC. The study included 402 patients with NSCLC and found that high levels of LY6K were associated with worse overall survival, even after adjusting for other factors that may affect survival.\n\nOverall, the available evidence is not consistent in terms of whether overexpression of LY6K is associated with better or worse prognosis for NSCLC patients. Further research is needed to better understand the role of LY6K in NSCLC and its potential as a prognostic factor.",
    "llama-7b_fact_raw": "1. Overexpression of LY6K is not consistently associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. A study in the journal Cancer Research in 2016 associated high levels of LY6K with improved overall survival in patients with NSCLC.\n3. The 2016 study on LY6K in Cancer Research included 186 patients with NSCLC.\n4. A study in Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in NSCLC patients, based on a sample size of 422 patients.\n5. Research published in Oncotarget in 2019 suggested that high levels of LY6K were associated with worse overall survival in NSCLC patients after adjusting for other factors.",
    "llama-7b_fact": [
      "Overexpression of LY6K is not consistently associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "A study in the journal Cancer Research in 2016 associated high levels of LY6K with improved overall survival in patients with NSCLC.",
      "The 2016 study on LY6K in Cancer Research included 186 patients with NSCLC.",
      "A study in Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in NSCLC patients, based on a sample size of 422 patients.",
      "Research published in Oncotarget in 2019 suggested that high levels of LY6K were associated with worse overall survival in NSCLC patients after adjusting for other factors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: A study in the journal Cancer Research in 2016 associated high levels of LY6K with worse overall survival in patients with NSCLC.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n2. Plk1: Plk1 is dephosphorylated by Cdk1 during cytokinesis, leading to its inactivation and the completion of mitotic spindle assembly.\n3. Aurora B: Aurora B is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of chromosome segregation.\n4. Cdc20: Cdc20 is dephosphorylated by Cdk1 during cytokinesis, leading to its release from securin and its activation of the anaphase-promoting complex/cyclosome (APC/C) for the degradation of securin and other inhibitors of mitosis.\n5. Cdc25C: Cdc25C is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of mitotic exit.\n\nThese Cdk targets are dephosphorylated by Cdk1 during cytokinesis, allowing for the completion of cell division and the formation of two daughter cells.",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Plk1 is dephosphorylated by Cdk1 during cytokinesis, which leads to its inactivation.\n3. Aurora B is dephosphorylated by Cdk1 during cytokinesis, which leads to its activation.\n4. Cdc20 is dephosphorylated by Cdk1 during cytokinesis, which leads to its role in activating the anaphase-promoting complex/cyclosome (APC/C).\n5. Cdc25C is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of mitotic exit.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Plk1 is dephosphorylated by Cdk1 during cytokinesis, which leads to its inactivation.",
      "Aurora B is dephosphorylated by Cdk1 during cytokinesis, which leads to its activation.",
      "Cdc20 is dephosphorylated by Cdk1 during cytokinesis, which leads to its role in activating the anaphase-promoting complex/cyclosome (APC/C).",
      "Cdc25C is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of mitotic exit."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is not dephosphorylated by Cdk1; instead, Cyclin B1 is a regulatory protein that binds to Cdk1 (cyclin-dependent kinase 1), forming a complex that is essential for the progression of cells through the cell cycle. Cyclin B1 is degraded during mitosis, which leads to inactivation of the Cdk1 complex.\n2. FALSE [correction]: Plk1 is not dephosphorylated by Cdk1 during cytokinesis. Plk1 (Polo-like kinase 1) is an essential kinase that regulates various stages of mitosis, including cytokinesis. It is typically activated through phosphorylation, and its activity is regulated by its own phosphorylation status and by interactions with other regulatory proteins, not directly by Cdk1.\n3. FALSE [correction]: Aurora B is not dephosphorylated by Cdk1 during cytokinesis to lead to its activation. Aurora B kinase is part of the Chromosomal Passenger Complex and plays a pivotal role in cytokinesis. Its activation and function are regulated through autophosphorylation and interactions with other proteins, such as INCENP (Inner Centromere Protein), not directly by Cdk1.\n4. FALSE [correction]: Cdc20 is not dephosphorylated by Cdk1 to activate the anaphase-promoting complex/cyclosome (APC/C). Cdc20 is a coactivator of the APC/C that helps target specific proteins for degradation, leading to progression from metaphase to anaphase. The regulation of Cdc20's role in APC/C activation is more complex and involves multiple checkpoints and regulatory mechanisms, but it is not dephosphorylated by Cdk1.\n5. FALSE [correction]: Cdc25C is not dephosphorylated by Cdk1; rather, it is a phosphatase that activates Cdk1 by removing inhibitory phosphates from it. The activation of Cdc25C leads to the activation of Cdk1, not the other way around. Moreover, the activation of Cdc25C itself is tightly regulated during the cell cycle.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a medication that is used to treat the symptoms of mild to moderate Alzheimer's disease. It is a type of drug called a cholinesterase inhibitor, which works by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is different from other cholinesterase inhibitors, such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), in that it also inhibits the enzyme butyrylcholinesterase. Butyrylcholinesterase is an enzyme that breaks down acetylcholine, so by inhibiting it, Xanamem can increase the levels of acetylcholine in the brain for a longer period of time.\n\nXanamem was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of Alzheimer's disease. It is available in tablet form and is usually taken twice a day, with meals. Like other cholinesterase inhibitors, Xanamem may cause side effects such as nausea, diarrhea, and vomiting. It is important for patients to discuss any side effects they experience with their healthcare provider.",
    "llama-7b_fact_raw": "1. Xanamem is used to treat symptoms of mild to moderate Alzheimer's disease.\n2. Xanamem is a type of drug called a cholinesterase inhibitor, which increases acetylcholine levels in the brain.\n3. Xanamem also inhibits the enzyme butyrylcholinesterase to help increase and maintain acetylcholine levels.\n4. The FDA approved Xanamem for the treatment of Alzheimer's disease in 2018.\n5. Xanamem is taken in tablet form, typically twice a day with meals.",
    "llama-7b_fact": [
      "Xanamem is used to treat symptoms of mild to moderate Alzheimer's disease.",
      "Xanamem is a type of drug called a cholinesterase inhibitor, which increases acetylcholine levels in the brain.",
      "Xanamem also inhibits the enzyme butyrylcholinesterase to help increase and maintain acetylcholine levels.",
      "The FDA approved Xanamem for the treatment of Alzheimer's disease in 2018.",
      "Xanamem is taken in tablet form, typically twice a day with meals."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The drug \"Xanamem\" does not appear to be a recognized medication as of my last knowledge update in 2023, therefore I cannot verify the statements regarding its use, mechanism of action, FDA approval, or administration.]",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in regulating the cellular response to oxidative stress in yeast. Hof1 is a ubiquitin-conjugating enzyme that adds ubiquitin molecules to other proteins, marking them for degradation by the proteasome. Cyk3 is a member of the cytochrome c oxidase complex, which is responsible for generating ATP through the oxidation of molecular oxygen.\n\nWhen cells are exposed to oxidative stress, such as when they are subjected to high levels of reactive oxygen species (ROS), the Hof1-Cyk3 interaction is activated. This interaction causes Hof1 to transfer ubiquitin molecules to Cyk3, marking it for degradation by the proteasome. The degradation of Cyk3 leads to a decrease in the production of ATP through the cytochrome c oxidase complex, which in turn reduces the cell's ability to generate energy and respond to oxidative stress.\n\nThe activation of the Hof1-Cyk3 interaction in response to oxidative stress is thought to play a role in protecting the cell from damage caused by ROS. By reducing the activity of the cytochrome c oxidase complex, the cell is able to reduce the production of reactive oxygen species and limit the damage caused by oxidative stress.\n\nOverall, the Hof1-Cyk3 interaction plays an important role in regulating the cellular response to oxidative stress in yeast, helping to protect the cell from damage caused by reactive oxygen species.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.\n2. Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation.\n3. Cyk3 is part of the cytochrome c oxidase complex which is involved in ATP production through oxidation of molecular oxygen.\n4. Activation of the Hof1-Cyk3 interaction leads to ubiquitination and degradation of Cyk3 by the proteasome.\n5. The degradation of Cyk3 results in decreased ATP production, which is a response mechanism to reduce oxidative stress damage.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.",
      "Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation.",
      "Cyk3 is part of the cytochrome c oxidase complex which is involved in ATP production through oxidation of molecular oxygen.",
      "Activation of the Hof1-Cyk3 interaction leads to ubiquitination and degradation of Cyk3 by the proteasome.",
      "The degradation of Cyk3 results in decreased ATP production, which is a response mechanism to reduce oxidative stress damage."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Hof1 is not a ubiquitin-conjugating enzyme. It is a protein that plays a role in cytokinesis in yeast. Ubiquitin-conjugating enzymes are generally denoted by the E2 enzyme classification and have a distinct catalytic role.\n3. FALSE [correction]: Cyk3 is not part of the cytochrome c oxidase complex. Cyk3 is a protein involved in the regulation of cell wall synthesis and cytokinesis in yeast. The cytochrome c oxidase complex is part of the mitochondrial electron transport chain involved in ATP production, but Cyk3 is not a component of this complex.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "T-UCRs (tumor-infiltrating urokinase-type plasminogen activator receptors) have been implicated in various types of cancer, including gastric cancer. Gastric cancer is a type of cancer that starts in the lining of the stomach and can spread to other parts of the body.\n\nStudies have shown that high levels of T-UCRs are associated with poor prognosis in patients with gastric cancer. T-UCRs can promote cancer cell growth, invasion, and metastasis by activating the proteolytic enzyme urokinase-type plasminogen activator (u-PA), which degrades the extracellular matrix and promotes cancer cell migration and invasion.\n\nSeveral studies have identified specific T-UCRs that are implicated in gastric cancer. For example, a study published in the journal Cancer Research in 2012 found that T-UCR-1, a specific type of T-UCR, is highly expressed in gastric cancer tissues and correlates with poor prognosis in patients with gastric cancer. Another study published in the journal Oncology Reports in 2015 found that T-UCR-2, another type of T-UCR, is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion.\n\nIn summary, T-UCRs, particularly T-UCR-1 and T-UCR-2, have been implicated in gastric cancer and are thought to play a role in promoting cancer cell growth, invasion, and metastasis. Further research is needed to better understand the role of T-UCRs in gastric cancer and to identify potential therapeutic targets for this type of cancer.",
    "llama-7b_fact_raw": "1. T-UCRs are associated with various types of cancer, including gastric cancer.\n2. High levels of T-UCRs are associated with poor prognosis in patients with gastric cancer.\n3. T-UCRs can promote cancer cell growth, invasion, and metastasis in gastric cancer.\n4. T-UCR-1 is a specific type of T-UCR that is highly expressed in gastric cancer tissues and correlates with poor prognosis.\n5. T-UCR-2 is another type of T-UCR that is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion.",
    "llama-7b_fact": [
      "T-UCRs are associated with various types of cancer, including gastric cancer.",
      "High levels of T-UCRs are associated with poor prognosis in patients with gastric cancer.",
      "T-UCRs can promote cancer cell growth, invasion, and metastasis in gastric cancer.",
      "T-UCR-1 is a specific type of T-UCR that is highly expressed in gastric cancer tissues and correlates with poor prognosis.",
      "T-UCR-2 is another type of T-UCR that is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion."
    ],
    "llama-7b_judge_raw": "1. TRUE - Transcribed ultra-conserved regions (T-UCRs) are indeed associated with various types of cancer including gastric cancer.\n2. TRUE - High levels of T-UCRs have been observed to be associated with poor prognosis in patients with various types of cancer, including gastric cancer.\n3. TRUE - T-UCRs have been reported to have the potential to promote cancer cell growth, invasion, and metastasis, although the specific mechanisms may vary and are the subject of ongoing research.\n4. UNKNOWN - Without specific scientific literature or research data to substantiate the claim about \"T-UCR-1\" and its expression in gastric cancer tissues, it is not possible to verify this statement.\n5. UNKNOWN - Similarly to statement 4, without specific data about \"T-UCR-2,\" this statement cannot be verified and remains unknown.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect various organs and systems in the body. The LSI was developed in 1982 by the National Lupus Assessment Team, which was composed of rheumatologists, dermatologists, and other healthcare professionals.\n\nThe LSI is based on a comprehensive review of the patient's medical history, physical examination findings, and laboratory results. The index assigns a score to each of these factors, which are then combined to produce a total LSI score. The score ranges from 0 to 100, with higher scores indicating more severe disease activity.\n\nThe LSI takes into account several key factors, including:\n\n1. Malar rash: The presence or absence of a butterfly-shaped rash on the cheeks (malar rash) is assessed on a scale of 0 to 3.\n2. Discoid rash: The presence or absence of a scaly, red rash on the skin is assessed on a scale of 0 to 3.\n3. Oral ulcers: The presence or absence of oral ulcers is assessed on a scale of 0 to 3.\n4. Photosensitivity: The degree of sensitivity to sunlight is assessed on a scale of 0 to 3.\n5. Renal involvement: The presence or absence of kidney involvement is assessed on a scale of 0 to 3.\n6. Hematologic abnormalities: The presence or absence of hematologic abnormalities, such as anemia or thrombocytopenia, is assessed on a scale of 0 to 3.\n7. Fever: The presence or absence of fever is assessed on a scale of 0 to 3.\n8. Mental status: The patient's mental status is assessed on a scale of 0 to 3.\n\nEach factor is assigned a score based on the degree of severity, with higher scores indicating more severe disease activity. The scores for each factor are then added together to produce the total LSI score.\n\nThe LSI ha",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in 1982 by the National Lupus Assessment Team, comprised of healthcare professionals including rheumatologists and dermatologists.\n3. The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.\n4. Malar rash, discoid rash, oral ulcers, photosensitivity, renal involvement, hematologic abnormalities, fever, and mental status are factors evaluated in the LSI.\n5. Each factor in the LSI is assessed on a scale of 0 to 3, with the total score determining the severity of the disease.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in 1982 by the National Lupus Assessment Team, comprised of healthcare professionals including rheumatologists and dermatologists.",
      "The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.",
      "Malar rash, discoid rash, oral ulcers, photosensitivity, renal involvement, hematologic abnormalities, fever, and mental status are factors evaluated in the LSI.",
      "Each factor in the LSI is assessed on a scale of 0 to 3, with the total score determining the severity of the disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized index known as the Lupus Severity Index (LSI) developed by the National Lupus Assessment Team in 1982. However, the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a tool used to assess disease activity in SLE patients. The SLEDAI was developed in the late 1980s.\n3. FALSE [correction]: The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) does range from 0 to 105, with higher scores indicating more severe disease activity. However, since the LSI is not a recognized tool, this statement is incorrect referring to it.\n4. TRUE [assuming that LSI refers to a hypothetical or misnamed SLE activity assessment tool similar to SLEDAI; however, the name \"LSI\" itself is not accurate for any well-known, widely-used tool]\n5. FALSE [correction]: In the SLEDAI, which is a tool for assessing SLE, not the non-existent LSI, each clinical or laboratory variable can contribute various points to the total score depending on the severity and presence of the symptom or finding. The scale is not limited to 0 to 3 for each factor.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur in a person's DNA and are not inherited from their parents. These mutations can occur at any point during the formation of reproductive cells (eggs or sperm) and can result in genetic disorders.\n\nZSWIM6 is a gene that has been associated with several genetic disorders caused by de novo mutations. ZSWIM6 encodes a protein that plays a role in the endoplasmic reticulum (ER) stress response, which is a mechanism that the cell uses to deal with stress and maintain cellular homeostasis.\n\nHere are some disorders caused by de novo mutations in ZSWIM6:\n\n1. Danon disease: Danon disease is a rare genetic disorder that affects the heart and other organs. It is caused by mutations in genes involved in the ER stress response, including ZSWIM6. People with Danon disease often have enlarged hearts, abnormal heart rhythms, and other cardiovascular problems.\n2. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): ARSACS is a neurological disorder that affects coordination and balance. It is caused by mutations in genes involved in the ER stress response, including ZSWIM6. People with ARSACS often have spasticity, ataxia (lack of coordination), and other neurological symptoms.\n3. Congenital disorders of glycosylation (CDG): Congenital disorders of glycosylation are a group of genetic disorders that affect the way the body produces glycoproteins, which are proteins that have sugar molecules attached to them. Mutations in genes involved in the ER stress response, including ZSWIM6, can cause congenital disorders of glycosylation.\n\nIn summary, ZSWIM6 is a gene that has been associated with several genetic disorders caused by de novo mutations, including Danon disease, autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), and congenital disorders of glycosylation. These disorders can affect the heart,",
    "llama-7b_fact_raw": "1. De novo mutations in ZSWIM6 can cause genetic disorders.\n2. ZSWIM6 is involved in the endoplasmic reticulum stress response.\n3. Danon disease, associated with mutations in ZSWIM6, causes cardiovascular problems such as enlarged hearts and abnormal heart rhythms.\n4. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurological disorder linked to mutations in ZSWIM6 and results in symptoms like spasticity and ataxia.\n5. Congenital disorders of glycosylation (CDG) can be caused by mutations in ZSWIM6 and affect glycoprotein production.",
    "llama-7b_fact": [
      "De novo mutations in ZSWIM6 can cause genetic disorders.",
      "ZSWIM6 is involved in the endoplasmic reticulum stress response.",
      "Danon disease, associated with mutations in ZSWIM6, causes cardiovascular problems such as enlarged hearts and abnormal heart rhythms.",
      "Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurological disorder linked to mutations in ZSWIM6 and results in symptoms like spasticity and ataxia.",
      "Congenital disorders of glycosylation (CDG) can be caused by mutations in ZSWIM6 and affect glycoprotein production."
    ],
    "llama-7b_judge_raw": "1. TRUE: De novo mutations refer to genetic alterations that are present for the first time in one family member as a result of a mutation in a germ cell (egg or sperm) of one of the parents, or a mutation that arises in the fertilized egg itself during early embryogenesis. While I can't verify the specific disorders caused by mutations in ZSWIM6 as of my last update, it is plausible that mutations in any gene, including ZSWIM6, can lead to genetic disorders.\n\n2. UNKNOWN: Without specific scientific references to confirm or deny the involvement of ZSWIM6 in the endoplasmic reticulum stress response, this statement is unclear.\n\n3. FALSE [correction]: Danon disease is associated with mutations in the LAMP2 gene, not ZSWIM6. It is a X-linked genetic disorder that indeed causes problems including enlarged hearts (cardiomyopathy) and abnormal heart rhythms (arrhythmias).\n\n4. FALSE [correction]: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is associated with mutations in the SACS gene, not ZSWIM6. It is a condition characterized by spasticity and ataxia, among other neurological symptoms.\n\n5. UNKNOWN: Congenital disorders of glycosylation (CDG) are a group of metabolic disorders that affect glycoprotein production and are typically caused by mutations in various genes involved in the glycosylation pathway. Without specific information on ZSWIM6's involvement, the statement's accuracy is undeterminable.\n\nEach of these statements would typically require up-to-date research for confirmation since the field of genetics is constantly advancing and new findings are published regularly.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "The Koos Classification is a system used to classify congenital talipes equinovarus (CTEV), also known as clubfoot. CTEV is a condition in which a baby is born with one or both feet turned inward and downward, making it difficult for the child to walk properly. The Koos Classification is a way to categorize the severity of CTEV based on the position and shape of the foot and ankle.\n\nThere are four main categories in the Koos Classification:\n\n1. Type I: This is the mildest form of CTEV, characterized by a normal-looking foot and ankle.\n2. Type II: In this category, the foot is turned inward and downward, but the ankle is also turned outward.\n3. Type III: In this more severe form of CTEV, the foot is turned inward and downward, and the ankle is also turned inward.\n4. Type IV: This is the most severe form of CTEV, in which the foot is turned inward and downward, and the ankle is also turned inward and downward.\n\nThe Koos Classification is important because it helps doctors to determine the best treatment plan for each individual case of CTEV. Treatment options may include physical therapy, casting, and surgery, depending on the severity of the condition.",
    "llama-7b_fact_raw": "1. The Koos Classification is used to classify congenital talipes equinovarus, also known as clubfoot.\n2. The Koos Classification categorizes the severity of clubfoot based on the position and shape of the foot and ankle.\n3. Type I of the Koos Classification is characterized by a normal-looking foot and ankle.\n4. Type II, III, and IV of the Koos Classification indicate progressively more severe forms of clubfoot, with variations in the positioning of the foot and ankle.\n5. The Koos Classification aids doctors in determining the appropriate treatment plan for cases of clubfoot.",
    "llama-7b_fact": [
      "The Koos Classification is used to classify congenital talipes equinovarus, also known as clubfoot.",
      "The Koos Classification categorizes the severity of clubfoot based on the position and shape of the foot and ankle.",
      "Type I of the Koos Classification is characterized by a normal-looking foot and ankle.",
      "Type II, III, and IV of the Koos Classification indicate progressively more severe forms of clubfoot, with variations in the positioning of the foot and ankle.",
      "The Koos Classification aids doctors in determining the appropriate treatment plan for cases of clubfoot."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Type I of the Koos Classification indicates the mildest form of clubfoot, most characterized by the position of the foot being only slightly abnormal, not a normal-looking foot and ankle.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway, which is a key signaling pathway involved in cell growth, proliferation, and survival. In vivo, AZD8601 has been shown to have anti-tumor effects in various preclinical studies.\n\nOne study published in the journal Cancer Research in 2012 investigated the effects of AZD8601 in a mouse model of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. The study found that treatment with AZD8601 resulted in a significant reduction in tumor growth and increased survival of the mice compared to controls. The researchers concluded that AZD8601 may be a promising therapeutic agent for the treatment of PDAC.\n\nAnother study published in the journal Clinical Cancer Research in 2014 investigated the effects of AZD8601 in combination with chemotherapy in a mouse model of breast cancer. The study found that treatment with AZD8601 in combination with chemotherapy resulted in a significant reduction in tumor growth and increased survival of the mice compared to chemotherapy alone. The researchers concluded that AZD8601 may have potential as an adjuvant therapy for breast cancer.\n\nOverall, the in vivo data suggests that AZD8601 has anti-tumor effects in preclinical studies and may be a promising therapeutic agent for the treatment of various types of cancer. However, further clinical trials are needed to confirm these findings and determine the safety and efficacy of AZD8601 in humans.",
    "llama-7b_fact_raw": "1. AZD8601 is an inhibitor of the PI3K/mTOR pathway, which plays a role in cell growth, proliferation, and survival.\n2. AZD8601 has demonstrated anti-tumor effects in preclinical studies according to in vivo data.\n3. A study published in the journal Cancer Research in 2012 showed that AZD8601 significantly reduced tumor growth and increased survival in a mouse model of pancreatic ductal adenocarcinoma.\n4. A 2014 study in the journal Clinical Cancer Research found that combining AZD8601 with chemotherapy significantly reduced tumor growth and increased survival in a mouse model of breast cancer compared to chemotherapy alone.\n5. Further clinical trials are necessary to assess the safety and efficacy of AZD8601 in humans.",
    "llama-7b_fact": [
      "AZD8601 is an inhibitor of the PI3K/mTOR pathway, which plays a role in cell growth, proliferation, and survival.",
      "AZD8601 has demonstrated anti-tumor effects in preclinical studies according to in vivo data.",
      "A study published in the journal Cancer Research in 2012 showed that AZD8601 significantly reduced tumor growth and increased survival in a mouse model of pancreatic ductal adenocarcinoma.",
      "A 2014 study in the journal Clinical Cancer Research found that combining AZD8601 with chemotherapy significantly reduced tumor growth and increased survival in a mouse model of breast cancer compared to chemotherapy alone.",
      "Further clinical trials are necessary to assess the safety and efficacy of AZD8601 in humans."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the PI3K/mTOR pathway; rather, it is an mRNA-based therapy designed to encode for vascular endothelial growth factor A (VEGF-A) which is involved in the restoration of the vascular system.\n2. UNKNOWN\n3. FALSE [correction]: Since AZD8601 is designed for vascular therapy and not as an anti-tumor treatment, the statement is likely incorrect or about a different compound.\n4. FALSE [correction]: Given that AZD8601 is not an anti-tumor drug, but a vascular therapy, this statement appears to be incorrect or about a different compound, unless there is specific research linking AZD8601 to breast cancer treatment in combination with chemotherapy which is not publicly known as of my knowledge cutoff date.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFS, or Secure Attention Handshakes, are created through a multi-step process that involves several parties working together to establish a secure and trusted connection. Here's a detailed explanation of how SAHFS are created:\n\n1. Authentication: The first step in creating a SAHFS is authentication. This involves verifying the identity of the parties involved in the handshake, ensuring that they are who they claim to be. This is typically done through the use of digital certificates or public key infrastructure (PKI) systems.\n2. Key Agreement: Once the parties have been authenticated, they can proceed to the key agreement phase. In this step, they exchange cryptographic keys that will be used to encrypt and decrypt data transmitted between them. The keys are exchanged using a secure protocol, such as the Secure Shell (SSH) protocol, to prevent eavesdropping and tampering.\n3. Confidentiality: Once the keys have been agreed upon, the parties can establish confidentiality. This means that any data transmitted between them will be encrypted, ensuring that it cannot be intercepted or read by unauthorized parties.\n4. Integrity: The next step is to establish integrity. This means that the data transmitted between the parties will be verified to ensure that it has not been tampered with. This is typically done through the use of digital signatures, which are created using the same cryptographic keys used for encryption.\n5. Authenticity: Finally, the parties can establish authenticity. This means that the identity of the parties involved in the handshake can be verified, ensuring that they are who they claim to be. This is typically done through the use of digital certificates or public key infrastructure (PKI) systems.\n\nOnce all of these steps have been completed, a secure and trusted connection has been established between the parties involved in the SAHFS. This connection can be used to transmit data securely and confidentially, ensuring that sensitive information is protected from unauthorized access.",
    "llama-7b_fact_raw": "1. A step in the creation of SAHFS is authentication, involving verifying the identity of the parties using digital certificates or PKI systems.\n2. During the key agreement phase of SAHFS creation, parties exchange cryptographic keys using a secure protocol like SSH to encrypt and decrypt data.\n3. Confidentiality in SAHFS is established by encrypting data transmitted between parties to prevent unauthorized interception.\n4. Integrity during SAHFS creation involves verifying that transmitted data has not been tampered with, often using digital signatures.\n5. Authenticity in SAHFS is ensured by verifying the identity of the parties involved, typically with digital certificates or PKI systems.",
    "llama-7b_fact": [
      "A step in the creation of SAHFS is authentication, involving verifying the identity of the parties using digital certificates or PKI systems.",
      "During the key agreement phase of SAHFS creation, parties exchange cryptographic keys using a secure protocol like SSH to encrypt and decrypt data.",
      "Confidentiality in SAHFS is established by encrypting data transmitted between parties to prevent unauthorized interception.",
      "Integrity during SAHFS creation involves verifying that transmitted data has not been tampered with, often using digital signatures.",
      "Authenticity in SAHFS is ensured by verifying the identity of the parties involved, typically with digital certificates or PKI systems."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: During the key agreement phase of SAHFS creation, parties exchange cryptographic keys using a protocol like Diffie-Hellman to securely establish a shared secret.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically binds to other proteins that contain PDZ domains, forming a stable complex. One of the proteins that SATB1 interacts with through its PDZ domain is the postsynaptic density protein 93 (PSD93). This interaction is important for the localization and function of SATB1 in the postsynaptic density of neurons, where it plays a role in the regulation of gene expression and synaptic plasticity.\n\nIn addition to its interaction with PSD93, the PDZ domain in SATB1 also interacts with other proteins that are involved in various cellular processes, such as cell adhesion, signal transduction, and protein degradation. These interactions help to regulate the activity of SATB1 and ensure its proper localization and function in the cell.\n\nOverall, the PDZ domain in SATB1 plays a crucial role in its function as a transcription factor by mediating protein-protein interactions with other proteins that are involved in various cellular processes. These interactions help to regulate the activity of SATB1 and ensure its proper localization and function in the cell.",
    "llama-7b_fact_raw": "1. The PDZ domain is a protein interaction domain present in the transcription factor SATB1 (Special AT-rich binding protein 1).\n2. The function of the PDZ domain in SATB1 is to mediate protein-protein interactions.\n3. SATB1, through its PDZ domain, can form a stable complex with other proteins that also contain PDZ domains.\n4. One of the interacting partners of the SATB1 PDZ domain is the postsynaptic density protein 93 (PSD93), which is important for SATB1's localization and function in neurons.\n5. The PDZ domain in SATB1 enables interactions with proteins involved in various cellular processes, such as cell adhesion, signal transduction, and protein degradation.",
    "llama-7b_fact": [
      "The PDZ domain is a protein interaction domain present in the transcription factor SATB1 (Special AT-rich binding protein 1).",
      "The function of the PDZ domain in SATB1 is to mediate protein-protein interactions.",
      "SATB1, through its PDZ domain, can form a stable complex with other proteins that also contain PDZ domains.",
      "One of the interacting partners of the SATB1 PDZ domain is the postsynaptic density protein 93 (PSD93), which is important for SATB1's localization and function in neurons.",
      "The PDZ domain in SATB1 enables interactions with proteins involved in various cellular processes, such as cell adhesion, signal transduction, and protein degradation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The PDZ domain is a common protein interaction module, but SATB1 does not contain a PDZ domain. It is known more for its matrix attachment regions (MARs), which recognize specific DNA sequences.\n2. UNKNOWN: Since the first statement is false, and SATB1 does not contain a PDZ domain, the specific function of a PDZ domain in SATB1 cannot be established.\n3. UNKNOWN: As SATB1 does not have a PDZ domain, it cannot form a complex through a nonexistent PDZ domain with other proteins.\n4. FALSE [correction]: Since SATB1 does not have a PDZ domain, it cannot interact with PSD93 through a PDZ domain. Any interaction between SATB1 and PSD93 would not be mediated by a PDZ domain.\n5. FALSE [correction]: Given that SATB1 lacks a PDZ domain, it does not enable interactions through this domain. However, SATB1 does interact with various cellular proteins affecting processes such as transcription regulation and chromatin remodeling, but not through a PDZ domain.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the principles of mindfulness and acceptance. Mindfulness involves being present in the current moment and observing one's thoughts and feelings without judgment. Acceptance involves acknowledging and embracing difficult emotions and experiences, rather than trying to avoid or control them.\n\nThe BLISS technique encourages individuals to focus on the positive aspects of their lives, such as their strengths, accomplishments, and gratitude. This helps to shift the focus away from negative thoughts and emotions, and promotes a more positive outlook.\n\nIn addition to mindfulness and acceptance, the BLISS technique also incorporates elements of self-compassion. This involves treating oneself with kindness, understanding, and patience, even in the face of difficult emotions or experiences.\n\nOverall, the BLISS technique is based on the idea that by focusing on the positive aspects of our lives, we can cultivate a more positive mindset and improve our overall well-being.",
    "llama-7b_fact_raw": "1. The BLISS technique is based on principles of mindfulness and acceptance.\n2. Mindfulness in the context of the BLISS technique involves being present in the current moment without judgment.\n3. Acceptance in the BLISS technique means acknowledging and embracing difficult emotions and experiences.\n4. The BLISS technique encourages focusing on positive aspects of life, such as strengths, accomplishments, and gratitude.\n5. The BLISS technique incorporates elements of self-compassion, which includes treating oneself with kindness and patience.",
    "llama-7b_fact": [
      "The BLISS technique is based on principles of mindfulness and acceptance.",
      "Mindfulness in the context of the BLISS technique involves being present in the current moment without judgment.",
      "Acceptance in the BLISS technique means acknowledging and embracing difficult emotions and experiences.",
      "The BLISS technique encourages focusing on positive aspects of life, such as strengths, accomplishments, and gratitude.",
      "The BLISS technique incorporates elements of self-compassion, which includes treating oneself with kindness and patience."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe responses \"UNKNOWN\" are given as the BLISS technique is not a standardized or widely recognized term in psychological practices as of my knowledge cutoff date, and thus without specific context, it's not possible to confirm or correct the statements related to it. The other responses are based on the common understanding of the terms \"mindfulness\" and \"acceptance\" as well as the general principle of self-compassion.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptors are a subtype of the neurokinin-1 (NK1) receptor, which are G-protein-coupled receptors that bind to the neurokinin peptide substance P. NK3 receptors are primarily found in the central nervous system and play a role in the regulation of pain, inflammation, and emotion.\n\nHere are three NK3R antagonists:\n\n1. AP33584: AP33584 is a selective NK3 receptor antagonist that has been studied for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has a good safety profile in clinical trials.\n2. AMG9810: AMG9810 is another selective NK3 receptor antagonist that has been developed for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has also been studied for the treatment of pruritus (itching) in patients with chronic kidney disease.\n3. LY341495: LY341495 is a non-selective NK1/NK3 receptor antagonist that has been studied for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has also been studied for the treatment of pruritus in patients with chronic kidney disease.",
    "llama-7b_fact_raw": "1. AP33584 is a selective NK3 receptor antagonist studied for chronic pain treatment.\n2. AMG9810 is a selective NK3 receptor antagonist that has been developed to treat chronic pain and has been studied for treating pruritus in patients with chronic kidney disease.\n3. LY341495 is a non-selective NK1/NK3 receptor antagonist that has been studied for chronic pain treatment and pruritus in chronic kidney disease patients.\n4. NK3 receptors are found primarily in the central nervous system.\n5. NK3 receptors are involved in the regulation of pain, inflammation, and emotion.",
    "llama-7b_fact": [
      "AP33584 is a selective NK3 receptor antagonist studied for chronic pain treatment.",
      "AMG9810 is a selective NK3 receptor antagonist that has been developed to treat chronic pain and has been studied for treating pruritus in patients with chronic kidney disease.",
      "LY341495 is a non-selective NK1/NK3 receptor antagonist that has been studied for chronic pain treatment and pruritus in chronic kidney disease patients.",
      "NK3 receptors are found primarily in the central nervous system.",
      "NK3 receptors are involved in the regulation of pain, inflammation, and emotion."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific data or references on AP33584, it is not possible to confirm whether this statement is true or false.\n2. FALSE [correction]: AMG9810 is not a selective NK3 receptor antagonist; it is actually a selective TRPV1 receptor antagonist that has been studied for the treatment of conditions like chronic pain and pruritus.\n3. UNKNOWN: LY341495 specificity and the conditions it has been studied for can't be confirmed without additional data or references.\n4. TRUE: NK3 receptors are indeed found primarily in the central nervous system where they play a role in a variety of functions.\n5. TRUE: NK3 receptors are involved in regulating various physiological functions which can include pain, inflammation, and emotion, among others.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is known as dronabinol. It is a synthetic form of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Dronabinol was developed as a medication to treat nausea and vomiting associated with cancer chemotherapy, as well as to improve appetite and weight gain in patients with AIDS.\n\nDronabinol acts as an inverse agonist of the ghrelin receptor, which means that it binds to the receptor but does not stimulate it to produce the typical effects of ghrelin, such as increasing hunger and stimulating appetite. Instead, dronabinol has been shown to reduce hunger and food intake in both healthy volunteers and patients with anorexia associated with cancer or AIDS.\n\nWhile dronabinol has been used as a medication for several decades, its role as an oral ghrelin receptor inverse agonist was not well understood until recently. However, studies have shown that dronabinol's inverse agonist activity at the ghrelin receptor may contribute to its appetite-stimulating effects in patients with anorexia.",
    "llama-7b_fact_raw": "1. Dronabinol is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC).\n3. Dronabinol was developed to treat nausea and vomiting caused by cancer chemotherapy and to improve appetite and weight gain in patients with AIDS.\n4. As an inverse agonist of the ghrelin receptor, dronabinol reduces hunger and food intake.\n5. The ghrelin receptor inverse agonist activity of dronabinol may contribute to its appetite-stimulating effects in patients with anorexia associated with cancer or AIDS.",
    "llama-7b_fact": [
      "Dronabinol is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC).",
      "Dronabinol was developed to treat nausea and vomiting caused by cancer chemotherapy and to improve appetite and weight gain in patients with AIDS.",
      "As an inverse agonist of the ghrelin receptor, dronabinol reduces hunger and food intake.",
      "The ghrelin receptor inverse agonist activity of dronabinol may contribute to its appetite-stimulating effects in patients with anorexia associated with cancer or AIDS."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC) and is not an inverse agonist of the ghrelin receptor. It is actually an agonist of the cannabinoid receptors CB1 and CB2.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: As an agonist of the cannabinoid receptors, not an inverse agonist of the ghrelin receptor, dronabinol actually stimulates appetite and increases food intake.\n5. FALSE [correction]: The ghrelin receptor inverse agonist activity would not contribute to appetite-stimulating effects since dronabinol is not an inverse agonist of the ghrelin receptor. Its appetite-stimulating effects are due to its agonistic activity on the cannabinoid receptors.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup O1 strain of the bacterium Vibrio cholerae. The protective efficacy of Vaxchora against moderate to severe cholera has been evaluated in several clinical trials.\n\nOne clinical trial, known as the CHOICE (Cholera Immunization for Oral Vaccine Efficacy in Children) trial, enrolled over 17,000 children aged 1-15 years in Bangladesh, India, and Nepal. The children were randomly assigned to receive either Vaxchora or a placebo. The trial found that Vaxchora was highly effective in preventing cholera in children, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nAnother clinical trial, known as the CHOICE-II (Cholera Immunization for Oral Vaccine Efficacy in Children II) trial, enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal. The children were randomly assigned to receive either Vaxchora or a placebo. The trial found that Vaxchora was highly effective in preventing cholera in children, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nIn addition to these clinical trials, Vaxchora has also been shown to be highly effective in preventing cholera in adults. A clinical trial conducted in Haiti found that Vaxchora was highly effective in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nOverall, the protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in multiple clinical trials in children and adults. The vaccine has been shown to be highly effective in preventing cholera, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.",
    "llama-7b_fact_raw": "1. Vaxchora is a vaccine approved for preventing cholera caused by the serogroup O1 strain of Vibrio cholerae.\n2. The CHOICE trial included over 17,000 children aged 1-15 years from Bangladesh, India, and Nepal, who were randomly assigned to receive Vaxchora or a placebo.\n3. In the CHOICE trial, Vaxchora was found to have a statistically significant reduction in the incidence of cholera among the vaccinated group compared to the placebo group.\n4. The CHOICE-II trial enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal and also found Vaxchora to be highly effective in preventing cholera.\n5. A clinical trial in Haiti demonstrated high efficacy of Vaxchora in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.",
    "llama-7b_fact": [
      "Vaxchora is a vaccine approved for preventing cholera caused by the serogroup O1 strain of Vibrio cholerae.",
      "The CHOICE trial included over 17,000 children aged 1-15 years from Bangladesh, India, and Nepal, who were randomly assigned to receive Vaxchora or a placebo.",
      "In the CHOICE trial, Vaxchora was found to have a statistically significant reduction in the incidence of cholera among the vaccinated group compared to the placebo group.",
      "The CHOICE-II trial enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal and also found Vaxchora to be highly effective in preventing cholera.",
      "A clinical trial in Haiti demonstrated high efficacy of Vaxchora in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe veracity of statements 2 through 5 cannot be determined without specific information regarding the results of the CHOICE trial and any additional trials mentioned.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "The first cholera vaccine approved in the US was the killed whole-cell cholera vaccine, also known as Dukoral. It was approved by the US Food and Drug Administration (FDA) in 2000. The vaccine is made from a killed form of the bacteria that causes cholera and is administered orally in a single dose. It provides protection against cholera for up to two years.",
    "llama-7b_fact_raw": "1. The first cholera vaccine approved in the US was the killed whole-cell cholera vaccine, known as Dukoral.\n2. The US Food and Drug Administration (FDA) approved Dukoral in 2000.\n3. The vaccine is made from a killed form of the bacteria that causes cholera.\n4. Dukoral is administered orally.\n5. Dukoral provides protection against cholera for up to two years.",
    "llama-7b_fact": [
      "The first cholera vaccine approved in the US was the killed whole-cell cholera vaccine, known as Dukoral.",
      "The US Food and Drug Administration (FDA) approved Dukoral in 2000.",
      "The vaccine is made from a killed form of the bacteria that causes cholera.",
      "Dukoral is administered orally.",
      "Dukoral provides protection against cholera for up to two years."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was not Dukoral, but Vaxchora, a live, attenuated vaccine.\n2. FALSE [correction]: The US Food and Drug Administration (FDA) approved Vaxchora, the first cholera vaccine in the US, in 2016. Dukoral has not been approved for use in the United States; it is approved and used in other parts of the world.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is X-linked agammaglobulinemia (XLA). XLA is caused by mutations in the BTK gene, which is located on the X chromosome. The BTK gene provides instructions for making a protein called Bruton's tyrosine kinase, which is essential for the development and function of B cells, a type of immune cell that produces antibodies.\n\nIndividuals with XLA have a severe deficiency of B cells and antibodies, which leaves them vulnerable to infections. XLA is an autosomal recessive disorder, meaning that an individual must inherit two copies of the mutated BTK gene (one from each parent) to develop the condition. However, because the BTK gene is located on the X chromosome, X-linked recessive disorders like XLA are more common in males, who have only one X chromosome, than in females, who have two X chromosomes.\n\nOther monogenic causes of CVID in Europeans include autosomal recessive mutations in the FCGR3A and FCGR3B genes, which encode the low-affinity immunoglobulin G (IgG) Fc receptors on the surface of B cells. These mutations can lead to reduced expression or function of the Fc receptors, resulting in impaired antibody production and immunodeficiency.\n\nIn summary, X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans, caused by mutations in the BTK gene on the X chromosome. Other monogenic causes of CVID in Europeans include mutations in the FCGR3A and FCGR3B genes.",
    "llama-7b_fact_raw": "1. X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. The BTK gene mutation causes X-linked agammaglobulinemia.\n3. The BTK gene is located on the X chromosome.\n4. Bruton's tyrosine kinase, made by the BTK gene, is essential for B cell development and function.\n5. Mutations in the FCGR3A and FCGR3B genes are other monogenic causes of CVID in Europeans.\n\n(Note: The answer incorrectly describes XLA as an autosomal recessive disorder when it is, in fact, an X-linked recessive disorder, and this has not been included as a factual statement to avoid propagating incorrect information.)",
    "llama-7b_fact": [
      "X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "The BTK gene mutation causes X-linked agammaglobulinemia.",
      "The BTK gene is located on the X chromosome.",
      "Bruton's tyrosine kinase, made by the BTK gene, is essential for B cell development and function.",
      "Mutations in the FCGR3A and FCGR3B genes are other monogenic causes of CVID in Europeans.",
      "ote: The answer incorrectly describes XLA as an autosomal recessive disorder when it is, in fact, an X-linked recessive disorder, and this has not been included as a factual statement to avoid propagating incorrect information.)"
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: X-linked agammaglobulinemia (XLA) is not the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans. XLA is a separate immunodeficiency disorder, and CVID has various genetic causes, but it is typically not caused by the same gene mutation responsible for XLA.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN (The statement may have inaccuracies because CVID is a heterogeneous disorder, and while mutations in the FCGR3A and FCGR3B genes have been associated with immune dysregulation, it is not clear if they are established monogenic causes for CVID specifically in Europeans without further context.)\n6. UNKNOWN (This statement appears to be a note rather than a factual statement and it hints at an error but does not provide a full context to judge the truthfulness of an actual statement about XLA.)",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 gene, also known as Interferon, alpha-inducible protein 1, plays a role in the regulation of the interferon signaling pathway. Interferons are a group of proteins that are produced by cells in response to the presence of viruses or other pathogens. They play a crucial role in the immune system by activating immune cells and inducing the production of antiviral proteins.\n\nIn the context of Systemic Lupus Erythematosus (SLE), the IFIT1 gene has been implicated in the development and progression of the disease. Studies have shown that individuals with SLE have lower levels of IFIT1 compared to healthy individuals. Additionally, genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.\n\nFurthermore, IFIT1 has been shown to play a role in the regulation of the interferon signaling pathway, which is known to be dysregulated in SLE. The interferon signaling pathway plays a crucial role in the immune system by activating immune cells and inducing the production of antiviral proteins. Dysregulation of this pathway has been linked to the development of autoimmune diseases such as SLE.\n\nIn summary, the role of the IFIT1 gene in SLE is to play a role in the regulation of the interferon signaling pathway, which is known to be dysregulated in the disease. Additionally, lower levels of IFIT1 and genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.",
    "llama-7b_fact_raw": "1. The IFIT1 gene is involved in the regulation of the interferon signaling pathway.\n2. Interferons are proteins produced by cells in response to pathogens and are important for immune system activation.\n3. Studies indicate that individuals with Systemic Lupus Erythematosus often have lower levels of IFIT1 compared to healthy individuals.\n4. Genetic variations in the IFIT1 gene have been associated with an increased risk of developing Systemic Lupus Erythematosus.\n5. Dysregulation of the interferon signaling pathway, where IFIT1 is involved, has been linked to the development of autoimmune diseases such as SLE.",
    "llama-7b_fact": [
      "The IFIT1 gene is involved in the regulation of the interferon signaling pathway.",
      "Interferons are proteins produced by cells in response to pathogens and are important for immune system activation.",
      "Studies indicate that individuals with Systemic Lupus Erythematosus often have lower levels of IFIT1 compared to healthy individuals.",
      "Genetic variations in the IFIT1 gene have been associated with an increased risk of developing Systemic Lupus Erythematosus.",
      "Dysregulation of the interferon signaling pathway, where IFIT1 is involved, has been linked to the development of autoimmune diseases such as SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nSarcoma is a rare type of cancer, and it can be difficult to diagnose and treat. The 100,000 Genomes Project has sequenced the genomes of several patients with sarcoma in order to identify genetic mutations that may be driving the cancer. This information can be used to develop more personalized treatments for patients with sarcoma.\n\nIn addition to sequencing the genomes of patients with sarcoma, the 100,000 Genomes Project has also sequenced the genomes of healthy individuals with a family history of sarcoma. This information can be used to identify inherited genetic mutations that may increase the risk of developing sarcoma.\n\nOverall, the 100,000 Genomes Project has made significant efforts to sequence the genomes of patients with sarcoma in order to improve diagnosis and treatment of this rare and complex type of cancer.",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative that sequences whole genomes from NHS patients with cancer or rare diseases.\n2. The project has included efforts to sequence genomes of patients with sarcoma to identify genetic mutations associated with the cancer.\n3. Sarcoma affects the soft tissues and bones and is considered a rare type of cancer.\n4. The project has sequenced genomes of healthy individuals with a family history of sarcoma to identify inherited genetic mutations.\n5. The information obtained from the 100,000 Genomes Project is intended to develop more personalized treatments for sarcoma patients.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative that sequences whole genomes from NHS patients with cancer or rare diseases.",
      "The project has included efforts to sequence genomes of patients with sarcoma to identify genetic mutations associated with the cancer.",
      "Sarcoma affects the soft tissues and bones and is considered a rare type of cancer.",
      "The project has sequenced genomes of healthy individuals with a family history of sarcoma to identify inherited genetic mutations.",
      "The information obtained from the 100,000 Genomes Project is intended to develop more personalized treatments for sarcoma patients."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats. Armadillo repeats are a type of protein domain that is named after the protein structure known as the \"armadillo\" repeat, which is found in proteins such as p53 and beta-catenin. Armadillo repeats are composed of a series of tandem repeats of a particular amino acid sequence, and they are often involved in protein-protein interactions.\n\nALEX1 is a protein that has been implicated in a variety of cellular processes, including cell proliferation, differentiation, and apoptosis. It is thought to play a role in the regulation of the cell cycle, and it has been shown to interact with a number of other proteins, including p53 and beta-catenin. It is likely that the armadillo repeats in ALEX1 are involved in these protein-protein interactions.\n\nOverall, the presence of armadillo repeats in ALEX1 suggests that this protein may have a role in regulating cellular processes through its interactions with other proteins. Further research is needed to fully understand the function of ALEX1 and its role in cellular signaling.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. Armadillo repeats are involved in protein-protein interactions.\n3. Proteins such as p53 and beta-catenin also contain armadillo repeats.\n4. ALEX1 has been implicated in cellular processes including cell proliferation, differentiation, and apoptosis.\n5. ALEX1 interacts with proteins including p53 and beta-catenin.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "Armadillo repeats are involved in protein-protein interactions.",
      "Proteins such as p53 and beta-catenin also contain armadillo repeats.",
      "ALEX1 has been implicated in cellular processes including cell proliferation, differentiation, and apoptosis.",
      "ALEX1 interacts with proteins including p53 and beta-catenin."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Proteins such as p53 and beta-catenin do not contain armadillo repeats; p53 is a tumor suppressor protein containing DNA-binding domains, and beta-catenin is involved in cell-adhesion and also acts as a signaling molecule in the Wnt pathway, but it does not have armadillo repeats. Proteins with armadillo repeats include β-catenin-related proteins, plakophilins, ARVCF, and p120 catenin, among others.\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\nWithout specific scientific literature or reliable databases to verify the specific characteristics of protein ALEX1, such as its structure or interaction partners, statements 1, 4, and 5 cannot be accurately determined as true or false. Furthermore, since statement 3 contains incorrect information about which proteins have armadillo repeats, it casts further doubt on the accuracy of the claims related to ALEX1 and its functions or interactions.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that remove histone modifications. Here are some examples:\n\n1. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone tails, leading to a more compact chromatin structure and the repression of gene expression. Examples of HDACs include HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10.\n2. Histone demethylases: Histone demethylases remove methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression. Examples of histone demethylases include JMJD3, KDM6A, KDM6B, and KDM6C.\n3. Lysine-specific demethylase 1 (LSD1): LSD1 removes methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression.\n4. Jumonji domain-containing histone demethylases: These enzymes remove methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression. Examples of jumonji domain-containing histone demethylases include JMJD3, KDM6A, and KDM6B.\n5. Lysine-specific demethylase 5A (LSD5): LSD5 removes methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression.",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails.\n2. HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10 are examples of histone deacetylases.\n3. Histone demethylases are enzymes that remove methyl groups from lysine residues on histone tails.\n4. JMJD3, KDM6A, KDM6B, and KDM6C are examples of histone demethylases.\n5. Lysine-specific demethylase 1 (LSD1) is an enzyme that removes methyl groups from lysine residues on histone tails.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails.",
      "HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10 are examples of histone deacetylases.",
      "Histone demethylases are enzymes that remove methyl groups from lysine residues on histone tails.",
      "JMJD3, KDM6A, KDM6B, and KDM6C are examples of histone demethylases.",
      "Lysine-specific demethylase 1 (LSD1) is an enzyme that removes methyl groups from lysine residues on histone tails."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and the risk of brain tumors is complex and has been the subject of much research and debate.\n\nOn one hand, CT scans use X-rays to produce detailed images of the body's internal structures, including the brain. This can be useful for diagnosing a wide range of conditions, including brain tumors. However, CT scans also expose the body to ionizing radiation, which can increase the risk of cancer, including brain tumors.\n\nStudies have suggested that the risk of brain tumors may increase with the number of CT scans a person has undergone. This is because each CT scan exposes the body to a small amount of ionizing radiation, which can accumulate over time and increase the risk of cancer.\n\nHowever, it's worth noting that the risk of brain tumors from CT scans is generally considered to be low. Most people who undergo CT scans do not develop brain tumors as a result. In addition, the benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks.\n\nIn summary, while CT scans do expose the body to ionizing radiation, which can increase the risk of cancer, the risk of brain tumors from CT scans is generally considered to be low. The decision to undergo a CT scan should be made on a case-by-case basis, taking into account the potential benefits and risks.",
    "llama-7b_fact_raw": "1. CT scans use X-rays to produce detailed images of the body's internal structures, including the brain.\n2. CT scans expose the body to ionizing radiation, which can increase the risk of cancer.\n3. The risk of brain tumors may increase with the number of CT scans a person has undergone due to cumulative exposure to ionizing radiation.\n4. The overall risk of brain tumors from CT scans is generally considered to be low.\n5. The benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks.",
    "llama-7b_fact": [
      "CT scans use X-rays to produce detailed images of the body's internal structures, including the brain.",
      "CT scans expose the body to ionizing radiation, which can increase the risk of cancer.",
      "The risk of brain tumors may increase with the number of CT scans a person has undergone due to cumulative exposure to ionizing radiation.",
      "The overall risk of brain tumors from CT scans is generally considered to be low.",
      "The benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "Otx2 is a transcription factor that is primarily associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).\n\nPluripotency refers to the ability of stem cells to differentiate into any cell type in the body. There are three main types of pluripotency:\n\n1. Embryonic stem cell pluripotency: Embryonic stem cells are derived from the inner cell mass of the blastocyst and have the ability to differentiate into all cell types in the body. Otx2 is required for the maintenance of embryonic stem cell pluripotency.\n2. Induced pluripotent stem cell pluripotency: Induced pluripotent stem cells (iPSCs) are derived from adult cells that have been reprogrammed to have the ability to differentiate into any cell type in the body. Otx2 is also required for the maintenance of iPSC pluripotency.\n3. Mesenchymal stem cell pluripotency: Mesenchymal stem cells (MSCs) are found in various tissues and have the ability to differentiate into cells of the mesenchymal lineage, including bone, cartilage, fat, and muscle. Otx2 is not required for the maintenance of MSC pluripotency.\n\nIn summary, Otx2 is primarily associated with the maintenance and regulation of pluripotency in embryonic stem cells and induced pluripotent stem cells, and is not required for the maintenance of mesenchymal stem cell pluripotency.",
    "llama-7b_fact_raw": "1. Otx2 is a transcription factor associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs).\n2. Otx2 is involved in the regulation of pluripotency in induced pluripotent stem cells (iPSCs).\n3. Embryonic stem cells are derived from the inner cell mass of a blastocyst and can differentiate into all cell types in the body.\n4. Induced pluripotent stem cells (iPSCs) are derived from adult cells that are reprogrammed to differentiate into any cell type in the body.\n5. Otx2 is not required for the maintenance of pluripotency in mesenchymal stem cells (MSCs), which can differentiate into cells of the mesenchymal lineage.",
    "llama-7b_fact": [
      "Otx2 is a transcription factor associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs).",
      "Otx2 is involved in the regulation of pluripotency in induced pluripotent stem cells (iPSCs).",
      "Embryonic stem cells are derived from the inner cell mass of a blastocyst and can differentiate into all cell types in the body.",
      "Induced pluripotent stem cells (iPSCs) are derived from adult cells that are reprogrammed to differentiate into any cell type in the body.",
      "Otx2 is not required for the maintenance of pluripotency in mesenchymal stem cells (MSCs), which can differentiate into cells of the mesenchymal lineage."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation:\n1. Otx2 is indeed known to be a transcription factor that has roles in the maintenance and regulation of pluripotency in embryonic stem cells (ESCs).\n2. Similarly, Otx2 is also implicated in the regulation of pluripotency in induced pluripotent stem cells (iPSCs).\n3. The statement about embryonic stem cells (ESCs) being derived from the inner cell mass of a blastocyst and their differentiation potential to all cell types in the body is correct.\n4. The statement correctly describes induced pluripotent stem cells (iPSCs) as being derived from adult cells that are reprogrammed to regain pluripotency and the ability to differentiate into any cell type in the body.\n5. While Otx2 is not typically associated with mesenchymal stem cells (MSCs), the statement is essentially true in that MSCs are pluripotent and can differentiate into cells of the mesenchymal lineage, which includes osteoblasts, chondrocytes, myocytes, and adipocytes. Otx2's main role is not described in relation to MSCs, which have a different lineage specification, thus the transcription factor isn't required for MSC maintenance of pluripotency.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed or easily quantifiable number. DHS are regions of the genome that are more accessible to DNaseI, an enzyme that cuts DNA at specific sites, and are therefore more likely to be transcriptionally active. The number of DHS at a particular locus can vary depending on a variety of factors, including the stage of differentiation of the cells in which the locus is expressed, the level of transcriptional activity at the locus, and the presence of regulatory elements that influence DNaseI sensitivity.\n\nIn general, the beta globin locus is a region of chromosome 16 that contains genes responsible for producing the beta chains of hemoglobin. The locus includes several genes, including the beta globin genes themselves, as well as regulatory elements such as enhancers and silencers that control the expression of the genes. The number of DHS at the beta globin locus can vary depending on the tissue or cell type in which the locus is expressed, as well as the stage of differentiation of those cells.\n\nFor example, in erythroid cells, which are responsible for producing red blood cells, the beta globin locus is highly active and may contain many DHS. In contrast, in non-erythroid cells, such as fibroblasts, the beta globin locus may be less active and contain fewer DHS. The number of DHS at the beta globin locus can also vary depending on the stage of differentiation of erythroid cells, with more DHS appearing as the cells mature.\n\nOverall, while the number of DHS at the beta globin locus is not a fixed or easily quantifiable number, it can vary depending on a variety of factors, including the tissue or cell type in which the locus is expressed, the stage of differentiation of those cells, and the level of transcriptional activity at the locus.",
    "llama-7b_fact_raw": "1. DNaseI hypersensitive sites (DHS) are regions of the genome that are more accessible to the enzyme DNaseI.\n2. The beta globin locus is located on chromosome 16.\n3. The beta globin locus contains genes responsible for producing the beta chains of hemoglobin.\n4. The number of DNaseI hypersensitive sites can vary depending on the stage of differentiation of the cells.\n5. Erythroid cells, which are responsible for producing red blood cells, may have a higher number of DHS at the beta globin locus compared to non-erythroid cells.",
    "llama-7b_fact": [
      "DNaseI hypersensitive sites (DHS) are regions of the genome that are more accessible to the enzyme DNaseI.",
      "The beta globin locus is located on chromosome 16.",
      "The beta globin locus contains genes responsible for producing the beta chains of hemoglobin.",
      "The number of DNaseI hypersensitive sites can vary depending on the stage of differentiation of the cells.",
      "Erythroid cells, which are responsible for producing red blood cells, may have a higher number of DHS at the beta globin locus compared to non-erythroid cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The beta globin locus is located on chromosome 11.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "There are several European influenza vaccines available, including:\n\n1. Fluarix: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline (GSK). It is approved for use in adults and children aged 3 years and older.\n2. FluLaval: This is another inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n3. Fluzone: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n4. Fluad: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults aged 65 years and older.\n5. FluMist: This is a live attenuated influenza vaccine (LAIV) that is manufactured by MedImmune. It is approved for use in healthy children and adults aged 2-49 years old who are not pregnant.\n6. Fluarix Quadrivalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n7. Fluarix Tetravalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n8. Fluzone High-Dose: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults aged 65 years and older.\n9. Fluzone Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n10. Fluad Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults aged 65 years and older.",
    "llama-7b_fact_raw": "1. Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in adults and children aged 3 years and older.\n2. FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.\n3. Fluzone is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.\n4. Fluad is an inactivated influenza vaccine manufactured by Seqirus approved for use in adults aged 65 years and older.\n5. FluMist is a live attenuated influenza vaccine manufactured by MedImmune approved for use in healthy children and adults aged 2-49 years old who are not pregnant.",
    "llama-7b_fact": [
      "Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in adults and children aged 3 years and older.",
      "FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.",
      "Fluzone is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.",
      "Fluad is an inactivated influenza vaccine manufactured by Seqirus approved for use in adults aged 65 years and older.",
      "FluMist is a live attenuated influenza vaccine manufactured by MedImmune approved for use in healthy children and adults aged 2-49 years old who are not pregnant."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an inactivated influenza vaccine manufactured by GlaxoSmithKline approved for use in adults and children aged 6 months and older.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "Yes, the Paramyxovirus geneome is segmented and negative-sense RNA.\n\nParamyxoviruses are a family of viruses that include several important human pathogens, such as measles, mumps, and respiratory syncytial virus. These viruses have a single-stranded, negative-sense RNA genome, which means that the viral RNA is complementary to the antisense (positive-sense) RNA of the host cell.\n\nParamyxoviruses also have a segmented genome, which means that the RNA genome is divided into segments that are separated by non-coding regions. Each segment encodes a specific protein or group of proteins, and the segments are assembled during the replication process to form a complete, infectious virus particle. The segmented nature of the Paramyxovirus genome allows the virus to evolve and adapt more quickly than single-stranded RNA viruses that do not have segmented genomes.",
    "llama-7b_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. Paramyxoviruses belong to a family of viruses which includes pathogens such as measles, mumps, and respiratory syncytial virus.\n3. The Paramyxovirus genome is composed of single-stranded RNA.\n4. The viral RNA of Paramyxoviruses is complementary to the antisense (positive-sense) RNA of the host cell.\n5. The RNA genome of Paramyxoviruses is segmented, divided into separate segments by non-coding regions.",
    "llama-7b_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "Paramyxoviruses belong to a family of viruses which includes pathogens such as measles, mumps, and respiratory syncytial virus.",
      "The Paramyxovirus genome is composed of single-stranded RNA.",
      "The viral RNA of Paramyxoviruses is complementary to the antisense (positive-sense) RNA of the host cell.",
      "The RNA genome of Paramyxoviruses is segmented, divided into separate segments by non-coding regions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The RNA genome of Paramyxoviruses is non-segmented, meaning it consists of a single continuous strand of RNA, not divided into separate segments.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "Roflumilast cream is a medication that is used to treat a condition called chronic obstructive pulmonary disease (COPD). COPD is a group of lung diseases that includes chronic bronchitis and emphysema. It is characterized by the blockage of airflow in the lungs and can cause symptoms such as shortness of breath, coughing, and wheezing.\n\nRoflumilast cream works by reducing inflammation in the lungs, which can help to improve airflow and reduce symptoms of COPD. It is typically used in combination with other medications, such as bronchodilators and corticosteroids, to treat COPD.\n\nIt is worth noting that Roflumilast cream is not a cure for COPD, but it can help to manage the symptoms of the disease and improve quality of life. It is important for individuals with COPD to work closely with their healthcare provider to determine the best treatment plan for their individual needs.",
    "llama-7b_fact_raw": "1. Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).\n2. Chronic obstructive pulmonary disease is a group of lung diseases that includes chronic bronchitis and emphysema.\n3. COPD is characterized by the blockage of airflow in the lungs.\n4. Roflumilast cream helps improve airflow and reduce symptoms of COPD by reducing inflammation in the lungs.\n5. Roflumilast cream is typically used alongside other medications such as bronchodilators and corticosteroids to treat COPD.",
    "llama-7b_fact": [
      "Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "Chronic obstructive pulmonary disease is a group of lung diseases that includes chronic bronchitis and emphysema.",
      "COPD is characterized by the blockage of airflow in the lungs.",
      "Roflumilast cream helps improve airflow and reduce symptoms of COPD by reducing inflammation in the lungs.",
      "Roflumilast cream is typically used alongside other medications such as bronchodilators and corticosteroids to treat COPD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roflumilast is not a cream; it is an oral medication taken as a pill used to treat chronic obstructive pulmonary disease (COPD). There may be a topical form of roflumilast for other conditions, but it is not used to treat COPD.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: As roflumilast is not a cream but an oral medication, this statement is inaccurate. However, roflumilast as an oral medication does help improve airflow and reduce symptoms of COPD by reducing inflammation in the lungs.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Here are some of the most commonly used tools:\n\n1. RNAhybrid: RNAhybrid is a bioinformatics tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly sensitive and specific.\n2. MatInspector: MatInspector is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n3. RNAprom: RNAprom is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n4. RNAPIII-BP: RNAPIII-BP is a bioinformatics tool that uses a machine learning approach to identify potential RNA polymerase III promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n5. RNAz: RNAz is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n\nOverall, these tools have been shown to be highly accurate in identifying and visualizing ncRNA promoters, and they are widely used in the field of ncRNA research.",
    "llama-7b_fact_raw": "1. RNAhybrid identifies promoter regions in ncRNAs using a hybridization-based approach which includes sequence and structural information.\n2. MatInspector is a bioinformatics tool that identifies potential ncRNA promoter regions using machine learning with sequence and structural data.\n3. RNAprom uses machine learning to identify potential promoter regions in ncRNAs by analyzing sequence and structural information.\n4. RNAPIII-BP is a bioinformatics tool designed to identify RNA polymerase III promoter regions in ncRNAs using machine learning.\n5. RNAz utilizes machine learning to identify potential promoter regions in ncRNAs, relying on both sequence and structural cues for its analysis.",
    "llama-7b_fact": [
      "RNAhybrid identifies promoter regions in ncRNAs using a hybridization-based approach which includes sequence and structural information.",
      "MatInspector is a bioinformatics tool that identifies potential ncRNA promoter regions using machine learning with sequence and structural data.",
      "RNAprom uses machine learning to identify potential promoter regions in ncRNAs by analyzing sequence and structural information.",
      "RNAPIII-BP is a bioinformatics tool designed to identify RNA polymerase III promoter regions in ncRNAs using machine learning.",
      "RNAz utilizes machine learning to identify potential promoter regions in ncRNAs, relying on both sequence and structural cues for its analysis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool that predicts microRNA targets by finding the energetically most favorable hybridization sites of a small RNA within a large RNA sequence.\n2. FALSE [correction]: MatInspector is a bioinformatics tool that identifies transcription factor binding sites within sequences of DNA, not ncRNA promoter regions.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: RNAz is a program used to predict structurally conserved and thermodynamically stable RNA secondary structures within multiple sequence alignments, not specifically to identify promoter regions in ncRNAs.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "Sure, here are some examples of genes that the SWIM tool has identified as being down-regulated in glioblastoma:\n\n1. TP53: This gene, also known as p53, is a tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified TP53 as being down-regulated in glioblastoma.\n2. CDKN2A: This gene, also known as p16, is another tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified CDKN2A as being down-regulated in glioblastoma.\n3. PTEN: This gene encodes a phosphatase that negatively regulates the PI3K/AKT signaling pathway. The SWIM tool has identified PTEN as being down-regulated in glioblastoma.\n4. CDKN2B: This gene, also known as p14, is another tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified CDKN2B as being down-regulated in glioblastoma.\n5. SMAD4: This gene encodes a transcription factor that plays a role in the TGF-beta signaling pathway. The SWIM tool has identified SMAD4 as being down-regulated in glioblastoma.\n6. PTCH1: This gene encodes a receptor that plays a role in the Hedgehog signaling pathway. The SWIM tool has identified PTCH1 as being down-regulated in glioblastoma.\n7. CDKN1B: This gene, also known as p21, is a tumor suppressor gene that is frequently down-regulated in glioblastoma. The SWIM tool has identified CDKN1B as being down-regulated in glioblastoma.\n\nThese are just a few examples of the many genes that the SWIM tool has identified as being down-regulated in glioblastoma.",
    "llama-7b_fact_raw": "1. The SWIM tool has identified the TP53 gene as being down-regulated in glioblastoma.\n2. The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.\n3. The SWIM tool has identified the PTEN gene as being down-regulated in glioblastoma.\n4. The SWIM tool has identified the CDKN2B gene as being down-regulated in glioblastoma.\n5. The SWIM tool has identified the SMAD4 gene as being down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "The SWIM tool has identified the TP53 gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the PTEN gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN2B gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the SMAD4 gene as being down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or results of the SWIM (Somatically mutated and WIld-type Matched) tool's analysis, it is impossible to verify the accuracy of the statements regarding gene regulation in glioblastoma. These statements require reference to specific scientific data or study results to be validated.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (Three-dimensional architecture of the genome). Some of these packages include:\n\n1. TADMatrix: This package provides tools for analyzing and visualizing TADs in a genome. It can be used to identify TAD boundaries, calculate TAD properties, and visualize TADs in 3D.\n2. TADtools: This package provides tools for analyzing and visualizing TADs in a genome. It can be used to identify TAD boundaries, calculate TAD properties, and visualize TADs in 2D and 3D.\n3. GenomePlotR: This package provides tools for visualizing and analyzing genomic data. It can be used to visualize TADs in 2D and 3D, as well as to visualize other genomic features such as chromosomes, genes, and regulatory regions.\n4. Hi-C: This package provides tools for analyzing Hi-C data, which is used to study the 3D architecture of the genome. It can be used to analyze Hi-C data, identify TAD boundaries, and calculate TAD properties.\n5. GROMACS: This package provides tools for simulating and analyzing molecular systems. It can be used to study the 3D organization of chromosomes and other genomic features.\n\nThese are just a few examples of R packages that have been developed for studying TADs. There are many other packages available that may be useful for this purpose, depending on the specific research question and analysis methods being used.",
    "llama-7b_fact_raw": "1. The TADMatrix package provides tools for analyzing, visualizing, and identifying TAD boundaries in a genome.\n2. TADtools is an R package designed to analyze and visualize TADs, with capabilities for 2D and 3D visualization.\n3. GenomePlotR is an R package that can visualize genomic data including TADs and other genomic features like chromosomes and genes.\n4. The Hi-C package is used for analyzing Hi-C data to study the three-dimensional architecture of the genome and identify TAD boundaries.\n5. GROMACS is an R package that facilitates the simulation and analysis of molecular systems, relevant to studying the 3D organization of chromosomes.",
    "llama-7b_fact": [
      "The TADMatrix package provides tools for analyzing, visualizing, and identifying TAD boundaries in a genome.",
      "TADtools is an R package designed to analyze and visualize TADs, with capabilities for 2D and 3D visualization.",
      "GenomePlotR is an R package that can visualize genomic data including TADs and other genomic features like chromosomes and genes.",
      "The Hi-C package is used for analyzing Hi-C data to study the three-dimensional architecture of the genome and identify TAD boundaries.",
      "GROMACS is an R package that facilitates the simulation and analysis of molecular systems, relevant to studying the 3D organization of chromosomes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: GROMACS is not an R package. It is a versatile package to perform molecular dynamics, i.e., simulate the Newtonian equations of motion for systems with hundreds to millions of particles. It is not specifically designed for studying the 3D organization of chromosomes or analyzing Hi-C data.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "One bioconductor tool that has been developed for accessing bacterial regulatory networks is the \"Biclustering of Regulatory Networks\" (BiclustR) package.\n\nBiclustR is a bioconductor package that allows for the identification of biclusters in regulatory networks, which are groups of genes that are co-expressed and co-regulated. Biclustering is a powerful tool for identifying patterns and relationships within large datasets, and can be used to identify key regulatory modules within bacterial populations.\n\nThe BiclustR package provides a set of functions for biclustering regulatory networks, as well as tools for visualizing and analyzing the results. The package can be used to identify biclusters of genes that are involved in specific biological processes, or that are regulated by specific transcription factors.\n\nOverall, the BiclustR package is a valuable tool for accessing bacterial regulatory networks, and can be used to identify key regulatory modules and patterns within these networks.",
    "llama-7b_fact_raw": "1. Biclustering of Regulatory Networks (BiclustR) is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BiclustR allows for the identification of biclusters in regulatory networks.\n3. Biclusters are groups of genes that are co-expressed and co-regulated.\n4. The BiclustR package includes functions for biclustering as well as tools for visualizing and analyzing results.\n5. BiclustR can be used to identify biclusters of genes involved in specific biological processes or regulated by specific transcription factors.",
    "llama-7b_fact": [
      "Biclustering of Regulatory Networks (BiclustR) is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BiclustR allows for the identification of biclusters in regulatory networks.",
      "Biclusters are groups of genes that are co-expressed and co-regulated.",
      "The BiclustR package includes functions for biclustering as well as tools for visualizing and analyzing results.",
      "BiclustR can be used to identify biclusters of genes involved in specific biological processes or regulated by specific transcription factors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Biclustering of Expression Data (BiclustR) is a bioconductor package designed for the analysis of gene expression data, not specifically for accessing bacterial regulatory networks. \n2. TRUE \n3. TRUE \n4. TRUE \n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "The shikimate pathway is a biosynthetic pathway that produces aromatic amino acids, which are the building blocks of many important biomolecules, including hormones, neurotransmitters, and antibiotics. The end products of the shikimate pathway are the aromatic amino acids that are synthesized through this pathway.\n\nThe aromatic amino acids that are produced through the shikimate pathway include:\n\n1. Phenylalanine: This amino acid is a precursor to the neurotransmitters dopamine and norepinephrine, as well as the hormone epinephrine.\n2. Tyrosine: This amino acid is a precursor to the skin pigment melanin, as well as the neurotransmitters dopamine and norepinephrine.\n3. Tryptophan: This amino acid is a precursor to the neurotransmitter serotonin, as well as the hormone melatonin.\n4. Valine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n5. Leucine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n6. Isoleucine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n\nIn summary, the end products of the shikimate pathway are the aromatic amino acids phenylalanine, tyrosine, tryptophan, valine, leucine, and isoleucine, which are essential building blocks for many important biomolecules in the body.",
    "llama-7b_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Phenylalanine, an aromatic amino acid produced by the shikimate pathway, is a precursor to dopamine, norepinephrine, and epinephrine.\n3. Tyrosine, another product of the shikimate pathway, is a precursor to melanin, dopamine, and norepinephrine.\n4. Tryptophan is produced via the shikimate pathway and serves as a precursor to serotonin and melatonin.\n5. Valine, leucine, and isoleucine are listed as end products of the shikimate pathway but are actually branched-chain amino acids, not aromatic amino acids, and are not directly produced by this pathway.",
    "llama-7b_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Phenylalanine, an aromatic amino acid produced by the shikimate pathway, is a precursor to dopamine, norepinephrine, and epinephrine.",
      "Tyrosine, another product of the shikimate pathway, is a precursor to melanin, dopamine, and norepinephrine.",
      "Tryptophan is produced via the shikimate pathway and serves as a precursor to serotonin and melatonin.",
      "Valine, leucine, and isoleucine are listed as end products of the shikimate pathway but are actually branched-chain amino acids, not aromatic amino acids, and are not directly produced by this pathway."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Tyrosine is a precursor to melanin, dopamine, and norepinephrine, but it is not a product of the shikimate pathway. It is derived from phenylalanine, which is an aromatic amino acid produced by the shikimate pathway.\n4. TRUE\n5. TRUE\n",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome.\n\nNelson's syndrome is a rare condition that occurs in patients with prostate cancer who have undergone surgery or radiation therapy to treat benign prostatic hyperplasia (BPH) or prostate cancer. It is characterized by the growth of excessive smooth muscle tissue in the prostate gland, leading to compression of the base of the skull and symptoms such as headaches, visual disturbances, and dizziness.\n\nCabergoline is a dopamine agonist that is used to treat hyperprolactinemia, a condition in which the body produces too much prolactin, a hormone that stimulates breast milk production. However, cabergoline has also been shown to be effective in the treatment of Nelson's syndrome.\n\nStudies have shown that cabergoline can reduce the size of the prostate gland and alleviate symptoms such as headaches, visual disturbances, and dizziness in patients with Nelson's syndrome. It works by decreasing the production of prolactin, which helps to shrink the excessive smooth muscle tissue in the prostate gland and relieve compression of the base of the skull.\n\nIn summary, cabergoline is an effective treatment option for patients with Nelson's syndrome, a rare condition that occurs in patients with prostate cancer and is characterized by the growth of excessive smooth muscle tissue in the prostate gland. Cabergoline works by reducing the production of prolactin, which helps to shrink the excessive smooth muscle tissue and alleviate symptoms such as headaches, visual disturbances, and dizziness.",
    "llama-7b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is characterized by the growth of excessive smooth muscle tissue in the prostate gland.\n3. Symptoms of Nelson's syndrome include headaches, visual disturbances, and dizziness.\n4. Cabergoline is a dopamine agonist used to treat hyperprolactinemia.\n5. Studies have shown cabergoline can reduce the size of the prostate gland in patients with Nelson's syndrome.\n\nPlease note, there is an error in the provided answer, Nelson's syndrome occurs in patients who have had their adrenal glands removed, typically due to Cushing's disease, and has nothing to do with prostate cancer or benign prostatic hyperplasia (BPH). Therefore, statements 2 and 5 contain factual inaccuracies as they pertain to the wrong condition and should be disregarded.",
    "llama-7b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is characterized by the growth of excessive smooth muscle tissue in the prostate gland.",
      "Symptoms of Nelson's syndrome include headaches, visual disturbances, and dizziness.",
      "Cabergoline is a dopamine agonist used to treat hyperprolactinemia.",
      "Studies have shown cabergoline can reduce the size of the prostate gland in patients with Nelson's syndrome.",
      "ease note, there is an error in the provided answer, Nelson's syndrome occurs in patients who have had their adrenal glands removed, typically due to Cushing's disease, and has nothing to do with prostate cancer or benign prostatic hyperplasia (BPH). Therefore, statements 2 and 5 contain factual inaccuracies as they pertain to the wrong condition and should be disregarded."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used for the treatment of Nelson's syndrome; it is used primarily to treat disorders associated with hyperprolactinemia. Nelson's syndrome is often treated with radiation or surgery.\n2. FALSE [correction]: Nelson's syndrome is characterized by excessive production of adrenocorticotropic hormone (ACTH) after the removal of the adrenal glands, not by the growth of excessive smooth muscle tissue in the prostate gland.\n3. TRUE: Symptoms of Nelson's syndrome can include headaches and visual disturbances due to the enlargement of the pituitary gland and its impact on surrounding structures; however, dizziness is not a commonly cited symptom, so the statement is partially incorrect.\n4. TRUE: Cabergoline is indeed a dopamine agonist that is commonly used to treat hyperprolactinemia.\n5. FALSE [correction]: The claim that cabergoline can reduce the size of the prostate gland in patients with Nelson's syndrome is incorrect because Nelson's syndrome does not involve the prostate gland.\n6. UNKNOWN: This appears to be an editorial note rather than a statement about the topic, but it correctly identifies errors in statements 2 and 5.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder that is characterized by a range of physical and developmental abnormalities. The main manifestation of Liebenberg syndrome is intellectual disability, which can range from mild to severe and may affect a person's ability to learn, communicate, and take care of themselves.\n\nIn addition to intellectual disability, people with Liebenberg syndrome may also have other physical abnormalities, such as:\n\n* Delayed development: Children with Liebenberg syndrome may take longer to reach developmental milestones, such as walking and talking, than typical children.\n* Small stature: People with Liebenberg syndrome may be shorter than average and may have a thin build.\n* Heart defects: Some people with Liebenberg syndrome may have abnormalities of the heart and blood vessels, such as a hole in the heart or narrowing of the blood vessels.\n* Eye abnormalities: People with Liebenberg syndrome may have abnormalities of the eyes, such as cataracts or glaucoma.\n* Hearing loss: Some individuals with Liebenberg syndrome may have hearing loss.\n* Dental abnormalities: Children with Liebenberg syndrome may have abnormalities of the teeth and gums.\n\nThese physical abnormalities can vary in severity among individuals with Liebenberg syndrome, and some people may have only a few of these symptoms while others may have many.",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Individuals with Liebenberg syndrome may experience delayed development.\n4. People with Liebenberg syndrome can have heart defects, such as a hole in the heart or narrowing of the blood vessels.\n5. Some individuals with Liebenberg syndrome may suffer from hearing loss or have dental abnormalities.",
    "llama-7b_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Individuals with Liebenberg syndrome may experience delayed development.",
      "People with Liebenberg syndrome can have heart defects, such as a hole in the heart or narrowing of the blood vessels.",
      "Some individuals with Liebenberg syndrome may suffer from hearing loss or have dental abnormalities."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The main manifestation of Liebenberg syndrome is the development of arm features that resemble those of a leg.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nLiebenberg syndrome is a rare condition characterized by the malformation of the elbow joints and the presence of features in the arms that resemble those of legs. However, the specific symptoms such as heart defects, hearing loss, or dental abnormalities are not typical features associated with this syndrome, making statements about those conditions unclear without more information.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been developed for the treatment of various cancers. Here are some examples:\n\n1. Midostaurin (Rydapt): This is an FDA-approved oral MPS1 kinase inhibitor that is used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis. Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) and MPS1 kinase pathways.\n2. ENMD-2076: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. ENMD-2076 targets the MPS1 kinase and has shown promising results in preclinical studies.\n3. PF-04217900: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. PF-04217900 targets the MPS1 kinase and has shown promising results in preclinical studies.\n4. GSK2879552: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. GSK2879552 targets the MPS1 kinase and has shown promising results in preclinical studies.\n\nThese are just a few examples of orally bioavailable MPS1 kinase inhibitors that are currently being developed for the treatment of various cancers. However, it's worth noting that the development of these drugs is ongoing, and more research is needed to fully understand their potential benefits and risks.",
    "llama-7b_fact_raw": "1. Midostaurin (Rydapt) is an FDA-approved oral MPS1 kinase inhibitor used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis.\n2. ENMD-2076 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.\n3. PF-04217900 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.\n4. GSK2879552 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.\n5. Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) in addition to the MPS1 kinase.",
    "llama-7b_fact": [
      "Midostaurin (Rydapt) is an FDA-approved oral MPS1 kinase inhibitor used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis.",
      "ENMD-2076 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
      "PF-04217900 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
      "GSK2879552 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
      "Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) in addition to the MPS1 kinase."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Midostaurin (Rydapt) is an FDA-approved oral kinase inhibitor used for the treatment of acute myeloid leukemia (AML) and advanced systemic mastocytosis. It is not specifically an MPS1 kinase inhibitor but does inhibit multiple kinases including FLT3 and KIT.\n2. UNKNOWN: Without specific information about the current development status of ENMD-2076, we cannot verify whether it's being developed specifically as an MPS1 kinase inhibitor or for other targets as well.\n3. FALSE [correction]: PF-04217903 is a MET kinase inhibitor, not an MPS1 kinase inhibitor, and it has been investigated for the treatment of various solid tumors.\n4. FALSE [correction]: GSK2879552 is not an MPS1 kinase inhibitor but an LSD1 inhibitor being explored for the treatment of certain types of cancer, such as small cell lung carcinoma (SCLC).\n5. TRUE: Midostaurin does target the FMS-like tyrosine kinase 3 (FLT3) in addition to other kinases. It is used for the treatment of AML with FLT3 mutations.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known by the trade name Simponi, is a medication that is used to treat several inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a biologic drug that is administered as an injection and works by targeting a specific protein called tumor necrosis factor (TNF).\n\nAs of my knowledge cutoff in September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes. The medication is primarily used to treat inflammatory conditions, and its effects on glucose metabolism have not been extensively studied.\n\nHowever, it is worth noting that some studies have suggested that TNF may play a role in the development of insulin resistance and type 2 diabetes. Therefore, it is possible that golimumab, or similar medications that target TNF, could potentially be used to treat diabetes in the future. However, more research would be needed to determine the safety and effectiveness of using golimumab or other TNF inhibitors for this purpose.\n\nIn summary, while golimumab has been tested and approved for the treatment of inflammatory conditions, there is no information available indicating that it has been specifically tested or approved for the treatment of diabetes. However, TNF may play a role in the development of insulin resistance and type 2 diabetes, and further research is needed to determine the potential of using TNF inhibitors like golimumab for diabetes treatment.",
    "llama-7b_fact_raw": "1. Golimumab, known by the trade name Simponi, is used to treat several inflammatory conditions.\n2. It is a biologic drug administered as an injection.\n3. Golimumab works by targeting a protein called tumor necrosis factor (TNF).\n4. As of September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes.\n5. TNF may play a role in the development of insulin resistance and type 2 diabetes.",
    "llama-7b_fact": [
      "Golimumab, known by the trade name Simponi, is used to treat several inflammatory conditions.",
      "It is a biologic drug administered as an injection.",
      "Golimumab works by targeting a protein called tumor necrosis factor (TNF).",
      "As of September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes.",
      "TNF may play a role in the development of insulin resistance and type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes rapid aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1",
    "llama-7b_fact_raw": "NO FACTS\n\nThe response provided incorrectly states progeria as being caused by an autosomal recessive gene. The condition is actually caused by a mutation in the LMNA gene, which typically occurs as a new (de novo) mutation rather than being inherited in an autosomal recessive pattern. Therefore, there are no factual statements about the mode of inheritance that can be extracted from the answer.",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "Common variants at 12q14 and 12q24 have been associated with various traits and diseases.\n\nAt 12q14, a common variant near the CDKN2A gene has been associated with an increased risk of melanoma, a type of skin cancer. The CDKN2A gene encodes proteins that regulate cell growth and division, and mutations in this gene have been linked to several types of cancer, including melanoma.\n\nAt 12q24, a common variant near the CDKN2B gene has been associated with an increased risk of prostate cancer. The CDKN2B gene encodes proteins that regulate cell growth and division, and mutations in this gene have been linked to several types of cancer, including prostate cancer.\n\nIn addition to these associations, common variants at 12q14 and 12q24 have also been associated with other traits and diseases. For example, a common variant near the CDKN2A gene has been associated with an increased risk of Alzheimer's disease, while a common variant near the CDKN2B gene has been associated with an increased risk of Parkinson's disease.\n\nOverall, common variants at 12q14 and 12q24 are associated with a variety of traits and diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the role of these variants in human health and disease.",
    "llama-7b_fact_raw": "1. Common variants near the CDKN2A gene at 12q14 have been associated with an increased risk of melanoma.\n2. The CDKN2A gene is related to proteins that regulate cell growth and division.\n3. Mutations in the CDKN2A gene have been linked to several types of cancer, including melanoma.\n4. Common variants near the CDKN2B gene at 12q24 have been associated with an increased risk of prostate cancer.\n5. A common variant near the CDKN2B gene at 12q24 has also been associated with an increased risk of Parkinson's disease.",
    "llama-7b_fact": [
      "Common variants near the CDKN2A gene at 12q14 have been associated with an increased risk of melanoma.",
      "The CDKN2A gene is related to proteins that regulate cell growth and division.",
      "Mutations in the CDKN2A gene have been linked to several types of cancer, including melanoma.",
      "Common variants near the CDKN2B gene at 12q24 have been associated with an increased risk of prostate cancer.",
      "A common variant near the CDKN2B gene at 12q24 has also been associated with an increased risk of Parkinson's disease."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Common variants near the CDKN2B gene at 9p21 have been associated with an increased risk of prostate cancer, not 12q24.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are G protein-coupled receptors that play important roles in various cellular processes, including cell-cell adhesion, migration, and axon guidance. The ligands of the Roundabout receptors are proteins or peptides that bind to the extracellular domain of the receptor and activate its intracellular signaling pathway.\n\nThere are several known ligands of the Roundabout receptors, including:\n\n1. Robo4: Robo4 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion, thereby maintaining tissue integrity.\n2. Robo1: Robo1 is another transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n3. Robo3: Robo3 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n4. Robo2: Robo2 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n5. Robo5: Robo5 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n6. Robo6: Robo6 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process is regulated by a complex network of signaling molecules and transcription factors, including TFII-I.\n\nTFII-I is a component of the basal transcription complex, which is responsible for initiating transcription of genes in the absence of other transcription factors. In megakaryopoiesis, TFII-I is recruited to the promoter region of genes that are specifically expressed in megakaryocytes, where it plays a role in activating the transcription of these genes.\n\nOne of the genes that is specifically expressed in megakaryocytes and whose transcription is regulated by TFII-I is the platelet-derived growth factor receptor alpha (PDGFRα) gene. PDGFRα is a receptor tyrosine kinase that plays an important role in the development and maturation of megakaryocytes. Activation of PDGFRα by its ligand, platelet-derived growth factor (PDGF), is required for the proliferation and differentiation of megakaryocytes. TFII-I is required for the transcription of the PDGFRα gene and for the activation of PDGFRα signaling during megakaryopoiesis.\n\nIn summary, TFII-I plays an important role in the regulation of gene expression during megakaryopoiesis by activating the transcription of genes that are specifically expressed in megakaryocytes, including the PDGFRα gene. The activation of PDGFRα signaling by TFII-I is required for the proliferation and differentiation of megakaryocytes, making TFII-I an important regulator of megakaryopoiesis.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor involved in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process by which megakaryocytes, bone marrow cells that produce platelets, are formed.\n3. TFII-I is part of the basal transcription complex, which initiates transcription of genes without other transcription factors.\n4. The transcription of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which is crucial for megakaryocyte development, is regulated by TFII-I.\n5. Activation of the PDGFRα receptor by platelet-derived growth factor is essential for the proliferation and differentiation of megakaryocytes and requires TFII-I.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor involved in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process by which megakaryocytes, bone marrow cells that produce platelets, are formed.",
      "TFII-I is part of the basal transcription complex, which initiates transcription of genes without other transcription factors.",
      "The transcription of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which is crucial for megakaryocyte development, is regulated by TFII-I.",
      "Activation of the PDGFRα receptor by platelet-derived growth factor is essential for the proliferation and differentiation of megakaryocytes and requires TFII-I."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TFII-I is not a part of the basal transcription complex, which is made up of general transcription factors and RNA polymerase. TFII-I is a transcription factor that can regulate gene expression but is not part of this core complex.\n4. UNKNOWN (While TFII-I is involved in the regulation of gene expression during megakaryopoiesis, without specific evidence in the context, we can't definitively say it regulates the PDGFRα gene.)\n5. UNKNOWN (While it’s true that activation of the PDGFRα receptor by platelet-derived growth factor is essential for the proliferation and differentiation of megakaryocytes, the role of TFII-I in this specific process is not clearly stated and would require specific evidence.)",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "As of my knowledge cutoff date in September 2021, there were several versions of ExpansionHunter, including:\n\n1. ExpansionHunter Classic: This was the original version of ExpansionHunter, which was released in 2016. It was a browser-based game that allowed players to explore a procedurally generated galaxy, discover new planets, and fight against hostile alien creatures to expand their empire.\n2. ExpansionHunter Reborn: This version of ExpansionHunter was released in 2018 and was a major update to the original game. It introduced new features such as improved graphics, a new user interface, and more advanced gameplay mechanics.\n3. ExpansionHunter Mobile: This version of ExpansionHunter was released in 2019 and was a mobile version of the game. It was designed to be played on smartphones and tablets, and allowed players to continue their adventures on the go.\n4. ExpansionHunter Universe: This version of ExpansionHunter was released in 2020 and was a spin-off of the original game. It was a multiplayer online battle arena (MOBA) game that allowed players to form teams and battle against other players in real-time.\n\nIt's possible that there may be additional versions of ExpansionHunter that have been released since my knowledge cutoff date in September 2021, but these are the versions that were available at that time.",
    "llama-7b_fact_raw": "1. ExpansionHunter Classic was the original version of ExpansionHunter released in 2016.\n2. ExpansionHunter Reborn, an updated version of the original game, was released in 2018.\n3. ExpansionHunter Mobile, designed for smartphones and tablets, was released in 2019.\n4. ExpansionHunter Universe, a spin-off multiplayer online battle arena game, was released in 2020.\n\nPlease note that the provided statements are contingent on the accuracy of the given answer and assume the described versions of \"ExpansionHunter\" refer to an actual game. If no such game exists, or if the versions provided do not correspond to real releases, then the statements could not be verified and would be considered invalid.",
    "llama-7b_fact": [
      "ExpansionHunter Classic was the original version of ExpansionHunter released in 2016.",
      "ExpansionHunter Reborn, an updated version of the original game, was released in 2018.",
      "ExpansionHunter Mobile, designed for smartphones and tablets, was released in 2019.",
      "ExpansionHunter Universe, a spin-off multiplayer online battle arena game, was released in 2020.",
      "ease note that the provided statements are contingent on the accuracy of the given answer and assume the described versions of \"ExpansionHunter\" refer to an actual game. If no such game exists, or if the versions provided do not correspond to real releases, then the statements could not be verified and would be considered invalid."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note]: There is not enough context to verify the statements about \"ExpansionHunter\" and its different versions or releases. If \"ExpansionHunter\" is not a well-documented or well-known game, then it's particularly challenging to verify these statements without additional information, and they should be treated as unknown. Additionally, the last statement appears to be incomplete and does not provide a complete thought that can be assessed for accuracy.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, which is a major component of cartilage. Adamts18 has been shown to be involved in the regulation of hormone receptor signaling in several ways.\n\nFirst, Adamts18 has been shown to play a role in the regulation of estrogen receptor signaling in breast cancer cells. Estrogen receptor signaling is important for the development and progression of breast cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in estrogen receptor signaling.\n\nSecond, Adamts18 has been shown to play a role in the regulation of androgen receptor signaling in prostate cancer cells. Androgen receptor signaling is important for the development and progression of prostate cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in androgen receptor signaling.\n\nThird, Adamts18 has been shown to play a role in the regulation of thyroid hormone receptor signaling in thyroid cancer cells. Thyroid hormone receptor signaling is important for the development and progression of thyroid cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in thyroid hormone receptor signaling.\n\nOverall, these studies suggest that Adamts18 plays a role in the regulation of hormone receptor signaling by degrading aggrecan, which in turn affects the expression of genes involved in hormone receptor signaling. Further studies are needed to fully understand the role of Adamts18 in hormone receptor signaling and its potential as a therapeutic target for the treatment of hormone-dependent cancers.",
    "llama-7b_fact_raw": "1. Adamts18, known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, a major component of cartilage.\n2. Adamts18 is involved in the regulation of estrogen receptor signaling in breast cancer cells.\n3. The degradation of aggrecan by Adamts18 affects the expression of genes involved in estrogen receptor signaling.\n4. Adamts18 plays a role in the regulation of androgen receptor signaling in prostate cancer cells by affecting gene expression through aggrecan degradation.\n5. Adamts18 is implicated in the regulation of thyroid hormone receptor signaling in thyroid cancer cells by modifying gene expression following aggrecan degradation.",
    "llama-7b_fact": [
      "Adamts18, known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, a major component of cartilage.",
      "Adamts18 is involved in the regulation of estrogen receptor signaling in breast cancer cells.",
      "The degradation of aggrecan by Adamts18 affects the expression of genes involved in estrogen receptor signaling.",
      "Adamts18 plays a role in the regulation of androgen receptor signaling in prostate cancer cells by affecting gene expression through aggrecan degradation.",
      "Adamts18 is implicated in the regulation of thyroid hormone receptor signaling in thyroid cancer cells by modifying gene expression following aggrecan degradation."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2) are enzymes known to degrade the proteoglycan aggrecan, not ADAMTS18.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While ADAMTS18 is indeed an enzyme and a member of the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family, it is not typically referred to as aggrecanase-1. The statements regarding ADAMTS18's specific roles in hormone receptor signaling in various cancer cells would require specific scientific references to determine their validity, hence the responses are unknown.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is a chemotherapy drug that belongs to the group of alkylating agents. It works by interfering with the process of DNA replication, which is necessary for the growth and division of cells.\n\nDuring DNA replication, the two strands of DNA that make up the double helix separate, and each strand serves as a template for the synthesis of a new complementary strand. Thiazovivin interferes with this process by binding to the sugar-phosphate backbone of DNA, which prevents the separation of the strands and the synthesis of the new complementary strands.\n\nAs a result, the cell is unable to divide and reproduce, leading to cell death. Thiazovivin is particularly effective against rapidly dividing cells, such as those found in cancer cells. However, it can also cause damage to normal cells that divide frequently, such as those in the bone marrow, leading to side effects such as hair loss, nausea, and anemia.",
    "llama-7b_fact_raw": "1. Thiazovivin is a chemotherapy drug categorized as an alkylating agent.\n2. Thiazovivin disrupts DNA replication by binding to the sugar-phosphate backbone of DNA.\n3. The binding of Thiazovivin prevents the separation of DNA strands during replication.\n4. Thiazovivin induces cell death by inhibiting cell division and reproduction.\n5. Thiazovivin is especially effective against rapidly dividing cells, like cancer cells.",
    "llama-7b_fact": [
      "Thiazovivin is a chemotherapy drug categorized as an alkylating agent.",
      "Thiazovivin disrupts DNA replication by binding to the sugar-phosphate backbone of DNA.",
      "The binding of Thiazovivin prevents the separation of DNA strands during replication.",
      "Thiazovivin induces cell death by inhibiting cell division and reproduction.",
      "Thiazovivin is especially effective against rapidly dividing cells, like cancer cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not classified as a chemotherapy drug or as an alkylating agent; it is a small molecule inhibitor of ROCK (Rho-associated protein kinase), which may have implications in enhancing stem cell survival and promoting cell reprogramming.\n\n2. FALSE [correction]: Since Thiazovivin is not an alkylating agent, it does not bind to the sugar-phosphate backbone of DNA to disrupt DNA replication. It works by inhibiting ROCK which is involved in various cellular functions but not directly by binding DNA.\n\n3. FALSE [correction]: Thiazovivin does not prevent the separation of DNA strands during replication, as it is not acting directly on DNA but rather inhibits the ROCK enzyme.\n\n4. UNKNOWN: Without specific information on Thiazovivin's exact mechanisms, it's not possible to determine whether it induces cell death specifically by inhibiting cell division and reproduction, even though inhibitors of ROCK can affect cell division.\n\n5. UNKNOWN: The effectiveness of Thiazovivin against rapidly dividing cells such as cancer cells would depend on the specific context of its use in research or treatment, and this statement requires more detailed evidence or references to confirm its accuracy.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  }
]